


**CUMULATIVE
SUPPLEMENT 10
October 2024**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2024

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**Cumulative Supplement 10
October 2024**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	ix
1.5	AVAILABILITY OF THE EDITION.....	x
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	xi
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xii
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Products Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**CUMULATIVE SUPPLEMENT 10
October 2024**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug

Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPR) of any changes or corrections. The DOBPR can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ACI HEALTHCARE LTD (ACI)	STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)
AKORN OPERATING CO LLC (AKORN)	EPIC PHARMA LLC (EPIC PHARMA LLC)
AKORN OPERATING CO LLC (AKORN)	SCIEGEN PHARMACEUTICALS INC (SCIEGEN PHARMS INC)
CADILA HEALTHCARE LTD (CADILA)	ZYDUS LIFESCIENCES LTD (ZYDUS LIFESCIENCES)
EXTROVIS AG (EXTROVIS)	RISING PHARMA HOLDINGS INC (RISING)
GLAXOSMITHKLINE (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)

GLAXOSMITHKLINE CONSUMER HEALTHCARE (GLAXOSMITHKLINE CONS)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLENMARK GENERICS INC USA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LIMITED (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD INDIA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK PHARMACEUTICALS SA (GLENMARK PHARMS)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
GLENMARK PHARMACEUTICALS SA SWITZERLAND (GLENMARK PHARMS SA)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
LUPIN LTD (LUPIN LTD)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	XIROMED LLC (XIROMED)
MYLAN PHARMACEUTICALS INC (MYLAN)	NATCO PHARMA LTD (NATCO)
MYLAN PHARMACEUTICALS INC (MYLAN)	NATCO PHARMA LTD (NATCO PHARMA)
MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NATCO PHARMA LTD (NATCO PHARMA)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)

MYLAN TECHNOLOGIES INC (MYLAN TECHNOLOGIES)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
PAR PHARMACEUTICAL (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM INC)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR STERILE PRODUCTS LLC (PAR STERILE PRODUCTS)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
SAPTALIS PHARMACEUTICALS LLC (SAPTALIS PHARMS)	SCIEGEN PHARMACEUTICALS INC (SCIEGEN PHARMS INC)
STERISCIENCE PTE LTD (STERISCIENCE)	STERISCIENCE SPECIALITIES PTE LTD (STERISCIENCE SPECLTS)
STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)	ESJAY PHARMA LLC (ESJAY PHARMA)
TARO PHARMACEUTICALS USA INC (TARO)	TARO PHARMACEUTICALS INC (TARO)
VERTICE PHARMA MANAGEMENT CORP (VERTICE)	ENCUBE ETHICALS PRIVATE LTD (ENCUBE)
ZYDUS WORLDWIDE DMCC (ZYDUS)	ZYDUS LIFESCIENCES GLOBAL FZE (ZYDUS LIFESCIENCES)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with

approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2023</u>	<u>MAR</u> <u>2024</u>	<u>JUN</u> <u>2024</u>	<u>SEP</u> <u>2024</u>	<u>DEC</u> <u>2024</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23099 2784 (12.1%)	23058 2802 (12.2%)	23182 2763 (11.9%)	23346 2741 (11.7%)	
MULTISOURCE	20315 (87.9%)	20256 (87.8%)	20419 (88.1%)	20605 (88.3%)	
THERAPEUTICALLY EQUIVALENT	20252 (87.7%)	20198 (87.6%)	20332 (87.7%)	20522 (87.9%)	
NOT THERAPEUTICALLY EQUIVALENT	63 (0.3%)	58 (0.3%)	87 (0.4%)	83 (0.4%)	
EXCEPTIONS ⁴	46 (0.2%)	46 (0.2%)	47 (0.2%)	47 (0.2%)	
NEW MOLECULAR ENTITIES APPROVED	32	18	14	19	
NUMBER OF APPLICANTS	1214	1219	1214	1191	

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

<u>ABACAVIR SULFATE; LAMIVUDINE</u>									
TABLET; ORAL									
ABACAVIR SULFATE AND LAMIVUDINE									
AB	!	CIPLA	EQ 600MG BASE; 300MG	A091144	001	Mar 28, 2017	Jan	CHRS	
TABLET, FOR SUSPENSION; ORAL									
ABACAVIR SULFATE AND LAMIVUDINE									
	+	@ MYLAN LABS LTD	EQ 60MG BASE; 30MG	N204311	001	Dec 22, 2023	Jan	DISC	
	+	@ NORVIUM BIOSCIENCE	EQ 60MG BASE; 30MG	N204311	001	Dec 22, 2023	Aug	CAHN	
<u>ABIRATERONE ACETATE</u>									
TABLET; ORAL									
ABIRATERONE ACETATE									
AB		MSN	500MG	A210686	002	Apr 24, 2024	Apr	NEWA	
<u>ACAMPROSATE CALCIUM</u>									
TABLET, DELAYED RELEASE; ORAL									
ACAMPROSATE CALCIUM									
		@ GLENMARK PHARMS LTD	333MG	A202229	001	Jul 16, 2013	Aug	DISC	
AB	!	ZYDUS PHARMS	333MG	A205995	001	May 26, 2017	Aug	CHRS	
<u>ACARBOSE</u>									
TABLET; ORAL									
ACARBOSE									
AB		SOMERSET THERAPS LLC	25MG	A091343	001	Oct 17, 2013	Sep	CAHN	
AB			50MG	A091343	002	Oct 17, 2013	Sep	CAHN	
AB			100MG	A091343	003	Oct 17, 2013	Sep	CAHN	
<u>ACETAMINOPHEN; BUTALBITAL</u>									
TABLET; ORAL									
BUTALBITAL AND ACETAMINOPHEN									
AA		QUAGEN	300MG; 50MG	A214305	001	Feb 01, 2024	Jan	NEWA	
AA			325MG; 50MG	A214291	001	Jan 18, 2024	Jan	NEWA	
<u>ACETAMINOPHEN; BUTALBITAL; CAFFEINE</u>									
CAPSULE; ORAL									
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE									
		@ KEY THERAP	300MG; 50MG; 40MG	A206615	001	Aug 04, 2017	May	DISC	
AA			300MG; 50MG; 40MG	A206615	001	Aug 04, 2017	Apr	CAHN	
AA		QUAGEN	300MG; 50MG; 40MG	A214288	001	Feb 08, 2024	Jan	NEWA	
AA			325MG; 50MG; 40MG	A216376	001	Mar 12, 2024	Mar	NEWA	
AA		SENORES PHARMS	300MG; 50MG; 40MG	A214087	001	Aug 13, 2021	Feb	CAHN	
AA			325MG; 50MG; 40MG	A214087	002	Aug 13, 2021	Feb	CAHN	
TABLET; ORAL									
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE									
AA		QUAGEN	325MG; 50MG; 40MG	A214287	001	Jan 18, 2024	Jan	NEWA	
<u>ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE</u>									
CAPSULE; ORAL									
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE									
		@ NOSTRUM LABS INC	325MG; 50MG; 40MG; 30MG	A075929	001	Apr 22, 2002	May	DISC	
<u>ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE</u>									
CAPSULE; ORAL									
TREZIX									
		@ KEY THERAP	320.5MG; 30MG; 16MG	A204785	001	Nov 26, 2014	May	DISC	
			320.5MG; 30MG; 16MG	A204785	001	Nov 26, 2014	Apr	CAHN	
<u>ACETAMINOPHEN; CODEINE PHOSPHATE</u>									
SOLUTION; ORAL									
ACETAMINOPHEN AND CODEINE PHOSPHATE									
		@ AKORN	120MG/5ML; 12MG/5ML	A040119	001	Apr 26, 1996	Feb	DISC	
		@ PAI HOLDINGS	120MG/5ML; 12MG/5ML	A040119	001	Apr 26, 1996	May	CAHN	
		@ STRIDES PHARMA	120MG/5ML; 12MG/5ML	A086366	001		Sep	CAHN	
TABLET; ORAL									
ACETAMINOPHEN AND CODEINE PHOSPHATE									
AA	!	SPECGX LLC	300MG; 60MG	A040419	003	May 31, 2001	Apr	CHRS	
AA		STRIDES PHARMA	300MG; 15MG	A089990	001	Sep 30, 1988	Apr	CMFD	
AA			300MG; 30MG	A089805	001	Sep 30, 1988	Apr	CMFD	
AA			300MG; 60MG	A089828	001	Sep 30, 1988	Apr	CMFD	

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ SUN PHARM INDS LTD 300MG;30MG

A085868 001

Jan DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@ AMNEAL PHARMS	300MG;10MG	A207137	001	Nov 29, 2016	Jul DISC	
	@ AMNEAL PHARMS NY	300MG;5MG	A206869	001	Jun 23, 2017	Jul DISC	
>D>	!	ASCENT PHARMS INC	325MG;2.5MG	A211487	001	Nov 07, 2018	Oct CTEC
>A> AA	!		325MG;2.5MG	A211487	001	Nov 07, 2018	Oct CTEC
>D>	@	ELITE LABS INC	325MG;2.5MG	A209924	001	Nov 16, 2018	Oct CTEC
>A> AA			325MG;2.5MG	A209924	001	Nov 16, 2018	Oct CTEC
	@		325MG;2.5MG	A209924	001	Nov 16, 2018	Jun CAHN
>D>	@		325MG;5MG	A209924	002	Nov 16, 2018	Oct CTEC
>A> AA			325MG;5MG	A209924	002	Nov 16, 2018	Oct CTEC
	@		325MG;5MG	A209924	002	Nov 16, 2018	Jun CAHN
>D>	@		325MG;7.5MG	A209924	003	Nov 16, 2018	Oct CTEC
>A> AA			325MG;7.5MG	A209924	003	Nov 16, 2018	Oct CTEC
	@		325MG;7.5MG	A209924	003	Nov 16, 2018	Jun CAHN
>D>	@		325MG;10MG	A209924	004	Nov 16, 2018	Oct CTEC
>A> AA			325MG;10MG	A209924	004	Nov 16, 2018	Oct CTEC
	@		325MG;10MG	A209924	004	Nov 16, 2018	Jun CAHN
	@	ENDO OPERATIONS	300MG;5MG	A090415	001	Jan 24, 2011	May CAHN
	@		300MG;7.5MG	A090415	002	Jan 24, 2011	May CAHN
	@		300MG;10MG	A090415	003	Jan 24, 2011	May CAHN
AA		GRANULES	325MG;5MG	A211729	001	Jan 03, 2020	Jul CMFD
AA			325MG;7.5MG	A211729	002	Jan 03, 2020	Jul CMFD
AA			325MG;10MG	A211729	003	Jan 03, 2020	Jul CMFD
	@	PRINSTON INC	325MG;5MG	A214928	001	Dec 30, 2021	Mar DISC
	@		325MG;7.5MG	A214928	002	Dec 30, 2021	Mar DISC
	@		325MG;10MG	A214928	003	Dec 30, 2021	Mar DISC
	@	SANALUZ	325MG;5MG	A211690	001	Feb 07, 2020	Sep CAHN
	@		325MG;7.5MG	A211690	002	Feb 07, 2020	Sep CAHN
	@		325MG;10MG	A211690	003	Feb 07, 2020	Sep CAHN

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

COMBOGESIC

+!	AFT PHARMS LTD	325MG;97.5MG	N209471	001	Mar 01, 2023	Sep CMFD
+!	AFT PHARMS US	325MG;97.5MG	N209471	001	Mar 01, 2023	Sep CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

@ ENDO OPERATIONS 325MG/5ML;5MG/5ML

A203573 001 Dec 18, 2014 May CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA		ELITE LABS INC	325MG;5MG	A209385	001	Jul 02, 2018	Aug CMFD
	@		325MG;5MG	A209385	001	Jul 02, 2018	Jun CAHN
AA			325MG;7.5MG	A209385	002	Jul 02, 2018	Aug CMFD
	@		325MG;7.5MG	A209385	002	Jul 02, 2018	Jun CAHN
AA			325MG;10MG	A209385	003	Jul 02, 2018	Aug CMFD
	@		325MG;10MG	A209385	003	Jul 02, 2018	Jun CAHN
	@	ENDO OPERATIONS	325MG;2.5MG	A090733	001	Jul 11, 2013	May CAHN
	@		325MG;5MG	A040105	001	Jul 30, 1996	May CAHN
	@		325MG;7.5MG	A090734	001	Jul 11, 2013	May CAHN
	@		325MG;10MG	A090734	002	Jul 11, 2013	May CAHN
AA		GRANULES	325MG;2.5MG	A211708	001	Oct 31, 2019	Jul CMFD
AA			325MG;5MG	A211708	002	Oct 31, 2019	Jul CMFD
AA			325MG;7.5MG	A211708	003	Oct 31, 2019	Jul CMFD
AA			325MG;10MG	A211708	004	Oct 31, 2019	Jul CMFD
	@	SANALUZ	325MG;5MG	A207574	001	Dec 13, 2016	Sep CAHN
		PERCOCET					
AA	!	ENDO OPERATIONS	325MG;2.5MG	A040330	001	Jun 25, 1999	Apr CAHN
AA	!		325MG;5MG	A040330	002	Jun 25, 1999	Apr CAHN
	+ @		325MG;5MG	A085106	002		May CAHN
AA	!		325MG;7.5MG	A040330	003	Nov 23, 2001	Apr CAHN
AA	!		325MG;10MG	A040330	004	Nov 23, 2001	Apr CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

@ SUN PHARM INDS INC 325MG; 37.5MG

A077184 001 Dec 16, 2005 Aug DISC

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

	@ AJANTA PHARMA LTD	125MG	A211151	001	Sep 11, 2023	Feb	DISC
	@	250MG	A211151	002	Sep 11, 2023	Feb	DISC
AB	EPIC PHARMA LLC	125MG	A218023	001	May 14, 2024	May	NEWA
AB		250MG	A218023	002	May 14, 2024	May	NEWA
BX	EYWA PHARMA	125MG	A211556	001	Oct 18, 2019	Jun	CTEC
BX		250MG	A211556	002	Oct 18, 2019	Jun	CTEC
BX	HIBROW HLTHCARE	125MG	A211556	001	Oct 18, 2019	Jul	CAHN
BX		250MG	A211556	002	Oct 18, 2019	Jul	CAHN
	@ TORRENT	125MG	A213706	001	Jan 26, 2024	Jan	DISC
AB		125MG	A213706	001	Jan 26, 2024	Jan	NEWA
	@	250MG	A213706	002	Jan 26, 2024	Jan	DISC
AB		250MG	A213706	002	Jan 26, 2024	Jan	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

@ ENDO OPERATIONS EQ 500MG BASE/VIAL

A205358 001 Jun 20, 2017 May CAHN

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

VOSOL

+ @ HIKMA

2%

N012179 001

Apr CRLD

@

2%

N012179 001

Apr DISC

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

AP GLENMARK PHARMS INC 6GM/30ML (200MG/ML)

A213693 001 Feb 03, 2022 Sep CAHN

AP SOMERSET THERAPS LLC 6GM/30ML (200MG/ML)

A218397 001 Jun 07, 2024 May NEWA

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

@ EXELA PHARMA 20%

A205643 001 Nov 01, 2023 Feb DISC

ACETYLCYSTEINE LYSINE

FOR SOLUTION; ORAL

LEGUBETI

+ @ GALEPHAR

EQ 500MG BASE/PACKET

N215040 001 Feb 13, 2024 Jun DISC

+!

EQ 500MG BASE/PACKET

N215040 001 Feb 13, 2024 Feb NEWA

+ @

EQ 2.5GM BASE/PACKET

N215040 002 Feb 13, 2024 Jun DISC

+!

EQ 2.5GM BASE/PACKET

N215040 002 Feb 13, 2024 Feb NEWA

ACITRETIN

CAPSULE; ORAL

ACITRETIN

AB ALEMBIC 10MG

A217774 001 Aug 05, 2024 Jul NEWA

AB 17.5MG

A217774 002 Aug 05, 2024 Jul NEWA

AB 25MG

A217774 003 Aug 05, 2024 Jul NEWA

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+ @ ENDO OPERATIONS 8MG; 60MG

N019806 001 Mar 25, 1994 May CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB ADAPTIS 200MG

A075090 001 Jan 26, 1999 Sep CAHN

CREAM; TOPICAL

ACYCLOVIR

AB TARO 5%

A205470 001 Jun 12, 2024 Jul CAHN

AB 5%

A205470 001 Jun 12, 2024 May NEWA

	OINTMENT; TOPICAL							
	ACYCLOVIR							
	@ COSETTE	5%		A205591	001	Nov 13, 2017	Mar	DISC
	SUSPENSION; ORAL							
	ACYCLOVIR							
	@ HIKMA	200MG/5ML		A077026	001	Jun 07, 2005	Mar	DISC
	@ VISTAPHARM LLC	200MG/5ML		A213951	001	Jan 11, 2021	Mar	CAHN
	<u>ACYCLOVIR SODIUM</u>							
	INJECTABLE; INJECTION							
	ACYCLOVIR SODIUM							
AP	DDREG PHARMA	EQ 50MG BASE/ML		A215404	001	Jun 25, 2024	Jun	NEWA
AP	FRESENIUS KABI USA	EQ 50MG BASE/ML		A215404	001	Jun 25, 2024	Jul	CAHN
	@ NORVIUM BIOSCIENCE	EQ 500MG BASE/VIAL		A203927	001	Mar 29, 2017	Jun	CAHN
	@	EQ 1GM BASE/VIAL		A203927	002	Mar 29, 2017	Jun	CAHN
AP	SLATE RUN PHARMA	EQ 50MG BASE/ML		A218111	001	Jan 08, 2024	Sep	CAHN
	<u>ADAGRASIE</u>							
	TABLET; ORAL							
	KRAZATI							
	+! BRISTOL	200MG		N216340	001	Dec 12, 2022	Sep	CAHN
	<u>ADAPALENE</u>							
	LOTION; TOPICAL							
	DIFFERIN							
	+ @ GALDERMA LABS LP	0.1%		N022502	001	Mar 17, 2010	May	DISC
	<u>ADEFOVIR DIPIVOXIL</u>							
	TABLET; ORAL							
	ADEFOVIR DIPIVOXIL							
AB	! SIGMAPHARM LABS LLC	10MG		A202051	001	Aug 29, 2013	Jun	CHRS
	HEPSERA							
	+ @ GILEAD	10MG		N021449	001	Sep 20, 2002	Jun	DISC
	<u>ADENOSINE</u>							
	INJECTABLE; INJECTION							
	ADENOSINE							
>D>	@ MYLAN LABS LTD	3MG/ML		A078640	001	Mar 21, 2014	Oct	CAHN
>A>	@ NORVIUM BIOSCIENCE	3MG/ML		A078640	001	Mar 21, 2014	Oct	CAHN
	SOLUTION; INTRAVENOUS							
	ADENOSINE							
	@ HOSPIRA	60MG/20ML (3MG/ML)		A203883	001	Mar 24, 2014	Feb	DISC
	@	90MG/30ML (3MG/ML)		A203883	002	Mar 24, 2014	Feb	DISC
	<u>ALBENDAZOLE</u>							
	TABLET; ORAL							
	ALBENDAZOLE							
AB	ALEMBIC	200MG		A215652	001	Sep 04, 2024	Aug	NEWA
	@ STRIDES PHARMA	200MG		A210011	001	Dec 07, 2018	Sep	DISC
	<u>ALBUTEROL SULFATE</u>							
	AEROSOL, METERED; INHALATION							
	ALBUTEROL SULFATE							
AB2	ARMSTRONG PHARMS	EQ 0.09MG BASE/INH		A212447	001	May 21, 2024	May	NEWA
	POWDER, METERED; INHALATION							
	PROAIR DIGIHALER							
	+ @ TEVA BRANDED PHARM	EQ 0.09MG BASE/INH		N205636	002	Dec 21, 2018	Jun	DISC
	SOLUTION; INHALATION							
	ACCUNEB							
	+ @ NORVIUM BIOSCIENCE	EQ 0.021% BASE		N020949	002	Apr 30, 2001	Jul	CAHN
	+ @	EQ 0.042% BASE		N020949	001	Apr 30, 2001	Jul	CAHN
	ALBUTEROL SULFATE							
AN	LEXENPHARM	EQ 0.021% BASE		A215571	001	May 03, 2024	Apr	NEWA
AN		EQ 0.042% BASE		A215571	002	May 03, 2024	Apr	NEWA
AN	LUOXIN AUROVITAS	EQ 0.021% BASE		A211888	001	Apr 20, 2020	Jun	CMFD
AN		EQ 0.042% BASE		A211888	002	Apr 20, 2020	Jun	CMFD
	@ NORVIUM BIOSCIENCE	EQ 0.083% BASE		A072652	001	Feb 21, 1992	Jun	CAHN
	@ WATSON LABS	EQ 0.021% BASE		A077772	001	Sep 25, 2007	Jun	DISC
	@	EQ 0.042% BASE		A077772	002	Sep 25, 2007	Jun	DISC

	SYRUP;ORAL								
	ALBUTEROL SULFATE								
	@ HIKMA	EQ 2MG BASE/5ML	A074749	001	Jan 30, 1998	Mar	DISC		
	TABLET;ORAL								
	ALBUTEROL SULFATE								
BX	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Jun	CTEC		
BX		EQ 4MG BASE	A210948	002	Mar 15, 2019	Jun	CTEC		
	@ HIBROW HLTHCARE	EQ 2MG BASE	A213524	001	Oct 08, 2020	Sep	CAHN		
	@	EQ 4MG BASE	A213524	002	Oct 08, 2020	Sep	CAHN		
	<u>ALBUTEROL SULFATE; BUDESONIDE</u>								
	AEROSOL, METERED; INHALATION								
	AIRSUPRA								
	+! ASTRAZENECA	EQ 0.09MG BASE/INH;0.08MG/INH	N214070	001	Jan 10, 2023	Jan	CPOT		
	<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>								
	SOLUTION; INHALATION								
	ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE								
	@ AIPING PHARM INC	EQ 0.083% BASE;0.017% DUONEB	A076867	001	Dec 21, 2006	Sep	CAHN		
	+ @ NORVIUM BIOSCIENCE	EQ 0.083% BASE;0.017%	N020950	001	Mar 21, 2001	Jul	CAHN		
	<u>ALCOHOL</u>								
	SOLUTION; INTRA-ARTERIAL								
	ABLYSINOL								
	+ @ BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018	Jun	DISC		
	<u>ALENDRONATE SODIUM</u>								
	TABLET;ORAL								
	ALENDRONATE SODIUM								
AB	IPCA LABS LTD	EQ 10MG BASE	A206387	001	Jun 04, 2024	May	NEWA		
AB		EQ 35MG BASE	A206387	002	Jun 04, 2024	May	NEWA		
AB		EQ 40MG BASE	A206387	003	Jun 04, 2024	May	NEWA		
AB		EQ 70MG BASE	A206387	004	Jun 04, 2024	May	NEWA		
	<u>ALFUZOSIN HYDROCHLORIDE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	ALFUZOSIN HYDROCHLORIDE								
	@ NORVIUM BIOSCIENCE	10MG	A079014	001	Jul 18, 2011	Jun	CAHN		
	<u>ALISKIREN HEMIFUMARATE</u>								
	TABLET;ORAL								
	ALISKIREN HEMIFUMARATE								
AB	ENDO OPERATIONS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Apr	CAHN		
AB		EQ 300MG BASE	A206665	002	Mar 22, 2019	Apr	CAHN		
	<u>ALLOPURINOL</u>								
	TABLET;ORAL								
	ALLOPURINOL								
AB	ENDO OPERATIONS	100MG	A075798	001	Jun 27, 2003	Apr	CAHN		
AB		300MG	A075798	002	Jun 27, 2003	Apr	CAHN		
AB	HARMAN FINOCHEM	200MG	A214443	003	Jun 17, 2024	Jun	NFTG		
	@ LUPIN LTD	100MG	A211807	001	Dec 14, 2023	Apr	DISC		
	@	300MG	A211807	002	Dec 14, 2023	Apr	DISC		
	ZYLOPRIM								
AB	+ CASPER PHARMA LLC	200MG	N016084	003	Aug 04, 2022	Jun	CFTG		
	<u>ALOSETRON HYDROCHLORIDE</u>								
	TABLET;ORAL								
	ALOSETRON HYDROCHLORIDE								
	@ ENDO OPERATIONS	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	May	CAHN		
	@	EQ 1MG BASE	A206113	002	Feb 23, 2018	May	CAHN		
	@ EYWA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Sep	CAHN		
	@	EQ 1MG BASE	A211621	002	Sep 16, 2019	Sep	CAHN		
	@ HIBROW HLTHCARE	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Sep	CAHN		
	@	EQ 1MG BASE	A211621	002	Sep 16, 2019	Sep	CAHN		

ALPELISIB

GRANULES;ORAL
VIJOICE

+!	NOVARTIS	50MG/PACKET	N218466	001	Apr 24, 2024	Apr	NEWA
----	----------	-------------	---------	-----	--------------	-----	------

ALPRAZOLAM

TABLET;ORAL
ALPRAZOLAM

AB	CHARTWELL RX	0.25MG	A207507	001	Jul 09, 2018	Mar	CAHN
AB		0.5MG	A207507	002	Jul 09, 2018	Mar	CAHN
AB		1MG	A207507	003	Jul 09, 2018	Mar	CAHN
AB		2MG	A207507	004	Jul 09, 2018	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

@	ANCHEN PHARMS	0.5MG	A078469	001	Sep 29, 2011	Mar	DISC
@		1MG	A078469	002	Sep 29, 2011	Mar	DISC
@		2MG	A078469	003	Sep 29, 2011	Mar	DISC
@		3MG	A078469	004	Sep 29, 2011	Mar	DISC
@	ENDO OPERATIONS	0.5MG	A078442	001	Oct 15, 2007	May	CAHN
@		0.5MG	A078469	001	Sep 29, 2011	May	CAHN
@		1MG	A078442	002	Oct 15, 2007	May	CAHN
@		1MG	A078469	002	Sep 29, 2011	May	CAHN
@		2MG	A078442	003	Oct 15, 2007	May	CAHN
@		2MG	A078469	003	Sep 29, 2011	May	CAHN
@		3MG	A078442	004	Oct 15, 2007	May	CAHN
@		3MG	A078469	004	Sep 29, 2011	May	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

AB	ENDO OPERATIONS	0.25MG	A078088	001	Jan 09, 2009	Apr	CAHN
AB		0.5MG	A078088	002	Jan 09, 2009	Apr	CAHN
AB	!	1MG	A078088	003	Jan 09, 2009	Apr	CAHN
AB		2MG	A078088	004	Jan 09, 2009	Apr	CAHN

ALPROSTADIL

INJECTABLE;INJECTION
EDEX

@	ENDO OPERATIONS	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr	CAHN
AP	+	0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr	CAHN
	+!	0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr	CAHN
AP	+	0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr	CAHN
	+!	0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr	CAHN
AP	+!	0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr	CAHN
	+!	0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr	CAHN

SUPPOSITORY;URETHRAL

MUSE

+	@	MYLAN SPECIALITY LP	0.25MG	N020700	002	Nov 19, 1996	Jun	DISC
+	@		0.5MG	N020700	003	Nov 19, 1996	Jun	DISC
+	@		1MG	N020700	004	Nov 19, 1996	Jun	DISC

AMANTADINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
AMANTADINE HYDROCHLORIDE

AB	ZYDUS	EQ 68.5MG BASE	A214897	001	Aug 26, 2024	Aug	NFTG	
	GOCOVRI							
AB	+	SUPERMUS PHARMS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug	NFTG
	+		EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug	CAHN
	+!		EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug	CAHN

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

@	CHARTWELL RX	50MG/5ML	A076352	001	Sep 10, 2004	Aug	CAHN		
>D>	AA	!	CMP PHARMA INC	50MG/5ML	A075819	001	Sep 11, 2002	Oct	DISC
>A>		@		50MG/5ML	A075819	001	Sep 11, 2002	Oct	DISC
		@	ENDO OPERATIONS	50MG/5ML	A077992	001	Dec 12, 2006	May	CAHN
		@	GENUS	50MG/5ML	A076352	001	Sep 10, 2004	Jan	CAHN
>D>		@	XTTRIUM LABS INC	50MG/5ML	A075060	001	Dec 24, 1998	Oct	CMFD
>A>	AA			50MG/5ML	A075060	001	Dec 24, 1998	Oct	CMFD

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

@	ADAPTIS	100MG	A212407	001	May 27, 2022	Sep	CAHN
AB	ZHEJIANG JUTAI PHARM	100MG	A218598	001	Sep 26, 2024	Sep	NEWA

TABLET, EXTENDED RELEASE;ORAL
OSMOLEX ER

+ @	ADAMAS OPERATIONS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Apr	DISC
+ @		EQ 193MG BASE	N209410	002	Feb 16, 2018	Apr	DISC
+ @	SUPERMUS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Aug	CAHN
+ @		EQ 161MG BASE	N209410	004	Apr 22, 2020	Aug	CAHN
+ @		EQ 193MG BASE	N209410	002	Feb 16, 2018	Aug	CAHN
+ @		EQ 258MG BASE	N209410	003	Feb 16, 2018	Aug	CAHN

AMBRISENTAN

TABLET;ORAL
AMBRISENTAN

@	ENDO OPERATIONS	5MG	A209509	001	Apr 10, 2019	May	CAHN
@		10MG	A209509	002	Apr 10, 2019	May	CAHN
@	PAR PHARM INC	5MG	A209509	001	Apr 10, 2019	Apr	DISC
@		10MG	A209509	002	Apr 10, 2019	Apr	DISC

AMCINONIDE

LOTION;TOPICAL
AMCINONIDE

!	GENUS	0.1%	A076329	001	Nov 06, 2002	Jan	CAHN
---	-------	------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL
AMCINONIDE

AB	!	GENUS	0.1%	A076096	001	Nov 19, 2002	Jan	CAHN
----	---	-------	------	---------	-----	--------------	-----	------

AMIFOSTINE

INJECTABLE;INJECTION
ETHYOL

>D>	@	CLINIGEN	375MG/VIAL	N020221	002	Sep 10, 1999	Oct	CAHN
>D>	+!		500MG/VIAL	N020221	001	Dec 08, 1995	Oct	CAHN
>A>	@	COSETTE	375MG/VIAL	N020221	002	Sep 10, 1999	Oct	CAHN
>A>	+ @		500MG/VIAL	N020221	001	Dec 08, 1995	Oct	DISC
>A>	+!		500MG/VIAL	N020221	001	Dec 08, 1995	Oct	CAHN

AMIKACIN SULFATE

INJECTABLE;INJECTION
AMIKACIN SULFATE

AP		QILU	EQ 250MG BASE/ML	A218146	001	Mar 19, 2024	Mar	NEWA
----	--	------	------------------	---------	-----	--------------	-----	------

AMILORIDE HYDROCHLORIDE

TABLET;ORAL
AMILORIDE HYDROCHLORIDE

AB	!	ENDO OPERATIONS	5MG	A070346	001	Jan 22, 1986	Apr	CAHN
----	---	-----------------	-----	---------	-----	--------------	-----	------

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION
CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER
BAXTER HLTHCARE 8%;14GM/100ML

N020734	019	Apr 13, 2021	Apr	NEWA
---------	-----	--------------	-----	------

AMINOCAPROIC ACID

SOLUTION;ORAL
AMICAR

+ @	HIKMA	0.25GM/ML	N015230	002		Mar	DISC	
AA	MSN	0.25GM/ML	A215100	001	Sep 26, 2024	Sep	NEWA	
AA	!	TRUPHARMA	0.25GM/ML	A212494	001	Aug 11, 2020	Sep	CAHN
AA	!	TULEX PHARMS INC	0.25GM/ML	A212494	001	Aug 11, 2020	Mar	CHRS
	@	VISTAPHARM LLC	0.25GM/ML	A212814	001	Feb 26, 2020	Mar	CAHN

TABLET;ORAL
AMICAR

+ @	HIKMA	500MG	N015197	001		Mar	DISC	
+ @		1GM	N015197	002	Jun 24, 2004	Mar	DISC	
		AMINOCAPROIC ACID						
	@	ADAPTIS	500MG	A212110	001	Jun 14, 2021	Sep	CAHN
AB		APPCO	500MG	A213944	001	Sep 14, 2022	Sep	CAHN
AB		1GM	A213944	002	Sep 14, 2022	Sep	CAHN	

AMINOLEVULINIC ACID HYDROCHLORIDE

SOLUTION; TOPICAL

LEVULAN

>D>	+	DUSA	20%	N020965	001	Dec 03, 1999	Oct	CAHN
>A>	+	SUN PHARM INDS INC	20%	N020965	001	Dec 03, 1999	Oct	CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

	@	HOSPIRA	50MG/ML	A203884	001	Nov 25, 2013	May	DISC
AP		ZHEJIANG POLY PHARM	50MG/ML	A218253	001	Sep 11, 2024	Aug	NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB		AIPING PHARM INC	10MG	A212654	002	Sep 29, 2021	May	CMFD
AB			25MG	A212654	001	Apr 07, 2020	May	CMFD
AB			50MG	A212654	003	Sep 29, 2021	May	CMFD
AB			75MG	A212654	004	Sep 29, 2021	May	CMFD
AB			100MG	A212654	005	Sep 29, 2021	May	CMFD
AB			150MG	A212654	006	Sep 29, 2021	May	CMFD
AB		BRECKENRIDGE	10MG	A216243	001	Jun 06, 2022	Sep	CAHN
AB			25MG	A216243	002	Jun 06, 2022	Sep	CAHN
AB			50MG	A216243	003	Jun 06, 2022	Sep	CAHN
AB			75MG	A216243	004	Jun 06, 2022	Sep	CAHN
AB			100MG	A216243	005	Jun 06, 2022	Sep	CAHN
AB			150MG	A216243	006	Jun 06, 2022	Sep	CAHN
AB		CENTAUR PHARMS PVT	10MG	A216243	001	Jun 06, 2022	Aug	CAHN
AB			25MG	A216243	002	Jun 06, 2022	Aug	CAHN
AB			50MG	A216243	003	Jun 06, 2022	Aug	CAHN
AB			75MG	A216243	004	Jun 06, 2022	Aug	CAHN
AB			100MG	A216243	005	Jun 06, 2022	Aug	CAHN
AB			150MG	A216243	006	Jun 06, 2022	Aug	CAHN
	@	ENDO OPERATIONS	10MG	A040218	001	Sep 11, 1997	May	CAHN
	@		25MG	A040218	002	Sep 11, 1997	May	CAHN
	@		50MG	A040218	003	Sep 11, 1997	May	CAHN
	@		75MG	A040218	004	Sep 11, 1997	May	CAHN
	@		100MG	A040218	005	Sep 11, 1997	May	CAHN
	@		150MG	A040218	006	Sep 11, 1997	May	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

	@	AIPING PHARM INC	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Feb	CAHN
	@		EQ 5MG BASE	A077759	002	Jul 09, 2007	Feb	CAHN
	@		EQ 10MG BASE	A077759	003	Jul 09, 2007	Feb	CAHN
BX		LUPIN	EQ 2.5MG BASE	A078043	001	Jul 12, 2007	Jun	CTEC
BX			EQ 5MG BASE	A078043	002	Jul 12, 2007	Jun	CTEC
BX			EQ 10MG BASE	A078043	003	Jul 12, 2007	Jun	CTEC
	@	SCIEGEN PHARMS INC	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Sep	CAHN
	@		EQ 5MG BASE	A077759	002	Jul 09, 2007	Sep	CAHN
	@		EQ 10MG BASE	A077759	003	Jul 09, 2007	Sep	CAHN
	@	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Jan	DISC
	@		EQ 5MG BASE	A077974	002	Jul 09, 2007	Jan	DISC
	@		EQ 10MG BASE	A077974	003	Jul 09, 2007	Jan	DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

	@	AMNEAL	EQ 2.5MG BASE; 10MG	A077215	001	Dec 07, 2018	Apr	CAHN
	@		EQ 5MG BASE; 10MG	A077215	002	Dec 07, 2018	Apr	CAHN
	@		EQ 5MG BASE; 20MG	A077215	003	Dec 07, 2018	Apr	CAHN
	@		EQ 10MG BASE; 20MG	A077215	004	Dec 07, 2018	Apr	CAHN
AB		HERITAGE	EQ 2.5MG BASE; 10MG	A091431	001	Dec 30, 2013	Sep	CAHN
AB			EQ 5MG BASE; 10MG	A091431	002	Dec 30, 2013	Sep	CAHN
AB			EQ 5MG BASE; 20MG	A091431	003	Dec 30, 2013	Sep	CAHN
AB			EQ 5MG BASE; 40MG	A091431	004	Dec 30, 2013	Sep	CAHN
AB			EQ 10MG BASE; 20MG	A091431	005	Dec 30, 2013	Sep	CAHN
AB			EQ 10MG BASE; 40MG	A091431	006	Dec 30, 2013	Sep	CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL							
	@ GLENMARK PHARMS LTD	EQ 5MG BASE;20MG	A207807	001	Jul 05, 2017	Sep	DISC
	@	EQ 5MG BASE;40MG	A207807	002	Jul 05, 2017	Sep	DISC
	@	EQ 10MG BASE;20MG	A207807	003	Jul 05, 2017	Sep	DISC
	@	EQ 10MG BASE;40MG	A207807	004	Jul 05, 2017	Sep	DISC
AB	SCIEGEN PHARMS INC	EQ 5MG BASE;20MG	A209010	001	Dec 03, 2018	Feb	CMFD
AB		EQ 5MG BASE;40MG	A209010	002	Dec 03, 2018	Feb	CMFD
AB		EQ 10MG BASE;20MG	A209010	003	Dec 03, 2018	Feb	CMFD
AB		EQ 10MG BASE;40MG	A209010	004	Dec 03, 2018	Feb	CMFD

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

+	@ ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Sep	DISC
+	@	EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Sep	DISC
+	@	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Sep	DISC

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

>A>	AB	MACLEODS PHARMS LTD	EQ 5MG BASE;160MG	A207292	001	Oct 11, 2024	Oct	NEWA
>A>	AB		EQ 5MG BASE;320MG	A207292	003	Oct 11, 2024	Oct	NEWA
>A>	AB		EQ 10MG BASE;160MG	A207292	002	Oct 11, 2024	Oct	NEWA
>A>	AB		EQ 10MG BASE;320MG	A207292	004	Oct 11, 2024	Oct	NEWA

AMOXAPINE

TABLET;ORAL

AMOXAPINE

	@	CHARTWELL RX	25MG	A072879	002	Jun 28, 1991	Jun	CMS1
	@		50MG	A072879	003	Jun 28, 1991	Jun	CMS1
	@		100MG	A072879	004	Jun 28, 1991	Jun	CMS1

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

AB		CHARTWELL RX	400MG/5ML	A065319	002	Jun 18, 2007	May	CAHN
	@	DAVA PHARMS INC	125MG/5ML	A062927	001	Nov 25, 1988	Mar	DISC
	@		250MG/5ML	A062927	002	Nov 25, 1988	Mar	DISC
	@	ENDO OPERATIONS	125MG/5ML	A062927	001	Nov 25, 1988	May	CAHN
	@		250MG/5ML	A062927	002	Nov 25, 1988	May	CAHN
AB	+	US ANTIBIOTICS	400MG/5ML	N050760	002	Apr 15, 1999	Apr	CMFD

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL

OMECLAMOX-PAK

+	@	CUMBERLAND	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Sep	CTNA
---	---	------------	--	---------	-----	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		CIPLA	250MG/5ML;EQ 62.5MG BASE/5ML	A065431	001	Nov 25, 2008	Jul	CAHN
AB			600MG/5ML;EQ 42.9MG BASE/5ML	A065420	001	Dec 02, 2013	Jul	CAHN

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	AUROBINDO PHARMA LTD	500MG;EQ 125MG BASE	A091569	002	Jan 20, 2012	Oct	CHRS
>A>	AB	!	500MG;EQ 125MG BASE	A091569	002	Jan 20, 2012	Oct	CHRS
>D>	AB	!	SANDOZ INC	A065117	001	Nov 27, 2002	Oct	DISC
>A>		@	500MG;EQ 125MG BASE	A065117	001	Nov 27, 2002	Oct	DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	@	CHARTWELL RX	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002	Jul	CAHN
	@		400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002	Jul	CAHN

<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE</u>									
CAPSULE, EXTENDED RELEASE;ORAL									
		ADDERALL XR 10							
AB1	+	TAKEDA PHARMS USA	2.5MG;2.5MG;2.5MG;2.5MG	N021303	001	Oct 11, 2001	Jan	CTEC	
		ADDERALL XR 15							
AB1	+	TAKEDA PHARMS USA	3.75MG;3.75MG;3.75MG;3.75MG	N021303	006	May 22, 2002	Jan	CTEC	
		ADDERALL XR 20							
AB1	+	TAKEDA PHARMS USA	5MG;5MG;5MG;5MG	N021303	002	Oct 11, 2001	Jan	CTEC	
		ADDERALL XR 25							
AB1	+	TAKEDA PHARMS USA	6.25MG;6.25MG;6.25MG;6.25MG	N021303	004	May 22, 2002	Jan	CTEC	
		ADDERALL XR 30							
AB1	+!	TAKEDA PHARMS USA	7.5MG;7.5MG;7.5MG;7.5MG	N021303	003	Oct 11, 2001	Jan	CTEC	
		ADDERALL XR 5							
AB1	+	TAKEDA PHARMS USA	1.25MG;1.25MG;1.25MG;1.25MG	N021303	005	May 22, 2002	Jan	CTEC	
		DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
AB1		ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302	001	Jun 22, 2012	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A077302	002	Jun 22, 2012	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A077302	003	Jun 22, 2012	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A077302	004	Jun 22, 2012	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A077302	005	Jun 22, 2012	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A077302	006	Jun 22, 2012	Jan	CTEC	
AB1		ANI PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan	CTEC	
AB1		ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A214959	001	Sep 29, 2021	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A214959	002	Sep 29, 2021	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A214959	003	Sep 29, 2021	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A214959	004	Sep 29, 2021	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A214959	005	Sep 29, 2021	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A214959	006	Sep 29, 2021	Jan	CTEC	
AB1		ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A212037	001	Dec 11, 2019	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A212037	002	Dec 11, 2019	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A212037	003	Dec 11, 2019	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A212037	004	Dec 11, 2019	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A212037	005	Dec 11, 2019	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A212037	006	Dec 11, 2019	Jan	CTEC	
AB1		@ ENDO OPERATIONS	1.25MG;1.25MG;1.25MG;1.25MG	A206159	001	May 31, 2019	May	CAHN	
		@	2.5MG;2.5MG;2.5MG;2.5MG	A206159	002	May 31, 2019	May	CAHN	
		@	3.75MG;3.75MG;3.75MG;3.75MG	A206159	003	May 31, 2019	May	CAHN	
		@	5MG;5MG;5MG;5MG	A206159	004	May 31, 2019	May	CAHN	
		@	6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May 31, 2019	May	CAHN	
		@	7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May 31, 2019	May	CAHN	
AB1		GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A217027	006	Jan 23, 2023	Jan	CTEC	
AB1		IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Jan	CTEC	
AB1		LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Jan	CTEC	
AB1		RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651	001	May 17, 2019	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A210651	002	May 17, 2019	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A210651	003	May 17, 2019	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A210651	004	May 17, 2019	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A210651	005	May 17, 2019	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A210651	006	May 17, 2019	Jan	CTEC	
AB1		SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019	Jan	CTEC	
AB2			3.125MG;3.125MG;3.125MG;3.125MG	A211546	001	Aug 31, 2023	Jan	CTEC	

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019	Jan	CTEC
AB1		5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019	Jan	CTEC
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A211546	002	Aug 31, 2023	Jan	CTEC
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019	Jan	CTEC
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019	Jan	CTEC
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A211546	003	Aug 31, 2023	Jan	CTEC
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A211546	004	Aug 31, 2023	Jan	CTEC
AB2	SUN PHARM INDS INC	3.125MG;3.125MG;3.125MG;3.125MG	A215997	001	Sep 27, 2023	Jan	CTEC
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A215997	002	Sep 27, 2023	Jan	CTEC
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A215997	003	Sep 27, 2023	Jan	CTEC
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A215997	004	Sep 27, 2023	Jan	CTEC
	@ SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019	Jul	DISC
AB1		1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019	Jan	CTEC
	@	2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	Jul	DISC
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	Jan	CTEC
	@	3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	Jul	DISC
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	Jan	CTEC
	@	5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	Jul	DISC
AB1		5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	Jan	CTEC
	@	6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	Jul	DISC
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	Jan	CTEC
	@	7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Jul	DISC
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Jan	CTEC
AB2	TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Jan	CTEC
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Jan	CTEC
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Jan	CTEC
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Jan	CTEC
	MYDAYIS						
AB2	+ TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017	Jan	CTEC
AB2	+	6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017	Jan	CTEC
AB2	+	9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017	Jan	CTEC
AB2	+!	12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017	Jan	CTEC

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
AB	ORYZA	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Sep	CAHN
AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Sep	CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Sep	CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Sep	CAHN
AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Sep	CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Sep	CAHN

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE							
AA	SANALUZ	5MG	A212582	001	Feb 04, 2020	Sep	CAHN
AA		10MG	A212582	002	Feb 04, 2020	Sep	CAHN
AA	SENORES PHARMS	5MG	A212901	001	May 22, 2020	Feb	CAHN
AA		10MG	A212901	002	May 22, 2020	Feb	CAHN
	@ SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Mar	DISC
	@	10MG	A214574	002	Jan 27, 2021	Mar	DISC
	EVEKEO						
AA	AZURITY	5MG	A200166	001	Aug 09, 2012	Mar	CAHN
AA	!	10MG	A200166	002	Aug 09, 2012	Mar	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT							
+	@ AZURITY	5MG	N209905	001	Jan 30, 2019	Apr	DISC
+	@	10MG	N209905	002	Jan 30, 2019	Apr	DISC
+	@	15MG	N209905	003	Jan 30, 2019	Apr	DISC
+	@	20MG	N209905	004	Jan 30, 2019	Apr	DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM							
	@ MEDIMETRIKS PHARMS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Sep	CAHN
	@	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Sep	CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATEFOR SUSPENSION;ORAL
AMPICILLIN TRIHYDRATE

@ ENDO OPERATIONS	EQ 125MG BASE/5ML	A 062982	001	Feb 10, 1989	May	CAHN
@	EQ 250MG BASE/5ML	A 062982	002	Feb 10, 1989	May	CAHN

APIXABANTABLET;ORAL
APIXABAN

@ APOTEX	2.5MG	A 210091	001	Feb 16, 2024	May	DISC
AB	2.5MG	A 210091	001	Feb 16, 2024	Feb	NEWA
@	5MG	A 210091	002	Feb 16, 2024	May	DISC
AB	5MG	A 210091	002	Feb 16, 2024	Feb	NEWA

APOMORPHINE HYDROCHLORIDEINJECTABLE;SUBCUTANEOUS
APOMORPHINE HYDROCHLORIDE

AP	TRUPHARMA	30MG/3ML (10MG/ML)	A 212025	001	Feb 23, 2022	Sep	CAHN
----	-----------	--------------------	----------	-----	--------------	-----	------

APREMILASTTABLET;ORAL
APREMILAST

AB	MANKIND PHARMA	10MG	A 211734	001	Feb 07, 2024	Jan	NEWA
AB		20MG	A 211734	002	Feb 07, 2024	Jan	NEWA
AB		30MG	A 211734	003	Feb 07, 2024	Jan	NEWA

APROCITENTANTABLET;ORAL
TRYVIO

+!	IDORSIA	12.5MG	N 217686	001	Mar 19, 2024	Mar	NEWA
----	---------	--------	----------	-----	--------------	-----	------

ARFORMOTEROL TARTRATESOLUTION;INHALATION
ARFORMOTEROL TARTRATE

AN	AIPING PHARM INC	EQ 0.015MG BASE/2ML	A 214901	001	Apr 02, 2024	Aug	CAHN
>A>	BE PHARMS	EQ 0.015MG BASE/2ML	A 213762	001	Jun 22, 2021	Oct	CAHN
AN	CF PHARMTECH	EQ 0.015MG BASE/2ML	A 216303	001	May 17, 2024	May	NEWA
AN	DR REDDYS	EQ 0.015MG BASE/2ML	A 215032	001	Jun 03, 2024	May	NEWA
AN	PHARMAMAX	EQ 0.015MG BASE/2ML	A 214901	001	Apr 02, 2024	Mar	NEWA
>D>	SLATE RUN PHARMA	EQ 0.015MG BASE/2ML	A 213762	001	Jun 22, 2021	Oct	CAHN
AN	WILSHIRE PHARMS INC	EQ 0.015MG BASE/2ML	A 216815	001	Nov 25, 2022	Jul	CAHN

ARIMOCLOMOL CITRATECAPSULE;ORAL
MIPLYFFA

+	ZEVRA DENMARK	EQ 47MG BASE	N 214927	001	Sep 20, 2024	Sep	NEWA
+		EQ 62MG BASE	N 214927	002	Sep 20, 2024	Sep	NEWA
+		EQ 93MG BASE	N 214927	003	Sep 20, 2024	Sep	NEWA
+!		EQ 124MG BASE	N 214927	004	Sep 20, 2024	Sep	NEWA

ARIPIPIRAZOLEFILM;ORAL
OPIPZA

+	XIAMEN LP PHARM CO	2MG	N 216655	001	Jul 22, 2024	Jul	NEWA
+		5MG	N 216655	002	Jul 22, 2024	Jul	NEWA
+!		10MG	N 216655	003	Jul 22, 2024	Jul	NEWA

TABLET;ORAL
ARIPIPIRAZOLE

@ BRECKENRIDGE	2MG	A 091279	001	Jan 09, 2017	Aug	DISC	
@	5MG	A 091279	002	Jan 09, 2017	Aug	DISC	
@	10MG	A 091279	003	Jan 09, 2017	Aug	DISC	
@	15MG	A 091279	004	Jan 09, 2017	Aug	DISC	
@	20MG	A 091279	005	Jan 09, 2017	Aug	DISC	
@	30MG	A 091279	006	Jan 09, 2017	Aug	DISC	
AB	LUPIN	2MG	A 205589	001	Mar 18, 2024	Mar	NEWA
AB		5MG	A 205589	002	Mar 18, 2024	Mar	NEWA
AB		10MG	A 205589	003	Mar 18, 2024	Mar	NEWA
AB		15MG	A 205589	004	Mar 18, 2024	Mar	NEWA
AB		20MG	A 205589	005	Mar 18, 2024	Mar	NEWA
AB		30MG	A 205589	006	Mar 18, 2024	Mar	NEWA

ARIPIPRAZOLE LAUROXILSUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
ARISTADA INITIO KIT

+ ALKERMES INC 675MG/2.4ML (281.25MG/ML) N209830 001 Jun 29, 2018 Jan CPOT

ASCIMINIB HYDROCHLORIDETABLET; ORAL
SCEMBLIX

+ NOVARTIS EQ 100MG BASE N215358 003 Apr 18, 2024 Apr NEWA

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID
AA TARO 4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM A207498 001 Jun 28, 2024 Jun NEWAASPIRIN; BUTALBITAL; CAFFEINECAPSULE; ORAL
LANORINAL

AA ! SANDOZ 325MG; 50MG; 40MG A086996 002 Oct 11, 1985 Jan CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN
@ GENUS

325MG; 200MG

A040116 001 Apr 25, 1996 Aug CAHN

ASPIRIN; DIPYRIDAMOLECAPSULE, EXTENDED RELEASE; ORAL
ASPIRIN AND DIPYRIDAMOLE

AB ENDO OPERATIONS 25MG; 200MG A207944 001 Jan 18, 2017 Apr CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDETABLET; ORAL
PERCODAN

AA +! ENDO OPERATIONS 325MG; 4.8355MG N007337 007 Aug 05, 2005 May CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

PERCODAN

@ ENDO OPERATIONS 325MG; 4.5MG; 0.38MG

N007337 006 May CAHN

PERCODAN-DEMI

@ ENDO OPERATIONS 325MG; 2.25MG; 0.19MG

N007337 005 May CAHN

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

@ AMNEAL EQ 150MG BASE

A209717 002 Jun 01, 2020 Sep DISC

@ EQ 200MG BASE

A209717 003 Jun 01, 2020 Sep DISC

@ EQ 300MG BASE

A209717 004 Jun 01, 2020 Sep DISC

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

AB APOTEX EQ 10MG BASE A078983 001 May 30, 2017 Mar CPOT

AB EQ 18MG BASE A078983 002 May 30, 2017 Mar CPOT

AB EQ 25MG BASE A078983 003 May 30, 2017 Mar CPOT

AB EQ 40MG BASE A078983 004 May 30, 2017 Mar CPOT

AB EQ 60MG BASE A078983 005 May 30, 2017 Mar CPOT

AB EQ 80MG BASE A078983 006 May 30, 2017 Mar CPOT

AB EQ 100MG BASE A078983 007 May 30, 2017 Mar CPOT

AB AUROBINDO PHARMA EQ 10MG BASE A079016 001 May 30, 2017 Mar CPOT

AB EQ 18MG BASE A079016 002 May 30, 2017 Mar CPOT

AB EQ 25MG BASE A079016 003 May 30, 2017 Mar CPOT

AB EQ 40MG BASE A079016 004 May 30, 2017 Mar CPOT

AB EQ 60MG BASE A079016 005 May 30, 2017 Mar CPOT

AB EQ 80MG BASE A079016 006 May 30, 2017 Mar CPOT

AB EQ 100MG BASE A079016 007 May 30, 2017 Mar CPOT

AB DR REDDYS EQ 10MG BASE A090609 001 Feb 23, 2018 Mar CPOT

AB EQ 18MG BASE A090609 002 Feb 23, 2018 Mar CPOT

AB EQ 25MG BASE A090609 003 Feb 23, 2018 Mar CPOT

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		EQ	40MG	BASE	A090609	004	Feb 23, 2018	Mar	CPOT
AB		EQ	60MG	BASE	A090609	005	Feb 23, 2018	Mar	CPOT
AB		EQ	80MG	BASE	A090609	006	Feb 23, 2018	Mar	CPOT
AB		EQ	100MG	BASE	A090609	007	Feb 23, 2018	Mar	CPOT
AB	GLENMARK PHARMS LTD	EQ	10MG	BASE	A079019	001	May 30, 2017	Mar	CPOT
AB		EQ	18MG	BASE	A079019	002	May 30, 2017	Mar	CPOT
AB		EQ	25MG	BASE	A079019	003	May 30, 2017	Mar	CPOT
AB		EQ	40MG	BASE	A079019	004	May 30, 2017	Mar	CPOT
AB		EQ	60MG	BASE	A079019	005	May 30, 2017	Mar	CPOT
AB		EQ	80MG	BASE	A079019	006	May 30, 2017	Mar	CPOT
AB		EQ	100MG	BASE	A079019	007	May 30, 2017	Mar	CPOT
AB	HETERO LABS LTD V	EQ	10MG	BASE	A202682	001	Mar 11, 2021	Mar	CPOT
AB		EQ	18MG	BASE	A202682	002	Mar 11, 2021	Mar	CPOT
AB		EQ	25MG	BASE	A202682	003	Mar 11, 2021	Mar	CPOT
AB		EQ	40MG	BASE	A202682	004	Mar 11, 2021	Mar	CPOT
AB		EQ	60MG	BASE	A202682	005	Mar 11, 2021	Mar	CPOT
AB		EQ	80MG	BASE	A202682	006	Mar 11, 2021	Mar	CPOT
AB		EQ	100MG	BASE	A202682	007	Mar 11, 2021	Mar	CPOT
AB	STRIDES PHARMA	EQ	10MG	BASE	A079021	001	Feb 18, 2021	Aug	CMFD
AB	@	EQ	10MG	BASE	A079021	001	Feb 18, 2021	Mar	CPOT
AB		EQ	18MG	BASE	A079021	002	Feb 18, 2021	Aug	CMFD
AB	@	EQ	18MG	BASE	A079021	002	Feb 18, 2021	Mar	CPOT
AB		EQ	25MG	BASE	A079021	003	Feb 18, 2021	Aug	CMFD
AB	@	EQ	25MG	BASE	A079021	003	Feb 18, 2021	Mar	CPOT
AB		EQ	40MG	BASE	A079021	004	Feb 18, 2021	Aug	CMFD
AB	@	EQ	40MG	BASE	A079021	004	Feb 18, 2021	Mar	CPOT
AB		EQ	60MG	BASE	A079021	005	Feb 18, 2021	Aug	CMFD
AB	@	EQ	60MG	BASE	A079021	005	Feb 18, 2021	Mar	CPOT
AB		EQ	80MG	BASE	A079021	006	Feb 18, 2021	Aug	CMFD
AB	@	EQ	80MG	BASE	A079021	006	Feb 18, 2021	Mar	CPOT
AB		EQ	100MG	BASE	A079021	007	Feb 18, 2021	Aug	CMFD
AB	@	EQ	100MG	BASE	A079021	007	Feb 18, 2021	Mar	CPOT
AB	TEVA PHARMS USA	EQ	10MG	BASE	A079022	001	May 30, 2017	Mar	CPOT
AB		EQ	18MG	BASE	A079022	002	May 30, 2017	Mar	CPOT
AB		EQ	25MG	BASE	A079022	003	May 30, 2017	Mar	CPOT
AB		EQ	40MG	BASE	A079022	004	May 30, 2017	Mar	CPOT
AB		EQ	60MG	BASE	A079022	005	May 30, 2017	Mar	CPOT
AB		EQ	80MG	BASE	A079022	006	May 30, 2017	Mar	CPOT
AB		EQ	100MG	BASE	A079022	007	May 30, 2017	Mar	CPOT
AB	ZYDUS PHARMS USA INC	EQ	10MG	BASE	A079017	007	Apr 05, 2023	Mar	CPOT
AB		EQ	18MG	BASE	A079017	001	Sep 16, 2010	Mar	CPOT
AB		18MG			A079017	001	Sep 16, 2010	Jan	CMS1
AB		EQ	25MG	BASE	A079017	002	Sep 16, 2010	Mar	CPOT
AB		25MG			A079017	002	Sep 16, 2010	Jan	CMS1
AB		EQ	40MG	BASE	A079017	003	Sep 16, 2010	Mar	CPOT
AB		40MG			A079017	003	Sep 16, 2010	Jan	CMS1
AB		EQ	60MG	BASE	A079017	004	Sep 16, 2010	Mar	CPOT
AB		60MG			A079017	004	Sep 16, 2010	Jan	CMS1
AB		EQ	80MG	BASE	A079017	005	Sep 16, 2010	Mar	CPOT
AB		80MG			A079017	005	Sep 16, 2010	Jan	CMS1
AB		EQ	100MG	BASE	A079017	006	Sep 16, 2010	Mar	CPOT
AB		100MG			A079017	006	Sep 16, 2010	Jan	CMS1
	STRATTERA								
	@ LILLY	EQ	5MG	BASE	N021411	001	Nov 26, 2002	Mar	CPOT
AB	+	EQ	10MG	BASE	N021411	002	Nov 26, 2002	Mar	CPOT
AB	+	EQ	18MG	BASE	N021411	003	Nov 26, 2002	Mar	CPOT
AB	+	EQ	25MG	BASE	N021411	004	Nov 26, 2002	Mar	CPOT
AB	+	EQ	40MG	BASE	N021411	005	Nov 26, 2002	Mar	CPOT
AB	+	EQ	60MG	BASE	N021411	006	Nov 26, 2002	Mar	CPOT
AB	+	EQ	80MG	BASE	N021411	007	Feb 14, 2005	Mar	CPOT
AB	+	EQ	100MG	BASE	N021411	008	Feb 14, 2005	Mar	CPOT

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	ANBISON LAB	EQ	10MG	BASE	A211886	001	Jan 25, 2024	Jan	NEWA
AB		EQ	20MG	BASE	A211886	002	Jan 25, 2024	Jan	NEWA
AB		EQ	40MG	BASE	A211886	003	Jan 25, 2024	Jan	NEWA
AB		EQ	80MG	BASE	A211886	004	Jan 25, 2024	Jan	NEWA
AB	AUROBINDO PHARMA LTD	EQ	10MG	BASE	A217118	001	Feb 13, 2024	Feb	NEWA
AB		EQ	20MG	BASE	A217118	002	Feb 13, 2024	Feb	NEWA
AB		EQ	40MG	BASE	A217118	003	Feb 13, 2024	Feb	NEWA

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		EQ 80MG BASE	A217118	004	Feb 13, 2024	Feb	NEWA
	@ CADILA PHARMS LTD	EQ 10MG BASE	A212103	001	Oct 16, 2023	Apr	DISC
	@	EQ 20MG BASE	A212103	002	Oct 16, 2023	Apr	DISC
	@	EQ 40MG BASE	A212103	003	Oct 16, 2023	Apr	DISC
	@	EQ 80MG BASE	A212103	004	Oct 16, 2023	Apr	DISC
	@ INVAGEN PHARMS	EQ 10MG BASE	A204846	001	Jan 09, 2017	Mar	DISC
	@	EQ 20MG BASE	A204846	002	Jan 09, 2017	Mar	DISC
	@	EQ 40MG BASE	A204846	003	Jan 09, 2017	Mar	DISC
	@	EQ 80MG BASE	A204846	004	Jan 09, 2017	Mar	DISC
AB	LAURUS	EQ 10MG BASE	A214513	001	Jan 22, 2024	Jan	NEWA
AB		EQ 20MG BASE	A214513	002	Jan 22, 2024	Jan	NEWA
AB		EQ 40MG BASE	A214513	003	Jan 22, 2024	Jan	NEWA
AB		EQ 80MG BASE	A214513	004	Jan 22, 2024	Jan	NEWA
	@ LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Aug	DISC
BX		EQ 10MG BASE	A204991	001	Mar 06, 2019	Jun	CTEC
	@	EQ 20MG BASE	A204991	002	Mar 06, 2019	Aug	DISC
BX		EQ 20MG BASE	A204991	002	Mar 06, 2019	Jun	CTEC
	@	EQ 40MG BASE	A204991	003	Mar 06, 2019	Aug	DISC
BX		EQ 40MG BASE	A204991	003	Mar 06, 2019	Jun	CTEC
	@	EQ 80MG BASE	A204991	004	Mar 06, 2019	Aug	DISC
BX		EQ 80MG BASE	A204991	004	Mar 06, 2019	Jun	CTEC
AB	MACLEODS PHARMS LTD	EQ 10MG BASE	A208480	001	Jun 03, 2024	May	NEWA
AB		EQ 20MG BASE	A208480	002	Jun 03, 2024	May	NEWA
AB		EQ 40MG BASE	A208480	003	Jun 03, 2024	May	NEWA
AB		EQ 80MG BASE	A208480	004	Jun 03, 2024	May	NEWA
AB	SHANDONG XINHUA	EQ 10MG BASE	A211886	001	Jan 25, 2024	Mar	CAHN
AB		EQ 20MG BASE	A211886	002	Jan 25, 2024	Mar	CAHN
AB		EQ 40MG BASE	A211886	003	Jan 25, 2024	Mar	CAHN
AB		EQ 80MG BASE	A211886	004	Jan 25, 2024	Mar	CAHN
BX	UMEDICA	EQ 10MG BASE	A213853	001	Aug 19, 2020	Jun	CTEC
BX		EQ 20MG BASE	A213853	002	Aug 19, 2020	Jun	CTEC
BX		EQ 40MG BASE	A213853	003	Aug 19, 2020	Jun	CTEC
BX		EQ 80MG BASE	A213853	004	Aug 19, 2020	Jun	CTEC

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

@ NORVIUM BIOSCIENCE	10MG/ML	A206096	001	Jun 22, 2017	Jun	CAHN
ATRACURIUM BESYLATE PRESERVATIVE FREE						
@ NORVIUM BIOSCIENCE	10MG/ML	A206001	001	Apr 07, 2017	Jun	CAHN

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE

AP	SOMERSET THERAPS LLC	0.4MG/ML (0.4MG/ML)	A215969	001	Jul 03, 2024	Jun	NEWA
AP		1MG/ML (1MG/ML)	A215969	002	Jul 03, 2024	Jun	NEWA
SOLUTION/DROPS; OPHTHALMIC							
ATROPINE SULFATE							
AT1	! AMNEAL	1%	A214752	001	Jul 14, 2022	Apr	CTEC
AT1	APOTEX	1%	A215624	001	Nov 26, 2021	Apr	CTEC
AT1	MANKIND PHARMA	1%	A218148	001	Jan 08, 2024	Apr	CTEC
AT1	+ RISING	1%	N206289	001	Jul 18, 2014	Apr	CTEC
AT2	SOMERSET	1%	A217791	001	Apr 29, 2024	Apr	NFTG
AT1	SOMERSET THERAPS LLC	1%	A215618	001	Jul 01, 2024	Jun	NEWA
ISOPTO ATROPINE							
AT2	+! ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Apr	CFTG

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ ANI PHARMS	0.025MG;2.5MG	A086727	001			Mar	DISC
@ MYLAN	0.025MG;2.5MG	A085762	001			Apr	DISC

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

@ NORVIUM BIOSCIENCE	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991	Jul	CAHN
+ @	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Jul	CAHN

AVACINCAPTAD PEGOL SODIUMSOLUTION; INTRAVITREAL
IZERVAY

+!	ASTELLAS	EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)	N217225	001	Aug 04, 2023	Jan CAHN
----	----------	--	---------	-----	--------------	----------

AVANAFILTABLET; ORAL
AVANAFIL

AB	HETERO LABS LTD V	50MG	A209266	001	Jun 14, 2024	Jun NFTG
AB		100MG	A209266	002	Jun 14, 2024	Jun NFTG
AB		200MG	A209266	003	Jun 14, 2024	Jun NFTG
STENDRA						
AB	+ METUCHEN PHARMS	50MG	N202276	001	Apr 27, 2012	Jun CFTG
AB	+	100MG	N202276	002	Apr 27, 2012	Jun CFTG
AB	+!	200MG	N202276	003	Apr 27, 2012	Jun CFTG

AVIBACTAM SODIUM; CEFTAZIDIMEPOWDER; INTRAVENOUS
AVYCAZ

+!	ABBVIE	EQ 0.5GM BASE; 2GM/VIAL	N206494	001	Feb 25, 2015	Sep CAHN
----	--------	-------------------------	---------	-----	--------------	----------

AZACITIDINEPOWDER; INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

>A>	AP	HETERO LABS LTD VI	100MG/VIAL	A215765	001	Oct 15, 2024	Oct NEWA
	AP	MSN LABS PVT LTD	100MG/VIAL	A212580	001	May 16, 2024	May NEWA
>D>	@	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Oct CAHN
>A>	@	NORVIUM BIOSCIENCE	100MG/VIAL	A204949	001	Apr 28, 2016	Oct CAHN

AZELAIC ACIDGEL; TOPICAL
AZELAIC ACID

AB	TARO	15%	A210549	001	Aug 23, 2019	Apr CAHN
----	------	-----	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
OPTIVAR

+	@	NORVIUM BIOSCIENCE	0.05%	N021127	001	May 22, 2000	Jul CAHN
---	---	--------------------	-------	---------	-----	--------------	----------

SPRAY, METERED; NASAL
ASTELIN

+	@	NORVIUM BIOSCIENCE	0.137MG/SPRAY	N020114	001	Nov 01, 1996	Jul CAHN
	@	HIKMA	0.137MG/SPRAY	A091444	001	Oct 24, 2014	Mar DISC

AZITHROMYCININJECTABLE; INJECTION
AZITHROMYCIN

@	NORVIUM BIOSCIENCE	EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009	Jun CAHN
@	SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923	001	Apr 02, 2013	May DISC

TABLET; ORAL
AZITHROMYCIN

@	PHARMOBEDIANT	EQ 500MG BASE	A211318	001	Mar 17, 2021	Sep CAHN
@	YUNG SHIN PHARM	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb DISC

BACLOFENINJECTABLE; INTRATHECAL
BACLOFEN

@	ACIC PHARMS	0.5MG/ML	A216309	001	Aug 10, 2023	Jan DISC
@		2MG/ML	A216309	002	Aug 10, 2023	Jan DISC
@	HERITAGE	0.5MG/ML	A216309	001	Aug 10, 2023	Sep CAHN
@		2MG/ML	A216309	002	Aug 10, 2023	Sep CAHN

TABLET; ORAL
BACLOFEN

AB	ANDAS 5 HOLDING	5MG	A212378	003	Apr 30, 2021	Aug CAHN
AB		10MG	A212378	001	Oct 09, 2020	Aug CAHN
AB		20MG	A212378	002	Oct 09, 2020	Aug CAHN
AB	ENDO OPERATIONS	10MG	A077068	002	Aug 30, 2005	Apr CAHN
AB		20MG	A077068	001	Aug 30, 2005	Apr CAHN
BX	EYWA	5MG	A211555	003	Nov 30, 2021	Jul CAHN
BX		10MG	A211555	001	Feb 01, 2019	Jul CAHN

TABLET;ORAL

BACLOFEN

BX		20MG	A211555	002	Feb 01, 2019	Jul	CAHN	
BX	EYWA PHARMA	5MG	A211555	003	Nov 30, 2021	Jun	CTEC	
BX		10MG	A211555	001	Feb 01, 2019	Jun	CTEC	
BX		20MG	A211555	002	Feb 01, 2019	Jun	CTEC	
>A>	AB	GRAVITI PHARMS	5MG	A217788	003	Oct 24, 2024	Oct	NEWA
		@ IMPAX	5MG	A077971	003	Jul 07, 2021	Mar	DISC
		@	10MG	A077971	001	Oct 26, 2007	Mar	DISC
		@	20MG	A077971	002	Oct 26, 2007	Mar	DISC
		@ NORVIUM BIOSCIENCE	20MG	A077121	002	Jul 29, 2005	Jul	CAHN
	AB	RUBICON	15MG	A209102	004	Feb 05, 2024	Feb	CTEC
			15MG	A209102	004	Feb 05, 2024	Jan	NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB	ZYDUS LIFESCIENCES	750MG	A217592	001	Jun 08, 2023	Mar	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

BARICITINIB

TABLET;ORAL

BARICITINIB

		@ AUROBINDO PHARMA LTD	1MG	A217542	001	Jul 22, 2024	Aug	DISC
AB			1MG	A217542	001	Jul 22, 2024	Jul	NFTG
		@	2MG	A217542	002	Jul 22, 2024	Aug	DISC
AB			2MG	A217542	002	Jul 22, 2024	Jul	NFTG
		OLUMIANT						
	+	ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019	Aug	CTEC
AB	+		1MG	N207924	002	Oct 08, 2019	Jul	CFTG
	+		2MG	N207924	001	May 31, 2018	Aug	CTEC
AB	+		2MG	N207924	001	May 31, 2018	Jul	CFTG

BENDAMUSTINE HYDROCHLORIDE

>A>		POWDER;INTRAVENOUS						
>A>		BENDAMUSTINE HYDROCHLORIDE						
>A>	AP	ACCORD HLTHCARE	25MG/VIAL	A205574	001	Dec 07, 2022	Oct	CDFR
>A>	AP		100MG/VIAL	A205574	002	Dec 07, 2022	Oct	CDFR
>A>	AP	APOTEX	25MG/VIAL	A204230	001	Jun 05, 2023	Oct	CDFR
>A>	AP		100MG/VIAL	A204230	002	Jun 05, 2023	Oct	CDFR
>A>	AP	BRECKENRIDGE	25MG/VIAL	A205447	001	Feb 14, 2023	Oct	CDFR
>A>	AP		100MG/VIAL	A205447	002	Feb 14, 2023	Oct	CDFR
>A>	AP	DR REDDYS	25MG/VIAL	A205376	001	Dec 07, 2022	Oct	CDFR
>A>	AP		100MG/VIAL	A205376	002	Dec 07, 2022	Oct	CDFR
>A>	AP	EUGIA PHARMA	25MG/VIAL	A214739	001	Jun 05, 2023	Oct	CDFR
>A>	AP		100MG/VIAL	A214739	002	Jun 05, 2023	Oct	CDFR
>A>	AP	MEITHEAL	25MG/VIAL	A211001	001	Jun 05, 2023	Oct	CDFR
>A>	AP		100MG/VIAL	A211001	002	Jun 05, 2023	Oct	CDFR
>A>		@ NANG KUANG PHARM CO	25MG/VIAL	A206554	001	Jun 07, 2023	Oct	CDFR
>A>		@	100MG/VIAL	A206554	002	Jun 07, 2023	Oct	CDFR
>A>		@ NORVIUM BIOSCIENCE	25MG/VIAL	A204104	001	Apr 28, 2023	Oct	CDFR
>A>		@	100MG/VIAL	A204104	002	Apr 28, 2023	Oct	CDFR
>A>		TREANDA						
>A>	AP	+! CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Oct	CDFR
>A>	AP	+!	100MG/VIAL	N022249	001	Mar 20, 2008	Oct	CDFR
>D>		POWDER;IV (INFUSION)						
>D>		BENDAMUSTINE HYDROCHLORIDE						
>D>	AP	ACCORD HLTHCARE	25MG/VIAL	A205574	001	Dec 07, 2022	Oct	CDFR
>D>	AP		100MG/VIAL	A205574	002	Dec 07, 2022	Oct	CDFR
>D>	AP	APOTEX	25MG/VIAL	A204230	001	Jun 05, 2023	Oct	CDFR
>D>	AP		100MG/VIAL	A204230	002	Jun 05, 2023	Oct	CDFR
>D>	AP	BRECKENRIDGE	25MG/VIAL	A205447	001	Feb 14, 2023	Oct	CDFR
>D>	AP		100MG/VIAL	A205447	002	Feb 14, 2023	Oct	CDFR
>D>	AP	DR REDDYS	25MG/VIAL	A205376	001	Dec 07, 2022	Oct	CDFR
>D>	AP		100MG/VIAL	A205376	002	Dec 07, 2022	Oct	CDFR
>D>	AP	EUGIA PHARMA	25MG/VIAL	A214739	001	Jun 05, 2023	Oct	CDFR
>D>	AP		100MG/VIAL	A214739	002	Jun 05, 2023	Oct	CDFR
>D>	AP	MEITHEAL	25MG/VIAL	A211001	001	Jun 05, 2023	Oct	CDFR
>D>	AP		25MG/VIAL	A211001	001	Jun 05, 2023	Jun	CAHN
>D>	AP		100MG/VIAL	A211001	002	Jun 05, 2023	Oct	CDFR
>D>	AP		100MG/VIAL	A211001	002	Jun 05, 2023	Jun	CAHN
>D>		@ NANG KUANG PHARM CO	25MG/VIAL	A206554	001	Jun 07, 2023	Oct	CDFR
>D>		@	100MG/VIAL	A206554	002	Jun 07, 2023	Oct	CDFR
>D>		@ NORVIUM BIOSCIENCE	25MG/VIAL	A204104	001	Apr 28, 2023	Oct	CDFR

	POWDER;IV (INFUSION)						
	BENDAMUSTINE HYDROCHLORIDE						
	@	25MG/VIAL	A204104	001	Apr 28, 2023	Jun	CAHN
>D>	@	100MG/VIAL	A204104	002	Apr 28, 2023	Oct	CDFR
	@	100MG/VIAL	A204104	002	Apr 28, 2023	Jun	CAHN
>D>	TREANDA						
>D>	AP	+! CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Oct CDFR
>D>	AP	+!	100MG/VIAL	N022249	001	Mar 20, 2008	Oct CDFR
>A>	SOLUTION;INTRAVENOUS						
>A>	BENDEKA						
>A>	+	! EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015	Oct CDFR
>A>	TREANDA						
>A>	+	@ CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013	Oct CDFR
>A>	+	@	180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013	Oct CDFR
	VIVIMUSTA						
	+	! AZURITY	100MG/4ML (25MG/ML)	N212209	001	Dec 07, 2022	Jul CAHN
>D>	SOLUTION;IV (INFUSION)						
>D>	BENDEKA						
>D>	+	! EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015	Oct CDFR
>D>	TREANDA						
>D>	+	@ CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013	Oct CDFR
>D>	+	@	180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013	Oct CDFR

BENZGALANTAMINE GLUCONATE

TABLET, DELAYED RELEASE;ORAL
ZUNVEYL

	+	! ALPHA COGNITION	EQ 5MG BASE	N218549	001	Jul 26, 2024	Jul NEWA
	+		EQ 10MG BASE	N218549	002	Jul 26, 2024	Jul NEWA
	+		EQ 15MG BASE	N218549	003	Jul 26, 2024	Jul NEWA

BENZONATATE

CAPSULE;ORAL
BENZONATATE

>D>	AA	ACELLA	100MG	A091310	001	Jan 16, 2015	Oct DISC
>A>		@	100MG	A091310	001	Jan 16, 2015	Oct DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	PADAGIS ISRAEL	3.75%;EQ 1.2% BASE	A209610	001	Aug 20, 2024	Aug	NEWA
----	----------------	--------------------	---------	-----	--------------	-----	------

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL
ERYTHROMYCIN AND BENZOYL PEROXIDE

AB	RISING	5%;3%	A065385	001	Sep 18, 2015	Sep	CAHN
----	--------	-------	---------	-----	--------------	-----	------

BENZTROPINE MESYLATE

TABLET;ORAL
BENZTROPINE MESYLATE

AA	AIPING PHARM INC	0.5MG	A040103	001	Dec 12, 1996	Aug	CMFD
AA		1MG	A040103	002	Dec 12, 1996	Aug	CMFD
AA		2MG	A040103	003	Dec 12, 1996	Aug	CMFD
AA	ENDO OPERATIONS	0.5MG	A040715	001	Aug 27, 2007	Apr	CAHN
AA		1MG	A040715	002	Aug 27, 2007	Apr	CAHN
AA		2MG	A040715	003	Aug 27, 2007	Apr	CAHN
	@ INVAGEN PHARMS	0.5MG	A090294	001	Mar 29, 2010	Mar	DISC
	@	1MG	A090294	002	Mar 29, 2010	Mar	DISC
	@	2MG	A090294	003	Mar 29, 2010	Mar	DISC
AA	! NUVO PHARM	0.5MG	A204713	001	Apr 14, 2015	Jul	CAHN
AA	!	1MG	A204713	002	Apr 14, 2015	Jul	CAHN
AA	!	2MG	A204713	003	Apr 14, 2015	Jul	CAHN

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC
BEPOTASTINE BESILATE

AT	SOMERSET THERAPS LLC	1.5%	A217770	001	Aug 14, 2024	Aug	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

BERDAZIMER SODIUMGEL;TOPICAL
ZELSUVMI

+! LNHC EQ 10.3% BASE N217424 001 Jan 05, 2024 Jan NEWA

BETAMETHASONE DIPROPIONATELOTION, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATE

@ HIKMA EQ 0.05% BASE A208849 001 Oct 11, 2019 Mar DISC

OINTMENT, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATEAB AUROBINDO PHARMA LTD EQ 0.05% BASE A218289 001 Apr 10, 2024 Mar NEWA
@ PADAGIS US EQ 0.05% BASE A206118 001 Nov 09, 2017 Jan CAHNBETAMETHASONE DIPROPIONATE; CLOTRIMAZOLECREAM;TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB ! TARO EQ 0.05% BASE;1% A075673 001 May 29, 2001 Apr CAHN

BETAMETHASONE VALERATEAEROSOL, FOAM;TOPICAL
BETAMETHASONE VALERATE

AB ALEMBIC 0.12% A215832 001 Aug 22, 2024 Aug NEWA

LOTION;TOPICAL
BETAMETHASONE VALERATEAB KANCHAN HLTHCARE EQ 0.1% BASE A070052 001 Jul 31, 1985 Aug CAHN
AB SCIEGEN PHARMS INC EQ 0.1% BASE A070052 001 Jul 31, 1985 Sep CAHNBEXAROTENECAPSULE;ORAL
BEXAROTENE

AB ASCENT PHARMS INC 75MG A208628 001 Sep 06, 2024 Aug NEWA

BICALUTAMIDETABLET;ORAL
BICALUTAMIDEAB CHARTWELL RX 50MG A091011 001 Jun 10, 2015 Jan CAHN
@ RISING 50MG A079185 001 Jul 06, 2009 Feb CAHNBIMATOPROSTSOLUTION/DROPS;TOPICAL
BIMATOPROST

@ HIKMA 0.03% A203051 001 Oct 09, 2018 Mar DISC

BIRCH TRITERPENESGEL;TOPICAL
FILSUVEZ

+! CHIESI 10% N215064 001 Dec 18, 2023 Jan CAHN

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDECAPSULE;ORAL
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB NOVAST LABS 140MG;125MG;125MG A217511 001 Jul 03, 2023 Sep CAHN

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDETABLET, CHEWABLE, TABLET, CAPSULE;ORAL
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE>A> ! AILEX PHARMS LLC 262.4MG, N/A, N/A;N/A, 250MG, A202584 001 Nov 30, 2018 Oct CAHN
N/A;N/A, N/A, 500MG>D> ! NOSTRUM LABS INC 262.4MG, N/A, N/A;N/A, 250MG, A202584 001 Nov 30, 2018 Oct CAHN
N/A;N/A, N/A, 500MGBISOPROLOL FUMARATETABLET;ORAL
BISOPROLOL FUMARATEAB HARMAN FINOCHEM 5MG A217617 001 Jan 18, 2024 Jan NEWA
AB 10MG A217617 002 Jan 18, 2024 Jan NEWA
AB TRUPHARMA 5MG A075474 001 Oct 25, 2002 Sep CAHN
AB 10MG A075474 002 Oct 25, 2002 Sep CAHN

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

BIVALIRUDIN

@	HOSPIRA	250MG/VIAL	A090811	001	Jul 14, 2015	Aug	DISC
@		250MG/VIAL	A090816	001	Jul 14, 2015	May	DISC

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

@	TEVA PHARMS USA	EQ 15 UNITS BASE/VIAL	A065033	001	Jun 27, 2000	Jan	DISC
@		EQ 30 UNITS BASE/VIAL	A065033	002	Jun 27, 2000	Jan	DISC

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

AP	HETERO LABS LTD VI	3.5MG/VIAL	A212204	001	May 03, 2024	Apr	NEWA
	@ NORVIUM BIOSCIENCE	3.5MG/VIAL	A205160	001	Oct 31, 2022	Jun	CAHN
AP	RELIANCE LIFE SCI	3.5MG/VIAL	A211898	001	Oct 11, 2022	May	CAHN
	SOLUTION; INTRAVENOUS, SUBCUTANEOUS						
	BORTEZOMIB						
+!	SHILPA	3.5MG/1.4ML (2.5MG/ML)	N212782	001	Aug 26, 2024	Aug	NEWA

BOSENTAN

TABLET; ORAL

BOSENTAN

@	ENDO OPERATIONS	62.5MG	A205699	001	Apr 26, 2019	Apr	CAHN
@		125MG	A205699	002	Apr 26, 2019	Apr	CAHN

BREMELANOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

+!	COSETTE	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Apr	CAHN
----	---------	--	---------	-----	--------------	-----	------

BREXPIRAZOLE

TABLET; ORAL

BREXPIRAZOLE

@	ALKEM LABS LTD	0.25MG	A213782	001	Nov 28, 2023	Sep	DISC
@		0.5MG	A213782	002	Nov 28, 2023	Sep	DISC
@		1MG	A213782	003	Nov 28, 2023	Sep	DISC
@		2MG	A213782	004	Nov 28, 2023	Sep	DISC
@		3MG	A213782	005	Nov 28, 2023	Sep	DISC
@		4MG	A213782	006	Nov 28, 2023	Sep	DISC
@	ANDA REPOSITORY	0.25MG	A213758	001	Oct 25, 2023	Sep	CAHN
@		0.5MG	A213758	002	Oct 25, 2023	Sep	CAHN
@		1MG	A213758	003	Oct 25, 2023	Sep	CAHN
@		2MG	A213758	004	Oct 25, 2023	Sep	CAHN
@		3MG	A213758	005	Oct 25, 2023	Sep	CAHN
@		4MG	A213758	006	Oct 25, 2023	Sep	CAHN
@	CELLTRION	0.25MG	A213758	001	Oct 25, 2023	Sep	CAHN
@		0.5MG	A213758	002	Oct 25, 2023	Sep	CAHN
@		1MG	A213758	003	Oct 25, 2023	Sep	CAHN
@		2MG	A213758	004	Oct 25, 2023	Sep	CAHN
@		3MG	A213758	005	Oct 25, 2023	Sep	CAHN
@		4MG	A213758	006	Oct 25, 2023	Sep	CAHN
@	HETERO LABS LTD V	0.25MG	A213669	001	Nov 20, 2023	Sep	DISC
@		0.5MG	A213669	002	Nov 20, 2023	Sep	DISC
@		1MG	A213669	003	Nov 20, 2023	Sep	DISC
@		2MG	A213669	004	Nov 20, 2023	Sep	DISC
@		3MG	A213669	005	Nov 20, 2023	Sep	DISC
@		4MG	A213669	006	Nov 20, 2023	Sep	DISC
@	OPTIMUS	0.25MG	A213758	001	Oct 25, 2023	Sep	DISC
@		0.5MG	A213758	002	Oct 25, 2023	Sep	DISC
@		1MG	A213758	003	Oct 25, 2023	Sep	DISC
@		2MG	A213758	004	Oct 25, 2023	Sep	DISC
@		3MG	A213758	005	Oct 25, 2023	Sep	DISC
@		4MG	A213758	006	Oct 25, 2023	Sep	DISC
	REXULTI						
+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Sep	CTEC
+		0.5MG	N205422	002	Jul 10, 2015	Sep	CTEC
+		1MG	N205422	003	Jul 10, 2015	Sep	CTEC
+!		2MG	N205422	004	Jul 10, 2015	Sep	CTEC

TABLET;ORAL
REXULTI

+		3MG	N205422	005	Jul 10, 2015	Sep CTEC
+		4MG	N205422	006	Jul 10, 2015	Sep CTEC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC
BRIMONIDINE TARTRATE

AB	LUPIN LTD	0.1%	A213215	001	Aug 26, 2024	Aug NEWA
AB	SANDOZ	0.1%	A203172	001	Mar 04, 2024	Feb NEWA
AB	SOMERSET THERAPS LLC	0.1%	A216906	001	Aug 09, 2024	Aug NEWA
AT	UPSHER SMITH LABS	0.15%	A216772	001	Jun 12, 2024	May NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

AB	GLENMARK PHARMS LTD	0.2%;EQ 0.5% BASE	A214987	001	May 16, 2024	May NEWA
AB	SOMERSET	0.2%;EQ 0.5% BASE	A216114	001	Sep 10, 2024	Aug NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC
BROMFENAC SODIUM

AB	ALEMBIC	EQ 0.07% ACID	A214340	001	Jul 08, 2024	Jun NEWA
AB	AMNEAL	EQ 0.07% ACID	A210962	001	Jul 29, 2024	Jul NEWA
AB	APOTEX	EQ 0.07% ACID	A207334	001	Jul 08, 2024	Jun NEWA
AB	LUPIN LTD	EQ 0.075% ACID	A211239	001	Feb 02, 2024	Jan NFTG
AB	+! BROMSITE SUN PHARM	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Jan CFTG

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL
PARLODEL

>A>	AB	+ ESJAY PHARMA	EQ 5MG BASE	N017962	002	Mar 01, 1982	Oct CAHN
>D>	AB	+ SS PHARMA	EQ 5MG BASE	N017962	002	Mar 01, 1982	Oct CAHN

TABLET;ORAL
PARLODEL

>A>	AB	+ ESJAY PHARMA	EQ 2.5MG BASE	N017962	001		Oct CAHN
>D>	AB	+ SS PHARMA	EQ 2.5MG BASE	N017962	001		Oct CAHN

BUDESONIDE

AEROSOL, FOAM;RECTAL
BUDESONIDE

AB	! PADAGIS ISRAEL	2MG/ACTUATION	A215328	001	Apr 12, 2023	Jun CHRS
AB	+ UCERIS SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Jun CHRS

POWDER, METERED;INHALATION
PULMICORT FLEXHALER

+	CHEPLAPHARM	0.08MG/INH	N021949	001	Jul 12, 2006	Jun CAHN
+!		0.16MG/INH	N021949	002	Jul 12, 2006	Jun CAHN

SUSPENSION;INHALATION
BUDESONIDE

@	EUGIA PHARMA	0.5MG/2ML	A216667	001	Nov 29, 2023	May DISC
---	--------------	-----------	---------	-----	--------------	----------

SUSPENSION;ORAL
EOHILIA

+!	TAKEDA PHARMS USA	2MG/10ML	N213976	001	Feb 09, 2024	Feb NEWA
----	-------------------	----------	---------	-----	--------------	----------

BUMETANIDE

INJECTABLE;INJECTION
BUMETANIDE

@	HOSPIRA	0.25MG/ML	A074332	001	Oct 31, 1994	May DISC
AP	LUPIN LTD	0.25MG/ML	A217153	001	Sep 17, 2024	Sep NEWA
AP	QILU PHARM HAINAN	0.25MG/ML	A219116	001	Sep 19, 2024	Sep NEWA

TABLET;ORAL
BUMETANIDE

AB	APPCO	0.5MG	A212931	001	Sep 18, 2024	Sep NEWA
AB		1MG	A212931	002	Sep 18, 2024	Sep NEWA
AB		2MG	A212931	003	Sep 18, 2024	Sep NEWA
AB	RISING	0.5MG	A212019	001	Dec 12, 2019	Jun CTEC
AB		1MG	A212019	002	Dec 12, 2019	Jun CTEC
AB		2MG	A212019	003	Dec 12, 2019	Jun CTEC

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION
BUPIVACAINE LIPOSOME

AP	HENGRUI PHARMA	133MG/10ML (13.3MG/ML)	A214348	001	Jul 01, 2024	Jun	NFTG
AP		266MG/20ML (13.3MG/ML)	A214348	002	Jul 01, 2024	Jun	NFTG
EXPAREL							
AP	+! PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Jun	CFTG
AP	+!	266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011	Jun	CFTG
SOLUTION; INFILTRATION							
POSIMIR							
	+! INNOCOLL	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Aug	CDFR

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE

AP	ASPIRO	0.25%	A217821	001	Mar 27, 2024	Mar	NEWA
AP		0.5%	A217821	002	Mar 27, 2024	Mar	NEWA
AP		0.75%	A217821	003	Mar 27, 2024	Mar	NEWA
AP	MEITHEAL	0.25%	A216039	001	Jun 23, 2023	Jun	CAHN
AP		0.25%	A216040	001	Dec 27, 2023	Jun	CAHN
AP		0.5%	A216039	002	Jun 23, 2023	Jun	CAHN
AP		0.5%	A216040	002	Dec 27, 2023	Jun	CAHN
AP		0.75%	A216040	003	Dec 27, 2023	Jun	CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
VIVACAINE

!	SEPTODONT	0.5%; 0.0091MG/ML	A077250	001	Sep 27, 2006	Jan	CTNA
---	-----------	-------------------	---------	-----	--------------	-----	------

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL
BUPRENORPHINE

AB	DIFGEN PHARMS	5MCG/HR	A210272	001	Sep 23, 2021	Sep	CAHN
AB		7.5MCG/HR	A210272	002	Sep 23, 2021	Sep	CAHN
AB		10MCG/HR	A210272	003	Sep 23, 2021	Sep	CAHN
AB		15MCG/HR	A210272	004	Sep 23, 2021	Sep	CAHN
AB		20MCG/HR	A210272	005	Sep 23, 2021	Sep	CAHN

BUPRENORPHINE HYDROCHLORIDE

IMPLANT; IMPLANTATION
PROBUPHINE

+ @	REACK PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Apr	CAHN
-----	--------------	----------------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION
BUPRENORPHINE HYDROCHLORIDE

@	AM REGENT	EQ 0.3MG BASE/ML	A078331	001	Mar 27, 2007	Jan	DISC
---	-----------	------------------	---------	-----	--------------	-----	------

TABLET; SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE

@	NORVIUM BIOSCIENCE	EQ 2MG BASE	A201066	001	Mar 06, 2015	Jun	CAHN
@		EQ 8MG BASE	A201066	002	Mar 06, 2015	Jun	CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	DIFGEN PHARMS	EQ 8MG BASE; EQ 2MG BASE	A212756	001	Jun 02, 2022	Sep	CAHN
AB		EQ 12MG BASE; EQ 3MG BASE	A212756	002	Jun 02, 2022	Sep	CAHN

BUPROPION HYDROCHLORIDE

TABLET; ORAL
BUPROPION HYDROCHLORIDE

AB	AUROBINDO PHARMA USA	75MG	A075491	001	Apr 17, 2000	Apr	CMFD
AB		100MG	A075491	002	Apr 17, 2000	Apr	CMFD
@	INVAGEN PHARMS	75MG	A207389	001	Sep 18, 2017	Mar	DISC
@		100MG	A207389	002	Sep 18, 2017	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL
BUPROPION HYDROCHLORIDE

@	ANCHEN PHARMS	100MG	A091459	001	Jun 09, 2011	Feb	DISC
@		150MG	A091459	002	Jun 09, 2011	Feb	DISC
@		150MG	A091520	001	Jun 09, 2011	Feb	DISC
@		200MG	A091459	003	Jun 09, 2011	Feb	DISC
@	ENDO OPERATIONS	100MG	A091459	001	Jun 09, 2011	May	CAHN
@		150MG	A077284	001	Dec 14, 2006	May	CAHN

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

	@	150MG	A091459	002	Jun 09, 2011	May	CAHN	
	@	150MG	A091520	001	Jun 09, 2011	May	CAHN	
	@	200MG	A091459	003	Jun 09, 2011	May	CAHN	
	@	300MG	A077284	002	Dec 14, 2006	May	CAHN	
>A>	AB1	GRANULES	100MG	A218385	001	Oct 17, 2024	Oct	NEWA
>A>	AB1		150MG	A218385	002	Oct 17, 2024	Oct	NEWA
>A>	AB1		200MG	A218385	003	Oct 17, 2024	Oct	NEWA
	@	INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Mar	DISC
	@		150MG	A206556	001	Aug 26, 2016	Mar	DISC
	@		150MG	A206674	002	Feb 09, 2016	Mar	DISC
	@		200MG	A206674	003	Feb 09, 2016	Mar	DISC
	@		300MG	A206556	002	Aug 26, 2016	Mar	DISC
	@	RISING	150MG	A090941	001	May 03, 2010	Feb	CAHN
	@	SUN PHARM	150MG	A078866	002	Apr 06, 2010	Jul	DISC
	@		200MG	A078866	003	Apr 06, 2010	May	DISC
AB3		TWI PHARMS	150MG	A210081	001	Nov 03, 2017	Mar	CAHN
AB3			300MG	A210081	002	Nov 03, 2017	Mar	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

AB		AIPING PHARM INC	5MG	A202087	001	Dec 16, 2015	Jan	CAHN
AB			10MG	A202087	002	Dec 16, 2015	Jan	CAHN
AB			15MG	A202087	003	Dec 16, 2015	Jan	CAHN
AB			30MG	A202087	004	Dec 16, 2015	Jan	CAHN
	@	AMNEAL PHARMS CO	5MG	A208829	001	May 24, 2017	Mar	DISC
	@		7.5MG	A208829	002	May 24, 2017	Mar	DISC
	@		10MG	A208829	003	May 24, 2017	Mar	DISC
	@		15MG	A208829	004	May 24, 2017	Mar	DISC
	@		30MG	A208829	005	May 24, 2017	Mar	DISC

BUSULFAN

INJECTABLE;INJECTION
BUSULFAN

AP		EUGIA PHARMA	6MG/ML	A215102	001	Jun 25, 2024	Jun	NEWA
	@	NORVIUM BIOSCIENCE	6MG/ML	A205184	001	Jul 13, 2018	Jun	CAHN
AP		PRINSTON INC	6MG/ML	A215235	001	Sep 11, 2024	Aug	NEWA

BUTABARBITAL SODIUM

TABLET;ORAL
BUTISOL SODIUM

	@	NORVIUM BIOSCIENCE	15MG	N000793	002		Jun	CAHN
+	@		30MG	N000793	004		Jun	CAHN
	@		50MG	N000793	003		Jun	CAHN
	@		100MG	N000793	005		Jun	CAHN

CABAZITAXEL

SOLUTION;INTRAVENOUS
CABAZITAXEL

+	@	ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Jun	DISC
+	@	ACTAVIS	60MG/6ML (10MG/ML)	N207970	001	Mar 14, 2024	Sep	DISC
+	!		60MG/6ML (10MG/ML)	N207970	001	Mar 14, 2024	Mar	NEWA

CABERGOLINE

TABLET;ORAL
CABERGOLINE

	@	NORVIUM BIOSCIENCE	0.5MG	A202947	001	Dec 02, 2013	Jun	CAHN
AB		SKG PHARMA	0.5MG	A218618	001	Jun 26, 2024	Jun	NEWA
>A>	AB	SOMERSET THERAPS LLC	0.5MG	A218109	001	Sep 09, 2024	Oct	CAHN
>D>	AB	WELDING	0.5MG	A218109	001	Sep 09, 2024	Oct	CAHN
AB			0.5MG	A218109	001	Sep 09, 2024	Aug	NEWA

CALCIPOTRIENE

SOLUTION;TOPICAL
CALCIPOTRIENE

	@	HIKMA	0.005%	A077579	001	Nov 19, 2009	Mar	DISC
--	---	-------	--------	---------	-----	--------------	-----	------

CALCITONIN SALMONINJECTABLE; INJECTION
CALCITONIN-SALMON

AP		CIPLA	200 IU/ML	A213766	001	Sep 20, 2024	Sep	NEWA
AP		DR REDDYS	200 IU/ML	A215715	001	Apr 11, 2024	Apr	NEWA
SPRAY, METERED; NASAL								
CALCITONIN-SALMON								
AB	!	APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Jul	CTEC
AB		ENDO OPERATIONS	200 IU/SPRAY	A076979	001	Jun 08, 2009	Jul	CMFD
		@	200 IU/SPRAY	A076979	001	Jun 08, 2009	May	CAHN
MIACALCIN								
	+	@ NORVIUM BIOSCIENCE	200 IU/SPRAY	N020313	002	Aug 17, 1995	Jul	CAHN

CALCITRIOLCAPSULE; ORAL
CALCITRIOL

>D>	AB	SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Oct	DISC
>A>		@	0.25MCG	A204556	001	Feb 21, 2019	Oct	DISC
>D>	AB		0.5MCG	A204556	002	Feb 21, 2019	Oct	DISC
>A>		@	0.5MCG	A204556	002	Feb 21, 2019	Oct	DISC
ROCALTROL								
>A>	AB	+ ESJAY PHARMA	0.25MCG	N018044	001		Oct	CAHN
>A>	AB	+	0.5MCG	N018044	002		Oct	CAHN
>D>	AB	+ SS PHARMA	0.25MCG	N018044	001		Oct	CAHN
>D>	AB	+	0.5MCG	N018044	002		Oct	CAHN
SOLUTION; ORAL								
CALCITRIOL								
AA		ANDA REPOSITORY	1MCG/ML	A203973	001	Jul 28, 2023	Sep	CAHN
ROCALTROL								
>A>	AA	+! ESJAY PHARMA	1MCG/ML	N021068	001	Nov 20, 1998	Oct	CAHN
>D>	AA	+! SS PHARMA	1MCG/ML	N021068	001	Nov 20, 1998	Oct	CAHN

CALCIUM ACETATECAPSULE; ORAL
CALCIUM ACETATE

AB	!	INVAGEN PHARMS	667MG	A203135	001	Feb 07, 2013	Apr	CHRS
		PHOSLO GELCAPS						
	+	@ FRESENIUS MEDCL	667MG	N021160	003	Apr 02, 2001	Apr	DISC

CALCIUM CHLORIDEINJECTABLE; INJECTION
CALCIUM CHLORIDE

AP		AMNEAL	100MG/ML	A217524	001	Jul 08, 2024	Jun	NEWA
----	--	--------	----------	---------	-----	--------------	-----	------

CALCIUM GLUCONATESOLUTION; INTRAVENOUS
CALCIUM GLUCONATE

AP		AMNEAL	1GM/10ML (100MG/ML)	A216611	001	May 10, 2024	May	NEWA
AP			5GM/50ML (100MG/ML)	A216611	002	May 10, 2024	May	NEWA
AP			10GM/100ML (100MG/ML)	A216611	003	May 10, 2024	May	NEWA
AP		NIVAGEN PHARMS INC	10GM/100ML (100MG/ML)	A213071	003	Apr 30, 2024	Apr	NEWA

CAPECITABINETABLET; ORAL
CAPECITABINE

AB		HETERO LABS LTD V	150MG	A210203	001	Mar 05, 2024	Feb	NEWA
AB			500MG	A210203	002	Mar 05, 2024	Feb	NEWA
		@ HIKMA	150MG	A200483	001	Jul 14, 2016	Sep	DISC
		@	500MG	A200483	002	Jul 14, 2016	Sep	DISC

CAPREOMYCIN SULFATEINJECTABLE; INJECTION
CAPREOMYCIN SULFATE

		@ NORVIUM BIOSCIENCE	EQ 1GM BASE/VIAL	A202634	001	Nov 27, 2017	Jun	CAHN
--	--	----------------------	------------------	---------	-----	--------------	-----	------

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

AB	ANDAS 5 HOLDING	12.5MG	A 074677	004	May 30, 1997	Aug	CAHN
AB		25MG	A 074677	002	May 30, 1997	Aug	CAHN
AB		50MG	A 074677	001	May 30, 1997	Aug	CAHN
AB		100MG	A 074677	003	May 30, 1997	Aug	CAHN
AB	INNOGENIX	12.5MG	A 074677	004	May 30, 1997	Mar	CAHN
AB		25MG	A 074677	002	May 30, 1997	Mar	CAHN
AB		50MG	A 074677	001	May 30, 1997	Mar	CAHN
AB		100MG	A 074677	003	May 30, 1997	Mar	CAHN
AB	STASON PHARMS	12.5MG	A 074677	004	May 30, 1997	Feb	CAHN
AB		25MG	A 074677	002	May 30, 1997	Feb	CAHN
AB		50MG	A 074677	001	May 30, 1997	Feb	CAHN
AB		100MG	A 074677	003	May 30, 1997	Feb	CAHN

CARBAMAZEPINE

TABLET;ORAL

CARBAMAZEPINE

AB	BIONPHARMA	200MG	A 218221	001	Feb 16, 2024	Feb	NEWA
BX	UMEDICA	100MG	A 207798	001	Apr 15, 2020	Jun	CTEC
BX		200MG	A 207798	002	Apr 15, 2020	Jun	CTEC

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

	@ AMNEAL PHARMS	100MG	A 212704	001	Sep 22, 2023	Feb	DISC
	@	200MG	A 212704	002	Sep 22, 2023	Feb	DISC
	@	400MG	A 212704	003	Sep 22, 2023	Feb	DISC
	@ APOTEX	100MG	A 213159	001	Mar 08, 2024	May	DISC
AB		100MG	A 213159	001	Mar 08, 2024	Mar	NEWA
	@	200MG	A 213159	002	Mar 08, 2024	May	DISC
AB		200MG	A 213159	002	Mar 08, 2024	Mar	NEWA
	@	400MG	A 213159	003	Mar 08, 2024	May	DISC
AB		400MG	A 213159	003	Mar 08, 2024	Mar	NEWA
AB	EPIC PHARMA LLC	100MG	A 216235	001	Mar 02, 2023	Sep	CAHN
AB		200MG	A 216235	002	Mar 02, 2023	Sep	CAHN
AB		400MG	A 216235	003	Mar 02, 2023	Sep	CAHN
AB	NOVAST LABS	100MG	A 216404	001	Dec 02, 2022	Sep	CAHN
AB		200MG	A 216404	002	Dec 02, 2022	Sep	CAHN
AB		400MG	A 216404	003	Dec 02, 2022	Sep	CAHN
>A>	AB	OSMOTICA PHARM US	A 215664	001	Oct 22, 2024	Oct	NEWA
>A>	AB		A 215664	002	Oct 22, 2024	Oct	NEWA
>A>	AB		A 215664	003	Oct 22, 2024	Oct	NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

	@ NORVIUM BIOSCIENCE	12.5MG;200MG;50MG	A 203424	001	Aug 13, 2020	Jun	CAHN
	@	18.75MG;200MG;75MG	A 203424	002	Aug 13, 2020	Jun	CAHN
	@	25MG;200MG;100MG	A 203424	003	Aug 13, 2020	Jun	CAHN
	@	31.25MG;200MG;125MG	A 203424	004	Aug 13, 2020	Jun	CAHN
	@	37.5MG;200MG;150MG	A 203424	005	Aug 13, 2020	Jun	CAHN
	@	50MG;200MG;200MG	A 203424	006	Aug 13, 2020	Jun	CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL

CREXONT

+	IMPAX	35MG;140MG	N 217186	001	Aug 07, 2024	Aug	NEWA
+		52.5MG;210MG	N 217186	002	Aug 07, 2024	Aug	NEWA
+		70MG;280MG	N 217186	003	Aug 07, 2024	Aug	NEWA
+	!	87.5MG;350MG	N 217186	004	Aug 07, 2024	Aug	NEWA

RYTARY

+	IMPAX	23.75MG;95MG	N 203312	001	Jan 07, 2015	May	CAHN
+		36.25MG;145MG	N 203312	002	Jan 07, 2015	May	CAHN
+		48.75MG;195MG	N 203312	003	Jan 07, 2015	May	CAHN
+	!	61.25MG;245MG	N 203312	004	Jan 07, 2015	May	CAHN

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

AB	RUBICON	25MG;100MG	A 217482	001	Jun 04, 2024	May	NEWA
AB		50MG;200MG	A 217482	002	Jun 04, 2024	May	NEWA

<u>CARBINOXAMINE MALEATE</u>									
SOLUTION; ORAL									
CARBINOXAMINE MALEATE									
	@ ENDO OPERATIONS	4MG/5ML		A040814	001	Feb 26, 2008	May	CAHN	
TABLET; ORAL									
CARBINOXAMINE MALEATE									
	@ INVAGEN PHARMS	4MG		A090435	001	Apr 15, 2010	Mar	DISC	
<u>CARBOPLATIN</u>									
INJECTABLE; INTRAVENOUS									
CARBOPLATIN									
	@ NORVIUM BIOSCIENCE	50MG/5ML (10MG/ML)		A077998	001	Apr 24, 2007	Jul	CAHN	
	@	150MG/15ML (10MG/ML)		A077998	002	Apr 24, 2007	Jul	CAHN	
	@	450MG/45ML (10MG/ML)		A077998	003	Apr 24, 2007	Jul	CAHN	
<u>CARBOPROST TROMETHAMINE</u>									
INJECTABLE; INJECTION									
CARBOPROST TROMETHAMINE									
	@ ANI PHARMS	EQ 0.25MG BASE/ML		A215901	001	Jan 25, 2024	Jul	DISC	
AP		EQ 0.25MG BASE/ML		A215901	001	Jan 25, 2024	Jan	NEWA	
AP	MICRO LABS	EQ 0.25MG BASE/ML		A218013	001	Apr 03, 2024	Mar	NEWA	
AP	STERISCIENCE SPECLTS	EQ 0.25MG BASE/ML		A216897	001	Jul 25, 2023	Aug	CAHN	
<u>CARISOPRODOL</u>									
TABLET; ORAL									
CARISOPRODOL									
	@ ALLIED	350MG		A211789	001	Oct 20, 2021	Aug	CAHN	
AB	CHARTWELL RX	250MG		A205126	001	Jul 08, 2015	Sep	CAHN	
AA		350MG		A205126	002	Jul 08, 2015	Sep	CAHN	
	@ MLV	350MG		A211789	001	Oct 20, 2021	Jul	DISC	
<u>CARMUSTINE</u>									
INJECTABLE; INJECTION									
CARMUSTINE									
	@ NORVIUM BIOSCIENCE	100MG/VIAL		A215368	001	Mar 03, 2023	Jun	CAHN	
POWDER; INTRAVENOUS									
CARMUSTINE									
	+ @ ACCORD HLTHCARE	50MG/VIAL		N215000	001	May 16, 2022	May	DISC	
	+ @	300MG/VIAL		N215000	002	May 16, 2022	May	DISC	
<u>CARVEDILOL</u>									
TABLET; ORAL									
CARVEDILOL									
	@ MLV	3.125MG		A078786	001	Dec 22, 2009	Aug	CAHN	
	@	6.25MG		A078786	002	Dec 22, 2009	Aug	CAHN	
	@	12.5MG		A078786	003	Dec 22, 2009	Aug	CAHN	
	@	25MG		A078786	004	Dec 22, 2009	Aug	CAHN	
	@ MYLAN	3.125MG		A077316	001	Sep 05, 2007	Apr	DISC	
	@ SUN PHARM INDS LTD	3.125MG		A076989	001	Sep 05, 2007	Jan	DISC	
	@	6.25MG		A076989	002	Sep 05, 2007	Jan	DISC	
	@	12.5MG		A076989	003	Sep 05, 2007	Jan	DISC	
	@	25MG		A076989	004	Sep 05, 2007	Jan	DISC	
COREG									
AB	+ WAYLIS THERAP	3.125MG		N020297	004	May 29, 1997	Apr	CAHN	
AB	+	6.25MG		N020297	003	Sep 14, 1995	Apr	CAHN	
AB	+!	12.5MG		N020297	002	Sep 14, 1995	Apr	CAHN	
AB	+	25MG		N020297	001	Sep 14, 1995	Apr	CAHN	
<u>CARVEDILOL PHOSPHATE</u>									
CAPSULE, EXTENDED RELEASE; ORAL									
COREG CR									
AB	+ WAYLIS THERAP	10MG		N022012	001	Oct 20, 2006	Apr	CAHN	
AB	+	20MG		N022012	002	Oct 20, 2006	Apr	CAHN	
AB	+!	40MG		N022012	003	Oct 20, 2006	Apr	CAHN	
AB	+	80MG		N022012	004	Oct 20, 2006	Apr	CAHN	

CASPOFUNGIN ACETATEPOWDER; INTRAVENOUS
CASPOFUNGIN ACETATE

AP	AREVA PHARMS	50MG/VIAL	A211263	001	Oct 01, 2021	Mar	CAHN
AP		70MG/VIAL	A211263	002	Oct 01, 2021	Mar	CAHN

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM

	QILU	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan	NEWA
	SOLUTION; INTRAVENOUS CEFAZOLIN IN DEXTROSE						
+	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021	May	CTNA
+		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	May	CTNA
+		EQ 3GM BASE/150ML (EQ 20MG BASE/ML)	N207131	003	May 31, 2024	May	NEWA

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

+	B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010	Jul	CHRS
+		EQ 1GM BASE/VIAL	N050821	001	May 06, 2010	Jul	CRLD
+		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010	Jul	CHRS
+		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010	Jul	CRLD
	CEFEPIME HYDROCHLORIDE						
	@ CHARTWELL RX	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Jun	CAHN
	@	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Jun	CAHN
	@	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Jun	CAHN
AP	HIKMA	EQ 1GM BASE/VIAL	A214402	001	May 22, 2024	May	NEWA
AP		EQ 2GM BASE/VIAL	A214402	002	May 22, 2024	May	NEWA

POWDER; INTRAVENOUS
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

!	SAMSON MEDCL	EQ 100GM BASE	A209408	001	Aug 21, 2018	Apr	CHRS
---	--------------	---------------	---------	-----	--------------	-----	------

CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAMPOWDER; INTRAVENOUS
EXBLIFEP

+	@ ALLECRA THERAPS	EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	May	DISC
+		EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	Feb	NEWA

CEFIXIMEFOR SUSPENSION; ORAL
CEFIXIME

	@ CHARTWELL RX	100MG/5ML	A206144	001	Nov 17, 2017	Jul	CAHN
	@	200MG/5ML	A206144	002	Nov 17, 2017	Jul	CAHN

CEFOTAXIME SODIUMINJECTABLE; INJECTION
CLAFORAN

+	@ STERIMAX	EQ 500MG BASE/VIAL	N050547	001		Jan	CAHN
+	@	EQ 1GM BASE/VIAL	N050547	002		Jan	CAHN
+	@	EQ 2GM BASE/VIAL	N050547	003		Jan	CAHN
+	@	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan	CAHN
	CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER						
	@ STERIMAX	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jan	CAHN
	@	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan	CAHN
	CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	@ STERIMAX	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan	CAHN
	@	EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan	CAHN

CEFOTETAN DISODIUMINJECTABLE; INJECTION
CEFOTAN

AP	+	PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb	CMFD
AP	+		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb	CMFD
	CEFOTETAN							
AP	!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	Feb	CTEC
AP	!		EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	Feb	CTEC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN

	@ NORVIUM BIOSCIENCE	EQ 1GM BASE/VIAL	A 062757	001	Jan 08, 1987	Jul CAHN
+	@	EQ 1GM BASE/VIAL	N050517	001		Jul CAHN
	@	EQ 2GM BASE/VIAL	A 062757	002	Jan 08, 1987	Jul CAHN
+	@	EQ 2GM BASE/VIAL	N050517	002		Jul CAHN
+	@	EQ 10GM BASE/VIAL	N050517	003		Jul CAHN
	MEFOXIN IN PLASTIC CONTAINER					
	@ NORVIUM BIOSCIENCE	EQ 20MG BASE/ML	A 063182	001	Jan 25, 1993	Jul CAHN
	@	EQ 40MG BASE/ML	A 063182	002	Jan 25, 1993	Jul CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

	@ CHARTWELL RX	EQ 50MG BASE/5ML	A 090031	001	Jan 14, 2009	Jul CAHN
	@	EQ 100MG BASE/5ML	A 090031	002	Jan 14, 2009	Jul CAHN

CEFPROZIL

TABLET; ORAL

CEFPROZIL

AB	ALKEM LABS LTD	250MG	A 090857	001	Apr 09, 2024	Mar NEWA
AB		500MG	A 090857	002	Apr 09, 2024	Mar NEWA

CEFTOBIPROLE MEDOCARIL SODIUM

POWDER; INTRAVENOUS

ZEVTERA

+	@ BASILEA PHARM ALLSCH	667MG/VIAL	N 218275	001	Apr 03, 2024	Aug DISC
+	!	667MG/VIAL	N 218275	001	Apr 03, 2024	Apr NEWA

CEFTRIAZONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAZONE

	@ DEVA HOLDING AS	EQ 250MG BASE/VIAL	A 210197	001	Jan 12, 2024	Jul DISC
AP		EQ 250MG BASE/VIAL	A 210197	001	Jan 12, 2024	Jan NEWA
	@	EQ 500MG BASE/VIAL	A 210197	002	Jan 12, 2024	Jul DISC
AP		EQ 500MG BASE/VIAL	A 210197	002	Jan 12, 2024	Jan NEWA
	@	EQ 1GM BASE/VIAL	A 210197	003	Jan 12, 2024	Jul DISC
AP		EQ 1GM BASE/VIAL	A 210197	003	Jan 12, 2024	Jan NEWA
	@	EQ 2GM BASE/VIAL	A 210197	004	Jan 12, 2024	Jul DISC
AP		EQ 2GM BASE/VIAL	A 210197	004	Jan 12, 2024	Jan NEWA

CELECOXIB

SOLUTION; ORAL

ELYXYB

+	!	SCILEX PHARMS	25MG/ML	N 212157	001	May 05, 2020	Jun CAHN
---	---	---------------	---------	----------	-----	--------------	----------

>D> CELECOXIB; TRAMADOL HYDROCHLORIDE

>D> TABLET; ORAL

>D> SEGLENTIS

>D>	+	!	KOWA PHARMS	56MG; 44MG	N 213426	001	Oct 15, 2021	Oct DISC
>A>	+	@		56MG; 44MG	N 213426	001	Oct 15, 2021	Oct DISC

CEPHALEXIN

TABLET; ORAL

CEPHALEXIN

AB	ALKEM LABS LTD	EQ 250MG BASE	A 218947	001	Sep 27, 2024	Sep NEWA	
AB		EQ 500MG BASE	A 218947	002	Sep 27, 2024	Sep NEWA	
AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A 218817	001	Sep 27, 2024	Sep NEWA	
AB		EQ 500MG BASE	A 218817	002	Sep 27, 2024	Sep NEWA	
	KEFLET						
	+	@ LILLY	EQ 250MG BASE	N 050440	003	Feb 26, 1987	Sep CRLD
	+	@	EQ 500MG BASE	N 050440	001		Sep CRLD

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL

CETIRIZINE HYDROCHLORIDE

	@ ACTAVIS MID ATLANTIC	5MG/5ML	A 078617	001	Feb 02, 2010	Feb CFRD
AA	AMNEAL PHARMS	5MG/5ML	A 090766	001	Oct 07, 2009	Feb CFRD
AA	APOZEAL PHARMS	5MG/5ML	A 078870	001	Apr 27, 2009	Jul CMFD
	@	5MG/5ML	A 078870	001	Apr 27, 2009	Feb CFRD

SOLUTION;ORAL

CETIRIZINE HYDROCHLORIDE

	@ AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009	Feb	CDFR
AA	BAJAJ	5MG/5ML	A090191	001	Nov 12, 2009	Feb	CDFR
AA	BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	Feb	CDFR
AA	CHARTWELL MOLECULAR	5MG/5ML	A078876	001	May 11, 2012	Feb	CDFR
	@ LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009	Feb	CDFR
AA	! PADAGIS US	5MG/5ML	A078398	001	Jun 17, 2008	Feb	CDFR
AA	PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008	Feb	CDFR
	@ RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008	Feb	CDFR
AA	TARO	5MG/5ML	A076601	001	Jun 20, 2008	Feb	CDFR
	@ TEVA PHARMS	5MG/5ML	A077279	001	May 27, 2008	Mar	DISC
AA		5MG/5ML	A077279	001	May 27, 2008	Feb	CDFR
	@ WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Feb	CDFR
	ZYRTEC						
	@ J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb	CDFR

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA	PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008	Jan	CMFD
----	-------------	---------	---------	-----	--------------	-----	------

CETRORELIX ACETATE

POWDER;SUBCUTANEOUS

CETRORELIX ACETATE

AP	GLAND	EQ 0.25MG BASE/VIAL	A218150	001	Apr 25, 2024	Apr	NEWA
AP	LIVZON GRP	EQ 0.25MG BASE/VIAL	A214540	001	Apr 24, 2024	Apr	NEWA
AP	QILU	EQ 0.25MG BASE/VIAL	A217776	001	Apr 16, 2024	Apr	NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	30MG	A206808	001	Sep 20, 2024	Sep	NEWA
----	---------------------	------	---------	-----	--------------	-----	------

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

	@ FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365	001	Aug 25, 1982	Feb	DISC
--	----------------------	------------------	---------	-----	--------------	-----	------

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB	WINDER LABS LLC	5MG;2.5MG	A212344	001	Jul 08, 2024	Jun	NEWA
----	-----------------	-----------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

	@ SAPTALIS PHARMS	0.12%	A074356	001	May 07, 1996	Jun	CAHN
	@ SCIEGEN PHARMS INC	0.12%	A074356	001	May 07, 1996	Aug	CAHN

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

NESACAINE

>D>	+!	FRESENIUS KABI USA	1%	N009435	001		Oct	DISC
>A>	+	@	1%	N009435	001		Oct	DISC

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A218630	001	Oct 03, 2024	Sep	NEWA
	@ RK PHARMA	EQ 500MG BASE/VIAL	A202493	001	Jun 18, 2014	Mar	DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	@ SCIEGEN PHARMS INC	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017	Sep	CAHN
--	----------------------	--------------------------	---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

AP	DEVA HLDING	25MG/ML	A218229	001	Sep 24, 2024	Sep	NEWA
AP	DR REDDYS	25MG/ML	A080365	001		Apr	CMFD
AP	GLAND PHARMA LTD	25MG/ML	A216911	001	Oct 04, 2024	Sep	NEWA
AP	+!	HIKMA	25MG/ML	A083329	001	Jun	CAHN

INJECTABLE; INJECTION

AB	Product Name	Strength	Manufacturer	Code	Start Date	End Date	Notes
	CHLORPROMAZINE HYDROCHLORIDE						
AP	ZYDUS PHARMS	25MG/ML		A217275 001	Mar 13, 2024	Mar	NEWA
	SYRUP; ORAL						
	SONAZINE						
	@ CHARTWELL RX	10MG/5ML		A083040 001		May	CAHN
	TABLET; ORAL						
	CHLORPROMAZINE HYDROCHLORIDE						
	@ CHARTWELL RX	10MG		A080439 001		Jul	CAHN
AB		10MG		A212630 001	Nov 29, 2021	Sep	CAHN
	@	25MG		A080439 002		Jul	CAHN
AB		25MG		A212630 002	Nov 29, 2021	Sep	CAHN
	@	50MG		A080439 003		Jul	CAHN
AB		50MG		A212630 003	Nov 29, 2021	Sep	CAHN
	@	100MG		A080439 004		Jul	CAHN
AB		100MG		A212630 004	Nov 29, 2021	Sep	CAHN
	@	200MG		A080439 005		Jul	CAHN
AB		200MG		A212630 005	Nov 29, 2021	Sep	CAHN
AB	ZAMEER PHARMS	10MG		A212630 001	Nov 29, 2021	Feb	CAHN
AB		25MG		A212630 002	Nov 29, 2021	Feb	CAHN
AB		50MG		A212630 003	Nov 29, 2021	Feb	CAHN
AB		100MG		A212630 004	Nov 29, 2021	Feb	CAHN
AB		200MG		A212630 005	Nov 29, 2021	Feb	CAHN
AB	ZYDUS LIFESCIENCES	10MG		A213368 001	Jan 17, 2020	Aug	CAHN
AB		25MG		A213368 002	Jan 17, 2020	Aug	CAHN
AB		50MG		A213368 003	Jan 17, 2020	Aug	CAHN
AB		100MG		A213368 004	Jan 17, 2020	Aug	CAHN
AB		200MG		A213368 005	Jan 17, 2020	Aug	CAHN

CHLORTHALIDONE

AB	Product Name	Strength	Manufacturer	Code	Start Date	End Date	Notes
	TABLET; ORAL						
	CHLORTHALIDONE						
AB	PHARMOBEDIANT	25MG		A212878 001	Feb 24, 2022	Sep	CAHN
AB		50MG		A212875 001	Feb 24, 2022	Sep	CAHN

CHLORZOXAZONE

AB	Product Name	Strength	Manufacturer	Code	Start Date	End Date	Notes
	TABLET; ORAL						
	CHLORZOXAZONE						
	@ APTAPHARMA INC	375MG		A212053 001	Sep 14, 2020	Apr	DISC
	@	750MG		A212053 002	Sep 14, 2020	Apr	DISC
	@ CHARTWELL RX	375MG		A212053 001	Sep 14, 2020	Sep	CAHN
	@	750MG		A212053 002	Sep 14, 2020	Sep	CAHN
AB	ENDO OPERATIONS	375MG		A212743 002	Apr 29, 2021	Apr	CAHN
AB		750MG		A212743 001	Nov 02, 2020	Apr	CAHN
AA	HAVIX	500MG		A210961 001	Jan 22, 2024	Jan	NEWA
	@ I3 PHARMS	375MG		A212053 001	Sep 14, 2020	Aug	CAHN
	@	750MG		A212053 002	Sep 14, 2020	Aug	CAHN
AA	RISING	250MG		A216925 001	Aug 09, 2023	Aug	CAHN
AA	SENORES PHARMS	250MG		A215158 001	Jul 29, 2021	Feb	CAHN
AA		500MG		A210961 001	Jan 22, 2024	Feb	CAHN
	@ TEVA PHARMS USA INC	375MG		A212898 001	Jun 17, 2020	Sep	DISC
	@	750MG		A212898 002	Jun 17, 2020	Sep	DISC

CHOLESTYRAMINE

AB	Product Name	Strength	Manufacturer	Code	Start Date	End Date	Notes
	POWDER; ORAL						
	CHOLESTYRAMINE LIGHT						
AB	ENDO OPERATIONS	EQ 4GM RESIN/PACKET		A077203 001	Aug 26, 2005	May	CAHN
AB		EQ 4GM RESIN/SCOOPFUL		A077203 002	Aug 26, 2005	May	CAHN
>A>	AB	MACLEODS PHARMS LTD		A209109 001	Oct 31, 2024	Oct	NEWA
>A>	AB			A209109 002	Oct 31, 2024	Oct	NEWA

CHOLINE FENOFIBRATE

AB	Product Name	Strength	Manufacturer	Code	Start Date	End Date	Notes
	CAPSULE, DELAYED RELEASE; ORAL						
	FENOFIBRIC ACID						
	@ ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID		A201573 002	Jul 18, 2013	Mar	DISC
	@	EQ 135MG FENOFIBRIC ACID		A201573 001	Jul 18, 2013	Mar	DISC
	@ ENDO OPERATIONS	EQ 45MG FENOFIBRIC ACID		A201573 002	Jul 18, 2013	May	CAHN
	@	EQ 135MG FENOFIBRIC ACID		A201573 001	Jul 18, 2013	May	CAHN
	@ MACLEODS PHARMS LTD	EQ 45MG FENOFIBRIC ACID		A207796 001	Feb 08, 2024	Aug	DISC
AB		EQ 45MG FENOFIBRIC ACID		A207796 001	Feb 08, 2024	Feb	NEWA
	@	EQ 135MG FENOFIBRIC ACID		A207796 002	Feb 08, 2024	Aug	DISC
AB		EQ 135MG FENOFIBRIC ACID		A207796 002	Feb 08, 2024	Feb	NEWA
AB	RISING	EQ 45MG FENOFIBRIC ACID		A211626 001	Jul 18, 2019	Aug	CAHN

CAPSULE, DELAYED RELEASE;ORAL
FENOFIBRIC ACID

AB		EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Aug	CAHN
	@ TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Aug	DISC
AB		EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Mar	CAHN
	@	EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Aug	DISC
AB		EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Mar	CAHN

CICLESONIDE

AEROSOL, METERED;NASAL
ZETONNA
+ @ COVIS

	0.037MG/INH	N202129	001	Jan 20, 2012	Aug	DISC
--	-------------	---------	-----	--------------	-----	------

CICLOPIROX

CREAM;TOPICAL
CICLOPIROX

AB	TARO	0.77%	A076790	001	Apr 12, 2005	Jan	CAHN
	SOLUTION;TOPICAL CICLOPIROX						
	@ COSETTE	8%	A078233	001	Sep 18, 2007	Jul	DISC
	@ HIKMA	8%	A078270	001	Sep 18, 2007	Mar	DISC

CILOSTAZOL

TABLET;ORAL
CILOSTAZOL

	@ RISING	50MG	A077323	002	Apr 20, 2006	Feb	CAHN
	@	100MG	A077323	001	Apr 20, 2006	Feb	CAHN

CIMETIDINE

TABLET;ORAL
CIMETIDINE

>D>	@ CHARTWELL MOLECULES	200MG	A074329	002	May 17, 1994	Oct	CMFD
>A>	AB	200MG	A074329	002	May 17, 1994	Oct	CMFD
>D>	@	300MG	A074329	003	May 17, 1994	Oct	CMFD
>A>	AB	300MG	A074329	003	May 17, 1994	Oct	CMFD
>D>	@	400MG	A074329	004	May 17, 1994	Oct	CMFD
>A>	AB	400MG	A074329	004	May 17, 1994	Oct	CMFD
>D>	@	800MG	A074329	001	May 17, 1994	Oct	CMFD
>A>	AB	800MG	A074329	001	May 17, 1994	Oct	CMFD

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
CIMETIDINE HYDROCHLORIDE

	@ COSETTE	EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997	Jun	CAHN
	@ ENDO OPERATIONS	EQ 300MG BASE/2ML	A074005	001	Aug 31, 1994	May	CAHN
	@	EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996	May	CAHN

SOLUTION;ORAL

	@ PHARM ASSOC	EQ 300MG BASE/5ML	A074553	001	Jan 27, 1997	Feb	DISC
--	---------------	-------------------	---------	-----	--------------	-----	------

CINACALCET HYDROCHLORIDE

TABLET;ORAL
CINACALCET HYDROCHLORIDE

>D>	AB	SUN PHARM	EQ 90MG BASE	A207008	003	Oct 11, 2018	Oct	DISC
>A>	@		EQ 90MG BASE	A207008	003	Oct 11, 2018	Oct	DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

	@ THE J MOLNER	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Jun	CAHN
--	----------------	--------------	---------	-----	--------------	-----	------

SOLUTION/DROPS;OTIC

CETRAXAL

>D>	+	KEY THERAP	EQ 0.2% BASE	N021918	001	May 01, 2009	Oct	CFTG
>A>	AB	+	EQ 0.2% BASE	N021918	001	May 01, 2009	Oct	CFTG
>A>		+	EQ 0.2% BASE	N021918	001	May 01, 2009	Apr	CAHN

CIPROFLOXACIN HYDROCHLORIDE

>A>	AB	IDENTIRX	EQ 0.2% BASE	A217887	001	Nov 05, 2024	Oct	NFTG
-----	----	----------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	AIPING PHARM INC	EQ 250MG BASE	A076593	002	Jun 09, 2004	Apr	CMFD
AB		EQ 500MG BASE	A076593	003	Jun 09, 2004	Apr	CMFD
AB		EQ 750MG BASE	A076593	004	Jun 09, 2004	Apr	CMFD

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL		CIPROFLOXACIN EXTENDED RELEASE							
	@ ANCHEN PHARMS	212.6MG;EQ	287.5MG BASE	A 078166	002	Nov 27, 2007	Mar	DISC	
	@	425.2MG;EQ	574.9MG BASE	A 078166	001	Nov 27, 2007	Mar	DISC	
	! DR REDDYS LABS LTD	425.2MG;EQ	574.9MG BASE	A 077701	001	Mar 26, 2007	Mar	CTEC	
AB	!	425.2MG;EQ	574.9MG BASE	A 077701	001	Mar 26, 2007	Mar	CHRS	
	@ ENDO OPERATIONS	212.6MG;EQ	287.5MG BASE	A 078166	002	Nov 27, 2007	May	CAHN	
	@	425.2MG;EQ	574.9MG BASE	A 078166	001	Nov 27, 2007	May	CAHN	

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC		CIPROFLOXACIN; DEXAMETHASONE							
AB	AMNEAL	0.3%;0.1%		A 216501	001	Mar 22, 2024	Mar	NEWA	

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION		CISATRACURIUM BESYLATE							
	@ CAPLIN	EQ 2MG	BASE/ML	A 217725	001	Jun 09, 2023	Apr	DISC	
	@	EQ 10MG	BASE/ML	A 217725	002	Jun 09, 2023	Apr	DISC	
AP	HAINAN POLY	EQ 2MG	BASE/ML	A 216538	001	Mar 08, 2024	Mar	NEWA	
AP	! MEITHEAL	EQ 2MG	BASE/ML	A 211668	001	Apr 25, 2019	Apr	CHRS	
AP	!	EQ 2MG	BASE/ML	A 211669	001	Apr 25, 2019	Apr	CHRS	
AP	!	EQ 10MG	BASE/ML	A 211668	002	Apr 25, 2019	Apr	CHRS	
AP	PIRAMAL CRITICAL	EQ 2MG	BASE/ML	A 215516	003	Dec 14, 2022	Mar	CMS1	
	CISATRACURIUM BESYLATE	PRESERVATIVE FREE							
AP	HAINAN POLY	EQ 2MG	BASE/ML	A 216539	001	Aug 27, 2024	Aug	NEWA	
AP		EQ 10MG	BASE/ML	A 216539	002	Aug 27, 2024	Aug	NEWA	
	NIMBEX								
	+ @ ABBVIE	EQ 2MG	BASE/ML	N 020551	001	Dec 15, 1995	Apr	DISC	
	NIMBEX PRESERVATIVE FREE								
	+ @ ABBVIE	EQ 2MG	BASE/ML	N 020551	003	Dec 15, 1995	Apr	DISC	
	+ @	EQ 10MG	BASE/ML	N 020551	002	Dec 15, 1995	Apr	DISC	

CISPLATIN

INJECTABLE;INJECTION		CISPLATIN							
AP	QILU	1MG/ML		A 218868	001	May 10, 2024	May	NEWA	

CITALOPRAM HYDROBROMIDE

TABLET;ORAL		CITALOPRAM HYDROBROMIDE							
AB	APOTEX	EQ 10MG	BASE	A 077046	001	Nov 24, 2004	Jan	CAHN	
AB		EQ 20MG	BASE	A 077046	002	Nov 24, 2004	Jan	CAHN	
AB		EQ 40MG	BASE	A 077046	003	Nov 24, 2004	Jan	CAHN	
	@ CHARTWELL RX	EQ 10MG	BASE	A 077040	001	Aug 17, 2005	Aug	CAHN	
	@	EQ 20MG	BASE	A 077040	002	Aug 17, 2005	Aug	CAHN	
	@	EQ 40MG	BASE	A 077040	003	Aug 17, 2005	Aug	CAHN	
	@ COSETTE	EQ 10MG	BASE	A 077048	001	Nov 16, 2004	Apr	DISC	
	@	EQ 20MG	BASE	A 077048	002	Nov 16, 2004	Apr	DISC	
	@	EQ 40MG	BASE	A 077048	003	Nov 16, 2004	Apr	DISC	
	@ TARO	EQ 10MG	BASE	A 077278	001	Mar 22, 2006	Jan	CAHN	
	@	EQ 20MG	BASE	A 077278	002	Mar 22, 2006	Jan	CAHN	
	@	EQ 40MG	BASE	A 077278	003	Mar 22, 2006	Jan	CAHN	

CLADRIBINE

INJECTABLE;INJECTION		CLADRIBINE							
	@ NORVIUM BIOSCIENCE	1MG/ML		A 200510	001	Oct 06, 2011	Jun	CAHN	

CLEMASTINE FUMARATE

SYRUP;ORAL		CLEMASTINE FUMARATE							
AA	! GENUS	EQ 0.5MG	BASE/5ML	A 073399	001	Jun 30, 1994	Aug	CTEC	
	@ NEW HEIGHTS	EQ 0.5MG	BASE/5ML	A 074884	001	Dec 17, 1997	Jan	CAHN	
AA	NEW HEIGHTSRX	EQ 0.5MG	BASE/5ML	A 074884	001	Dec 17, 1997	Aug	CMFD	
	@	EQ 0.5MG	BASE/5ML	A 074884	001	Dec 17, 1997	Jul	CAHN	
	TABLET;ORAL								
	CLEMASTINE FUMARATE								
	@ OMNIVIUM PHARMS	2.68MG		A 073459	001	Oct 31, 1993	Jun	CAHN	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

@ COSETTE EQ 150MG BASE
 @ EQ 300MG BASE

A063029 001 Sep 20, 1989 Apr DISC
 A063029 002 Aug 05, 2005 Apr DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA RISING EQ 75MG BASE/5ML

A201821 001 Aug 28, 2012 Sep CAHN

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

AB1 ALEMBIC EQ 1% BASE
 @ AMNEAL EQ 1% BASE
 AB1 QUAGEN EQ 1% BASE

A212466 001 Apr 02, 2024 Mar NEWA
 A215219 001 Nov 03, 2022 Feb DISC
 A211872 001 Jul 29, 2020 Sep CAHN

GEL;VAGINAL

XACIATO

+! ORGANON LLC EQ 2% BASE

N215650 001 Dec 07, 2021 Jan CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@ ENDO OPERATIONS EQ 1% BASE

A203343 001 May 29, 2015 Apr CAHN

CLOBAZAM

TABLET;ORAL

CLOBAZAM

@ ANDA REPOSITORY 10MG
 @ 20MG
 @ BRECKENRIDGE 20MG

A211959 001 Dec 09, 2020 Sep CAHN
 A211959 002 Dec 09, 2020 Sep CAHN
 A209308 002 Oct 22, 2018 Jan DISC

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB2 TARO 0.05%

A208563 001 Mar 14, 2024 Mar NEWA

CREAM;TOPICAL

CLOBETASOL PROPIONATE

@ COSETTE 0.05%

A074139 001 Aug 03, 1994 Apr DISC

CLOBETASOL PROPIONATE (EMOLLIENT)

>A> @ BEACH PRODS 0.05%

A209411 001 Aug 21, 2017 Oct CAHN

>D> @ PAI HOLDINGS PHARM 0.05%

A209411 001 Aug 21, 2017 Oct CAHN

CORMAX

@ HIKMA 0.05%

A074220 001 May 16, 1997 Mar DISC

GEL;TOPICAL

EMBELINE

@ HIKMA 0.05%

A076141 001 Apr 12, 2002 Mar DISC

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

>D> AB ENCUBE 0.05%

A211295 001 Nov 15, 2019 Oct CHRS

>A> AB ! 0.05%

A211295 001 Nov 15, 2019 Oct CHRS

>D> AB ! FOUGERA PHARMS 0.05%

A074407 001 Feb 23, 1996 Oct CHRS

>A> AB 0.05%

A074407 001 Feb 23, 1996 Oct CHRS

EMBELINE

@ HIKMA 0.05%

A074221 001 Mar 31, 1995 Mar DISC

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE

@ HIKMA 0.05%

A209871 001 Oct 27, 2017 Mar DISC

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

@ COSETTE 0.05%

A074331 001 Dec 15, 1995 Apr DISC

AT ENCUBE 0.05%

A076977 001 Aug 05, 2005 May CMFD

EMBELINE

@ HIKMA 0.05%

A074222 001 Dec 06, 1995 Mar DISC

SUSPENSION/DROPS;OPHTHALMIC

CLOBETASOL PROPIONATE

+! EYENOVIA 0.05%

N218158 001 Mar 04, 2024 May CAHN

+! FORMOSA 0.05%

N218158 001 Mar 04, 2024 Mar NEWA

CLOCORTOLONE PIVALATECREAM; TOPICAL
CLODERM

AB	+!	LEGACY PHARMA	0.1%	N017765	001			Apr	CAHN
----	----	---------------	------	---------	-----	--	--	-----	------

CLOMIPRAMINE HYDROCHLORIDECAPSULE; ORAL
CLOMIPRAMINE HYDROCHLORIDE

AB		CHARTWELL RX	25MG	A074364	001	Mar 29, 1996	Mar	CAHN
AB			50MG	A074364	002	Mar 29, 1996	Mar	CAHN
AB			75MG	A074364	003	Mar 29, 1996	Mar	CAHN
	@	MYLAN	25MG	A074947	001	Apr 30, 1998	May	DISC
	@		50MG	A074947	002	Apr 30, 1998	May	DISC
	@		75MG	A074947	003	Apr 30, 1998	May	DISC
	@	RK PHARMA	25MG	A213221	001	Jun 22, 2020	Mar	DISC
	@		50MG	A213221	002	Jun 22, 2020	Mar	DISC
	@		75MG	A213221	003	Jun 22, 2020	Mar	DISC
AB		TRUPHARMA	25MG	A210653	001	Apr 03, 2020	Sep	CAHN
AB			50MG	A210653	002	Apr 03, 2020	Sep	CAHN
AB			75MG	A210653	003	Apr 03, 2020	Sep	CAHN

CLONAZEPAMTABLET, ORALLY DISINTEGRATING; ORAL
CLONAZEPAM

AB		ENDO OPERATIONS	0.125MG	A077171	001	Aug 03, 2005	Apr	CAHN
AB			0.25MG	A077171	002	Aug 03, 2005	Apr	CAHN
AB			0.5MG	A077171	003	Aug 03, 2005	Apr	CAHN
AB	!		1MG	A077171	004	Aug 03, 2005	Apr	CAHN
AB			2MG	A077171	005	Aug 03, 2005	Apr	CAHN

CLONIDINESYSTEM; TRANSDERMAL
CLONIDINE

AB		DIFGEN PHARMS	0.1MG/24HR	A076157	001	Aug 18, 2009	Sep	CAHN
AB			0.2MG/24HR	A076157	002	Aug 18, 2009	Sep	CAHN
AB			0.3MG/24HR	A076157	003	Aug 18, 2009	Sep	CAHN

CLONIDINE HYDROCHLORIDESUSPENSION, EXTENDED RELEASE; ORAL
ONYDA XR

+! TRIS PHARMA INC 0.1MG/ML

N217645 001 May 24, 2024 May NEWA

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AB		TRUPHARMA	0.1MG	A070923	003	Sep 04, 1987	Sep	CAHN
AB			0.2MG	A070923	002	Sep 04, 1987	Sep	CAHN
AB			0.3MG	A070923	001	Sep 04, 1987	Sep	CAHN

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

	@	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	Mar	DISC
	@	BLUEPHARMA INDUSTRIA	0.1MG	A211433	001	Oct 12, 2018	Jan	CAHN
	@	ENDO OPERATIONS	0.1MG	A202983	001	Apr 02, 2014	May	CAHN
	@		0.1MG	A202984	001	Sep 30, 2013	May	CAHN
	@		0.2MG	A202983	002	Apr 02, 2014	May	CAHN
	@		0.2MG	A202984	002	Sep 30, 2013	May	CAHN
	@	SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018	May	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

	@	ACCORD HLTHCARE	EQ 75MG BASE	A202925	001	Mar 27, 2013	May	DISC
	@		EQ 300MG BASE	A202925	002	Mar 27, 2013	May	DISC
AB		DR REDDYS LABS LTD	EQ 75MG BASE	A091023	002	Aug 05, 2024	Jul	NEWA
AB		MSN	EQ 75MG BASE	A215388	001	Sep 20, 2024	Sep	NEWA

CLOTRIMAZOLESOLUTION; TOPICAL
CLOTRIMAZOLE

AT		TRUPHARMA	1%	A212281	001	Jul 25, 2019	Aug	CAHN
----	--	-----------	----	---------	-----	--------------	-----	------

TROCHE/LOZENGE; ORAL

CLOTRIMAZOLE

AB		THINQ PHARM-CRO PVT	10MG	A215641	001	Feb 29, 2024	Feb	NEWA
----	--	---------------------	------	---------	-----	--------------	-----	------

CLOZAPINE

TABLET;ORAL		CLOZARIL							
	+ @ HERITAGE LIFE	50MG	N019758	003	May 20, 2019	Aug	DISC		
	+ @	200MG	N019758	004	May 20, 2019	Aug	DISC		
TABLET, ORALLY DISINTEGRATING;ORAL		CLOZAPINE							
AB	BARR LABS INC	150MG	A090308	004	Nov 25, 2015	Jun	CMS1		
AB		200MG	A090308	005	Nov 25, 2015	Jun	CMS1		

COBICISTAT

TABLET;ORAL		COBICISTAT							
AB	MYLAN LABS LTD	150MG	A209986	001	Feb 07, 2024	Jan	NFTG		
AB	+! GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014	Jan	CFTG		

COCAINE HYDROCHLORIDE

SOLUTION;NASAL		GOPRELTO							
	+! NODEN PHARMA	4%	N209963	001	Dec 14, 2017	Jan	CAHN		

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL		PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE							
AA	! GENUS	10MG/5ML;5MG/5ML;6.25MG/5ML	A040660	001	Dec 07, 2006	Apr	CAHN		
	@ HIKMA	10MG/5ML;5MG/5ML;6.25MG/5ML	A040674	001	Dec 23, 2014	Mar	DISC		

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL		PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE							
	@ HIKMA	10MG/5ML;6.25MG/5ML	A040151	001	Aug 26, 1997	Mar	DISC		

COLCHICINE

CAPSULE;ORAL		COLCHICINE							
AB	ANNORA PHARMA	0.6MG	A217620	001	Apr 29, 2024	Apr	NEWA		
AB	AUROBINDO PHARMA LTD	0.6MG	A215463	001	Apr 29, 2024	Apr	NEWA		
AB	GRANULES	0.6MG	A210757	001	Apr 29, 2024	Apr	NEWA		
TABLET;ORAL		COLCHICINE							
AB	! ENDO OPERATIONS	0.6MG	A203976	001	Aug 12, 2021	May	CHRS		
	@ MYLAN	0.6MG	A209470	001	Sep 16, 2019	Apr	DISC		
	+ @ TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009	May	DISC		

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL		COLESEVELAM HYDROCHLORIDE							
	@ IMPAX	3.75GM/PACKET	A212886	001	Jan 18, 2023	May	DISC		

COLESTIPOL HYDROCHLORIDE

GRANULE;ORAL		FLAVORED COLESTID							
	+ @ PFIZER	5GM/PACKET	N017563	001		Jun	DISC		
	+ @	5GM/SCOOPFUL	N017563	002		Jun	DISC		
TABLET;ORAL		COLESTIPOL HYDROCHLORIDE							
AB	EDENBRIDGE PHARMS	1GM	A217667	001	Aug 16, 2024	Aug	NEWA		

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION		COLISTIMETHATE SODIUM							
AP	ADRASTEA PHARMA	EQ 150MG BASE/VIAL	A064216	001	Feb 26, 1999	Jul	CAHN		

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDESUSPENSION/DROPS;OTIC
COLY-MYCIN S

+!	ENDO OPERATIONS	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001			Apr	CAHN
----	-----------------	---	---------	-----	--	--	-----	------

COPPERSYSTEM;INTRAUTERINE
PARAGARD T 380A

+!	COOPERSURGICAL	309MG/COPPER	N018680	001	Nov 15, 1984		Jun	CDFR
----	----------------	--------------	---------	-----	--------------	--	-----	------

CORTICOTROPININJECTABLE;INJECTION
ACTHAR GEL (AUTOINJECTOR)

+!	MALLINCKRODT ARD	40 UNITS/0.5ML	N008372	003	Feb 29, 2024		Mar	NEWA
+!		80 UNITS/ML	N008372	004	Feb 29, 2024		Mar	NEWA

COSYNTROPININJECTABLE;INJECTION
COSYNTROPIN

>D>	@ MYLAN INSTITUTIONAL	0.25MG/VIAL	A090574	001	Dec 17, 2009		Oct	CAHN
	@	0.25MG/VIAL	A090574	001	Dec 17, 2009		May	DISC
>A>	@ NORVIUM BIOSCIENCE	0.25MG/VIAL	A090574	001	Dec 17, 2009		Oct	CAHN

CUPRIC CHLORIDEINJECTABLE;INJECTION
CUPRIC CHLORIDE

AP	RK PHARMA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024		May	CAHN
AP	SOMERSET	EQ 0.4MG COPPER/ML	A216113	001	Apr 30, 2024		Apr	NEWA
AP	STIRA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024		Apr	NEWA

CUPRIC SULFATEINJECTABLE;INJECTION
CUPRIC SULFATE

AP	! AM REGENT	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022		Aug	CTEC
AP	APOTEX CORP	EQ 0.4MG COPPER/ML	A218745	001	Aug 19, 2024		Aug	NEWA

CYANOCOBALAMINGEL, METERED;NASAL
NASCOBAL

	@ ENDO OPERATIONS	0.5MG/INH	N019722	001	Nov 05, 1996		May	CAHN
--	-------------------	-----------	---------	-----	--------------	--	-----	------

INJECTABLE;INJECTION
CYANOCOBALAMIN

	@ EUGIA PHARMA	1MG/ML	A213874	001	Dec 08, 2020		Jun	DISC
AP	MANKIND PHARMA	1MG/ML	A217839	001	Jul 10, 2024		Jun	NEWA

SPRAY, METERED;NASAL
CALOMIST

	@ ENDO OPERATIONS	25MCG/SPRAY	N022102	001	Jul 27, 2007		May	CAHN
--	-------------------	-------------	---------	-----	--------------	--	-----	------

CYANOCOBALAMIN

AB	! PADAGIS ISRAEL	0.5MG/SPRAY	A212458	001	Sep 09, 2020		Jul	CHRS
----	------------------	-------------	---------	-----	--------------	--	-----	------

NASCOBAL

	+ @ ENDO OPERATIONS	0.5MG/SPRAY	N021642	001	Jan 31, 2005		Jul	DISC
--	---------------------	-------------	---------	-----	--------------	--	-----	------

AB	+!	0.5MG/SPRAY	N021642	001	Jan 31, 2005		May	CAHN
----	----	-------------	---------	-----	--------------	--	-----	------

CYCLOBENZAPRINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	15MG	A207314	001	Jul 22, 2024		Jul	NEWA
AB		30MG	A207314	002	Jul 22, 2024		Jul	NEWA
AB	NOVAST LABS	15MG	A214732	001	Aug 27, 2024		Aug	NEWA
AB		30MG	A214732	002	Aug 27, 2024		Aug	NEWA

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

	@ AIPING PHARM INC	5MG	A072854	002	Feb 03, 2006		Jun	CAHN
	@	10MG	A072854	001	Nov 19, 1991		Jun	CAHN
AB	GRAVITI PHARMS	5MG	A218936	001	Sep 12, 2024		Sep	NEWA
AB		7.5MG	A218936	002	Sep 12, 2024		Sep	NEWA
AB		10MG	A218936	003	Sep 12, 2024		Sep	NEWA

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

AB	KANCHAN HLTHCARE	25MG	A209872	001	May 07, 2018	Aug	CAHN
AB		50MG	A209872	002	May 07, 2018	Aug	CAHN

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP	HIKMA	500MG/VIAL	A216958	001	Dec 18, 2023	Jan	CAHN
AP		1GM/VIAL	A216958	002	Dec 18, 2023	Jan	CAHN
AP		2GM/VIAL	A216958	003	Dec 18, 2023	Jan	CAHN

SOLUTION; INTRAVENOUS

CYCLOPHOSPHAMIDE

	+	!	AVYXA HOLDINGS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023	Jun	CAHN	
		+		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023	Jun	CAHN	
		+		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023	Jun	CAHN	
>D>	+	@	BAXTER HLTHCARE CORP	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Oct	CMFD	
>A>		+		500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Oct	CMFD	
		+	@	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Jan	CAHN	
>D>		+	@	1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Oct	CMFD	
>A>		+	!	1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Oct	CMFD	
		+	@	1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Jan	CAHN	
>D>		+	!	DR REDDYS	500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020	Oct	CFTG
>A>	AP		+		500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020	Oct	CFTG
			+		500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020	Jun	CAHN
>D>			+		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020	Oct	CFTG
>A>	AP		+		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020	Oct	CFTG
			+		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020	Jun	CAHN
			+		2GM/10ML (200MG/ML)	N212501	003	Nov 19, 2021	Jun	CAHN
>A>	AP		!	NEXUS	500MG/2.5ML (200MG/ML)	A216783	001	Oct 29, 2024	Oct	NFTG
>A>	AP				1GM/5ML (200MG/ML)	A216783	002	Oct 29, 2024	Oct	NFTG

CYCLOSERINE

CAPSULE; ORAL

SEROMYCIN

!	SANALUZ	250MG	A060593	001		Sep	CAHN
---	---------	-------	---------	-----	--	-----	------

CYCLOSPORINE

EMULSION; OPHTHALMIC

CYCLOSPORINE

AB	DEVA HOLDING AS	0.05%	A209811	001	May 21, 2024	May	NEWA
AB	SAPTALIS PHARMS	0.05%	A211943	001	Jul 05, 2024	Jun	NEWA
>D>	@	TEVA PHARMS USA INC	A203880	001	Dec 14, 2023	Oct	CMFD
>A>	AB		A203880	001	Dec 14, 2023	Oct	CMFD
	@		A203880	001	Dec 14, 2023	Jun	DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

	@	PATRIN	2MG/5ML	A204823	001	Dec 27, 2016	Apr	DISC
	@	PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013	Feb	DISC
AA	!	RISING	2MG/5ML	A040668	001	Jun 28, 2006	Sep	CAHN

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

@	CHARTWELL RX	4MG	A086808	001		Aug	CAHN
---	--------------	-----	---------	-----	--	-----	------

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

ELCYS

+	@	EXELA PHARMA	2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023	Jan	DISC
---	---	--------------	-----------------------	---------	-----	--------------	-----	------

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

DABIGATRAN ETEXILATE MESYLATE

AB	ALEMBIC	EQ 75MG BASE	A215233	001	Jun 14, 2024	Jun	NEWA
AB		EQ 110MG BASE	A215233	003	Aug 12, 2024	Aug	NEWA
AB		EQ 150MG BASE	A215233	002	Jun 14, 2024	Jun	NEWA
AB	ALKEM LABS LTD	EQ 110MG BASE	A208040	003	Sep 11, 2024	Aug	NEWA
AB	HETERO LABS LTD III	EQ 110MG BASE	A207961	003	Aug 13, 2024	Aug	NEWA
AB	MSN	EQ 75MG BASE	A213879	001	May 22, 2024	May	NEWA
AB		EQ 110MG BASE	A213879	003	Aug 12, 2024	Aug	NEWA
AB		EQ 150MG BASE	A213879	002	May 22, 2024	May	NEWA

<u>DACTINOMYCIN</u>										
INJECTABLE; INJECTION										
COSMEGEN										
	+	@ RECORDATI RARE	0.5MG/VIAL		N050682	001			Jan	DISC
AP	!	EUGIA PHARMA	0.5MG/VIAL		A203385	001	Nov 09, 2017		Jan	CHRS
<u>DALFOPRISTIN; QUINUPRISTIN</u>										
INJECTABLE; INTRAVENOUS										
SYNERCID										
	+	@ KING PHARMS	350MG/VIAL;150MG/VIAL		N050748	001	Sep 21, 1999		Sep	DISC
<u>DANICOPAN</u>										
TABLET; ORAL										
VOYDEYA										
	+	ALEXION PHARMS INC	50MG		N218037	001	Mar 29, 2024		Mar	NEWA
	+	!	100MG		N218037	002	Mar 29, 2024		Mar	NEWA
<u>DAPIPRAZOLE HYDROCHLORIDE</u>										
SOLUTION/DROPS; OPHTHALMIC										
DAPIPRAZOLE HYDROCHLORIDE										
	@	BARADAINA LLC	0.5%		A204902	001	May 30, 2019		Aug	CAHN
<u>DAPRODUSTAT</u>										
TABLET; ORAL										
JESDUVROQ										
	+	@ GLAXOSMITHKLINE	1MG		N216951	001	Feb 01, 2023		May	DISC
	+	@	2MG		N216951	002	Feb 01, 2023		May	DISC
	+	@	4MG		N216951	003	Feb 01, 2023		May	DISC
	+	@	6MG		N216951	004	Feb 01, 2023		May	DISC
	+	@	8MG		N216951	005	Feb 01, 2023		May	DISC
<u>DAPSONE</u>										
GEL; TOPICAL										
DAPSONE										
AB		ACRUX DDS	7.5%		A213636	001	Aug 26, 2024		Aug	NEWA
	@	PADAGIS ISRAEL	5%		A215087	001	Oct 31, 2023		Jan	DISC
	@		7.5%		A212657	001	Nov 01, 2023		Jan	DISC
AB		TARO	5%		A209506	001	Oct 16, 2017		Jun	CAHN
AB		TRUPHARMA	5%		A213907	001	Jun 06, 2023		Sep	CAHN
AB			7.5%		A213636	001	Aug 26, 2024		Sep	CAHN
AB		ZYDUS	7.5%		A214019	001	May 08, 2024		Apr	NEWA
AB		ZYDUS LIFESCIENCES	7.5%		A214019	001	May 08, 2024		May	CAHN
<u>DAPTOMYCIN</u>										
POWDER; INTRAVENOUS										
DAPTOMYCIN										
AP		BIOCON PHARMA	500MG/VIAL		A217215	001	Aug 29, 2024		Aug	NEWA
AP		FRESENIUS KABI USA	350MG/VIAL		A213396	001	Aug 01, 2024		Jul	NEWA
<u>DARIFENACIN HYDROBROMIDE</u>										
TABLET, EXTENDED RELEASE; ORAL										
DARIFENACIN HYDROBROMIDE										
	@	ENDO OPERATIONS	EQ 7.5MG BASE		A091190	001	Mar 13, 2015		May	CAHN
	@		EQ 15MG BASE		A091190	002	Mar 13, 2015		May	CAHN
<u>DARUNAVIR</u>										
TABLET; ORAL										
DARUNAVIR										
AB		ZYDUS LIFESCIENCES	600MG		A214085	001	Dec 13, 2023		May	CAHN
AB			800MG		A214085	002	Dec 13, 2023		May	CAHN
<u>DASATINIB</u>										
TABLET; ORAL										
DASATINIB										
AB		APOTEX	20MG		A202103	001	Jun 10, 2016		Aug	CMFD
AB			50MG		A202103	002	Jun 10, 2016		Aug	CMFD
AB			70MG		A202103	003	Jun 10, 2016		Aug	CMFD
AB			80MG		A203180	001	Nov 23, 2021		Aug	CMFD
AB			100MG		A202103	004	Jun 10, 2016		Aug	CMFD
AB			140MG		A203180	002	Nov 23, 2021		Aug	CMFD

TABLET;ORAL
SPRYCEL

AB	+	BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	Aug CTEC
AB	+		50MG	N021986	002	Jun 28, 2006	Aug CTEC
AB	+		70MG	N021986	003	Jun 28, 2006	Aug CTEC
AB	+		80MG	N021986	005	Oct 28, 2010	Aug CTEC
AB	+		100MG	N021986	004	May 30, 2008	Aug CTEC
AB	+		140MG	N021986	006	Oct 28, 2010	Aug CTEC

DECITABINE

INJECTABLE;INTRAVENOUS
DECITABINE

AP		HETERO LABS LTD VI	50MG/VIAL	A215355	001	May 10, 2024	May NEWA
----	--	--------------------	-----------	---------	-----	--------------	----------

DEFERASIROX

TABLET, FOR SUSPENSION;ORAL
DEFERASIROX

AB		GLENMARK SPECLT	125MG	A209433	001	Jan 06, 2020	May CAHN
AB			250MG	A209433	002	Jan 06, 2020	May CAHN
AB			500MG	A209433	003	Jan 06, 2020	May CAHN
AB		TEVA PHARMS USA	125MG	A207124	001	Sep 23, 2022	Jul CMFD
AB			250MG	A207124	002	Sep 23, 2022	Jul CMFD
AB			500MG	A207124	003	Sep 23, 2022	Jul CMFD
>A>	AB	TORRENT	125MG	A209426	001	Nov 05, 2024	Oct NEWA
>A>	AB		250MG	A209426	002	Nov 05, 2024	Oct NEWA
>A>	AB		500MG	A209426	003	Nov 05, 2024	Oct NEWA

DEFLAZACORT

SUSPENSION;ORAL
DEFLAZACORT

AB		TRIS PHARMA INC	22.75MG/ML	A217813	001	Apr 25, 2024	Apr NFTG
		EMFLAZA					
AB	+	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr CFTG
		TABLET;ORAL					
		DEFLAZACORT					
AB		AUROBINDO PHARMA LTD	6MG	A217123	001	Feb 09, 2024	Feb NFTG
AB			18MG	A217123	002	Feb 09, 2024	Feb NFTG
AB			30MG	A217123	003	Feb 09, 2024	Feb NFTG
AB			36MG	A217123	004	Feb 09, 2024	Feb NFTG
>A>	AB	UPSHER SMITH LABS	6MG	A216720	001	Nov 05, 2024	Oct NEWA
>A>	AB		18MG	A216720	002	Nov 05, 2024	Oct NEWA
>A>	AB		30MG	A216720	003	Nov 05, 2024	Oct NEWA
>A>	AB		36MG	A216720	004	Nov 05, 2024	Oct NEWA
		EMFLAZA					
AB	+	PTC THERAP	6MG	N208684	001	Feb 09, 2017	Feb CFTG
AB	+		18MG	N208684	002	Feb 09, 2017	Feb CFTG
AB	+		30MG	N208684	003	Feb 09, 2017	Feb CFTG
AB	+		36MG	N208684	004	Feb 09, 2017	Feb CFTG

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS
DEOXYCHOLIC ACID

AP		WILSHIRE PHARMS INC	20MG/2ML (10MG/ML)	A212296	001	Apr 02, 2021	Jul CAHN
		KYBELLA					
AP	+	ABBVIE	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Jan CAHN

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL
DESIPRAMINE HYDROCHLORIDE

AB		CHARTWELL RX	10MG	A072103	002	May 24, 1988	Mar CAHN
AB			25MG	A072103	003	May 24, 1988	Mar CAHN
AB			50MG	A072103	004	May 24, 1988	Mar CAHN
AB			75MG	A072103	005	Jun 20, 1988	Mar CAHN
AB			100MG	A072103	001	Jun 20, 1988	Mar CAHN
AB			150MG	A072103	006	Jun 20, 1988	Mar CAHN

DESLORATADINE

TABLET;ORAL
DESLORATADINE
@ CHARTWELL RX

			5MG	A078364	001	Dec 03, 2010	Jan CAHN
--	--	--	-----	---------	-----	--------------	----------

DESMOPRESSIN ACETATE

		INJECTABLE; INJECTION							
		DESMOPRESSIN ACETATE							
>D>	AP	SUN PHARM INDS LTD	0.004MG/ML	A091280	001	Jan 25, 2013	Oct	DISC	
>A>		@	0.004MG/ML	A091280	001	Jan 25, 2013	Oct	DISC	
		TABLET; ORAL							
		DESMOPRESSIN ACETATE							
		@ ACTAVIS LABS FL INC	0.1MG	A076470	001	Jul 01, 2005	Feb	DISC	
		@	0.2MG	A076470	002	Jul 01, 2005	Feb	DISC	
AB		AUROBINDO PHARMA	0.1MG	A213095	001	Mar 21, 2024	Mar	NEWA	
AB			0.2MG	A213095	002	Mar 21, 2024	Mar	NEWA	

DESOGESTREL; ETHINYL ESTRADIOL

		TABLET; ORAL-28							
		DESOGESTREL AND ETHINYL ESTRADIOL							
AB		NAARI PTE LTD	0.15MG;0.03MG	A207067	001	Sep 13, 2018	Apr	CMFD	
		@ XIROMED	0.15MG;0.03MG	A202085	001	May 20, 2015	Apr	CAHN	
		EMOQUETTE							
		@ ENDO OPERATIONS	0.15MG;0.03MG	A076675	001	Feb 25, 2011	May	CAHN	
		KIMIDESS							
		@ ENDO OPERATIONS	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	Aug	DISC	
AB			0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	May	CAHN	

DESONIDE

		OINTMENT; TOPICAL							
		DESONIDE							
		@ HIKMA	0.05%	A208836	001	Mar 27, 2017	Mar	DISC	

DESOXIMETASONE

		CREAM; TOPICAL							
		DESOXIMETASONE							
		@ COSETTE	0.25%	A209595	001	Mar 04, 2020	Mar	DISC	
		OINTMENT; TOPICAL							
		DESOXIMETASONE							
		@ COSETTE	0.25%	A206740	001	Dec 23, 2016	Apr	DISC	

DESVENLAFAXINE SUCCINATE

		TABLET, EXTENDED RELEASE; ORAL							
		DESVENLAFAXINE SUCCINATE							
		@ NORVIUM BIOSCIENCE	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun	CAHN	
		@	EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun	CAHN	

DEURUXOLITINIB PHOSPHATE

		TABLET; ORAL							
		LEQSELVI							
		+! SUN PHARM INDS INC	EQ 8MG BASE	N217900	001	Jul 25, 2024	Jul	NEWA	

DEUTETRABENAZINE

		TABLET, EXTENDED RELEASE; ORAL							
		AUSTEDO XR							
		+ TEVA	18MG	N216354	008	Jul 01, 2024	Jul	NEWA	
		+	30MG	N216354	004	May 29, 2024	May	NEWA	
		+	36MG	N216354	005	May 29, 2024	May	NEWA	
		+	42MG	N216354	006	May 29, 2024	May	NEWA	
>D>			48MG	N216354	007	May 29, 2024	Oct	CRLD	
>A>		+	48MG	N216354	007	May 29, 2024	Oct	CRLD	
			48MG	N216354	007	May 29, 2024	May	NEWA	

DEXAMETHASONE

		ELIXIR; ORAL							
		DEXAMETHASONE							
AA	!	KANCHAN HLTHCARE	0.5MG/5ML	A084754	001		Aug	CAHN	
AA		RISING	0.5MG/5ML	A090891	001	Jul 12, 2011	Sep	CAHN	
		TABLET; ORAL							
		DEXAMETHASONE							
		@ ABRAXEOLUS	0.25MG	A088149	001	Apr 28, 1983	Sep	CAHN	
AB		COREPHARMA	0.5MG	A218372	001	Sep 17, 2024	Sep	NEWA	
AB			0.75MG	A218372	002	Sep 17, 2024	Sep	NEWA	
AB			1MG	A218372	003	Sep 17, 2024	Sep	NEWA	
AB			1.5MG	A218372	004	Sep 17, 2024	Sep	NEWA	
AB			2MG	A218372	005	Sep 17, 2024	Sep	NEWA	

TABLET;ORAL

DEXAMETHASONE

AB		4MG	A218372	006	Sep 17, 2024	Sep NEWA
AB		6MG	A218372	007	Sep 17, 2024	Sep NEWA
	@ KEY THERAP	1.5MG	A088237	001	Apr 28, 1983	May DISC
BP		1.5MG	A088237	001	Apr 28, 1983	Apr CAHN
	@ PANGEA	0.25MG	A088149	001	Apr 28, 1983	Jan CAHN
AB	ZYDUS LIFESCIENCES	0.5MG	A216282	001	Feb 07, 2024	Mar CAHN
AB		0.75MG	A216282	002	Feb 07, 2024	Mar CAHN
AB		1MG	A216284	001	May 09, 2024	May CAHN
AB		1.5MG	A216282	003	Feb 07, 2024	Mar CAHN
AB		2MG	A216283	001	Feb 07, 2024	Mar CAHN
AB		4MG	A216282	004	Feb 07, 2024	Mar CAHN
AB		6MG	A216282	005	Feb 07, 2024	Mar CAHN
AB	ZYDUS PHARMS	0.5MG	A216282	001	Feb 07, 2024	Jan NEWA
AB		0.75MG	A216282	002	Feb 07, 2024	Jan NEWA
AB		1MG	A216284	001	May 09, 2024	May NEWA
AB		1.5MG	A216282	003	Feb 07, 2024	Jan NEWA
AB		2MG	A216283	001	Feb 07, 2024	Jan NEWA
AB		4MG	A216282	004	Feb 07, 2024	Jan NEWA
AB		6MG	A216282	005	Feb 07, 2024	Jan NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

	@ GENEYORK PHARMS	EQ 4MG PHOSPHATE/ML	A214890	002	Jul 28, 2023	Jul CMS1
	@	EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Feb DISC
AP	HIKMA	EQ 4MG PHOSPHATE/ML	A084282	001		Jun CAHN
	@	EQ 4MG PHOSPHATE/ML	A211451	001	Aug 01, 2023	Jul DISC
AP	!	EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Jun CAHN
AP	MICRO LABS	EQ 10MG PHOSPHATE/ML	A217797	001	Mar 27, 2024	Mar NEWA

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

	+ @ PAI HOLDINGS PHARM	2MG/5ML	A088251	001	Mar 23, 1984	Mar DISC
		POLMON				
	! CAPELLON PHARMS LLC	2MG/5ML	A202520	001	Jul 16, 2018	Mar CTEC
AA	!	2MG/5ML	A202520	001	Jul 16, 2018	Mar CHRS

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXLANSOPRAZOLE

AB	MYLAN	30MG	A205205	001	Jan 19, 2024	Jan NEWA
AB		60MG	A205205	002	Jan 19, 2024	Jan NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

	@ WILSHIRE PHARMS INC	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A212791	003	May 08, 2020	Jul CAHN
AP		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A212791	001	Dec 04, 2019	Jul CAHN
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A212791	002	Dec 04, 2019	Jul CAHN

SOLUTION;INTRAVENOUS

DEXMEDETOMIDINE HYDROCHLORIDE

AP	+! HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628	002	Oct 21, 2015	Sep CFTG
AP	+	EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001	Oct 21, 2015	Sep CFTG
AP	SOMERSET	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	A218112	002	Sep 24, 2024	Sep NFTG
AP		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	A218112	001	Sep 24, 2024	Sep NFTG

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXEDRINE SPANSULE

AB	+ IMPAX LABS INC	5MG	N017078	001		Aug CTNA
AB	+	10MG	N017078	002		Aug CTNA
AB	+!	15MG	N017078	003		Aug CTNA

CAPSULE, EXTENDED RELEASE; ORAL
DEXTROAMPHETAMINE SULFATE

	@ NORVIUM BIOSCIENCE	5MG	A206735	001	Jan 27, 2016	Jun	CAHN
	@	10MG	A206735	002	Jan 27, 2016	Jun	CAHN
	@	15MG	A206735	003	Jan 27, 2016	Jun	CAHN

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	AZURITY	2.5MG	A090533	001	Oct 25, 2011	Mar	CAHN
AA		5MG	A090533	002	Oct 25, 2011	Mar	CAHN
AA		7.5MG	A090533	003	Oct 25, 2011	Mar	CAHN
AA		10MG	A090533	004	Oct 25, 2011	Mar	CAHN
AA		15MG	A090533	005	Oct 25, 2011	Mar	CAHN
AA		20MG	A090533	006	Oct 25, 2011	Mar	CAHN
AA		30MG	A090533	007	Oct 25, 2011	Mar	CAHN
	@ TRIS PHARMA INC	5MG	A206095	001	Aug 18, 2022	Jan	DISC
	@	10MG	A206095	002	Aug 18, 2022	Jan	DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	+ ANI PHARMS	15MG/5ML; 6.25MG/5ML	N011265	002	Apr 02, 1984	Sep	CMFD
----	--------------	----------------------	---------	-----	--------------	-----	------

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

AB	HETERO LABS LTD III	20MG; 10MG	A218426	001	Aug 28, 2024	Aug	NEWA
----	---------------------	------------	---------	-----	--------------	-----	------

DIAZEPAM

FILM; BUCCAL

LIBERVANT

	+ AQUESTIVE	5MG	N218623	001	Apr 26, 2024	Apr	NEWA
	+	7.5MG	N218623	002	Apr 26, 2024	Apr	NEWA
	+	10MG	N218623	003	Apr 26, 2024	Apr	NEWA
	+	12.5MG	N218623	004	Apr 26, 2024	Apr	NEWA
	+!	15MG	N218623	005	Apr 26, 2024	Apr	NEWA

INJECTABLE; INJECTION

DIAZEPAM

AP	ALEMBIC	10MG/2ML (5MG/ML)	A218450	001	Apr 25, 2024	Apr	NEWA
AP	DR REDDYS	10MG/2ML (5MG/ML)	A218422	001	Jul 18, 2024	Jul	NEWA
	@ HIKMA	5MG/ML (5MG/ML)	A070311	002	Dec 16, 1985	Jan	NEWA
	@	10MG/2ML (5MG/ML)	A070311	003	Dec 16, 1985	Jan	NEWA
AP		50MG/10ML (5MG/ML)	A070311	001	Dec 16, 1985	Jan	CPOT

TABLET; ORAL

DIAZEPAM

	@ ENDO OPERATIONS	2MG	A070228	002	Sep 26, 1985	May	CAHN
	@	5MG	A070228	003	Sep 26, 1985	May	CAHN
	@	10MG	A070228	001	Sep 26, 1985	May	CAHN
AB	NUVO PHARM	2MG	A070464	002	Sep 10, 2024	Aug	NEWA
AB		5MG	A070464	003	Sep 10, 2024	Aug	NEWA

DICHLORPHENAMIDE

TABLET; ORAL

ORMALVI

AB	TORRENT	50MG	A215924	001	Dec 29, 2022	Feb	CTNA
----	---------	------	---------	-----	--------------	-----	------

DICLOFENAC POTASSIUM

FOR SOLUTION; ORAL

DICLOFENAC POTASSIUM

AB	ENDO OPERATIONS	50MG	A202964	001	May 02, 2016	May	CAHN
AB	TARO	50MG	A218011	001	Jun 14, 2024	Jun	NEWA

TABLET; ORAL

CATAFLAM

>D>	AB	AMICI	25MG	A076561	002	Jul 21, 2021	Oct	CAHN
>D>	AB		50MG	A076561	001	Mar 18, 2004	Oct	CAHN
>A>	AB	AMICI PHARMA	25MG	A076561	002	Jul 21, 2021	Oct	CAHN
>A>	AB		50MG	A076561	001	Mar 18, 2004	Oct	CAHN

DICLOFENAC SODIUM

SOLUTION;TOPICAL
 DICLOFENAC SODIUM
 AB ! LUPIN PHARMS 2% A208021 001 Sep 20, 2022 Mar CHRS

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL
 DICLOFENAC SODIUM AND MISOPROSTOL
 @ SANDOZ 50MG;0.2MG A200158 001 May 09, 2013 Jul DISC
 @ 75MG;0.2MG A200158 002 May 09, 2013 Jul DISC

DICLOXACILLIN SODIUM

CAPSULE;ORAL
 DICLOXACILLIN SODIUM
 @ CHARTWELL RX EQ 125MG BASE A061454 002 Jul CAHN
 @ EQ 250MG BASE A061454 001 Jul CAHN
 @ EQ 500MG BASE A061454 003 Jul CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL
 DICYCLOMINE HYDROCHLORIDE
 AB ANNORA PHARMA 10MG A218018 001 Jul 01, 2024 Jun NEWA
 INJECTABLE;INJECTION
 BENTYL
 + @ ABBVIE 10MG/ML N008370 001 Oct 15, 1984 Apr DISC
 BENTYL PRESERVATIVE FREE
 + @ ABBVIE 10MG/ML N008370 002 Oct 15, 1984 Aug DISC
 DICYCLOMINE HYDROCHLORIDE
 AP ! FOSUN PHARMA 10MG/ML A210979 001 Jul 02, 2018 Apr CHRS
 >A> AP SOMERSET THERAPS LLC 10MG/ML A214332 001 Nov 01, 2024 Oct NEWA
 >A> AP 10MG/ML A214333 001 Nov 01, 2024 Oct NEWA
 DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)
 AP ! HIKMA 10MG/ML A040465 001 Jun 30, 2003 Aug CHRS
 SYRUP;ORAL
 DICYCLOMINE HYDROCHLORIDE
 AA ! ENDO OPERATIONS 10MG/5ML A040169 001 Mar 24, 2005 Apr CAHN
 TABLET;ORAL
 DICYCLOMINE HYDROCHLORIDE
 AB ANNORA PHARMA 20MG A217566 001 May 07, 2024 Apr NEWA

DIFLORASONE DIACETATE

CREAM;TOPICAL
 DIFLORASONE DIACETATE
 @ ANI PHARMS 0.05% A076263 001 Dec 20, 2002 Sep DISC
 OINTMENT;TOPICAL
 DIFLORASONE DIACETATE
 @ SAPTALIS PHARMS 0.05% A206572 001 Jul 24, 2015 Jun CAHN
 @ SCIEGEN PHARMS INC 0.05% A206572 001 Jul 24, 2015 Aug CAHN

DIFLUNISAL

TABLET;ORAL
 DIFLUNISAL
 HERITAGE PHARMA 250MG A202845 002 Aug 16, 2024 Aug NEWA
 375MG A202845 003 Aug 16, 2024 Aug NFTG

DIFLUPREDNATE

EMULSION;OPHTHALMIC
 DIFLUPREDNATE
 AB EPIC PHARMA LLC 0.05% A207284 001 May 14, 2024 May NEWA

DIGOXIN

ELIXIR;ORAL
 DIGOXIN
 >D> AA AMICI 0.05MG/ML A215209 001 Mar 11, 2022 Oct CAHN
 >A> AA AMICI PHARMA 0.05MG/ML A215209 001 Mar 11, 2022 Oct CAHN
 AA VISTAPHARM LLC 0.05MG/ML A213000 001 Oct 04, 2019 Feb CAHN
 INJECTABLE;INJECTION
 DIGOXIN
 AP HIKMA 0.25MG/ML A083391 001 Jun CAHN

DIHYDROERGOTAMINE MESYLATE

		INJECTABLE; INJECTION							
		DIHYDROERGOTAMINE MESYLATE							
AP	CIPLA	1MG/ML		A212334	001	Sep 20, 2024	Sep	NEWA	
		SPRAY, METERED; NASAL							
		DIHYDROERGOTAMINE MESYLATE							
	@ AMNEAL	0.5MG/SPRAY		A214105	001	Jan 04, 2022	Mar	DISC	
	TRUDHESA								
	+! IMPEL PHARMS	0.725MG/SPRAY		N213436	001	Sep 02, 2021	Jun	CAHN	
	+! JN BIDCO	0.725MG/SPRAY		N213436	001	Sep 02, 2021	Feb	CAHN	

DILTIAZEM HYDROCHLORIDE

		CAPSULE, EXTENDED RELEASE; ORAL							
		DILTIAZEM HYDROCHLORIDE							
>A>	AB2	ALEMBIC	120MG	A218587	001	Oct 18, 2024	Oct	NEWA	
>A>	AB2		180MG	A218587	002	Oct 18, 2024	Oct	NEWA	
>A>	AB2		240MG	A218587	003	Oct 18, 2024	Oct	NEWA	
	AB3	ENDO OPERATIONS	120MG	A074984	001	Dec 20, 1999	Apr	CAHN	
	AB3		180MG	A074984	002	Dec 20, 1999	Apr	CAHN	
	AB3		240MG	A074984	003	Dec 20, 1999	Apr	CAHN	
	AB3		300MG	A074984	004	Dec 20, 1999	Apr	CAHN	
		@	360MG	A209766	001	May 30, 2018	May	CAHN	
		@ SUN PHARM	360MG	A090492	005	Oct 28, 2011	Feb	DISC	
	AB2	UTOPIC PHARMS	120MG	A216304	001	Aug 08, 2022	Sep	CAHN	
	AB2		180MG	A216304	002	Aug 08, 2022	Sep	CAHN	
	AB2		240MG	A216304	003	Aug 08, 2022	Sep	CAHN	
		TAZTIA XT							
		@ ACTAVIS LABS FL INC	120MG	A075401	001	Apr 10, 2003	Jul	DISC	
		@	180MG	A075401	002	Apr 10, 2003	Jul	DISC	
		@	240MG	A075401	003	Apr 10, 2003	Jul	DISC	
		@	300MG	A075401	004	Apr 10, 2003	Jul	DISC	
		@	360MG	A075401	005	Apr 10, 2003	Jul	DISC	
		INJECTABLE; INJECTION							
		DILTIAZEM HYDROCHLORIDE							
AP	HIKMA	5MG/ML		A078538	001	Dec 17, 2008	Mar	CAHN	
	@ HIKMA FARMACEUTICA	5MG/ML		A202651	001	Aug 09, 2012	Mar	DISC	

DIMETHYL FUMARATE

		CAPSULE, DELAYED RELEASE; ORAL							
		DIMETHYL FUMARATE							
AB	MACLEODS PHARMS LTD	120MG		A210377	001	Jun 26, 2024	Jun	NEWA	
AB		240MG		A210377	002	Jun 26, 2024	Jun	NEWA	

DIPHENHYDRAMINE HYDROCHLORIDE

		INJECTABLE; INJECTION							
		DIPHENHYDRAMINE HYDROCHLORIDE							
AP	GLAND PHARMA LTD	50MG/ML		A218448	001	Mar 20, 2024	Mar	NEWA	
	@ HIKMA	50MG/ML		A083183	001		Jun	CAHN	
AP	! MYLAN INSTITUTIONAL	50MG/ML		A040498	001	Jul 12, 2005	May	CHRS	

DIPYRIDAMOLE

		TABLET; ORAL							
		DIPYRIDAMOLE							
		@ CHARTWELL RX	25MG	A040898	001	Apr 23, 2008	Aug	CAHN	
		@	50MG	A040898	002	Apr 23, 2008	Aug	CAHN	
		@	75MG	A040898	003	Apr 23, 2008	Aug	CAHN	
		@ GENUS	25MG	A040898	001	Apr 23, 2008	Jan	CAHN	
		@	50MG	A040898	002	Apr 23, 2008	Jan	CAHN	
		@	75MG	A040898	003	Apr 23, 2008	Jan	CAHN	
AB	! IMPAX LABS	75MG		A040782	003	Jul 18, 2007	May	CHRS	
		PERSANTINE							
	+ @ BOEHRINGER INGELHEIM	25MG		N012836	003	Dec 22, 1986	May	DISC	
	+ @	50MG		N012836	004	Feb 06, 1987	May	DISC	
	+ @	75MG		N012836	005	Feb 06, 1987	May	DISC	

DIVALPROEX SODIUM

		TABLET, DELAYED RELEASE; ORAL							
		DIVALPROEX SODIUM							
		@ ENDO OPERATIONS	EQ 500MG VALPROIC ACID	A078411	001	Nov 03, 2008	May	CAHN	
		@ NORVIUM BIOSCIENCE	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009	Jun	CAHN	
		@	EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009	Jun	CAHN	

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

@ EQ 500MG VALPROIC ACID A090062 003 Mar 17, 2009 Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

@ ENDO OPERATIONS EQ 250MG VALPROIC ACID A078445 001 Feb 26, 2009 May CAHN

@ EQ 500MG VALPROIC ACID A078445 002 Aug 04, 2009 May CAHN

@ UTOPIC PHARMS EQ 250MG VALPROIC ACID A214462 001 Mar 15, 2021 Sep CAHN

@ EQ 500MG VALPROIC ACID A214462 002 Mar 15, 2021 Sep CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DOBUTAMINE HYDROCHLORIDE

AP SLATE RUN PHARMA EQ 12.5MG BASE/ML A216131 001 Dec 21, 2022 Sep CAHN

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

AP ACIC PHARMS 80MG/4ML (20MG/ML) A216677 002 Feb 28, 2024 Feb NEWA

AP 20MG/ML (20MG/ML) A216677 001 Feb 28, 2024 Feb NEWA

AP HERITAGE 80MG/4ML (20MG/ML) A216677 002 Feb 28, 2024 Sep CAHN

AP 20MG/ML (20MG/ML) A216677 001 Feb 28, 2024 Sep CAHN

@ NORVIUM BIOSCIENCE 20MG/ML (20MG/ML) A203892 001 May 11, 2023 Jun CAHN

@ 80MG/4ML (20MG/ML) A203892 002 May 11, 2023 Jun CAHN

SOLUTION;INTRAVENOUS

>A> BEIZRAY

>A> +! ZHUHAI 80MG/4ML (20MG/ML) N218711 001 Oct 23, 2024 Oct NEWA

DOCIVYX

+! AVYXA HOLDINGS 20MG/2ML (10MG/ML) N215813 001 Nov 22, 2022 Apr CMFD

+ @ 20MG/2ML (10MG/ML) N215813 001 Nov 22, 2022 Apr CTNA

+ @ 20MG/2ML (10MG/ML) N215813 001 Nov 22, 2022 Jan CAHN

+! 80MG/8ML (10MG/ML) N215813 002 Nov 22, 2022 Apr CMFD

+ @ 80MG/8ML (10MG/ML) N215813 002 Nov 22, 2022 Apr CTNA

+ @ 80MG/8ML (10MG/ML) N215813 002 Nov 22, 2022 Jan CAHN

+! 160MG/16ML (10MG/ML) N215813 003 Nov 22, 2022 Apr CMFD

+ @ 160MG/16ML (10MG/ML) N215813 003 Nov 22, 2022 Apr CTNA

+ @ 160MG/16ML (10MG/ML) N215813 003 Nov 22, 2022 Jan CAHN

DOLASETRON MESYLATE

TABLET;ORAL
ANZEMET

+ @ VALIDUS PHARMS 50MG N020623 001 Sep 11, 1997 Jun DISC

DOLUTEGRAVIR SODIUM

TABLET;ORAL
TIVICAY

+ @ VIIV HLTHCARE EQ 10MG BASE N204790 002 Jun 09, 2016 Jan DISC

+ @ EQ 25MG BASE N204790 003 Jun 09, 2016 Jan DISC

DONEPEZIL HYDROCHLORIDE

SYSTEM;TRANSDERMAL
ADLARITY

+ CORIUM 5MG/DAY N212304 001 Mar 11, 2022 Jun CAHN

+! 10MG/DAY N212304 002 Mar 11, 2022 Jun CAHN

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

@ ENDO OPERATIONS 23MG A202542 001 Jul 24, 2013 May CAHN

@ SUN PHARM INDS 5MG A090493 001 May 31, 2011 May DISC

@ 10MG A090493 002 May 31, 2011 May DISC

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

AB ! MACLEODS PHARMS LTD 10MG A201787 002 Dec 14, 2012 Mar CHRS

@ SANDOZ 5MG A091198 001 May 10, 2011 Mar DISC

@ 10MG A091198 002 May 10, 2011 Mar DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

@ HIKMA EQ 2% BASE A077846 001 Oct 28, 2008 Mar DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@ HIKMA	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	Mar	DISC
---------	-------------------------	---------	-----	--------------	-----	------

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB	AUROBINDO PHARMA USA	EQ 1MG BASE	A075509	001	Oct 19, 2000	Mar	CMFD
AB		EQ 2MG BASE	A075509	002	Oct 19, 2000	Mar	CMFD
AB		EQ 4MG BASE	A075509	003	Oct 19, 2000	Mar	CMFD
AB		EQ 8MG BASE	A075509	004	Oct 19, 2000	Mar	CMFD

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	ADAPTIS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Sep	CAHN
AB	AIPING PHARM INC	EQ 10MG BASE	A213474	001	Jul 28, 2020	Sep	CAHN
AB		EQ 25MG BASE	A213474	002	Jul 28, 2020	Sep	CAHN
AB		EQ 50MG BASE	A213474	003	Jul 28, 2020	Sep	CAHN
AB		EQ 75MG BASE	A213474	004	Jul 28, 2020	Sep	CAHN
AB		EQ 100MG BASE	A213474	005	Jul 28, 2020	Sep	CAHN
	@ ENDO OPERATIONS	EQ 10MG BASE	A071422	002	Nov 09, 1987	Apr	CAHN
	@	EQ 25MG BASE	A071422	003	Nov 09, 1987	Apr	CAHN
	@	EQ 50MG BASE	A071422	004	Nov 09, 1987	Apr	CAHN
	@	EQ 75MG BASE	A071422	005	Nov 09, 1987	Apr	CAHN
	@	EQ 100MG BASE	A071422	001	Nov 09, 1987	Apr	CAHN
AB	!	EQ 150MG BASE	A071422	006	Nov 09, 1987	Apr	CAHN
AB	LEADING	EQ 10MG BASE	A211619	001	Mar 09, 2021	Aug	CAHN
AB		EQ 25MG BASE	A211619	002	Mar 09, 2021	Aug	CAHN
AB		EQ 50MG BASE	A211619	003	Mar 09, 2021	Aug	CAHN
AB		EQ 75MG BASE	A211619	004	Mar 09, 2021	Aug	CAHN
AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Aug	CAHN
AB	VELZEN PHARMA PVT	EQ 150MG BASE	A211618	001	Mar 01, 2021	Aug	CAHN

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB	AJANTA PHARMA LTD	EQ 3MG BASE	A218564	001	Jul 01, 2024	Jun	NEWA
AB		EQ 6MG BASE	A218564	002	Jul 01, 2024	Jun	NEWA
	@ AUROBINDO PHARMA LTD	EQ 3MG BASE	A216041	001	Jul 25, 2024	Aug	DISC
AB		EQ 3MG BASE	A216041	001	Jul 25, 2024	Jul	NEWA
	@	EQ 6MG BASE	A216041	002	Jul 25, 2024	Aug	DISC
AB		EQ 6MG BASE	A216041	002	Jul 25, 2024	Jul	NEWA
AB	ZYDUS LIFESCIENCES	EQ 3MG BASE	A202761	001	Aug 16, 2023	Sep	CMFD
	@	EQ 3MG BASE	A202761	001	Aug 16, 2023	Jun	CAHN
AB		EQ 6MG BASE	A202761	002	Aug 16, 2023	Sep	CMFD
	@	EQ 6MG BASE	A202761	002	Aug 16, 2023	Jun	CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

	@ AMNEAL	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	Jan	DISC
	@	4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	Jan	DISC
	@	4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jul	DISC
AP		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jan	CMFD

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

>D>	+	PFIZER	150MG/75ML	N050629	003	Mar 28, 2011	Oct	DISC
>A>	+	@	150MG/75ML	N050629	003	Mar 28, 2011	Oct	DISC

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	FORDOZ	20MG/10ML (2MG/ML)	A215178	001	Jul 16, 2024	Jul	NEWA
AB		50MG/25ML (2MG/ML)	A215178	002	Jul 16, 2024	Jul	NEWA
AB	LUPIN	20MG/10ML (2MG/ML)	A215178	001	Jul 16, 2024	Sep	CAHN
AB		50MG/25ML (2MG/ML)	A215178	002	Jul 16, 2024	Sep	CAHN

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB	ALEMBIC	40MG	A217674	001	Jun 27, 2024	Jun	NEWA
AB	APOTEX	40MG	A217170	001	Jul 11, 2024	Jul	NEWA
	@ COSETTE	EQ 50MG BASE	A204446	001	May 28, 2015	Apr	DISC
	@	EQ 75MG BASE	A204446	002	May 28, 2015	Apr	DISC
	@	EQ 100MG BASE	A204446	003	May 28, 2015	Apr	DISC
AB	DR REDDYS	40MG	A218034	001	Apr 08, 2024	Mar	NFTG
AB	LUPIN	40MG	A216631	001	Apr 08, 2024	Mar	NFTG
	ORACEA						
AB	+! GALDERMA LABS LP	40MG	N050805	001	May 26, 2006	Mar	CFTG
	FOR SUSPENSION;ORAL						
	DOXYCYCLINE						
AB	! LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013	Jun	CHRS
	VIBRAMYCIN						
	+ @ PFIZER	EQ 25MG BASE/5ML	N050006	001		Jun	DISC
	TABLET;ORAL						
	DOXYCYCLINE						
	@ SOMERSET THERAPS LLC	EQ 50MG BASE	A065377	001	Nov 07, 2006	Sep	CAHN
	@	EQ 75MG BASE	A065377	002	Nov 07, 2006	Sep	CAHN
	@	EQ 100MG BASE	A065377	003	Nov 07, 2006	Sep	CAHN
	@	EQ 150MG BASE	A065427	001	Jun 07, 2007	Sep	CAHN

DOXYCYCLINE CALCIUM

SUSPENSION;ORAL

VIBRAMYCIN

	+ @ PFIZER	EQ 50MG BASE/5ML	N050480	001		Sep	DISC
--	------------	------------------	---------	-----	--	-----	------

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

ACTICLATE CAP

	+ @ CHARTWELL RX	EQ 75MG BASE	N208253	001	Apr 26, 2016	Jan	CAHN
--	------------------	--------------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

AP	ACIC PHARMS	EQ 100MG BASE/VIAL	A217854	001	Jul 23, 2024	Jul	NEWA
>D>	@ ENDO OPERATIONS	EQ 100MG BASE/VIAL	A216690	001	Dec 07, 2022	Oct	CMFD
>A>	AP	EQ 100MG BASE/VIAL	A216690	001	Dec 07, 2022	Oct	CMFD
AP	HAINAN POLY	EQ 100MG BASE/VIAL	A217685	001	Jun 21, 2024	Jun	NEWA
AP		EQ 200MG BASE/VIAL	A217685	002	Jun 21, 2024	Jun	NEWA
AP	HERITAGE	EQ 100MG BASE/VIAL	A217854	001	Jul 23, 2024	Sep	CAHN
>A>	AP	EQ 100MG BASE/VIAL	A218053	001	Oct 28, 2024	Oct	NEWA
AP	LUPIN LTD	EQ 100MG BASE/VIAL	A217794	001	Mar 14, 2024	Mar	NEWA
AP	SLATE RUN PHARMA	EQ 100MG BASE/VIAL	A217685	001	Jun 21, 2024	Sep	CAHN
AP		EQ 200MG BASE/VIAL	A217685	002	Jun 21, 2024	Sep	CAHN
	TABLET;ORAL						
	ACTICLATE						
AB	+ CHARTWELL RX	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jan	CAHN
AB	+!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jan	CAHN
	DOXYCYCLINE HYCLATE						
>D>	AB	EQ 50MG BASE	A062269	003	Oct 05, 1983	Oct	CAHN
>D>	AB	EQ 100MG BASE	A062269	002	Nov 08, 1982	Oct	CAHN
>A>	AB	EQ 50MG BASE	A062269	003	Oct 05, 1983	Oct	CAHN
>A>	AB	EQ 100MG BASE	A062269	002	Nov 08, 1982	Oct	CAHN
	@ NOSTRUM LABS INC	EQ 100MG BASE	A209560	001	Apr 15, 2024	May	DISC
AB		EQ 100MG BASE	A209560	001	Apr 15, 2024	Apr	NEWA
	@ ORYZA	EQ 100MG BASE	A213475	001	Mar 10, 2021	Aug	CAHN
	@ TORRENT	EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr	DISC
AB		EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr	NEWA
	@	EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr	DISC
AB		EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr	NEWA
	TABLET, DELAYED RELEASE;ORAL						
	DORYX						
	+ @ MAYNE PHARMA	EQ 75MG BASE	N050795	001	May 06, 2005	Feb	DISC
	+ @	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb	DISC

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

AB	ENDO OPERATIONS	10MG;10MG	A208518	001	Dec 06, 2017	Apr	CAHN
----	-----------------	-----------	---------	-----	--------------	-----	------

DRONABINOL

CAPSULE;ORAL

DRONABINOL

@ HIKMA 2.5MG

A079217 001 Jun 20, 2014 Mar DISC

@ 5MG

A079217 002 Jun 20, 2014 Mar DISC

@ 10MG

A079217 003 Jun 20, 2014 Mar DISC

@ SVC PHARMA 2.5MG

A078292 001 Jun 27, 2008 Aug DISC

@ 5MG

A078292 002 Jun 27, 2008 Aug DISC

@ 10MG

A078292 003 Jun 27, 2008 Aug DISC

SOLUTION;ORAL

SYNDROS

+ @ BENUVIA OPERATIONS 5MG/ML

N205525 001 Mar 23, 2017 Aug DISC

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

DRONEDARONE HYDROCHLORIDE

AB	LUPIN	EQ 400MG BASE	A205904	001	Jan 31, 2024	Jan	NFTG
----	-------	---------------	---------	-----	--------------	-----	------

MULTAQ

AB	+! SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009	Jan	CFTG
----	----------------------	---------------	---------	-----	--------------	-----	------

DROSPIRENONE

TABLET;ORAL

DROSPIRENONE

AB	LUPIN LTD	4MG	A216936	001	Sep 30, 2024	Sep	NFTG
----	-----------	-----	---------	-----	--------------	-----	------

SLYND

AB	+! EXELTIS USA INC	4MG	N211367	001	May 23, 2019	Sep	CFTG
----	--------------------	-----	---------	-----	--------------	-----	------

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

>A>	AB	ADAPTIS	100MG	A215265	001	Nov 01, 2021	Oct	CAHN
-----	----	---------	-------	---------	-----	--------------	-----	------

>A>	AB		200MG	A215265	002	Nov 01, 2021	Oct	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

>A>	AB		300MG	A215265	003	Nov 01, 2021	Oct	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

AB	SOMERSET THERAPS LLC	100MG	A214543	001	May 05, 2021	Sep	CAHN
----	----------------------	-------	---------	-----	--------------	-----	------

AB		200MG	A214543	002	May 05, 2021	Sep	CAHN
----	--	-------	---------	-----	--------------	-----	------

AB		300MG	A214543	003	May 05, 2021	Sep	CAHN
----	--	-------	---------	-----	--------------	-----	------

@ UPSHER SMITH LABS 100MG A213661 001 Feb 18, 2021 Apr DISC

@ 200MG A213661 002 Feb 18, 2021 Apr DISC

@ 300MG A213661 003 Feb 18, 2021 Apr DISC

>D>	AB	YAMPA	100MG	A215265	001	Nov 01, 2021	Oct	CAHN
-----	----	-------	-------	---------	-----	--------------	-----	------

AB		100MG	A215265	001	Nov 01, 2021	Sep	CAHN
----	--	-------	---------	-----	--------------	-----	------

>D>	AB		200MG	A215265	002	Nov 01, 2021	Oct	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

AB		200MG	A215265	002	Nov 01, 2021	Sep	CAHN
----	--	-------	---------	-----	--------------	-----	------

>D>	AB		300MG	A215265	003	Nov 01, 2021	Oct	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

AB		300MG	A215265	003	Nov 01, 2021	Sep	CAHN
----	--	-------	---------	-----	--------------	-----	------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DRIZALMA SPRINKLE

+ SUN PHARM EQ 20MG BASE N212516 001 Jul 19, 2019 Apr CMFD

+ EQ 30MG BASE N212516 002 Jul 19, 2019 Apr CMFD

+ EQ 40MG BASE N212516 003 Jul 19, 2019 Apr CMFD

+! EQ 60MG BASE N212516 004 Jul 19, 2019 Apr CMFD

DULOXETINE HYDROCHLORIDE

@ ANCHEN PHARMS EQ 20MG BASE A090780 001 Oct 28, 2015 Feb DISC

@ EQ 30MG BASE A090780 002 Oct 28, 2015 Feb DISC

@ EQ 60MG BASE A090780 003 Oct 28, 2015 Feb DISC

@ ENDO OPERATIONS EQ 20MG BASE A090780 001 Oct 28, 2015 May CAHN

@ EQ 30MG BASE A090780 002 Oct 28, 2015 May CAHN

@ EQ 60MG BASE A090780 003 Oct 28, 2015 May CAHN

DUTASTERIDECAPSULE;ORAL
AVODART

AB	+	WAYLIS THERAP	0.5MG	N021319	001	Nov 20, 2001	Mar	CAHN
AB		CHARTWELL	0.5MG	A200899	001	Nov 20, 2015	Mar	CAHN
		@ NORVIUM BIOSCIENCE	0.5MG	A203241	001	Jun 14, 2016	Jun	CAHN
		@ VINTAGE	0.5MG	A202421	001	Nov 20, 2015	Feb	DISC

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		AUROBINDO PHARMA	0.5MG;0.4MG	A213300	001	Jul 18, 2024	Jul	NEWA
AB		ENDO OPERATIONS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Apr	CAHN
AB	+	WAYLIS THERAP	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Apr	CAHN

DYPHYLLINE

TABLET;ORAL

LUFYLLIN

@ NORVIUM BIOSCIENCE 200MG
@ 400MGA084566 001 Jul CAHN
A084566 002 Jul CAHNEDARAVONE

SOLUTION;INTRAVENOUS

EDARAVONE

AP		DR REDDYS	60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr	NEWA
AP		GLAND PHARMA LTD	30MG/100ML (0.3MG/ML)	A216199	001	May 06, 2024	Apr	NFTG
AP			60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr	NFTG
AP		HIKMA	30MG/100ML (0.3MG/ML)	A215508	001	May 06, 2024	Apr	NFTG
AP		LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr	NEWA
>A>	AP	XGEN PHARMS	30MG/100ML (0.3MG/ML)	A217565	001	Oct 31, 2024	Oct	NEWA
>A>	AP		60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Oct	NEWA
AP		RADICAVA						
AP	+	! MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr	CFTG
AP	+		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	CFTG

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON

@ NORVIUM BIOSCIENCE 10MG/ML

A088873 001 Aug 06, 1985 Jul CAHN

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

AB		MACLEODS PHARMS LTD	600MG	A091579	001	May 10, 2024	May	NEWA
----	--	---------------------	-------	---------	-----	--------------	-----	------

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

ATRIPLA

	+	@ GILEAD SCIENCES	600MG;200MG;300MG	N021937	001	Jul 12, 2006	Sep	DISC
		EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE						
AB	!	AUROBINDO PHARMA	600MG;200MG;300MG	A203041	001	Sep 04, 2018	Sep	CHRS
		EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE						
		@ STRIDES PHARMA	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Mar	DISC
		EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE						
		@ MYLAN	600MG;200MG;300MG	A209061	001	Sep 05, 2024	Sep	DISC
AB			600MG;200MG;300MG	A209061	001	Sep 05, 2024	Aug	NEWA

EFINACONAZOLE

SOLUTION;TOPICAL

EFINACONAZOLE

AB		UMEDICA	10%	A211969	001	Jun 21, 2021	Aug	CAHN
		@ ZYDUS LIFESCIENCES	10%	A212178	001	Jul 15, 2022	May	CAHN

ELAFIBRANORTABLET;ORAL
IQIRVO

+! IPSEN 80MG N218860 001 Jun 10, 2024 Jun NEWA

ELIGLUSTAT TARTRATECAPSULE;ORAL
ELIGLUSTAT TARTRATE

AB APOTEX EQ 84MG BASE A212425 001 Jul 10, 2024 Jun NEWA

ELTROMBOPAG OLAMINEFOR SUSPENSION;ORAL
ELTROMBOPAG OLAMINE

AB ANNORA PHARMA EQ 12.5MG ACID/PACKET A216620 001 Apr 18, 2024 Apr NFTG

AB EQ 25MG ACID/PACKET A216620 002 Apr 18, 2024 Apr NFTG

PROMACTA KIT

AB + NOVARTIS EQ 12.5MG ACID/PACKET N207027 002 Sep 27, 2018 Apr CFTG

AB +! EQ 25MG ACID/PACKET N207027 001 Aug 24, 2015 Apr CFTG

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATETABLET;ORAL
DESCOVY

+ GILEAD SCIENCES INC 120MG;EQ 15MG BASE N208215 002 Jan 07, 2022 Sep CTEC

AB + 120MG;EQ 15MG BASE N208215 002 Jan 07, 2022 May CFTG

+! 200MG;EQ 25MG BASE N208215 001 Apr 04, 2016 Sep CTEC

AB +! 200MG;EQ 25MG BASE N208215 001 Apr 04, 2016 May CFTG

EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

AB @ APOTEX 120MG;EQ 15MG BASE A214053 001 May 17, 2024 Sep DISC

AB 120MG;EQ 15MG BASE A214053 001 May 17, 2024 May NFTG

@ 200MG;EQ 25MG BASE A214053 002 May 17, 2024 Sep DISC

AB 200MG;EQ 25MG BASE A214053 002 May 17, 2024 May NFTG

ENALAPRIL MALEATEFOR SOLUTION;ORAL
EPANED KIT

+ @ AZURITY 1MG/ML N204308 001 Aug 13, 2013 Mar CAHN

SOLUTION;ORAL

ENALAPRIL MALEATE

AB AMNEAL 1MG/ML A212894 001 Jun 29, 2022 Mar CMFD

TABLET;ORAL

ENALAPRIL MALEATE

>D> @ AIPING PHARM INC 2.5MG A075178 002 Mar 23, 2001 Oct CMFD

>A> AB 2.5MG A075178 002 Mar 23, 2001 Oct CMFD

>D> @ 5MG A075178 001 Mar 23, 2001 Oct CMFD

>A> AB 5MG A075178 001 Mar 23, 2001 Oct CMFD

>D> @ 10MG A075178 003 Mar 23, 2001 Oct CMFD

>A> AB 10MG A075178 003 Mar 23, 2001 Oct CMFD

>D> @ 20MG A075178 004 Mar 23, 2001 Oct CMFD

>A> AB 20MG A075178 004 Mar 23, 2001 Oct CMFD

AB UNIQUE PHARM 2.5MG A218531 001 Sep 19, 2024 Sep NEWA

AB 5MG A218531 002 Sep 19, 2024 Sep NEWA

AB 10MG A218531 003 Sep 19, 2024 Sep NEWA

AB 20MG A218531 004 Sep 19, 2024 Sep NEWA

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@ COSETTE 5MG;12.5MG A075727 001 Sep 18, 2001 Apr DISC

@ 10MG;25MG A075727 002 Sep 18, 2001 Apr DISC

ENSIFENTRINESUSPENSION;INHALATION
OHTUVAYRE

+! VERONA PHARMA 3MG/2.5ML N217389 001 Jun 26, 2024 Jun NEWA

ENTECAVIR

TABLET;ORAL

ENTECAVIR

@ PRINSTON INC 0.5MG A208782 001 Oct 10, 2017 Sep DISC

@ 1MG A208782 002 Oct 10, 2017 Sep DISC

@ SWISS PHARM 0.5MG A212106 001 Aug 10, 2020 Jul CAHN

TABLET;ORAL

	ENTECAVIR							
	@	1MG	A212106	002	Aug 10, 2020	Jul	CAHN	
	@ VITRUVIAS	0.5MG	A212106	001	Aug 10, 2020	Jun	DISC	
	@	1MG	A212106	002	Aug 10, 2020	Jun	DISC	
AB	YUNG SHIN PHARM	0.5MG	A208195	001	Nov 10, 2021	Jun	CMFD	
AB		1MG	A208195	002	Nov 10, 2021	Jun	CMFD	

ENZALUTAMIDE

	CAPSULE;ORAL							
	ENZALUTAMIDE							
AB	ZYDUS PHARMS	40MG	A209667	001	Sep 26, 2024	Sep	NEWA	
AB	+! ASTELLAS	40MG	N203415	001	Aug 31, 2012	Sep	CTEC	

EPHEDRINE HYDROCHLORIDE

	SOLUTION;INTRAVENOUS							
	REZIPRES							
	+ @ DR REDDYS LABS SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	May	DISC	

EPHEDRINE SULFATE

	SOLUTION;INTRAVENOUS							
	AKOVAZ							
>D>	+! EXELA PHARMA	25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021	Oct	CFTG	
>A> AP	+!	25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021	Oct	CFTG	
	EPHEDRINE SULFATE							
AP	CAPLIN	50MG/ML (50MG/ML)	A219050	001	Jul 18, 2024	Jul	NEWA	
	+! ENDO OPERATIONS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Apr	CAHN	
	+!	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Apr	CAHN	
>A> AP	HIKMA	25MG/5ML (5MG/ML)	A217721	001	Oct 11, 2024	Oct	NFTG	

EPINASTINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC							
	EPINASTINE HYDROCHLORIDE							
>D> AT	BRECKENRIDGE	0.05%	A090870	001	Mar 14, 2011	Oct	DISC	
>A>	@	0.05%	A090870	001	Mar 14, 2011	Oct	DISC	

EPINEPHRINE

	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
	EPINEPHRINE							
AP	AM REGENT	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	A217192	001	Sep 06, 2024	Aug	NEWA	
	+! BPI LABS	1MG/ML (1MG/ML)	N205029	005	Mar 04, 2024	Apr	NEWA	
	+!	30MG/30ML (1MG/ML)	N205029	004	Feb 14, 2024	Feb	NEWA	
	SOLUTION;INTRAVENOUS							
	EPINEPHRINE							
	+ @ BPI LABS	1MG/ML (1MG/ML)	N205029	003	May 12, 2023	Jun	DISC	
	SPRAY;NASAL							
	NEFFY							
	+! ARS PHARMS OPERATION	2MG/SPRAY	N214697	001	Aug 09, 2024	Aug	NEWA	

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

	INJECTABLE;INJECTION							
	XYLOCAINE W/ EPINEPHRINE							
	+ @ FRESENIUS KABI USA	0.01MG/ML;2%	N006488	003		Feb	CRLD	

EPIRUBICIN HYDROCHLORIDE

	INJECTABLE;INJECTION							
	EPIRUBICIN HYDROCHLORIDE							
	@ NORVIUM BIOSCIENCE	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007	Jul	CAHN	
	@	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007	Jul	CAHN	

EPLERENONE

	TABLET;ORAL							
	EPLERENONE							
	@ PRASCO	25MG	A203896	001	Feb 02, 2017	Mar	DISC	
	@	50MG	A203896	002	Feb 02, 2017	Mar	DISC	
AB	SLATE RUN PHARMA	25MG	A212765	001	Aug 10, 2020	Feb	CAHN	
AB		50MG	A212765	002	Aug 10, 2020	Feb	CAHN	

EPLONTERSEN SODIUM

SOLUTION; SUBCUTANEOUS
WAINUA (AUTOINJECTOR)

+!	ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Feb	CTNA
+!		EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Jan	CAHN

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION
EPOPROSTENOL SODIUM

AP1	MEITHEAL	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Jan	CAHN
AP1		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Jan	CAHN
AP2	MYLAN	EQ 0.5MG BASE/VIAL	A213913	001	Jun 12, 2024	May	NEWA
AP2		EQ 1.5MG BASE/VIAL	A213913	002	Jun 12, 2024	May	NEWA

EPTIFIBATIDE

INJECTABLE; INJECTION
EPTIFIBATIDE

	@ ACCORD HLTHCARE	2MG/ML	A205557	001	Nov 06, 2017	May	DISC
	@	75MG/100ML	A205557	002	Nov 06, 2017	May	DISC
AP	HONG KONG	2MG/ML	A213599	001	May 09, 2024	May	NEWA
AP		75MG/100ML	A213599	002	May 09, 2024	May	NEWA

ERGOCALCIFEROL

CAPSULE; ORAL
DRISDOL

>A>	AA	+ ESJAY PHARMA	50,000 IU	N003444	001		Oct	CAHN
>D>	AA	+ SS PHARMA	50,000 IU	N003444	001		Oct	CAHN

ERGOLOID MESYLATES

TABLET; ORAL
ERGOLOID MESYLATES

	@ SUN PHARM INDUSTRIES	1MG	A081113	001	Oct 31, 1991	Jul	DISC
--	------------------------	-----	---------	-----	--------------	-----	------

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL
ERGOMAR

!	PANGEA	2MG	A087693	001	Feb 24, 1983	Feb	CAHN
!	PHARMOBEDIENT	2MG	A087693	001	Feb 24, 1983	Sep	CAHN

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS
ERIBULIN MESYLATE

AP	BAXTER HLTHCARE CORP	1MG/2ML (0.5MG/ML)	A217250	001	Oct 01, 2024	Sep	NEWA
AP	GLAND PHARMA LTD	1MG/2ML (0.5MG/ML)	A218047	001	Apr 05, 2024	Mar	NFTG
AP	JIANGXI QINGFENG	1MG/2ML (0.5MG/ML)	A218281	001	Jun 28, 2024	Jun	NEWA
AP	LONG GROVE PHARMS	1MG/2ML (0.5MG/ML)	A214850	001	Jul 18, 2024	Jul	NEWA
	HALAVEN						
AP	+! EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010	Mar	CFTG

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL
ERLOTINIB HYDROCHLORIDE

AB	CHARTWELL RX	EQ 25MG BASE	A203843	001	Sep 13, 2024	Sep	CAHN
AB		EQ 150MG BASE	A203843	002	Sep 13, 2024	Sep	CAHN
AB	HETERO LABS LTD V	EQ 25MG BASE	A209267	001	May 24, 2024	May	NEWA
AB		EQ 100MG BASE	A209267	002	May 24, 2024	May	NEWA
AB		EQ 150MG BASE	A209267	003	May 24, 2024	May	NEWA
AB	HIKMA	EQ 25MG BASE	A203843	001	Sep 13, 2024	Sep	NEWA
AB		EQ 150MG BASE	A203843	002	Sep 13, 2024	Sep	NEWA
	@ NATCO PHARMA LTD	EQ 25MG BASE	A208488	001	Nov 05, 2019	Apr	DISC
	@	EQ 150MG BASE	A208488	003	Nov 05, 2019	Aug	DISC

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
ERTAPENEM SODIUM

>A>	AP	QILU	EQ 1GM BASE/VIAL	A218067	001	Oct 31, 2024	Oct	NEWA
		@ SUN PHARM	EQ 1GM BASE/VIAL	A209145	001	May 02, 2023	Jan	DISC

ERTUGLIFLOZIN

TABLET;ORAL		ERTUGLIFLOZIN					
AB	HETERO LABS LTD V	5MG	A217071	001	Sep 17, 2024	Sep	NEWA
AB		15MG	A217071	002	Sep 17, 2024	Sep	NEWA
STEGLATRO							
AB	+ MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Sep	CTEC
AB	+!	15MG	N209803	002	Dec 19, 2017	Sep	CTEC

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL		ERYTHROMYCIN					
AB	AZURITY	250MG	A062746	001	Dec 22, 1986	Mar	CAHN
OINTMENT;OPHTHALMIC		ERYTHROMYCIN					
AT	! BAUSCH AND LOMB	0.5%	A064067	001	Jul 29, 1994	Mar	CHRS
	@ PADAGIS US	0.5%	A062447	001	Sep 26, 1983	Mar	DISC
TABLET;ORAL		ERYTHROMYCIN					
AB	AZURITY	250MG	A061621	001		Mar	CAHN
AB		500MG	A061621	002		Mar	CAHN
TABLET, DELAYED RELEASE;ORAL		ERY-TAB					
AB	AZURITY	250MG	A062298	001		Mar	CAHN
AB		333MG	A062298	003	Mar 29, 1982	Mar	CAHN
AB	!	500MG	A062298	002		Mar	CAHN
ERYTHROMYCIN		TORRENT <th colspan="4"></th>					
AB		333MG	A211975	003	Aug 13, 2024	Aug	NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL		ERYTHROMYCIN ETHYLSUCCINATE					
	@ ENDO OPERATIONS	EQ 200MG BASE/5ML	A211991	001	Oct 23, 2019	May	CAHN
	@	EQ 400MG BASE/5ML	A211991	002	Oct 23, 2019	May	CAHN
TABLET;ORAL		E.E.S. 400					
	@ AZURITY	EQ 400MG BASE	A061905	001		Mar	CAHN
BX	!	EQ 400MG BASE	A061905	002	Aug 12, 1982	Mar	CAHN
ERYTHROMYCIN ETHYLSUCCINATE		AZURITY					
BX	!	EQ 400MG BASE	A061904	001		Mar	CAHN

ERYTHROMYCIN STEARATE

TABLET;ORAL		ERYTHROCIN STEARATE					
	@ AZURITY	EQ 125MG BASE	A060359	002		Mar	CAHN
	!	EQ 250MG BASE	A060359	001		Mar	CAHN
	@	EQ 500MG BASE	A060359	003		Mar	CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL		ESCITALOPRAM OXALATE					
	@ ANIMA	EQ 5MG BASE	A077512	001	Sep 12, 2012	Sep	CAHN
	@	EQ 10MG BASE	A077512	002	Sep 12, 2012	Sep	CAHN
	@	EQ 20MG BASE	A077512	003	Sep 12, 2012	Sep	CAHN
	@ PHARM ASSOC	EQ 5MG BASE	A077512	001	Sep 12, 2012	Mar	DISC
	@	EQ 10MG BASE	A077512	002	Sep 12, 2012	Mar	DISC
	@	EQ 20MG BASE	A077512	003	Sep 12, 2012	Mar	DISC

ESLICARBAZEPINE ACETATE

TABLET;ORAL		ESLICARBAZEPINE ACETATE					
	@ APOTEX	200MG	A211236	001	Dec 07, 2023	Apr	DISC
	@	400MG	A211236	002	Dec 07, 2023	Apr	DISC
	@	600MG	A211236	003	Dec 07, 2023	Apr	DISC
	@	800MG	A211236	004	Dec 07, 2023	Apr	DISC
	@ LUPIN LTD	200MG	A211246	001	Mar 27, 2024	Sep	DISC
AB		200MG	A211246	001	Mar 27, 2024	Mar	NEWA
	@	400MG	A211246	002	Mar 27, 2024	Sep	DISC
AB		400MG	A211246	002	Mar 27, 2024	Mar	NEWA
	@	600MG	A211246	003	Mar 27, 2024	Sep	DISC
AB		600MG	A211246	003	Mar 27, 2024	Mar	NEWA

TABLET;ORAL

ESLICARBAZEPINE ACETATE

	@	800MG		A211246	004	Mar 27, 2024	Sep	DISC
AB		800MG		A211246	004	Mar 27, 2024	Mar	NEWA
	@ TORRENT	200MG		A211227	001	Feb 27, 2024	Mar	DISC
AB		200MG		A211227	001	Feb 27, 2024	Feb	NEWA
	@	400MG		A211227	002	Feb 27, 2024	Mar	DISC
AB		400MG		A211227	002	Feb 27, 2024	Feb	NEWA
	@	600MG		A211227	003	Feb 27, 2024	Mar	DISC
AB		600MG		A211227	003	Feb 27, 2024	Feb	NEWA
	@	800MG		A211227	004	Feb 27, 2024	Mar	DISC
AB		800MG		A211227	004	Feb 27, 2024	Feb	NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

	@ GLENMARK SPECLT	EQ 20MG BASE		A209495	001	May 10, 2019	Sep	DISC
	@	EQ 40MG BASE		A209495	002	May 10, 2019	Sep	DISC
>A>	AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A208511	001	Oct 23, 2024	Oct	NEWA
>A>	AB		EQ 40MG BASE	A208511	002	Oct 23, 2024	Oct	NEWA

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

	@ ACCORD HLTHCARE	EQ 40MG BASE/VIAL		A205379	001	Sep 25, 2015	May	DISC
	! GLAND PHARMA LTD	EQ 20MG BASE/VIAL		A203349	001	Apr 01, 2020	May	CHRS
AP	! HAINAN POLY	EQ 40MG BASE/VIAL		A215732	001	Feb 10, 2022	Aug	CHRS
AP	! SLATE RUN PHARMA	EQ 40MG BASE/VIAL		A215732	001	Feb 10, 2022	Sep	CAHN
	@ SUN PHARM	EQ 40MG BASE/VIAL		A200882	002	Mar 18, 2013	May	DISC
	NEXIUM IV							
	+ @ ASTRAZENECA	EQ 40MG BASE/VIAL		N021689	002	Mar 31, 2005	Aug	DISC

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA

AB2	+	BAYER HLTHCARE	0.06MG/24HR	N020375	006	May 27, 2003	Sep	CTEC
		ESTRADIOL						
>D>	AB	MYLAN TECHNOLOGIES	0.06MG/24HR	A075182	005	Jul 20, 2006	Oct	CTEC
>A>	AB2		0.06MG/24HR	A075182	005	Jul 20, 2006	Oct	CTEC
	AB2	ZYDUS PHARMS	0.025MG/24HR	A202985	001	Mar 29, 2023	Sep	CMFD
	AB2		0.0375MG/24HR	A202985	002	Mar 29, 2023	Sep	CMFD
	AB2		0.05MG/24HR	A202985	003	Mar 29, 2023	Sep	CMFD
	AB2		0.06MG/24HR	A202985	004	Mar 29, 2023	Sep	CMFD
	AB2		0.075MG/24HR	A202985	005	Mar 29, 2023	Sep	CMFD
	AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Sep	CMFD

GEL;TRANSDERMAL

DIVIGEL

AB	+	VERTICAL PHARMS	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007	Jul	CPOT
AB	+		0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007	Jul	NEWA
AB	+		0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007	Jul	NEWA
AB	+		0.1% (0.75GM/PACKET)	N022038	004	Aug 17, 2018	Jul	NEWA
AB	+		0.1% (1.25GM/PACKET)	N022038	005	Dec 12, 2019	Jul	NEWA

ESTRADIOL

AB		AMNEAL	0.1% (0.25GM/PACKET)	A216055	001	Jul 12, 2024	Jul	NEWA
AB			0.1% (0.5GM/PACKET)	A216055	002	Jul 12, 2024	Jul	NEWA
AB			0.1% (0.75GM/PACKET)	A216055	003	Jul 12, 2024	Jul	NEWA
AB			0.1% (1GM/PACKET)	A216055	004	Jul 12, 2024	Jul	NEWA
AB			0.1% (1.25GM/PACKET)	A216055	005	Jul 12, 2024	Jul	NEWA
AB		CHEMO RESEARCH SL	0.1% (0.25GM/PACKET)	A211783	001	Aug 10, 2022	Jul	CPOT
AB			0.1% (0.5GM/PACKET)	A211783	002	Aug 10, 2022	Jul	NEWA
AB			0.1% (1GM/PACKET)	A211783	003	Aug 10, 2022	Jul	NEWA
AB		NOVITIUM PHARMA	0.1% (0.25GM/PACKET)	A217610	001	Aug 24, 2023	Jul	CPOT
AB			0.1% (0.5GM/PACKET)	A217610	002	Aug 24, 2023	Jul	NEWA
AB			0.1% (0.75GM/PACKET)	A217610	003	Aug 24, 2023	Jul	NEWA
AB			0.1% (1GM/PACKET)	A217610	004	Aug 24, 2023	Jul	NEWA
AB			0.1% (1.25GM/PACKET)	A217610	005	Aug 24, 2023	Jul	NEWA
AB		PADAGIS ISRAEL	0.1% (0.25GM/PACKET)	A216524	001	Nov 14, 2023	Jul	CPOT
AB			0.1% (0.5GM/PACKET)	A216524	002	Nov 14, 2023	Jul	NEWA
AB			0.1% (0.75GM/PACKET)	A216524	003	Nov 14, 2023	Jul	NEWA
AB			0.1% (1GM/PACKET)	A216524	004	Nov 14, 2023	Jul	NEWA
AB			0.1% (1.25GM/PACKET)	A216524	005	Nov 14, 2023	Jul	NEWA
AB		QUAGEN	0.1% (0.25GM/PACKET)	A217863	001	Jul 12, 2024	Sep	CAHN
AB			0.1% (0.5GM/PACKET)	A217863	002	Jul 12, 2024	Sep	CAHN

GEL;TRANSDERMAL								
ESTRADIOL								
AB		0.1% (0.75GM/PACKET)	A217863	003	Jul 12, 2024	Sep	CAHN	
AB		0.1% (1GM/PACKET)	A217863	004	Jul 12, 2024	Sep	CAHN	
AB		0.1% (1.25GM/PACKET)	A217863	005	Jul 12, 2024	Sep	CAHN	
AB	SOLARIS PHARMA CORP	0.1% (0.25GM/PACKET)	A217863	001	Jul 12, 2024	Jul	NEWA	
AB		0.1% (0.5GM/PACKET)	A217863	002	Jul 12, 2024	Jul	NEWA	
AB		0.1% (0.75GM/PACKET)	A217863	003	Jul 12, 2024	Jul	NEWA	
AB		0.1% (1GM/PACKET)	A217863	004	Jul 12, 2024	Jul	NEWA	
AB		0.1% (1.25GM/PACKET)	A217863	005	Jul 12, 2024	Jul	NEWA	
GEL, METERED;TRANSDERMAL								
ESTRADIOL								
>A>	AB	NOVITIUM PHARMA	0.06% (1.25GM/ACTIVATION)	A217882	001	Oct 23, 2024	Oct	NEWA
	AB	SOLARIS PHARMA CORP	0.06% (1.25GM/ACTIVATION)	A216160	001	Apr 22, 2024	Apr	NFTG
ESTROGEL								
AB	+!	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004	Apr	CFTG
TABLET;VAGINAL								
ESTRADIOL								
AB		AUROBINDO PHARMA	10MCG	A216550	001	Aug 02, 2024	Jul	NEWA
<u>ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE</u>								
INJECTABLE;INTRAMUSCULAR								
LUNELLE								
	+ @	PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N020874	001	Oct 05, 2000	Feb	CRLD
<u>ESTRADIOL VALERATE</u>								
INJECTABLE;INJECTION								
DELESTROGEN								
AO	+!	ENDO OPERATIONS	10MG/ML	N009402	002		Apr	CAHN
AO	+!		20MG/ML	N009402	004		Apr	CAHN
	+ @		40MG/ML	N009402	003		Sep	DISC
AO	+!		40MG/ML	N009402	003		Apr	CAHN
ESTRADIOL VALERATE								
AO	!	XIROMED	40MG/ML	A216656	003	Apr 28, 2023	Sep	CHRS
<u>ESTRADIOL; NORETHINDRONE ACETATE</u>								
TABLET;ORAL								
ESTRADIOL AND NORETHINDRONE ACETATE								
AB		NAARI PTE LTD	1MG;0.5MG	A210233	001	Feb 28, 2018	Apr	CMFD
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX</u>								
TABLET;ORAL								
MYFEMBREE								
	+!	SUMITOMO PHARMA	1MG;0.5MG;40MG	N214846	001	May 26, 2021	Sep	CAHN
<u>ESTRADIOL; NORGESTIMATE</u>								
TABLET;ORAL								
ESTRADIOL AND NORGESTIMATE								
	@	BARR	1MG,1MG;N/A,0.09MG	A076812	001	Apr 29, 2005	Aug	DISC
<u>ESTRAMUSTINE PHOSPHATE SODIUM</u>								
CAPSULE;ORAL								
EMCYT								
	+ @	PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045	001		Jun	DISC
<u>ESTROGENS, ESTERIFIED</u>								
TABLET;ORAL								
MENEST								
	@	MONARCH PHARMS	0.3MG	A084951	001		Jul	DISC
	@		0.625MG	A084948	001		Jul	DISC
	@		1.25MG	A084950	001		Jul	DISC
	@		2.5MG	A084949	001		Jul	DISC
<u>ESTROPIPATE</u>								
TABLET;ORAL								
ESTROPIPATE								
>D>	@	MYLAN	0.75MG	A040359	001	Aug 26, 1999	Oct	CAHN
>D>	@		1.5MG	A040359	002	Aug 26, 1999	Oct	CAHN
>D>	@		3MG	A040359	003	Aug 26, 1999	Oct	CAHN
>A>	@	NORVIUM BIOSCIENCE	0.75MG	A040359	001	Aug 26, 1999	Oct	CAHN
>A>	@		1.5MG	A040359	002	Aug 26, 1999	Oct	CAHN
>A>	@		3MG	A040359	003	Aug 26, 1999	Oct	CAHN

ESZOPICLONETABLET; ORAL
LUNESTA

AB	+	WAYLIS THERAP	1MG	N021476	001	Dec 15, 2004	Apr	CAHN
AB	+		2MG	N021476	002	Dec 15, 2004	Apr	CAHN
AB	+	!	3MG	N021476	003	Dec 15, 2004	Apr	CAHN

ETHACRYNATE SODIUMINJECTABLE; INJECTION
ETHACRYNATE SODIUM

AP		ENDO OPERATIONS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Apr	CAHN
AP		STERIMAX	EQ 50MG BASE/VIAL	A208663	001	Jun 09, 2020	Mar	CAHN

ETHACRYNIC ACIDTABLET; ORAL
ETHACRYNIC ACID

AB		ADAPTIS	25MG	A205609	001	Jun 30, 2016	Sep	CAHN
	@	ENDO OPERATIONS	25MG	A208501	001	Jul 21, 2017	May	CAHN
	@	PAR PHARM INC	25MG	A208501	001	Jul 21, 2017	Apr	DISC

ETHAMBUTOL HYDROCHLORIDETABLET; ORAL
MYAMBUTOL

AB	+	KANCHAN HLTHCARE	100MG	N016320	001		Aug	CAHN
	@		200MG	N016320	002		Aug	CAHN
AB	+	!	400MG	N016320	003		Aug	CAHN
	@		500MG	N016320	004		Aug	CAHN

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL
LEVONORGESTREL AND ETHINYL ESTRADIOL

AB		XIROMED	0.03MG; 0.15MG	A200490	001	Apr 21, 2015	Apr	CAHN
AB3		MINZOYA						
		LUPIN LTD	0.02MG; 0.1MG	A217087	001	Feb 15, 2024	Feb	NEWA
		LEVONORGESTREL AND ETHINYL ESTRADIOL						
	@	XIROMED	0.02MG; 0.1MG	A202247	001	Dec 08, 2014	Apr	CAHN
	@		0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202970	001	Mar 23, 2018	May	CAHN
		MYZILRA						
AB		ENDO OPERATIONS	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A077502	001	Nov 23, 2011	May	CAHN
		ORSYTHIA						
	@	ENDO OPERATIONS	0.02MG; 0.1MG	A077099	001	May 11, 2011	May	CAHN

ETHINYL ESTRADIOL; NORETHINDRONETABLET; ORAL-28
CYCLAFEM 0.5/35

	@	ENDO OPERATIONS	0.035MG; 0.5MG	A203413	001	Dec 16, 2015	Apr	CAHN
	@	ENDO OPERATIONS	0.035MG; 1MG	A076337	001	Nov 12, 2010	May	CAHN
	@	ENDO OPERATIONS	0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG	A076338	001	Nov 16, 2010	May	CAHN
		GILDAGIA						
AB		ENDO OPERATIONS	0.035MG; 0.4MG	A078376	001	Nov 06, 2012	May	CAHN
		NORETHINDRONE AND ETHINYL ESTRADIOL						
	@	XIROMED	0.035MG; 0.4MG	A200897	001	May 11, 2015	Apr	CAHN
	@		0.05MG; 1MG	A203006	001	Aug 05, 2013	Apr	CAHN

TABLET, CHEWABLE; ORAL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	+	!	TEVA BRANDED PHARM	0.025MG; 0.8MG	N022573	001	Dec 22, 2010	Mar	CAHN
----	---	---	--------------------	----------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATECAPSULE; ORAL
MERZEE

AB		WILSHIRE PHARMS INC	0.02MG; 1MG	A212706	001	Dec 18, 2020	Jul	CAHN
	@	AMNEAL PHARMS	0.02MG; 1MG	A214292	001	Jul 20, 2021	Feb	DISC

TABLET;ORAL							
GILDESS 24 FE							
AB	ENDO OPERATIONS	0.02MG;1MG	A090293	001	Dec 01, 2014	May	CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
	@ XIROMED	0.0025MG;0.5MG	A207260	001	Feb 02, 2017	Apr	CAHN
	@	0.005MG;1MG	A207259	001	Dec 27, 2016	Apr	CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	@ XIROMED	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	May	CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	@ XIROMED	0.02MG;1MG	A206120	001	Sep 12, 2017	May	CAHN
OSHIH							
	@ AUROBINDO PHARMA	0.02MG;1MG	A216558	001	Dec 06, 2023	May	DISC
TABLET;ORAL-21							
GILDESS 1.5/30							
	@ ENDO OPERATIONS	0.03MG;1.5MG	A077075	002	Jul 24, 2012	May	CAHN
GILDESS 1/20							
	@ ENDO OPERATIONS	0.02MG;1MG	A077077	002	Jul 24, 2012	May	CAHN
TABLET;ORAL-28							
GILDESS FE 1.5/30							
	@ ENDO OPERATIONS	0.03MG;1.5MG	A077075	001	Apr 28, 2005	May	CAHN
GILDESS FE 1/20							
	@ ENDO OPERATIONS	0.02MG;1MG	A077077	001	May 20, 2005	May	CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB	XIROMED	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Apr	CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
FEMLYV							
+	! MILLICENT PR	0.02MG;1MG	N218718	001	Jul 22, 2024	Jul	NEWA
<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>							
TABLET;ORAL-28							
NORGESTIMATE AND ETHINYL ESTRADIOL							
	@ XIROMED	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A202132	001	Sep 09, 2015	May	CAHN
	@	15MG,0.25MG	A201897	001	Jan 27, 2016	May	CAHN
	@	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A201897	001	Jan 27, 2016	May	CAHN
	@	15MG,0.25MG	A201897	001	Jan 27, 2016	May	CAHN
PREVIFEM							
AB	ENDO OPERATIONS	0.035MG;0.25MG	A076334	001	Jan 09, 2004	May	CAHN
TRI-PREVIFEM							
	@ ENDO OPERATIONS	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A076335	001	Mar 26, 2004	May	CAHN
	@	15MG,0.25MG	A076335	001	Mar 26, 2004	May	CAHN
<u>ETHOSUXIMIDE</u>							
CAPSULE;ORAL							
ETHOSUXIMIDE							
AB	EPIC PHARMA LLC	250MG	A040686	001	May 28, 2008	Jan	CAHN
<u>ETODOLAC</u>							
CAPSULE;ORAL							
ETODOLAC							
AB	IPCA LABS LTD	200MG	A205448	001	Aug 01, 2024	Jul	NEWA
AB		300MG	A205448	002	Aug 01, 2024	Jul	NEWA
TABLET;ORAL							
ETODOLAC							
AB	ABRAXEOLUS	400MG	A074903	001	Apr 11, 1997	Sep	CAHN
AB		500MG	A074903	002	Apr 19, 1999	Sep	CAHN
AB	ADAPTIS	400MG	A209888	001	Nov 30, 2018	Sep	CAHN
AB		500MG	A209888	002	Nov 30, 2018	Sep	CAHN
AB	EDENBRIDGE PHARMS	400MG	A209888	001	Nov 30, 2018	Jul	CMFD
AB		500MG	A209888	002	Nov 30, 2018	Jul	CMFD
AB	IPCA LABS LTD	400MG	A204729	001	May 01, 2024	Apr	NEWA
AB		500MG	A204729	002	May 01, 2024	Apr	NEWA
AB	PANGEA	400MG	A074903	001	Apr 11, 1997	Jun	CAHN
AB		500MG	A074903	002	Apr 19, 1999	Jun	CAHN
<u>ETOMIDATE</u>							
INJECTABLE;INJECTION							
ETOMIDATE							
	@ ENDO OPERATIONS	2MG/ML	A091297	001	Jun 20, 2012	May	CAHN

EZETIMIBE

TABLET;ORAL
EZETIMIBE

AB MACLEODS PHARMS LTD 10MG A211159 001 Apr 29, 2024 Apr NEWA

EZETIMIBE; SIMVASTATIN

TABLET;ORAL
EZETIMIBE AND SIMVASTATIN

AB AUROBINDO PHARMA USA 10MG;10MG A200082 001 Dec 17, 2020 Mar CMFD
 AB 10MG;20MG A200082 002 Dec 17, 2020 Mar CMFD
 AB 10MG;40MG A200082 003 Dec 17, 2020 Mar CMFD
 AB 10MG;80MG A200082 004 Dec 17, 2020 Mar CMFD

FAMOTIDINE

FOR SUSPENSION;ORAL
FAMOTIDINE

AB CEROVENE INC 40MG/5ML A217605 001 Jan 16, 2024 Jan NEWA
 >A> AB EPIC PHARMA LLC 40MG/5ML A218344 001 Oct 16, 2024 Oct NEWA
 AB UNICHEM 40MG/5ML A217605 001 Jan 16, 2024 Sep CAHN

TABLET;ORAL
FAMOTIDINE

AB MSN 20MG A217400 001 Aug 06, 2024 Jul NEWA
 AB 40MG A217400 002 Aug 06, 2024 Jul NEWA
 AB RISING 20MG A218181 001 Dec 22, 2023 Aug CAHN
 AB 40MG A218181 002 Dec 22, 2023 Aug CAHN

FAMOTIDINE; IBUPROFEN

TABLET;ORAL
FAMOTIDINE AND IBUPROFEN

@ TORRENT 26.6MG;800MG A215925 001 Mar 18, 2024 Mar NEWA
 IBUPROFEN AND FAMOTIDINE
 AB ! ALKEM LABS LTD 26.6MG;800MG A211890 001 Aug 03, 2021 Feb CHRS

FEBUXOSTAT

TABLET;ORAL
FEBUXOSTAT

@ LUPIN LTD 40MG A205406 001 Jan 17, 2024 Apr DISC
 AB 40MG A205406 001 Jan 17, 2024 Jan NEWA
 @ 80MG A205406 002 Jan 17, 2024 Apr DISC
 AB 80MG A205406 002 Jan 17, 2024 Jan NEWA
 BX MSN 40MG A210461 001 Dec 30, 2019 Jun CTEC
 BX 80MG A210461 002 Dec 30, 2019 Jun CTEC

FEDRATINIB HYDROCHLORIDE

CAPSULE;ORAL
INREBIC

+! BRISTOL-MYERS EQ 100MG BASE N212327 001 Aug 16, 2019 Feb CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL
FELODIPINE

AB ENDO OPERATIONS 2.5MG A200815 001 Oct 28, 2011 Apr CAHN
 AB 5MG A200815 002 Oct 28, 2011 Apr CAHN
 AB 10MG A200815 003 Oct 28, 2011 Apr CAHN

FENOFIBRATE

CAPSULE;ORAL
FENOFIBRATE (MICRONIZED)

AB CHARTWELL 67MG A211407 001 Jan 31, 2024 Mar CAHN
 AB 134MG A211407 002 Jan 31, 2024 Mar CAHN
 AB 200MG A211407 003 Jan 31, 2024 Mar CAHN
 @ INVAGEN PHARMS 67MG A207378 001 Mar 28, 2017 Mar DISC
 @ 134MG A207378 002 Mar 28, 2017 Mar DISC
 @ 200MG A207378 003 Mar 28, 2017 Mar DISC
 AB YOUNGTECH PHARMS INC 67MG A211407 001 Jan 31, 2024 Jan NEWA
 AB 134MG A211407 002 Jan 31, 2024 Jan NEWA
 AB 200MG A211407 003 Jan 31, 2024 Jan NEWA

TABLET;ORAL
FENOFIBRATE

AB ! AUROBINDO PHARMA 145MG A205118 002 May 05, 2016 Mar CHRS
 BX CREEKWOOD PHARMS 40MG A217732 001 Sep 07, 2023 Jun CTEC

<u>TABLET;ORAL</u>							
<u>FENOFIBRATE</u>							
BX		120MG		A217732	002	Sep 07, 2023	Jun CTEC
AB	!	MYLAN PHARMS INC	120MG	A204475	002	Jun 23, 2016	May CHRS
AB		RISING	48MG	A211122	001	Mar 18, 2020	Aug CAHN
AB			54MG	A210606	001	Aug 17, 2018	Aug CAHN
AB			145MG	A211122	002	Mar 18, 2020	Aug CAHN
AB			160MG	A210606	002	Aug 17, 2018	Aug CAHN
AB		YICHANG HUMANWELL	54MG	A218548	001	Apr 24, 2024	Apr NEWA
AB			160MG	A218548	002	Apr 24, 2024	Apr NEWA
<u>FENOGLIDE</u>							
	+	@ SALIX	40MG	N022118	001	Aug 10, 2007	May DISC
	+	@	120MG	N022118	002	Aug 10, 2007	May DISC
<u>TRICOR</u>							
	+	@ ABBVIE	48MG	N021656	001	Nov 05, 2004	Aug DISC
	+	@	145MG	N021656	002	Nov 05, 2004	Mar DISC
<u>FENOLDOPAM MESYLATE</u>							
<u>INJECTABLE; INJECTION</u>							
<u>CORLOPAM</u>							
	+	@ HOSPIRA	EQ 10MG BASE/ML	N019922	001	Sep 23, 1997	May DISC
<u>FENOLDOPAM MESYLATE</u>							
	@	HIKMA	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	May DISC
	@	SANDOZ	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	May DISC
<u>FENOPROFEN CALCIUM</u>							
<u>CAPSULE;ORAL</u>							
<u>FENOPROFEN CALCIUM</u>							
	@	MISEMER	EQ 200MG BASE	A215548	001	May 16, 2023	Aug DISC
			EQ 200MG BASE	A215548	001	May 16, 2023	May CTEC
	@		EQ 300MG BASE	A215548	002	May 16, 2023	Aug DISC
	@		EQ 400MG BASE	A215548	003	May 16, 2023	Aug DISC
		RISING	EQ 200MG BASE	A214475	002	Jul 26, 2024	Sep NEWA
			EQ 300MG BASE	A214475	003	Jul 26, 2024	Sep NEWA
	!		EQ 400MG BASE	A214475	001	Jul 18, 2022	Aug CTEC
AB	!		EQ 400MG BASE	A214475	001	Jul 18, 2022	May CHRS
<u>NALFON</u>							
	+	@ KEY THERAP	EQ 200MG BASE	N017604	003		May DISC
AB	+		EQ 200MG BASE	N017604	003		Apr CAHN
	+	@	EQ 400MG BASE	N017604	004	Jul 21, 2009	May DISC
AB	+	!	EQ 400MG BASE	N017604	004	Jul 21, 2009	Apr CAHN
<u>TABLET;ORAL</u>							
<u>FENOPROFEN CALCIUM</u>							
	@	KEY THERAP	EQ 600MG BASE	A072267	001	Aug 17, 1988	May DISC
	!		EQ 600MG BASE	A072267	001	Aug 17, 1988	Apr CAHN
<u>FENTANYL</u>							
<u>FILM, EXTENDED RELEASE;TRANSDERMAL</u>							
<u>FENTANYL-100</u>							
AB		DIFGEN PHARMS	100MCG/HR	A077449	004	Oct 20, 2008	Sep CAHN
<u>FENTANYL-12</u>							
AB		DIFGEN PHARMS	12.5MCG/HR	A077449	005	Sep 11, 2015	Sep CAHN
<u>FENTANYL-25</u>							
AB		DIFGEN PHARMS	25MCG/HR	A077449	001	Oct 20, 2008	Sep CAHN
<u>FENTANYL-37</u>							
AB		DIFGEN PHARMS	37.5MCG/HR	A077449	006	Dec 06, 2017	Sep CAHN
<u>FENTANYL-50</u>							
AB		DIFGEN PHARMS	50MCG/HR	A077449	002	Oct 20, 2008	Sep CAHN
<u>FENTANYL-62</u>							
AB		DIFGEN PHARMS	62.5MCG/HR	A077449	007	Dec 06, 2017	Sep CAHN
<u>FENTANYL-75</u>							
AB		DIFGEN PHARMS	75MCG/HR	A077449	003	Oct 20, 2008	Sep CAHN
<u>FENTANYL-87</u>							
AB		DIFGEN PHARMS	87.5MCG/HR	A077449	008	Dec 06, 2017	Sep CAHN
<u>FENTANYL CITRATE</u>							
<u>TABLET;BUCCAL, SUBLINGUAL</u>							
<u>FENTORA</u>							
	+	@ CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Sep DISC
	+	@	EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Sep DISC
	+	@	EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Sep DISC
	+	@	EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Sep DISC

	TABLET;BUCCAL, SUBLINGUAL								
	FENTORA								
	+ @	EQ 0.8MG BASE			N021947	005	Sep 25, 2006	Sep	DISC
	TROCHE/LOZENGE; TRANSMUCOSAL								
	ACTIQ								
	+ @ CEPHALON	EQ 0.2MG BASE			N020747	001	Nov 04, 1998	Sep	DISC
	+ @	EQ 0.4MG BASE			N020747	002	Nov 04, 1998	Sep	DISC
	+ @	EQ 0.6MG BASE			N020747	003	Nov 04, 1998	Sep	DISC
	+ @	EQ 0.8MG BASE			N020747	004	Nov 04, 1998	Sep	DISC
	+ @	EQ 1.2MG BASE			N020747	005	Nov 04, 1998	Sep	DISC
	+ @	EQ 1.6MG BASE			N020747	006	Nov 04, 1998	Sep	DISC
	<u>FESOTERODINE FUMARATE</u>								
	TABLET, EXTENDED RELEASE; ORAL								
	FESOTERODINE FUMARATE								
	@ ANI PHARMS	4MG			A204504	001	Jan 04, 2023	Apr	DISC
	@	8MG			A204504	002	Jan 04, 2023	Apr	DISC
	<u>FIDAXOMICIN</u>								
	TABLET; ORAL								
	DIFICID								
	+! CUBIST PHARMS LLC	200MG			N201699	001	May 27, 2011	Jul	CTEC
AB	+!	200MG			N201699	001	May 27, 2011	Jan	CFTG
	FIDAXOMICIN								
	@ ACTAVIS LABS FL	200MG			A208443	001	Jan 16, 2024	Jul	DISC
AB		200MG			A208443	001	Jan 16, 2024	Jan	NEWA
	<u>FINASTERIDE</u>								
	TABLET; ORAL								
	FINASTERIDE								
	@ CIPLA	1MG			A077335	001	Nov 20, 2014	Mar	DISC
	<u>FINASTERIDE; TADALAFIL</u>								
	CAPSULE; ORAL								
	ENTADFI								
	+ @ BLUE WATER BIOTECH	5MG; 5MG			N215423	001	Dec 09, 2021	Sep	DISC
AB	+!	5MG; 5MG			N215423	001	Dec 09, 2021	Mar	CFTG
	FINASTERIDE AND TADALAFIL								
	ZYDUS	5MG; 5MG			A218232	001	Mar 15, 2024	Mar	NFTG
AB	@ ZYDUS LIFESCIENCES	5MG; 5MG			A218232	001	Mar 15, 2024	Sep	DISC
AB		5MG; 5MG			A218232	001	Mar 15, 2024	May	CAHN
	<u>FINGOLIMOD HYDROCHLORIDE</u>								
	CAPSULE; ORAL								
	FINGOLIMOD HYDROCHLORIDE								
AB	AUROBINDO PHARMA LTD	EQ 0.5MG BASE			A207983	001	Feb 28, 2024	Feb	NEWA
AB	BIOCON LTD	EQ 0.5MG BASE			A207979	001	Dec 04, 2019	Feb	CMFD
	<u>FLORTAUCIPIR F-18</u>								
	SOLUTION; INTRAVENOUS								
	TAUVID								
	+ @ AVID RADIOPHARMS INC	30ML (8.1-51mCi/ML)			N212123	001	May 28, 2020	Jun	DISC
	+ @	50ML (8.1-51mCi/ML)			N212123	002	May 28, 2020	Jun	DISC
	<u>FLUCONAZOLE</u>								
	INJECTABLE; INJECTION								
	FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER								
	@ NORVIUM BIOSCIENCE	200MG/100ML (2MG/ML)			A076888	001	Mar 25, 2005	Jul	CAHN
	@	400MG/200ML (2MG/ML)			A076888	002	Mar 25, 2005	Jul	CAHN
	<u>FLUDARABINE PHOSPHATE</u>								
	INJECTABLE; INJECTION								
	FLUDARABINE PHOSPHATE								
	@ RISING	50MG/VIAL			A200648	001	Oct 16, 2012	Feb	CAHN
	<u>FLUDEOXYGLUCOSE F-18</u>								
	INJECTABLE; INTRAVENOUS								
	FLUDEOXYGLUCOSE F18								
AP	! CARDINAL HEALTH 414	20-500mCi/ML			A203603	002	Sep 27, 2018	May	CHRS
	@ SOFIE	20-500mCi/ML			A203665	001	Feb 14, 2013	May	DISC

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

	@ CHARTWELL RX	0.1MG	A216013	001	Oct 27, 2022	Sep CAHN
>A>	AB ZYDUS	0.1MG	A219251	001	Oct 16, 2024	Oct NEWA
>A>	AB ZYDUS LIFESCIENCES	0.1MG	A219251	001	Oct 16, 2024	Oct CAHN

FLUNISOLIDE

AEROSOL, METERED;INHALATION

AEROSPAN HFA

>D>	+ @ MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006	Oct CAHN
>A>	+ @ NORVIUM BIOSCIENCE	0.078MG/INH	N021247	001	Jan 27, 2006	Oct CAHN

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

AT	RISING	0.01%	A090982	001	Apr 25, 2016	Sep CAHN
AT		0.01%	A203377	001	Apr 25, 2016	Sep CAHN
AT	TARO	0.01%	A209336	001	May 19, 2016	Jan CAHN

OIL/DROPS;OTIC

FLAC

AT	ANDA REPOSITORY	0.01%	A210736	001	Apr 11, 2018	Sep CAHN
	FLUOCINOLONE ACETONIDE					
AT	RISING	0.01%	A203378	001	Apr 25, 2016	Sep CAHN
AT	TRUPHARMA	0.01%	A213264	001	Feb 05, 2021	Aug CAHN

SHAMPOO;TOPICAL

CAPEX

	+ @ GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990	May DISC
--	----------------------	-------	---------	-----	--------------	----------

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

	@ AMNEAL	0.1%	A211111	001	Jun 04, 2018	Jul DISC
	@ PADAGIS ISRAEL	0.1%	A090256	001	Jan 14, 2014	Jan DISC
	+ @ TARO	0.05%	N019117	001	Jun 26, 1984	Aug CAHN

GEL;TOPICAL

FLUOCINONIDE

	+ @ ALVOGEN	0.05%	N017373	001		May DISC
	@ COSETTE	0.05%	A072537	001	Feb 07, 1989	Apr DISC
	@ PADAGIS US	0.05%	A209030	001	Jun 19, 2018	Jan CAHN

SOLUTION;TOPICAL

FLUOCINONIDE

	@ COSETTE	0.05%	A071535	001	Dec 02, 1988	Apr DISC
--	-----------	-------	---------	-----	--------------	----------

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

AP	EUGIA PHARMA SPECLTS	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Apr CMFD
AP		1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Apr CMFD
AP		2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012	Apr CMFD
AP		5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012	Apr CMFD
AP	KINDOS	2.5GM/50ML (50MG/ML)	A216494	001	Sep 24, 2024	Sep NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB1	STRIDES PHARMA	EQ 10MG BASE	A076922	001	Dec 16, 2004	Sep CMFD
AB1		EQ 20MG BASE	A076922	002	Dec 16, 2004	Sep CMFD
AB		EQ 40MG BASE	A076922	003	Dec 16, 2004	Sep CMFD
	@ SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Jan DISC

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

	@ BAJAJ	EQ 20MG BASE/5ML	A075920	001	Jan 29, 2002	Mar CAHN
AA	UPSHER SMITH LABS	EQ 20MG BASE/5ML	A216953	001	Nov 15, 2022	Sep CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB	ENDO OPERATIONS	EQ 10MG BASE	A203836	001	Aug 19, 2016	Apr CAHN
AB		EQ 20MG BASE	A203836	002	Aug 19, 2016	Apr CAHN
AB		EQ 60MG BASE	A209419	001	Nov 16, 2017	Apr CAHN
AB	STRIDES PHARMA	EQ 10MG BASE	A212684	001	Apr 05, 2024	Mar NEWA
AB		EQ 20MG BASE	A212684	002	Apr 05, 2024	Mar NEWA

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE						
AB		EQ 60MG BASE	A212683	001	Sep 13, 2024	Sep NEWA
	@ TEVA	EQ 10MG BASE	A075872	001	Jan 29, 2002	Jan DISC
	@	EQ 20MG BASE	A075872	002	Jan 04, 2019	Jan DISC
	@ TEVA PHARMS USA	EQ 60MG BASE	A211051	001	Dec 03, 2018	Jan DISC
	@ UPSHER SMITH LABS	EQ 10MG BASE	A211696	001	Jan 30, 2019	Jun DISC
	@	EQ 20MG BASE	A211696	002	Jan 30, 2019	Jun DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE						
AB	ENDO OPERATIONS	EQ 25MG BASE;EQ 3MG BASE	A077742	001	Nov 02, 2012	Apr CAHN
AB		EQ 25MG BASE;EQ 6MG BASE	A077742	002	Nov 02, 2012	Apr CAHN
AB		EQ 25MG BASE;EQ 12MG BASE	A077742	003	Nov 02, 2012	Apr CAHN
AB		EQ 50MG BASE;EQ 6MG BASE	A077742	004	Nov 02, 2012	Apr CAHN
AB		EQ 50MG BASE;EQ 12MG BASE	A077742	005	Nov 02, 2012	Apr CAHN

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE						
AO	ENDO OPERATIONS	25MG/ML	A203732	001	Jul 03, 2014	Apr CAHN

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE						
AB	ALEMBIC	1MG	A218173	001	Jul 23, 2024	Jul NEWA
AB		2.5MG	A218173	002	Jul 23, 2024	Jul NEWA
AB		5MG	A218173	003	Jul 23, 2024	Jul NEWA
AB		10MG	A218173	004	Jul 23, 2024	Jul NEWA
AB	CHARTWELL RX	1MG	A215141	001	Oct 20, 2021	Sep CAHN
AB		2.5MG	A215141	002	Oct 20, 2021	Sep CAHN
AB		5MG	A215141	003	Oct 20, 2021	Sep CAHN
AB		10MG	A215141	004	Oct 20, 2021	Sep CAHN
AB	RISING	1MG	A218283	001	Jun 07, 2024	May NEWA
AB		2.5MG	A218283	002	Jun 07, 2024	May NEWA
AB		5MG	A218283	003	Jun 07, 2024	May NEWA
AB		10MG	A218283	004	Jun 07, 2024	May NEWA
AB	ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Feb CAHN
AB		2.5MG	A215141	002	Oct 20, 2021	Feb CAHN
AB		5MG	A215141	003	Oct 20, 2021	Feb CAHN
AB		10MG	A215141	004	Oct 20, 2021	Feb CAHN

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN						
	@ NATCO PHARMA	50MG	A074358	001	Jun 20, 1994	Aug CAHN
	@	100MG	A074358	002	Jun 20, 1994	Aug CAHN

FLURPIRIDAZ F-18

SOLUTION; INTRAVENOUS

FLURPIRIDAZ F-18						
	FLYRCADO					
+	GE HLTHCARE	5-55mCi/ML	N215168	001	Sep 27, 2024	Sep NEWA

FLUTICASONE PROPIONATE

POWDER; INHALATION

ARMONAIR DIGIHALER						
+	@ TEVA PHARM	0.055MG/INH	N208798	004	Feb 20, 2020	Jun DISC
+	@	0.113MG/INH	N208798	005	Feb 20, 2020	Jun DISC
+	@	0.232MG/INH	N208798	006	Feb 20, 2020	Jun DISC
SPRAY, METERED; NASAL						
	FLUTICASONE PROPIONATE					
	@ HIKMA	0.05MG/SPRAY	A077570	001	Jan 16, 2008	Mar DISC

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

AIRDUO DIGIHALER						
+	@ TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	004	Jul 12, 2019	Jun DISC
+	@	0.113MG/INH;EQ 0.014MG BASE/INH	N208799	005	Jul 12, 2019	Jun DISC
+	@	0.232MG/INH;EQ 0.014MG BASE/INH	N208799	006	Jul 12, 2019	Jun DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL
FLUVOXAMINE MALEATE

>A>	AB	AJANTA PHARMA LTD	100MG	A219055	001	Oct 17, 2024	Oct	NEWA
>A>	AB		150MG	A219055	002	Oct 17, 2024	Oct	NEWA
	AB	ENDO OPERATIONS	100MG	A091476	001	Mar 13, 2013	Apr	CAHN
	AB		150MG	A091476	002	Mar 13, 2013	Apr	CAHN

TABLET;ORAL

FLUVOXAMINE MALEATE

	AB	BIONPHARMA	25MG	A217917	001	Jan 22, 2024	Jan	NEWA
	AB		50MG	A217917	002	Jan 22, 2024	Jan	NEWA
	AB		100MG	A217917	003	Jan 22, 2024	Jan	NEWA

FOLIC ACID

TABLET;ORAL

FOLIC ACID

	@	ENDO OPERATIONS	1MG	A040756	001	Jun 04, 2010	May	CAHN
--	---	-----------------	-----	---------	-----	--------------	-----	------

FONDAPARINUX SODIUM

INJECTABLE;SUBCUTANEOUS

FONDAPARINUX SODIUM

	AP	HANGZHOU ZHONGMEI	2.5MG/0.5ML	A216493	001	Aug 19, 2024	Aug	NEWA
	AP		5MG/0.4ML	A216493	002	Aug 19, 2024	Aug	NEWA
	AP		7.5MG/0.6ML	A216493	003	Aug 19, 2024	Aug	NEWA
	AP		10MG/0.8ML	A216493	004	Aug 19, 2024	Aug	NEWA

FORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

>A>	AN	LEXENPHARM	0.02MG/2ML	A216426	001	Oct 22, 2024	Oct	NEWA
	AN	MICRO LABS	0.02MG/2ML	A218304	001	Jun 26, 2024	Jun	NEWA
	AN	RITEDOSE CORP	0.02MG/2ML	A216486	001	Nov 25, 2022	May	CAHN
	AN	WILSHIRE PHARMS INC	0.02MG/2ML	A215621	001	Dec 13, 2022	Jul	CAHN

FOSAMPRENAVIR CALCIUM

TABLET;ORAL

FOSAMPRENAVIR CALCIUM

	AB	! MYLAN	EQ 700MG BASE	A204060	001	Apr 15, 2016	Jan	CHRS
		LEXIVA						
		+ @ VIIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Jan	DISC

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

		@ ACCORD HLTHCARE	EQ 150MG BASE/VIAL	A204025	001	Aug 26, 2020	May	DISC
		@ GENEYORK PHARMS	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Jul	CAHN
>D>	AP	NAVINTA LLC	EQ 150MG BASE/VIAL	A212957	002	Aug 20, 2020	Oct	DISC
>A>		@	EQ 150MG BASE/VIAL	A212957	002	Aug 20, 2020	Oct	DISC

>A> FOSCARBIDOPA; FOSLEVODOPA

>A> SOLUTION;SUBCUTANEOUS

>A> VYALEV

>A>		+! ABBVIE	120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML)	N216962	001	Oct 16, 2024	Oct	NEWA
-----	--	-----------	--	---------	-----	--------------	-----	------

FOSCARNET SODIUM

INJECTABLE;INJECTION

FOSCARNET SODIUM

	AP	AMNEAL	2.4GM/100ML	A216602	001	Mar 01, 2024	Feb	NEWA
--	----	--------	-------------	---------	-----	--------------	-----	------

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL

FOSFOMYCIN TROMETHAMINE

	AA	AMNEAL	EQ 3GM BASE/PACKET	A216600	001	Mar 25, 2024	Mar	NEWA
--	----	--------	--------------------	---------	-----	--------------	-----	------

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

FOSPHENYTOIN SODIUM

	@	NORVIUM BIOSCIENCE	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Jul	CAHN
--	---	--------------------	-------------------------	---------	-----	--------------	-----	------

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

AB +! ENDO OPERATIONS EQ 2.5MG BASE N021006 001 Nov 08, 2001 Apr CAHN

FULVESTRANT

SOLUTION; INTRAMUSCULAR

FULVESTRANT

>A> @ AVYXA HOLDINGS 250MG/5ML (50MG/ML) N210063 001 Aug 19, 2019 Oct CAHN
 AO FRESENIUS KABI USA 250MG/5ML (50MG/ML) N210326 001 May 20, 2019 Aug CTEC
 >D> @ TEVA PHARMS USA INC 250MG/5ML (50MG/ML) N210063 001 Aug 19, 2019 Oct CAHN
 @ 250MG/5ML (50MG/ML) N210063 001 Aug 19, 2019 Jun DISC

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP HIKMA 10MG/ML N018267 001 Aug CMFD
 AP SABA ILAC SANAYIVE 10MG/ML A215856 001 Apr 02, 2024 Mar NEWA

TABLET; ORAL

FUROSEMIDE

>A> @ ESJAY PHARMA 20MG N018415 001 Jul 27, 1982 Oct CAHN
 >A> @ 40MG N018415 002 Jul 27, 1982 Oct CAHN
 >A> @ 80MG N018415 003 Nov 26, 1984 Oct CAHN
 @ MYLAN 20MG N018487 001 Sep DISC
 @ 40MG N018487 002 Sep DISC
 @ 80MG A070082 001 Oct 29, 1986 Sep DISC
 >D> @ STRIDES PHARMA 20MG N018415 001 Jul 27, 1982 Oct CAHN
 >D> @ 40MG N018415 002 Jul 27, 1982 Oct CAHN
 >D> @ 80MG N018415 003 Nov 26, 1984 Oct CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB RISING 100MG A207099 001 Mar 24, 2017 Aug CAHN
 AB 300MG A207099 002 Mar 24, 2017 Aug CAHN
 AB 400MG A207099 003 Mar 24, 2017 Aug CAHN
 @ SUN PHARM INDS LTD 100MG A077242 001 Aug 24, 2006 May DISC
 @ 300MG A077242 002 Aug 24, 2006 May DISC
 @ 400MG A077242 003 Aug 24, 2006 May DISC

SOLUTION; ORAL

GABAPENTIN

AA ANNORA PHARMA 250MG/5ML A217682 001 Jan 17, 2024 Jan NEWA

TABLET; ORAL

GABAPENTIN

AB2 ABON PHARMS LLC 600MG A203643 001 Sep 09, 2024 Sep CAHN
 AB1 ACTAVIS ELIZABETH 600MG A075694 001 Oct 21, 2004 Jan CTEC
 AB1 800MG A075694 002 Oct 21, 2004 Jan CTEC
 AB1 ALKEM LABS LTD 600MG A206402 001 Dec 23, 2015 Jan CTEC
 AB1 800MG A206402 002 Dec 23, 2015 Jan CTEC
 AB2 ANNORA PHARMA 300MG A218075 001 Feb 26, 2024 Feb NEWA
 AB2 600MG A218075 002 Feb 26, 2024 Feb NEWA
 AB1 APOTEX 100MG A077894 001 Oct 10, 2006 Jan CTEC
 AB1 300MG A077894 002 Oct 10, 2006 Jan CTEC
 AB1 400MG A077894 003 Oct 10, 2006 Jan CTEC
 AB1 ASCENT PHARMS INC 600MG A214957 001 Oct 01, 2021 Jan CTEC
 AB1 800MG A214957 002 Oct 01, 2021 Jan CTEC
 AB1 AUROBINDO PHARMA LTD 600MG A200651 001 Oct 06, 2011 Jan CTEC
 AB1 800MG A200651 002 Oct 06, 2011 Jan CTEC
 AB1 CSPC OUYI 600MG A207057 001 Oct 26, 2017 Jan CTEC
 AB1 800MG A207057 002 Oct 26, 2017 Jan CTEC
 AB1 GLENMARK PHARMS LTD 600MG A077662 001 Aug 18, 2006 Jan CTEC
 AB1 800MG A077662 002 Aug 18, 2006 Jan CTEC
 AB1 GRANULES 600MG A217116 001 Mar 28, 2023 Jan CTEC
 AB1 800MG A217116 002 Mar 28, 2023 Jan CTEC
 AB2 HUMANWELL 300MG A216252 001 Feb 26, 2024 Feb NEWA
 AB2 600MG A216252 002 Feb 26, 2024 Feb NEWA
 AB2 INCEPTA PHARMS LTD 600MG A203643 001 Sep 09, 2024 Aug NEWA
 @ INVAGEN PHARMS 600MG A202764 001 Oct 16, 2012 Mar DISC
 AB1 600MG A202764 001 Oct 16, 2012 Jan CTEC
 @ 800MG A202764 002 Oct 16, 2012 Mar DISC
 AB1 800MG A202764 002 Oct 16, 2012 Jan CTEC
 AB1 IPCA LABS LTD 600MG A209855 001 May 29, 2024 May NEWA

TABLET; ORAL									
GABAPENTIN									
AB1			800MG	A209855	002	May 29, 2024	May	NEWA	
AB1	IVAX SUB	TEVA PHARMS	100MG	A076017	001	Apr 28, 2004	Jan	CTEC	
AB1			300MG	A076017	002	Apr 28, 2004	Jan	CTEC	
AB1			400MG	A076017	003	Apr 28, 2004	Jan	CTEC	
AB1	LAURUS		600MG	A217965	001	Apr 08, 2024	Mar	NEWA	
AB1			800MG	A217965	002	Apr 08, 2024	Mar	NEWA	
AB1	RISING		600MG	A217995	001	Jul 19, 2023	Jan	CTEC	
AB1			800MG	A217995	002	Jul 19, 2023	Jan	CTEC	
AB1	RUBICON		600MG	A077661	004	Sep 13, 2006	Jan	CTEC	
AB1			800MG	A077661	005	Sep 13, 2006	Jan	CTEC	
AB1	SCIEGEN PHARMS INC		600MG	A205101	001	Feb 04, 2016	Jan	CTEC	
AB1			800MG	A205101	002	Feb 04, 2016	Jan	CTEC	
AB1	STRIDES PHARMA		600MG	A211313	001	Mar 04, 2024	Feb	NEWA	
AB1			800MG	A211313	002	Mar 04, 2024	Feb	NEWA	
>D>	AB1	SUN PHARM INDS LTD	600MG	A077525	001	Aug 24, 2006	Oct	DISC	
>A>		@	600MG	A077525	001	Aug 24, 2006	Oct	DISC	
	AB1		600MG	A077525	001	Aug 24, 2006	Jan	CTEC	
>D>	AB1		800MG	A077525	002	Aug 24, 2006	Oct	DISC	
>A>		@	800MG	A077525	002	Aug 24, 2006	Oct	DISC	
	AB1		800MG	A077525	002	Aug 24, 2006	Jan	CTEC	
AB2	ZYDUS PHARMS		300MG	A203934	001	Jan 24, 2024	Jan	NEWA	
AB2			600MG	A203934	002	Jan 24, 2024	Jan	NEWA	
AB1	ZYDUS PHARMS USA INC		600MG	A078926	001	Feb 11, 2011	Jan	CTEC	
AB1			800MG	A078926	002	Feb 11, 2011	Jan	CTEC	
GRALISE									
AB2	+	ALMATICA	300MG	N022544	001	Jan 28, 2011	Jan	CTEC	
AB2	+		600MG	N022544	002	Jan 28, 2011	Jan	CTEC	
BX	+		600MG	N022544	002	Jan 28, 2011	Jan	CHRS	
	+		900MG	N022544	005	Apr 18, 2023	Jan	CHRS	
NEURONTIN									
AB1	+	VIATRIS	600MG	N020882	001	Oct 09, 1998	Jan	CTEC	
AB1	+		800MG	N020882	002	Oct 09, 1998	Jan	CTEC	
<u>GADOBUTROL</u>									
SOLUTION; INTRAVENOUS									
GADOBUTROL									
AP	HENGRUI PHARMA		1.20944GM/2ML (604.72MG/ML)	A216081	003	Nov 17, 2022	Jul	CMS1	
AP			4.5354GM/7.5ML (604.72MG/ML)	A216081	004	Nov 17, 2022	Jul	CMS1	
AP			6.0472GM/10ML (604.72MG/ML)	A216081	005	Nov 17, 2022	Jul	CMS1	
AP			9.0708GM/15ML (604.72MG/ML)	A216081	006	Nov 17, 2022	Jul	CMS1	
<u>GADODIAMIDE</u>									
INJECTABLE; INJECTION									
OMNISCAN									
	+	@ GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007	Mar	CRLD	
	+	@	28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007	Mar	DISC	
<u>GADOTERATE MEGLUMINE</u>									
SOLUTION; INTRAVENOUS									
GADOTERATE MEGLUMINE									
AP	HAINAN POLY		1.8845GM/5ML (376.9MG/ML)	A218073	001	Jun 17, 2024	Jun	NEWA	
AP			3.769GM/10ML (376.9MG/ML)	A218073	002	Jun 17, 2024	Jun	NEWA	
AP			5.6535GM/15ML (376.9MG/ML)	A218073	003	Jun 17, 2024	Jun	NEWA	
AP			7.538GM/20ML (376.9MG/ML)	A218073	004	Jun 17, 2024	Jun	NEWA	
AP			37.69GM/100ML (376.9MG/ML)	A218073	005	Jun 17, 2024	Jun	NEWA	
<u>GANCICLOVIR SODIUM</u>									
INJECTABLE; INJECTION									
GANCICLOVIR SODIUM									
AP	ENDO OPERATIONS		EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	May	CAHN	
<u>GATIFLOXACIN</u>									
SOLUTION/DROPS; OPHTHALMIC									
GATIFLOXACIN									
	@	HIKMA	0.5%	A203189	001	Sep 03, 2014	Mar	DISC	

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

@	ACCORD HLTHCARE	EQ 200MG BASE/VIAL	A091594	001	Jul 25, 2011	Apr	DISC
@		EQ 1GM BASE/VIAL	A091594	002	Jul 25, 2011	Apr	DISC
@		EQ 2GM BASE/VIAL	A091594	003	Jul 25, 2011	Apr	DISC

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

>D>	AB	CARIBE HOLDINGS	600MG	A078012	001	Mar 26, 2007	Oct	CAHN
>A>	AB	EPIC PHARMA LLC	600MG	A078012	001	Mar 26, 2007	Oct	CAHN

GEPIRONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
EXXUA

+	@	FABRE KRAMER	EQ 18.2MG BASE	N021164	001	Sep 22, 2023	Jun	DISC
+	@		EQ 36.3MG BASE	N021164	002	Sep 22, 2023	Jun	DISC
+	@		EQ 54.5MG BASE	N021164	003	Sep 22, 2023	Jun	DISC
+	@		EQ 72.6MG BASE	N021164	004	Sep 22, 2023	Jun	DISC

GIVINOSTAT HYDROCHLORIDESUSPENSION; ORAL
DUVYZAT

+	!	ITALFARMACO SPA	EQ 8.86MG BASE/ML	N217865	001	Mar 21, 2024	Mar	NEWA
---	---	-----------------	-------------------	---------	-----	--------------	-----	------

GLATIRAMER ACETATEINJECTABLE; SUBCUTANEOUS
GLATIRAMER ACETATE

AP		SYNTHON PHARMS INC	20MG/ML	A203857	001	Sep 25, 2024	Sep	NEWA
AP			40MG/ML	A206873	001	Sep 25, 2024	Sep	NEWA

GLIPIZIDETABLET; ORAL
GLIPIZIDE

@	ACCORD HLTHCARE	5MG	A074550	001	Sep 11, 1997	May	DISC
@		10MG	A074550	002	Sep 11, 1997	May	DISC
@	SANDOZ	5MG	A074305	001	Apr 07, 1995	Jun	DISC
@		10MG	A074305	002	Apr 07, 1995	Jun	DISC

TABLET, EXTENDED RELEASE; ORAL
GLIPIZIDE

@	ENDO OPERATIONS	5MG	A076159	002	Sep 20, 2013	May	CAHN
@		10MG	A076159	001	Sep 20, 2013	May	CAHN

GLUCAGON HYDROCHLORIDEPOWDER; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
GLUCAGON

+	!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	002	Sep 19, 2019	Apr	CMS1
---	---	--------------------	------------------	---------	-----	--------------	-----	------

GLYBURIDE; METFORMIN HYDROCHLORIDETABLET; ORAL
GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB		HERITAGE	1.25MG; 250MG	A079009	001	Jun 03, 2009	Feb	CMFD
AB			2.5MG; 500MG	A079009	002	Jun 03, 2009	Feb	CMFD
AB			5MG; 500MG	A079009	003	Jun 03, 2009	Feb	CMFD

GLYCEROL PHENYLBUTYRATELIQUID; ORAL
GLYCEROL PHENYLBUTYRATE

@	ENDO OPERATIONS	1.1GM/ML	A205742	001	Dec 02, 2021	May	CAHN
---	-----------------	----------	---------	-----	--------------	-----	------

GLYCOPYRROLATEINJECTABLE; INJECTION
GLYCOPYRROLATE

AP		NIVAGEN PHARMS INC	0.2MG/ML	A212591	001	Oct 13, 2021	Feb	CAHN
AP		OMNIVIUM PHARMS	0.2MG/ML	A212871	001	Nov 29, 2022	Sep	CAHN
AP		UMEDICA	0.2MG/ML	A212591	001	Oct 13, 2021	Aug	CAHN

SOLUTION; INTRAMUSCULAR, INTRAVENOUS
GLYRX-PF

+	@	EXELA PHARMA	0.6MG/3ML (0.2MG/ML)	N210997	004	Dec 14, 2020	Sep	DISC
---	---	--------------	----------------------	---------	-----	--------------	-----	------

SOLUTION;ORAL							
GLYCOPYRROLATE							
AA	CHARTWELL RX	1MG/5ML	A216368	001	Aug 28, 2024	Aug	NEWA
AA	GRANULES	1MG/5ML	A214735	001	Aug 19, 2024	Aug	NEWA
AA	SAPTALIS PHARMS	1MG/5ML	A216297	001	Oct 07, 2024	Sep	NEWA
TABLET;ORAL							
GLYCOPYRROLATE							
AA	ADAPTIS	1MG	A091182	001	Feb 03, 2014	Aug	CAHN
AA		2MG	A091182	002	Feb 03, 2014	Aug	CAHN
!	LGM PHARMA	1.5MG	A091522	001	Mar 12, 2012	Jul	CHRS
AA	QUAGEN	1MG	A212696	001	Jul 10, 2024	Jun	NEWA
AA		2MG	A212696	002	Jul 10, 2024	Jun	NEWA
AA	VELZEN PHARMA PVT	1MG	A090195	001	Sep 21, 2012	Aug	CAHN
AA		2MG	A090195	002	Sep 21, 2012	Aug	CAHN
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE</u>							
SOLUTION;INTRAVENOUS							
PREVDUO							
+!	AZURITY	0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb	CAHN
<u>GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>							
SOLUTION/DROPS;OPHTHALMIC							
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN							
AT	NORDIC PHARMA	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A065187	001	Oct 28, 2005	Jun	CAHN
<u>GRANISETRON</u>							
INJECTABLE;SUBCUTANEOUS							
SUSTOL							
+!	HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016	Aug	CMS1
<u>GRISEOFULVIN, MICROSIZE</u>							
TABLET;ORAL							
FULVICIN-U/F							
AB	CHARTWELL RX	250MG	A060569	002		Jan	CTEC
		250MG	A060569	002		Jan	CAIN
AB		500MG	A060569	001		Jan	CTEC
		500MG	A060569	001		Jan	CAIN
GRISEOFULVIN							
AB	SANDOZ	250MG	A091592	001	Aug 07, 2013	Jan	CTEC
<u>GRISEOFULVIN, ULTRAMICROSIZE</u>							
TABLET;ORAL							
FULVICIN P/G							
AB	CHARTWELL RX	125MG	A061996	001		Jan	CTEC
		125MG	A061996	001		Jan	CAIN
AB		250MG	A061996	002		Jan	CTEC
		250MG	A061996	002		Jan	CAIN
FULVICIN P/G 165							
	CHARTWELL RX	165MG	A061996	003	Apr 06, 1982	Jan	CAIN
FULVICIN P/G 330							
	CHARTWELL RX	330MG	A061996	004	Apr 06, 1982	Jan	CAIN
<u>GUANFACINE HYDROCHLORIDE</u>							
TABLET;ORAL							
GUANFACINE HYDROCHLORIDE							
AB	XIROMED	EQ 1MG BASE	A218326	001	Feb 23, 2024	Feb	NEWA
AB		EQ 2MG BASE	A218326	002	Feb 23, 2024	Feb	NEWA
TABLET, EXTENDED RELEASE;ORAL							
GUANFACINE HYDROCHLORIDE							
AB	WANBANG BIOPHARMS	EQ 1MG BASE	A217638	001	Jun 12, 2024	May	NEWA
AB		EQ 2MG BASE	A217638	002	Jun 12, 2024	May	NEWA
AB		EQ 3MG BASE	A217638	003	Jun 12, 2024	May	NEWA
AB		EQ 4MG BASE	A217638	004	Jun 12, 2024	May	NEWA
<u>HALCINONIDE</u>							
OINTMENT;TOPICAL							
HALOG							
+ @	SUN PHARM INDS INC	0.1%	N017824	001		Jan	DISC

SOLUTION;TOPICAL
HALCINONIDE

ENCUBE	0.1%	A217671	001	May 29, 2024	May NFTG
HALOG					
+ @ SUN PHARM INDS INC	0.1%	N017823	001		Jan DISC

HALOBETASOL PROPIONATE

LOTION;TOPICAL
ULTRAVATE

+ @ MICAL PHARMS	0.05%	N208183	001	Nov 06, 2015	May CAHN
+ @ SUN PHARM INDUSTRIES	0.05%	N208183	001	Nov 06, 2015	May DISC

HALOPERIDOL

TABLET;ORAL
HALOPERIDOL

>A>	AB	AIPING PHARM INC	2MG	A071130	001	Feb 17, 1987	Oct CAHN
>A>	AB		5MG	A071130	002	Feb 17, 1987	Oct CAHN
>A>	AB		10MG	A071130	003	May 12, 1987	Oct CAHN
	AB	AUROBINDO PHARMA LTD	0.5MG	A218789	001	Apr 19, 2024	Apr NEWA
	AB		1MG	A218789	002	Apr 19, 2024	Apr NEWA
	AB		2MG	A218789	003	Apr 19, 2024	Apr NEWA
	AB		5MG	A218789	004	Apr 19, 2024	Apr NEWA
	AB		10MG	A218789	005	Apr 19, 2024	Apr NEWA
	AB		20MG	A218789	006	Apr 19, 2024	Apr NEWA
	AB	CHARTWELL RX	0.5MG	A071209	002	Nov 17, 1986	Jan CAHN
	AB		1MG	A071209	003	Nov 17, 1986	Jan CAHN
		@	2MG	A071209	004	Nov 17, 1986	Jan CAHN
	AB		5MG	A071209	001	Nov 17, 1986	Jan CAHN
	AB		10MG	A071210	001	Mar 11, 1988	Jan CAHN
	AB		20MG	A071211	001	Mar 11, 1988	Jan CAHN
	AB	MANKIND PHARMA	0.5MG	A216918	001	Apr 11, 2024	Apr NEWA
	AB		1MG	A216918	002	Apr 11, 2024	Apr NEWA
	AB		2MG	A216918	003	Apr 11, 2024	Apr NEWA
	AB		5MG	A216918	004	Apr 11, 2024	Apr NEWA
	AB		10MG	A216918	005	Apr 11, 2024	Apr NEWA
	AB		20MG	A216918	006	Apr 11, 2024	Apr NEWA
>D>	AB	SCIEGEN PHARMS INC	2MG	A071130	001	Feb 17, 1987	Oct CAHN
>D>	AB		5MG	A071130	002	Feb 17, 1987	Oct CAHN
	AB		5MG	A071130	002	Feb 17, 1987	May CMS1
>D>	AB		10MG	A071130	003	May 12, 1987	Oct CAHN
	AB		10MG	A071130	003	May 12, 1987	May CMS1

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

@ TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jan DISC
@	EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jan DISC

HALOPERIDOL LACTATE

CONCENTRATE;ORAL
HALOPERIDOL

AA		RUBICON	EQ 2MG BASE/ML	A218371	001	Jan 31, 2024	Jan NEWA
----	--	---------	----------------	---------	-----	--------------	----------

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

	@ ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	008		Jun CAHN
	@	5,000 UNITS/ML	N000552	009		Jun CAHN
	@	10,000 UNITS/ML	N000552	010		Jun CAHN
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>D>	HOSPIRA	5,000 UNITS/100ML	N018916	006	Jan 31, 1984	Oct CRLD
>A>	+	5,000 UNITS/100ML	N018916	006	Jan 31, 1984	Oct CHRS
>A>	+	5,000 UNITS/100ML	N018916	006	Jan 31, 1984	Oct CRLD
	HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5%					
	+ @ FRESENIUS KABI USA	40 UNITS/ML	N017029	021	Aug 24, 2017	Sep DISC
	+	40 UNITS/ML	N017029	021	Aug 24, 2017	Mar NEWA
	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%					
	+! FRESENIUS KABI USA	50 UNITS/ML	N017029	022	Aug 24, 2017	Mar NEWA
	+	100 UNITS/ML	N017029	023	Aug 24, 2017	Mar NEWA
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%					
	+! FRESENIUS KABI USA	50 UNITS/ML	N017029	024	Aug 24, 2017	Mar NEWA
	+	100 UNITS/ML	N017029	025	Aug 24, 2017	Mar NEWA

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D>		HOSPIRA	5,000 UNITS/100ML	N018916	007	Jan 31, 1984	Oct	CRLD
>A>	+	!	5,000 UNITS/100ML	N018916	007	Jan 31, 1984	Oct	CHRS
>A>	+		5,000 UNITS/100ML	N018916	007	Jan 31, 1984	Oct	CRLD
>D>			10,000 UNITS/100ML	N018916	008	Jan 31, 1984	Oct	CRLD
>A>	+	!	10,000 UNITS/100ML	N018916	008	Jan 31, 1984	Oct	CHRS
>A>	+		10,000 UNITS/100ML	N018916	008	Jan 31, 1984	Oct	CRLD
		LIQUAEMIN LOCK FLUSH						
	@	ASPEN GLOBAL INC	100 UNITS/ML	N000552	007		Jun	CAHN
		LIQUAEMIN SODIUM						
	@	ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	004		Jun	CAHN
	@		5,000 UNITS/ML	N000552	003		Jun	CAHN
	@		10,000 UNITS/ML	N000552	005		Jun	CAHN
	@		20,000 UNITS/ML	N000552	001		Jun	CAHN
	@		40,000 UNITS/ML	N000552	002		Jun	CAHN
		LIQUAEMIN SODIUM PRESERVATIVE FREE						
	@	ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986	Jun	CAHN
	@		5,000 UNITS/ML	N000552	012	Apr 11, 1986	Jun	CAHN
	@		10,000 UNITS/ML	N000552	013	Apr 11, 1986	Jun	CAHN

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS
SUPPRELIN LA

+	!	ENDO OPERATIONS	50MG	N022058	001	May 03, 2007	Apr	CAHN
		VANTAS						
+	@	ENDO OPERATIONS	50MG	N021732	001	Oct 12, 2004	May	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	!	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Mar	CHRS
	@	GENUS	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Apr	CAHN
	@	PAI HOLDINGS PHARM	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Mar	DISC
	@	SCIEGEN PHARMS INC	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Sep	CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP		ADRASTEIA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Feb	CAHN
AP	!	FRESENIUS KABI USA	20MG/ML	A040388	001	Mar 13, 2001	Aug	CHRS
	@	NORVIUM BIOSCIENCE	20MG/ML	A204680	001	Apr 28, 2016	Jun	CAHN
AP		RISING	20MG/ML	A040730	001	Apr 21, 2009	Aug	CHRS

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA		GLENMARK PHARMS LTD	10MG	A090527	001	May 29, 2009	Jul	CMS1
AA			25MG	A090527	002	May 29, 2009	Jul	CMS1
AA			50MG	A090527	003	May 29, 2009	Jul	CMS1
AA			100MG	A090527	004	May 29, 2009	Jul	CMS1
	@	INVAGEN PHARMS	10MG	A090255	001	Dec 15, 2008	Mar	DISC
	@		25MG	A090255	002	Dec 15, 2008	Mar	DISC
	@		50MG	A090255	003	Dec 15, 2008	Mar	DISC
	@		100MG	A090255	004	Dec 15, 2008	Mar	DISC
AA		MACLEODS PHARMS LTD	10MG	A211010	001	Aug 21, 2024	Aug	NEWA
AA			25MG	A211010	002	Aug 21, 2024	Aug	NEWA
AA			50MG	A211010	003	Aug 21, 2024	Aug	NEWA
AA			100MG	A211010	004	Aug 21, 2024	Aug	NEWA
	@	NORVIUM BIOSCIENCE	10MG	A090413	001	Dec 08, 2010	Jul	CAHN
	@		25MG	A090413	002	Dec 08, 2010	Jul	CAHN
	@		50MG	A090413	003	Dec 08, 2010	Jul	CAHN
	@		100MG	A090413	004	Dec 08, 2010	Jul	CAHN

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB		I3 PHARMS	37.5MG; 20MG	A215988	001	Jan 17, 2024	Jan	NEWA
----	--	-----------	--------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	IVAX SUB TEVA PHARMS	12.5MG	A083177	003	Sep 19, 2024	Sep	NEWA
	@ PRINSTON INC	25MG	A040412	001	Mar 29, 2002	Aug	DISC
	@	50MG	A040412	002	Mar 29, 2002	Aug	DISC

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	COREPHARMA	12.5MG;10MG	A076674	001	Oct 05, 2004	Sep	CMFD
AB		12.5MG;20MG	A076674	002	Oct 05, 2004	Sep	CMFD
AB		25MG;20MG	A076674	003	Oct 05, 2004	Sep	CMFD

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

	@ GRANULES	12.5MG;50MG	A218015	001	Sep 29, 2023	Mar	DISC
	@	12.5MG;100MG	A218015	002	Sep 29, 2023	Mar	DISC
	@	25MG;100MG	A218015	003	Sep 29, 2023	Mar	DISC

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

	@ SUN PHARM INDS	25MG;50MG	A090654	001	Jan 19, 2012	May	DISC
	@	25MG;100MG	A090654	002	Jan 19, 2012	May	DISC
	@	50MG;100MG	A090654	003	Jan 19, 2012	May	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

HYDROCHLOROTHIAZIDE AND OLMESARTAN MEDOXOMIL

AB	ALKEM LABS LTD	12.5MG;20MG	A207037	001	Jul 11, 2024	Jul	NEWA
AB		12.5MG;40MG	A207037	002	Jul 11, 2024	Jul	NEWA
AB		25MG;40MG	A207037	003	Jul 11, 2024	Jul	NEWA
	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE						
	@ TEVA PHARMS USA	12.5MG;40MG	A200532	002	Apr 24, 2017	May	DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>	@ CHARTWELL RX	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Oct	CMFD
>A>	AB	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Oct	CMFD
>D>	@	12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Oct	CMFD
>A>	AB	12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Oct	CMFD
>D>	@	25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Oct	CMFD
>A>	AB	25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Oct	CMFD
	@ INVAGEN PHARMS	12.5MG;EQ 10MG BASE	A201356	001	Apr 20, 2011	Mar	DISC
	@	12.5MG;EQ 20MG BASE	A201356	002	Apr 20, 2011	Mar	DISC
	@	25MG;EQ 20MG BASE	A201356	003	Apr 20, 2011	Mar	DISC

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	@ SCIEGEN PHARMS INC	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Sep	CAHN
--	----------------------	------------------	---------	-----	--------------	-----	------

HYDROCORTISONE BUTYRATE

LOTION; TOPICAL

HYDROCORTISONE BUTYRATE

AB	! LUPIN LTD	0.1%	A210209	001	Aug 17, 2018	Aug	CHRS
	LOCOID						
	+ @ BAUSCH	0.1%	N022076	001	May 18, 2007	Aug	DISC

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL

PANDEL

>D>	+! ANI PHARMS	0.1%	N020453	001	Feb 28, 1997	Oct	DISC
>A>	+ @	0.1%	N020453	001	Feb 28, 1997	Oct	DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
HYDROCORTISONE SODIUM SUCCINATE

AP	CIPLA	EQ 100MG BASE/VIAL	A214050	001	Sep 05, 2024	Aug NFTG
AP	+! PHARMACIA AND UPJOHN	EQ 100MG BASE/VIAL	N009866	001		Aug CFTG

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
DILAUDID

AP	+! FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	Feb CFTG
AP	+!	0.5MG/0.5ML	N019034	007	Feb 10, 2017	Feb CFTG
	+!	0.5MG/0.5ML	N019034	007	Feb 10, 2017	Jan NEWA
AP	+!	4MG/ML	N019034	005	Apr 30, 2009	Aug CMFD

HYDROMORPHONE HYDROCHLORIDE

AP	HIKMA	0.2MG/ML	A216899	001	Feb 09, 2024	Feb NFTG
AP		0.5MG/0.5ML	A216899	002	Feb 09, 2024	Feb NFTG
AP		1MG/ML	A216899	003	Feb 09, 2024	Feb NEWA
AP		2MG/ML	A216899	004	Feb 09, 2024	Feb NEWA
AP	HOSPIRA INC	4MG/ML	N200403	003	Dec 01, 2011	Aug CTEC

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

@	CHARTWELL	5MG/5ML	A207108	001	Apr 22, 2020	Sep CAHN
@	GENUS	5MG/5ML	A207108	001	Apr 22, 2020	Jan CAHN

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@	CHARTWELL	2MG	A077471	002	Dec 09, 2009	Sep CAHN
@		4MG	A077471	003	Dec 09, 2009	Sep CAHN
@		8MG	A077471	001	Dec 09, 2009	Sep CAHN
@	GENUS	2MG	A077471	002	Dec 09, 2009	Jan CAHN
@		4MG	A077471	003	Dec 09, 2009	Jan CAHN
@		8MG	A077471	001	Dec 09, 2009	Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

>A>	HYDROMORPHONE HYDROCHLORIDE					
>A>	OSMOTICA PHARM US	24MG	A205629	005	Oct 30, 2024	Oct NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	ALLIED	200MG	A040150	001	Jan 27, 1996	Jun CAHN
AB	! APPCO	100MG	A210441	002	Sep 19, 2022	Jun CHRS
AB	CREEKWOOD PHARMS	200MG	A040150	001	Jan 27, 1996	Jul CAHN
AB		200MG	A040150	001	Jan 27, 1996	Apr CMFD
	@	200MG	A040150	001	Jan 27, 1996	Jan CAHN
AB	SENORES PHARMS	200MG	A212902	001	May 14, 2020	Feb CAHN
AB	TEVA PHARMS	200MG	A040081	001	Sep 30, 1994	Feb CMFD

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

+ @	BAUSCH AND LOMB INC	5MG	N018771	001		Jul DISC
-----	---------------------	-----	---------	-----	--	----------

HYDROXYUREA

CAPSULE; ORAL

DROXIA

>D>						
>D>	+ CHEPLAPHARM	200MG	N016295	002	Feb 25, 1998	Oct DISC
>A>	+ @	200MG	N016295	002	Feb 25, 1998	Oct DISC
>D>	+ @	300MG	N016295	003	Feb 25, 1998	Oct DISC
>A>	+ @	300MG	N016295	003	Feb 25, 1998	Oct DISC
>D>	+ @	400MG	N016295	004	Feb 25, 1998	Oct DISC
>A>	+ @	400MG	N016295	004	Feb 25, 1998	Oct DISC

HYDROXYUREA

AB	QILU	500MG	A218021	001	Mar 06, 2024	Feb NEWA
----	------	-------	---------	-----	--------------	----------

SOLUTION; ORAL

XROMI

+!	NOVA LABS LTD	100MG/ML	N216593	001	Apr 04, 2024	Apr NEWA
----	---------------	----------	---------	-----	--------------	----------

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

AA	APOZEAL PHARMS	10MG/5ML	A210634	001	Feb 26, 2019	Jun	CMFD
>D>	@ PAI HOLDINGS PHARM	10MG/5ML	A040391	001	Apr 10, 2002	Oct	CMFD
>A>	AA	10MG/5ML	A040391	001	Apr 10, 2002	Oct	CMFD

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

@	INVAGEN PHARMS	10MG
@		25MG
@		50MG

A040812	001	Mar 12, 2008	Mar	DISC
A040812	002	Mar 12, 2008	Mar	DISC
A040812	003	Mar 12, 2008	Mar	DISC

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB	!	HERITAGE PHARMA	EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Jul	CHRS
AB		SANDOZ	EQ 50MG HYDROCHLORIDE	A086183	001		Jul	CHRS
		VISTARIL						
	+	@ PFIZER	EQ 100MG HYDROCHLORIDE	N011459	006		Jul	CRLD

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

@ SUN PHARM EQ 3MG BASE/3ML

A090853 001 Feb 14, 2014 May DISC

TABLET;ORAL

IBANDRONATE SODIUM

@ WATSON LABS TEVA EQ 150MG BASE

A079003 001 Mar 20, 2012 May DISC

IBRUTINIB

CAPSULE;ORAL

IBRUTINIB

@	ZYDUS LIFESCIENCES	70MG
@		140MG

A211344	001	Mar 31, 2021	Sep	CAHN
A211344	002	Mar 31, 2021	Sep	CAHN

TABLET;ORAL

IMBRUVICA

+! PHARMACYCLICS LLC 420MG

N210563 003 Feb 16, 2018 Jan CHRS

IBUPROFEN

TABLET;ORAL

IBUPROFEN

@	ENDO OPERATIONS	300MG
@		400MG
@		400MG
@		600MG
@		800MG
	SHANDONG XINHUA	300MG

A071230	001	Oct 22, 1986	May	CAHN
A071231	001	Oct 22, 1986	May	CAHN
A071644	001	Feb 01, 1988	May	CAHN
A071232	001	Oct 22, 1986	May	CAHN
A072004	001	Nov 18, 1987	May	CAHN
A202413	004	Jul 05, 2024	Jul	NEWA

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

IBUTILIDE FUMARATE

AP AVET LIFESCIENCES 0.1MG/ML

A204146 001 Apr 01, 2024 Mar NEWA

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

ICATIBANT ACETATE

AP	ALEMBIC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213773	001	Jun 14, 2024	Jun	NEWA
AP	WILSHIRE PHARMS INC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A211501	001	Sep 01, 2020	Jul	CAHN

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

AB	ASCENT PHARMS INC	1GM	A216811	002	Feb 16, 2024	Feb	NEWA
AB	ZYDUS LIFESCIENCES	500MG	A217656	001	Apr 20, 2023	Apr	CAHN
AB		1GM	A217656	002	Apr 20, 2023	Apr	CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDARUBICIN HYDROCHLORIDE
@ RISING

1MG/ML

A200144 001 Oct 11, 2012 Feb CAHN

ILOPROST

SOLUTION; INHALATION
VENTAVIS

+ @ ACTELION 10MCG/ML (10MCG/ML)
+ @ 20MCG/ML (20MCG/ML)

N021779 002 Dec 08, 2005 Mar DISC
N021779 003 Aug 07, 2009 Mar DISC

IMETELSTAT SODIUM

POWDER; INTRAVENOUS
RYTELO

+! GERON EQ 47MG BASE/VIAL
+! EQ 188MG BASE/VIAL

N217779 001 Jun 06, 2024 Jun NEWA
N217779 002 Jun 06, 2024 Jun NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
IMIPRAMINE HYDROCHLORIDE

AB ! LEADING 50MG
+ @ SPECGX LLC 10MG
+ @ 25MG
TOFRANIL
+ @ SPECGX LLC 50MG

A040903 003 Oct 24, 2012 Apr CHRS
A087846 002 May 22, 1984 Apr DISC
A087846 003 May 22, 1984 Apr DISC
A087846 001 May 22, 1984 Apr DISC

>A> INAVOLISIB

TABLET; ORAL
ITOVEBI

>A> + GENENTECH INC 3MG
>A> +! 9MG

N219249 001 Oct 10, 2024 Oct NEWA
N219249 002 Oct 10, 2024 Oct NEWA

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION
INDIUM IN 111 CHLORIDE

+ @ CURIUM 5mCi/0.5ML

N019841 001 Sep 27, 1994 Sep DISC

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION
INDIUM IN-111 PENTETREOTIDE KIT

AP SUN PHARM INDS INC 3mCi/ML
OCTREOSCAN
AP +! CURIUM 3mCi/ML

A212785 001 Jul 01, 2024 Jun NFTG
N020314 001 Jun 02, 1994 Jun CFTG

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

@ MYLAN 75MG

A202139 001 Mar 20, 2014 Aug CAHN

SUPPOSITORY; RECTAL
INDOMETHACIN

AB ZYDUS LIFESCIENCES 50MG

A216184 001 Aug 02, 2023 Apr CAHN

SUSPENSION; ORAL
INDOCIN

AB +! ZYLA 25MG/5ML

N018332 001 Oct 10, 1985 Jan CTEC

INDOMETHACIN

AB NOVITIUM PHARMA 25MG/5ML

A217883 001 Jan 12, 2024 Jan NEWA

INOTERSEN SODIUM

SOLUTION; SUBCUTANEOUS
TEGSEDI

+ @ AKCEA THERAPS EQ 284MG BASE/1.5ML (EQ 189.3MG
BASE/ML)

N211172 001 Oct 05, 2018 Sep DISC

IOBENGUANE I-131

SOLUTION; INTRAVENOUS
AZEDRA

+ @ PROGENICS PHARMS INC 15mCi/ML

N209607 001 Jul 30, 2018 Feb DISC

IOPAMIDOL

INJECTABLE; INJECTION		IOPAMIDOL					
AP	HAINAN POLY	51%		A217134	002	Apr 09, 2024	Mar NEWA
AP		61%		A217134	003	Apr 09, 2024	Mar NEWA
AP		76%		A217134	004	Apr 09, 2024	Mar NEWA
ISOVUE-250							
AP	+! BRACCO	51%		N018735	007	Jul 06, 1992	Mar CTEC
ISOVUE-300							
AP	+! BRACCO	61%		N018735	002	Dec 31, 1985	Mar CTEC
ISOVUE-370							
AP	+! BRACCO	76%		N018735	003	Dec 31, 1985	Mar CTEC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION		IPRATROPIUM BROMIDE					
	@ NORVIUM BIOSCIENCE	0.02%		A074755	001	Jan 10, 1997	Jul CAHN

IRBESARTAN

TABLET; ORAL		AVAPRO					
	+ @ SANOFI AVENTIS US	75MG		N020757	001	Sep 30, 1997	Jul DISC
IRBESARTAN							
AB	IPCA LABS LTD	75MG		A211056	001	May 22, 2024	May NEWA
AB		150MG		A211056	002	May 22, 2024	May NEWA
AB		300MG		A211056	003	May 22, 2024	May NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION		IRINOTECAN HYDROCHLORIDE					
	@ HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)		A090016	001	Jan 28, 2009	Jul DISC
	@	100MG/5ML (20MG/ML)		A090016	002	Jan 28, 2009	Jul DISC

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION		ISOPROTERENOL HYDROCHLORIDE					
	@ CIPLA	0.2MG/ML		A210322	001	Jun 12, 2018	Mar DISC
	@ EUGIA PHARMA	0.2MG/ML		A211864	001	Feb 09, 2021	Jun DISC
AP	GLAND PHARMA LTD	0.2MG/ML		A217648	001	Oct 03, 2024	Sep NEWA
AP	SOMERSET THERAPS LLC	0.2MG/ML		A211590	001	Aug 06, 2024	Jul NEWA

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL		DILATRATE-SR					
	+ @ ENDO OPERATIONS	40MG		N019790	001	Sep 02, 1988	May CAHN
TABLET; ORAL		ISOSORBIDE DINITRATE					
AB	ENDO OPERATIONS	40MG		A211290	001	Nov 23, 2021	Apr CAHN
AB	ZYDUS LIFESCIENCES	5MG		A213057	001	Nov 20, 2019	Aug CAHN
AB		10MG		A213057	002	Nov 20, 2019	Aug CAHN
AB		20MG		A213057	003	Nov 20, 2019	Aug CAHN
AB		30MG		A213057	004	Nov 20, 2019	Aug CAHN
AB		40MG		A213057	005	Nov 20, 2019	Aug CAHN

ISOSORBIDE MONONITRATE

TABLET; ORAL		MONOKET					
AB	+ OMNIVIVUM PHARMS	10MG		N020215	002	Jun 30, 1993	Jan CAHN
AB	+!	20MG		N020215	001	Jun 30, 1993	Jan CAHN
TABLET, EXTENDED RELEASE; ORAL		ISOSORBIDE MONONITRATE					
AB	CHARTWELL MOLECULAR	120MG		A075155	003	Aug 04, 2000	Mar CHRS
AB	! RICONPHARMA LLC	120MG		A210918	003	Nov 05, 2018	Mar CHRS
AB	SHANDONG	30MG		A214115	002	Feb 08, 2024	Feb NEWA
AB		60MG		A214115	003	Feb 08, 2024	Feb NEWA
AB		120MG		A214115	001	Apr 29, 2022	Mar CMFD
	@ ZYDUS PHARMS	30MG		A218255	001	Feb 15, 2024	Aug DISC
AB		30MG		A218255	001	Feb 15, 2024	Feb NEWA
	@	60MG		A218255	002	Feb 15, 2024	Aug DISC
AB		60MG		A218255	002	Feb 15, 2024	Feb NEWA
	@	120MG		A218255	003	Feb 15, 2024	Aug DISC

TABLET, EXTENDED RELEASE;ORAL
ISOSORBIDE MONONITRATE

AB 120MG A218255 003 Feb 15, 2024 Feb NEWA

ISOSULFAN BLUE

SOLUTION;SUBCUTANEOUS
ISOSULFAN BLUE

AP AM REGENT 1% A210294 001 May 17, 2023 May CDFR
 AP 50MG/5ML (10MG/ML) A210294 001 May 17, 2023 May CPOT
 @ BELOTECA 1% A210714 001 Jan 16, 2019 May CDFR
 @ 50MG/5ML (10MG/ML) A210714 001 Jan 16, 2019 May CPOT
 @ EUGIA PHARMA 1% A206831 001 Feb 02, 2016 May CDFR
 @ 50MG/5ML (10MG/ML) A206831 001 Feb 02, 2016 May CPOT
 @ FRESENIUS KABI USA 1% A211869 001 Sep 08, 2022 May CDFR
 @ 50MG/5ML (10MG/ML) A211869 001 Sep 08, 2022 May CPOT
 AP MEITHEAL 1% A213130 001 Nov 03, 2021 May CDFR
 AP 50MG/5ML (10MG/ML) A213130 001 Nov 03, 2021 May CPOT
 AP MSN 1% A216090 001 Sep 16, 2022 May CDFR
 AP 50MG/5ML (10MG/ML) A216090 001 Sep 16, 2022 May CPOT
 AP ! MYLAN INSTITUTIONAL 1% A090874 001 Jul 20, 2010 May CDFR
 AP ! 50MG/5ML (10MG/ML) A090874 001 Jul 20, 2010 May CPOT
 @ SOMERSET THERAPS LLC 1% A210558 001 Jul 12, 2019 May CDFR
 @ 50MG/5ML (10MG/ML) A210558 001 Jul 12, 2019 May CPOT
 LYMPHAZURIN
 + @ COVIDIEN 1% N018310 001 May CDFR
 + @ 50MG/5ML (10MG/ML) N018310 001 May CPOT

ISOTRETINOIN

CAPSULE;ORAL
ISOTRETINOIN

AB2 AUROBINDO PHARMA 10MG A218194 001 Jan 29, 2024 Jan NEWA
 AB2 20MG A218194 002 Jan 29, 2024 Jan NEWA
 AB2 25MG A218194 003 Jan 29, 2024 Jan NEWA
 AB2 30MG A218194 004 Jan 29, 2024 Jan NEWA
 AB2 35MG A218194 005 Jan 29, 2024 Jan NEWA
 AB2 40MG A218194 006 Jan 29, 2024 Jan NEWA

ITRACONAZOLE

CAPSULE;ORAL
ITRACONAZOLE

@ ACCORD HLTHCARE 100MG A205991 001 May 26, 2016 May DISC
 @ RISING 100MG A205724 001 Dec 13, 2016 Apr CAHN

IVABRADINE HYDROCHLORIDE

TABLET;ORAL
IVABRADINE HYDROCHLORIDE

AB BIONPHARMA EQ 5MG BASE A213276 001 Sep 05, 2024 Aug NEWA
 AB EQ 7.5MG BASE A213276 002 Sep 05, 2024 Aug NEWA
 AB INGENUS PHARMS LLC EQ 5MG BASE A214051 001 Dec 30, 2021 May CMFD
 AB EQ 7.5MG BASE A214051 002 Dec 30, 2021 May CMFD

IVERMECTIN

CREAM;TOPICAL
IVERMECTIN

AB ZYDUS LIFESCIENCES 1% A215210 001 Aug 02, 2022 Mar CAHN

TABLET;ORAL
IVERMECTIN

>A> AB SENORES PHARMS 3MG A218324 001 Oct 16, 2024 Oct NEWA

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
KETALAR

AP + ENDO OPERATIONS EQ 50MG BASE/ML N016812 002 Aug CHRS
 AP + EQ 100MG BASE/ML N016812 003 Aug CHRS

KETAMINE HYDROCHLORIDE

AP FRESENIUS KABI USA EQ 10MG BASE/ML A215808 001 Jan 13, 2023 Sep CMFD
 AP EQ 50MG BASE/ML A215808 002 Jan 13, 2023 Sep CMFD
 AP ! HIKMA EQ 50MG BASE/ML A074524 001 Mar 22, 1996 Aug CHRS
 AP ! EQ 100MG BASE/ML A074524 002 Mar 22, 1996 Aug CHRS

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL

KETOCONAZOLE
 AB ! XIROMED 2% A213601 001 May 21, 2021 Feb CHRS

CREAM;TOPICAL

KETOCONAZOLE
 AB TRUPHARMA 2% A215185 001 Nov 17, 2021 Aug CAHN

SHAMPOO;TOPICAL

KETOCONAZOLE
 AB COSETTE 2% A076942 001 Apr 11, 2005 Jul CAHN
 AB NOVITIUM PHARMA 2% A218498 001 Sep 16, 2024 Sep NEWA

TABLET;ORAL

KETOCONAZOLE
 AB SENORES PHARMS 200MG A075912 001 Jan 10, 2002 Feb CAHN

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

KETOROLAC TROMETHAMINE
 AT CAPLIN 0.5% A218204 001 Mar 26, 2024 Mar NEWA

L-GLUTAMINE

FOR SOLUTION;ORAL

ENDARI
 AA + EMMAUS MEDCL 5GM/PACKET N208587 001 Jul 07, 2017 Jun CFTG

L-GLUTAMINE

AA NOVITIUM PHARMA 5GM/PACKET A215647 001 Jul 08, 2024 Jun NFTG

LABETALOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

LABETALOL HYDROCHLORIDE
 + @ HIKMA 10MG/2ML (5MG/ML) N213330 005 Mar 18, 2022 Sep DISC
 +! 20MG/4ML (5MG/ML) N213330 006 Aug 19, 2024 Aug NEWA

TABLET;ORAL

LABETALOL HYDROCHLORIDE
 AB ANDAS 5 HOLDING 100MG A075215 001 Jul 29, 1999 Aug CAHN
 AB 200MG A075215 002 Jul 29, 1999 Aug CAHN
 AB 300MG A075215 003 Jul 29, 1999 Aug CAHN
 >A> APPCO 400MG A209603 004 Oct 18, 2024 Oct NEWA
 AB ENDO OPERATIONS 100MG A200908 001 Jul 10, 2012 Apr CAHN
 AB ! 200MG A200908 002 Jul 10, 2012 Apr CAHN
 AB 300MG A200908 003 Jul 10, 2012 Apr CAHN
 AB HIBROW HLTHCARE 100MG A207863 001 Feb 04, 2019 Sep CAHN
 AB 200MG A207863 002 Feb 04, 2019 Sep CAHN
 AB 300MG A207863 003 Feb 04, 2019 Sep CAHN

LACOSAMIDE

SOLUTION;INTRAVENOUS

LACOSAMIDE
 AP DR REDDYS 200MG/20ML (10MG/ML) A217718 001 Mar 25, 2024 Mar NEWA
 AP HAINAN POLY 200MG/20ML (10MG/ML) A217311 001 Feb 13, 2024 Feb NEWA
 AP HIKMA 200MG/20ML (10MG/ML) A216806 001 Apr 05, 2024 Mar NEWA
 AP SOMERSET THERAPS LLC 200MG/20ML (10MG/ML) A214960 001 Oct 09, 2024 Sep NEWA

SOLUTION;ORAL

LACOSAMIDE
 @ AMNEAL PHARMS 10MG/ML A204839 001 Mar 27, 2024 Apr DISC
 AA 10MG/ML A204839 001 Mar 27, 2024 Mar NEWA
 AA AUROBINDO PHARMA LTD 10MG/ML A209224 001 Jan 24, 2024 Jan NEWA
 AA CHARTWELL RX 10MG/ML A215154 001 May 15, 2024 May NEWA

TABLET;ORAL

LACOSAMIDE
 >D> AB AMNEAL PHARMS 50MG A204857 001 Mar 17, 2022 Oct DISC
 >A> @ 50MG A204857 001 Mar 17, 2022 Oct DISC
 >D> AB 100MG A204857 002 Mar 17, 2022 Oct DISC
 >A> @ 100MG A204857 002 Mar 17, 2022 Oct DISC
 >D> AB 150MG A204857 003 Mar 17, 2022 Oct DISC
 >A> @ 150MG A204857 003 Mar 17, 2022 Oct DISC
 >D> AB 200MG A204857 004 Mar 17, 2022 Oct DISC
 >A> @ 200MG A204857 004 Mar 17, 2022 Oct DISC
 AB KANCHAN HLTHCARE 50MG A218014 001 Apr 02, 2024 Sep CAHN
 AB 100MG A218014 002 Apr 02, 2024 Sep CAHN
 AB 150MG A218014 003 Apr 02, 2024 Sep CAHN

<u>TABLET;ORAL</u>							
<u>LACOSAMIDE</u>							
AB		200MG	A218014	004	Apr 02, 2024	Sep	CAHN
AB	MACLEODS PHARMS LTD	50MG	A208466	001	May 24, 2024	May	NEWA
AB		100MG	A208466	002	May 24, 2024	May	NEWA
AB		150MG	A208466	003	May 24, 2024	May	NEWA
AB		200MG	A208466	004	May 24, 2024	May	NEWA
AB	MEDLEY PHARMS	50MG	A218014	001	Apr 02, 2024	Mar	NEWA
AB		100MG	A218014	002	Apr 02, 2024	Mar	NEWA
AB		150MG	A218014	003	Apr 02, 2024	Mar	NEWA
AB		200MG	A218014	004	Apr 02, 2024	Mar	NEWA
AB	UNICHEM	50MG	A213109	001	Sep 04, 2024	Aug	NEWA
AB		100MG	A213109	002	Sep 04, 2024	Aug	NEWA
AB		150MG	A213109	003	Sep 04, 2024	Aug	NEWA
AB		200MG	A213109	004	Sep 04, 2024	Aug	NEWA
	@ ZYDUS PHARMS	50MG	A204947	001	Dec 15, 2023	May	DISC
	@	100MG	A204947	002	Dec 15, 2023	May	DISC
	@	150MG	A204947	003	Dec 15, 2023	May	DISC
	@	200MG	A204947	004	Dec 15, 2023	May	DISC
<u>LACTULOSE</u>							
<u>SOLUTION;ORAL</u>							
<u>LACTULOSE</u>							
AA	APOZEAL PHARMS	10GM/15ML	A207786	001	Jun 11, 2018	Jul	CMFD
	@ HIKMA	10GM/15ML	A074076	001	Jul 03, 1995	Mar	DISC
AA	! PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	Mar	CHRS
<u>SOLUTION;ORAL, RECTAL</u>							
<u>GENERLAC</u>							
AA	CHARTWELL RX	10GM/15ML	A074603	001	Oct 31, 1996	Jun	CAHN
<u>LACTULOSE</u>							
AA	APOZEAL PHARMS	10GM/15ML	A203762	001	Mar 27, 2015	Jul	CMFD
	@ PAI HOLDINGS PHARM	10GM/15ML	A074077	001	Jul 03, 1995	Feb	DISC
<u>LAMIVUDINE</u>							
<u>SOLUTION;ORAL</u>							
<u>EPIVIR-HBV</u>							
	+ @ GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998	Apr	DISC
<u>TABLET;ORAL</u>							
<u>EPIVIR-HBV</u>							
	+ @ GLAXOSMITHKLINE	100MG	N021003	001	Dec 08, 1998	Apr	DISC
<u>LAMIVUDINE</u>							
AB	! APOTEX	100MG	A202941	001	Jan 02, 2014	Apr	CHRS
	@ MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Jan	DISC
	@	300MG	A078545	002	Mar 05, 2019	Jan	DISC
	@ NATCO	150MG	A204528	001	Mar 04, 2016	Jun	CAHN
	@	300MG	A204528	002	Mar 04, 2016	Jun	CAHN
<u>LAMIVUDINE; ZIDOVUDINE</u>							
<u>TABLET;ORAL</u>							
<u>COMBIVIR</u>							
	+ @ VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997	Jan	DISC
<u>LAMIVUDINE AND ZIDOVUDINE</u>							
AB	EPIC PHARMA LLC	150MG;300MG	A206375	001	Apr 10, 2018	Sep	CAHN
AB	! HETERO LABS LTD III	150MG;300MG	A079124	001	Sep 17, 2015	Jan	CHRS
	@ NATCO	150MG;300MG	A204005	001	Aug 28, 2014	Jun	CAHN
	@ NORVIUM BIOSCIENCE	150MG;300MG	A079079	001	Aug 12, 2019	Jul	CAHN
<u>LAMOTRIGINE</u>							
<u>TABLET;ORAL</u>							
<u>LAMOTRIGINE</u>							
AB	GLENMARK PHARMS LTD	25MG	A090169	001	May 04, 2012	Jul	CMS1
AB		25MG	A090169	001	May 12, 2012	Mar	CAHN
AB		100MG	A090169	002	May 04, 2012	Jul	CMS1
AB		100MG	A090169	002	May 12, 2012	Mar	CAHN
AB		150MG	A090169	003	May 04, 2012	Jul	CMS1
AB		150MG	A090169	003	May 12, 2012	Mar	CAHN
AB		200MG	A090169	004	May 04, 2012	Jul	CMS1
AB		200MG	A090169	004	May 12, 2012	Mar	CAHN
AB	IPCA LABS	25MG	A204499	001	Sep 26, 2024	Sep	NEWA
AB		100MG	A204499	002	Sep 26, 2024	Sep	NEWA
AB		150MG	A204499	003	Sep 26, 2024	Sep	NEWA
AB		200MG	A204499	004	Sep 26, 2024	Sep	NEWA

TABLET;ORAL

LAMOTRIGINE

@	NORVIUM BIOSCIENCE	25MG	A078443	001	Feb 11, 2009	Jul	CAHN
@		100MG	A078443	002	Feb 11, 2009	Jul	CAHN
@		150MG	A078443	003	Feb 11, 2009	Jul	CAHN
@		200MG	A078443	004	Feb 11, 2009	Jul	CAHN

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB	ALEMBIC	200MG	A211821	001	Oct 01, 2024	Sep	NEWA
AB		250MG	A211821	002	Oct 01, 2024	Sep	NEWA
AB		300MG	A211821	003	Oct 01, 2024	Sep	NEWA
@	ANCHEN PHARMS	25MG	A201374	001	Dec 26, 2012	Feb	DISC
@		50MG	A201374	002	Dec 26, 2012	Feb	DISC
@		100MG	A201374	003	Dec 26, 2012	Feb	DISC
@		200MG	A201374	004	Dec 26, 2012	Feb	DISC
@		250MG	A201374	005	Dec 26, 2012	Feb	DISC
@		300MG	A201374	006	Dec 26, 2012	Feb	DISC
@	ENDO OPERATIONS	25MG	A201374	001	Dec 26, 2012	May	CAHN
AB		25MG	A201791	001	Jan 18, 2013	Apr	CAHN
@		50MG	A201374	002	Dec 26, 2012	May	CAHN
AB		50MG	A201791	002	Jan 18, 2013	Apr	CAHN
@		100MG	A201374	003	Dec 26, 2012	May	CAHN
AB		100MG	A201791	003	Jan 18, 2013	Apr	CAHN
@		200MG	A201374	004	Dec 26, 2012	May	CAHN
AB		200MG	A201791	004	Jan 18, 2013	Apr	CAHN
@		250MG	A201374	005	Dec 26, 2012	May	CAHN
AB		250MG	A201791	005	Jan 18, 2013	Apr	CAHN
@		300MG	A201374	006	Dec 26, 2012	May	CAHN
AB		300MG	A201791	006	Jan 18, 2013	Apr	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

AB	ENDO OPERATIONS	25MG	A204158	001	Oct 27, 2015	Apr	CAHN	
AB		50MG	A204158	002	Oct 27, 2015	Apr	CAHN	
AB		100MG	A204158	003	Oct 27, 2015	Apr	CAHN	
AB		200MG	A204158	004	Oct 27, 2015	Apr	CAHN	
>D>	@	IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013	Oct	CMFD
>A>	AB		25MG	A200828	001	Jul 15, 2013	Oct	CMFD
>D>	@		50MG	A200828	002	Jul 15, 2013	Oct	CMFD
>A>	AB		50MG	A200828	002	Jul 15, 2013	Oct	CMFD
>D>	@		100MG	A200828	003	Jul 15, 2013	Oct	CMFD
>A>	AB		100MG	A200828	003	Jul 15, 2013	Oct	CMFD
>D>	@		200MG	A200828	004	Jul 15, 2013	Oct	CMFD
>A>	AB		200MG	A200828	004	Jul 15, 2013	Oct	CMFD

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

LANREOTIDE ACETATE

AB	INVAGEN PHARMS	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	A217193	001	May 21, 2024	May	NFTG	
AB		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	A217193	002	May 21, 2024	May	NFTG	
AB		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	A217193	003	May 21, 2024	May	NFTG	
		SOMATULINE DEPOT						
AB	+!	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007	May	CFTG
AB	+!		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007	May	CFTG
AB	+!		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007	May	CFTG

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

>A>	AB	MACLEODS PHARMS LTD	15MG	A208671	001	Nov 04, 2024	Oct	NEWA
>A>	AB		30MG	A208671	002	Nov 04, 2024	Oct	NEWA
@		SANDOZ	15MG	A090331	001	Apr 23, 2010	Sep	DISC
@			30MG	A090331	002	Apr 23, 2010	Sep	DISC
@		SUN PHARM	15MG	A202637	001	Sep 13, 2013	May	DISC
@			30MG	A091509	001	Sep 13, 2013	May	DISC

LAPATINIB DITOSYLATE

TABLET;ORAL

LAPATINIB DITOSYLATE

AB	TEVA PHARMS USA INC	EQ 250MG BASE	A217968	001	Aug 16, 2024	Aug	NEWA
----	---------------------	---------------	---------	-----	--------------	-----	------

LATANOPROST

EMULSION;OPHTHALMIC

XELPROS

+ @ SUN PHARM

0.005%

N206185	001	Sep 12, 2018	Sep	DISC
---------	-----	--------------	-----	------

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

AT	RYAN LABS	0.005%	A202077	001	Feb 11, 2013	Sep	CAHN
----	-----------	--------	---------	-----	--------------	-----	------

LAZERTINIB MESYLATE

TABLET;ORAL

LAZCLUZE

+ JANSSEN BIOTECH

EQ 80MG BASE

N219008	001	Aug 19, 2024	Aug	NEWA
---------	-----	--------------	-----	------

+!

EQ 240MG BASE

N219008	002	Aug 19, 2024	Aug	NEWA
---------	-----	--------------	-----	------

LEFAMULIN ACETATE

SOLUTION;INTRAVENOUS

XENLETA

+! NABRIVA

EQ 150MG BASE/15ML (EQ 10MG
BASE/ML)

N211673	001	Aug 19, 2019	Apr	CMFD
---------	-----	--------------	-----	------

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

AB	NOVUGEN	2.5MG	A217281	001	Sep 11, 2024	Aug	NEWA
AB		5MG	A217281	002	Sep 11, 2024	Aug	NEWA
AB		10MG	A217281	003	Sep 11, 2024	Aug	NEWA
AB		15MG	A217281	004	Sep 11, 2024	Aug	NEWA
AB		20MG	A217281	005	Sep 11, 2024	Aug	NEWA
AB		25MG	A217281	006	Sep 11, 2024	Aug	NEWA
	@ QILU	2.5MG	A217265	001	Feb 22, 2024	Jul	DISC
AB		2.5MG	A217265	001	Feb 22, 2024	Feb	NEWA
	@	5MG	A217265	002	Feb 22, 2024	Jul	DISC
AB		5MG	A217265	002	Feb 22, 2024	Feb	NEWA
	@	10MG	A217265	003	Feb 22, 2024	Jul	DISC
AB		10MG	A217265	003	Feb 22, 2024	Feb	NEWA
	@	15MG	A217265	004	Feb 22, 2024	Jul	DISC
AB		15MG	A217265	004	Feb 22, 2024	Feb	NEWA
	@	20MG	A217265	005	Feb 22, 2024	Jul	DISC
AB		20MG	A217265	005	Feb 22, 2024	Feb	NEWA
	@	25MG	A217265	006	Feb 22, 2024	Jul	DISC
AB		25MG	A217265	006	Feb 22, 2024	Feb	NEWA

LETERMOVIR

PELLETS;ORAL

PREVYMIS

+ MSD

20MG/PACKET

N219104	001	Aug 30, 2024	Aug	NEWA
---------	-----	--------------	-----	------

+!

120MG/PACKET

N219104	002	Aug 30, 2024	Aug	NEWA
---------	-----	--------------	-----	------

LETROZOLE

TABLET;ORAL

LETROZOLE

AB	RYAN LABS	2.5MG	A091191	001	Jun 03, 2011	Sep	CAHN
----	-----------	-------	---------	-----	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

AP	MEITHEAL	EQ 50MG BASE/VIAL	A216590	001	Jul 19, 2023	Jun	CAHN
AP		EQ 100MG BASE/VIAL	A216590	002	Jul 19, 2023	Jun	CAHN
AP		EQ 200MG BASE/VIAL	A216590	003	Jul 19, 2023	Jun	CAHN
AP		EQ 350MG BASE/VIAL	A216590	004	Jul 19, 2023	Jun	CAHN
AP		EQ 500MG BASE/VIAL	A216590	005	Jul 19, 2023	Jun	CAHN

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

LEUCOVORIN CALCIUM

@ ABIC

EQ 3MG BASE/ML (EQ 3MG BASE/ML)

A089352	001	Jun 01, 1988	Sep	CPOT
---------	-----	--------------	-----	------

@

EQ 3MG BASE/ML

A089352	001	Jun 01, 1988	Sep	CDFR
---------	-----	--------------	-----	------

!

FRESENIUS KABI USA

EQ 10MG BASE/ML

A207226	001	Jul 27, 2018	Sep	CDFR
---------	-----	--------------	-----	------

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
LEUCOVORIN CALCIUM

!		EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Sep	CDFR
!		EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A207241	001	Mar 14, 2018	Sep	CPOT
!		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A207226	001	Jul 27, 2018	Sep	CPOT
+ @	HOSPIRA	EQ 3MG BASE/ML (EQ 3MG BASE/ML)	N008107	001		Sep	CPOT
+ @		EQ 3MG BASE/ML	N008107	001		Sep	CDFR
@	NOVAST LABS	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Sep	CDFR
@		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A210917	001	Nov 23, 2018	Sep	CPOT
LEUCOVORIN CALCIUM PRESERVATIVE FREE							
@	HIKMA	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Sep	CDFR
@		EQ 300MG BASE/30ML (EQ 10MG BASE/ML)	A040347	001	Apr 25, 2000	Sep	CPOT
@		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A040347	002	Apr 25, 2000	Sep	NEWA
@	HOSPIRA	EQ 10MG BASE/ML	A040147	001	Jun 25, 1997	Sep	CDFR
@		EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A040147	001	Jun 25, 1997	Sep	CPOT
@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A040147	002	Jun 25, 1997	Sep	NEWA
@	TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999	Sep	CDFR
@		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A040332	001	Jun 28, 1999	Sep	CPOT
WELLCOVORIN							
@	GLAXOSMITHKLINE	EQ 5MG BASE/ML (EQ 5MG BASE/ML)	A087439	001	Oct 19, 1982	Sep	CPOT
@		EQ 5MG BASE/ML	A087439	001	Oct 19, 1982	Sep	CDFR
@		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A087439	002	Oct 19, 1982	Sep	NEWA

LEUPROLIDE ACETATE

SOLUTION;SUBCUTANEOUS
LEUPROLIDE ACETATE

AP	AMNEAL	1MG/0.2ML	A215336	001	Oct 28, 2022	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A215336	001	Oct 28, 2022	Jul	CPOT
AP	EUGIA PHARMA	1MG/0.2ML	A212963	001	Jun 06, 2022	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A212963	001	Jun 06, 2022	Jul	CPOT
@	GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001	Jul	CDFR
@		14MG/2.8ML (1MG/0.2ML)	A075721	001	Nov 29, 2001	Jul	CPOT
AP	MEITHEAL	1MG/0.2ML	A075471	001	Oct 25, 2000	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A075471	001	Oct 25, 2000	Jul	CPOT
AP	RK PHARMA	1MG/0.2ML	A213829	001	Aug 13, 2021	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A213829	001	Aug 13, 2021	Jul	CPOT
AP	! SANDOZ	1MG/0.2ML	A074728	001	Aug 04, 1998	Jul	CDFR
AP	!	14MG/2.8ML (1MG/0.2ML)	A074728	001	Aug 04, 1998	Jul	CPOT
AP	SUN PHARM	1MG/0.2ML	A078885	001	Mar 09, 2009	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A078885	001	Mar 09, 2009	Jul	CPOT
>A>	AP UBI	14MG/2.8ML (1MG/0.2ML)	A217957	001	Oct 17, 2024	Oct	NEWA
LUPRON							
+ @	ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Jul	CDFR
+ @		14MG/2.8ML (1MG/0.2ML)	N019010	001	Apr 09, 1985	Jul	CPOT

LEVACETYLLEUCINE

FOR SUSPENSION;ORAL
AQNEURSA

+!	INTRABIO	1GM/PACKET	N219132	001	Sep 24, 2024	Sep	NEWA
----	----------	------------	---------	-----	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION
LEVALBUTEROL HYDROCHLORIDE

>A>	AN	MANKIND PHARMA	EQ 0.0103% BASE	A218770	001	Oct 21, 2024	Oct	NEWA
>A>	AN		EQ 0.021% BASE	A218770	002	Oct 21, 2024	Oct	NEWA
>A>	AN		EQ 0.042% BASE	A218770	003	Oct 21, 2024	Oct	NEWA
AN	!	MYLAN SPECIALITY LP	EQ 0.25% BASE	A078309	001	Mar 20, 2009	Apr	CHRS
@		NORVIUM BIOSCIENCE	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Jul	CAHN
@			EQ 0.021% BASE	A077800	002	Mar 15, 2013	Jul	CAHN
@			EQ 0.042% BASE	A077800	003	Mar 15, 2013	Jul	CAHN
@		SUN PHARM	EQ 0.0103% BASE	A207820	001	Nov 05, 2018	May	DISC
@			EQ 0.021% BASE	A207820	002	Nov 05, 2018	May	DISC
@			EQ 0.042% BASE	A207820	003	Nov 05, 2018	May	DISC
AN	!	TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr	CHRS
AN	!		EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr	CHRS
AN	!		EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr	CHRS

SOLUTION; INHALATION

XOPENEX

+ @	HIKMA	EQ 0.0103% BASE	N020837	003	Jan 30, 2002	Apr	DISC
+ @		EQ 0.021% BASE	N020837	001	Mar 25, 1999	Apr	DISC
+ @		EQ 0.042% BASE	N020837	002	Mar 25, 1999	Apr	DISC
+ @		EQ 0.25% BASE	N020837	004	Jul 18, 2003	Apr	DISC

LEVAMLODIPINE MALEATE

TABLET; ORAL

CONJUPRI

+ @	CSPC OUYI	EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Sep	DISC
+		EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Mar	CMFD
+ @		EQ 5MG BASE	N212895	003	Dec 19, 2019	Sep	DISC
+	!	EQ 5MG BASE	N212895	003	Dec 19, 2019	Mar	CMFD

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM

AP	ADRASTEIA PHARMA	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
	@ SUN PHARM INDS LTD	500MG/5ML (100MG/ML)	A090754	001	Jun 16, 2010	May	DISC
AP	XGEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jul	CAHN
	LEVETIRACETAM IN SODIUM CHLORIDE						
AP	B BRAUN MEDICAL INC	500MG/100ML (5MG/ML)	A209705	001	Feb 27, 2024	Feb	NEWA
AP		1GM/100ML (10MG/ML)	A209705	002	Feb 27, 2024	Feb	NEWA
AP		1.5GM/100ML (15MG/ML)	A209705	003	Feb 27, 2024	Feb	NEWA
AP	BAXTER HLTHCARE CORP	500MG/100ML (5MG/ML)	A217059	001	Oct 02, 2023	Feb	CTNA
AP		1GM/100ML (10MG/ML)	A217059	002	Oct 02, 2023	Feb	CTNA
AP		1.5GM/100ML (15MG/ML)	A217059	003	Oct 02, 2023	Feb	CTNA
	@ FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Mar	DISC
	@	1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Mar	DISC
	@	1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Mar	DISC
AP	HIKMA	500MG/100ML (5MG/ML)	A211356	001	Feb 12, 2024	Feb	NEWA
AP		1GM/100ML (10MG/ML)	A211356	002	Feb 12, 2024	Feb	NEWA
AP		1.5GM/100ML (15MG/ML)	A211356	003	Feb 12, 2024	Feb	NEWA

SOLUTION; ORAL

LEVETIRACETAM

	@ HIKMA	100MG/ML	A090601	001	Feb 28, 2012	Mar	DISC
	@ STRIDES PHARMA	100MG/ML	A214673	001	Nov 20, 2023	May	DISC

TABLET; ORAL

LEVETIRACETAM

	@ ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	May	DISC
	@	500MG	A090843	002	Feb 14, 2011	May	DISC
	@	750MG	A090843	003	Feb 14, 2011	May	DISC
	@	1GM	A090843	004	Feb 14, 2011	May	DISC
	@ GRANULES	250MG	A217878	001	Jun 13, 2023	Mar	DISC
	@	500MG	A217878	002	Jun 13, 2023	Mar	DISC
	@	750MG	A217878	003	Jun 13, 2023	Mar	DISC
	@	1GM	A217878	004	Jun 13, 2023	Mar	DISC
AB	INGENUS PHARMS LLC	250MG	A079042	001	Jan 15, 2009	Sep	CAHN
AB		500MG	A079042	002	Jan 15, 2009	Sep	CAHN
AB		750MG	A079042	003	Jan 15, 2009	Sep	CAHN
AB		1GM	A079042	004	Jan 15, 2009	Sep	CAHN
	@ INVAGEN PHARMS	250MG	A078234	001	Jan 15, 2009	Mar	DISC
	@	500MG	A078234	002	Jan 15, 2009	Mar	DISC
	@	750MG	A078234	003	Jan 15, 2009	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	@ ADAPTIS	500MG	A202167	001	Sep 04, 2015	Sep	CAHN
	@	750MG	A202167	002	Sep 04, 2015	Sep	CAHN
	@ ANCHEN PHARMS	500MG	A091360	001	Oct 04, 2011	Feb	DISC
	@	750MG	A091360	002	Oct 04, 2011	Feb	DISC
	@ ENDO OPERATIONS	500MG	A091360	001	Oct 04, 2011	May	CAHN
	@	750MG	A091360	002	Oct 04, 2011	May	CAHN
	@ PHARMADAX INC	500MG	A201464	001	May 25, 2012	Sep	DISC
	@	750MG	A201464	002	May 25, 2012	Sep	DISC
	@ PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Aug	DISC
	@	750MG	A202533	002	Jul 20, 2012	Aug	DISC

LEVOBUNOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
LEVOBUNOLOL HYDROCHLORIDE

@ CHARTWELL RX	0.5%	A074850	001	Oct 28, 1996	Jul	CAHN
----------------	------	---------	-----	--------------	-----	------

LEVOBUPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION
CHIROCAINE

+ @ PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997	001	Aug 05, 1999	Jun	CRLD
+ @	EQ 5MG BASE/ML	N020997	002	Aug 05, 1999	Jun	CRLD
+ @	EQ 7.5MG BASE/ML	N020997	003	Aug 05, 1999	Jun	CRLD

LEVOCARNITINESOLUTION; ORAL
LEVOCARNITINE

AA @ HIKMA	1GM/10ML	A077399	001	Oct 25, 2007	Mar	DISC
RISING	1GM/10ML	A076851	001	Aug 10, 2004	Sep	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB IPCA LABS LTD	5MG	A204626	001	May 06, 2024	Apr	NEWA
------------------	-----	---------	-----	--------------	-----	------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

@ NORVIUM BIOSCIENCE	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun	CAHN
@	EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun	CAHN
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP @ KNACK	EQ 250MG/50ML (EQ 5MG/ML)	A216164	001	Jan 29, 2024	Jul	DISC
	EQ 250MG/50ML (EQ 5MG/ML)	A216164	001	Jan 29, 2024	Jan	NEWA
AP @	EQ 500MG/100ML (EQ 5MG/ML)	A216164	002	Jan 29, 2024	Jul	DISC
AP @	EQ 500MG/100ML (EQ 5MG/ML)	A216164	002	Jan 29, 2024	Jan	NEWA
AP @	EQ 750MG/150ML (EQ 5MG/ML)	A216164	003	Jan 29, 2024	Jul	DISC
	EQ 750MG/150ML (EQ 5MG/ML)	A216164	003	Jan 29, 2024	Jan	NEWA

TABLET; ORAL

LEVOFLOXACIN

@ ANDA REPOSITORY	250MG	A090367	001	Jun 20, 2011	Sep	CAHN
@	500MG	A090367	002	Jun 20, 2011	Sep	CAHN
@	750MG	A090367	003	Jun 20, 2011	Sep	CAHN
@ CELLTRION	250MG	A090367	001	Jun 20, 2011	Apr	DISC
@	500MG	A090367	002	Jun 20, 2011	Apr	DISC
@	750MG	A090367	003	Jun 20, 2011	Apr	DISC

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS

FUSILEV

+ @ ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	May	DISC
+!	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar	CTEC

LEVOLEUCOVORIN CALCIUM

@ MEITHEAL	EQ 50MG BASE/VIAL	A211003	001	Aug 22, 2019	Mar	DISC
------------	-------------------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

@ NORVIUM BIOSCIENCE	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	Jun	CAHN
@	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	Jun	CAHN
@ PRAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Jul	CAHN

LEVONORGESTREL

SYSTEM; INTRAUTERINE

KYLEENA

+! BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016	Jun	CDFR
-------------------	--------	---------	-----	--------------	-----	------

LILETTA

+! MEDICINES360	52MG	N206229	001	Feb 26, 2015	Jun	CDFR
-----------------	------	---------	-----	--------------	-----	------

MIRENA

+! BAYER HLTHCARE	52MG	N021225	001	Dec 06, 2000	Jun	CDFR
-------------------	------	---------	-----	--------------	-----	------

SKYLA

+! BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013	Jun	CDFR
-------------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL
 LEVONORGESTREL
 @ XIROMED

0.75MG

A202740 001 Sep 02, 2016 May CAHN

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS
 LEVOTHYROXINE SODIUM
 @ ENDO OPERATIONS

200MCG/VIAL

A205366 001 Dec 07, 2015 May CAHN

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL
 LEVOTHYROXINE SODIUM

AB2	AUROBINDO PHARMA	0.137MG	A216414	001	Jul 16, 2024	Jul NEWA
AB2		0.15MG	A216414	002	Jul 16, 2024	Jul NEWA
AB2		0.175MG	A216414	003	Jul 16, 2024	Jul NEWA
AB2		0.2MG	A216414	004	Jul 16, 2024	Jul NEWA
AB2		0.3MG	A216414	005	Jul 16, 2024	Jul NEWA
AB1, AB2	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Sep CTEC
AB1, AB2		0.05MG	A211417	002	Dec 21, 2022	Sep CTEC
AB1, AB2		0.075MG	A211417	003	Dec 21, 2022	Sep CTEC
AB1, AB2		0.088MG	A211417	004	Dec 21, 2022	Sep CTEC
AB1, AB2		0.1MG	A211417	005	Dec 21, 2022	Sep CTEC
AB1, AB2		0.112MG	A211417	006	Dec 21, 2022	Sep CTEC
AB1, AB2		0.125MG	A211417	007	Dec 21, 2022	Sep CTEC
AB1, AB2		0.137MG	A211417	008	Dec 21, 2022	Sep CTEC
AB1, AB2		0.15MG	A211417	009	Dec 21, 2022	Sep CTEC
AB1, AB2		0.175MG	A211417	010	Dec 21, 2022	Sep CTEC
AB1, AB2		0.2MG	A211417	011	Dec 21, 2022	Sep CTEC
AB1, AB2		0.3MG	A211417	012	Dec 21, 2022	Sep CTEC
AB1, AB2, AB3, AB4	WATSON LABS TEVA	0.025MG	A207588	001	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.05MG	A207588	002	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.075MG	A207588	003	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.088MG	A207588	004	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.1MG	A207588	005	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.112MG	A207588	006	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.125MG	A207588	007	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.137MG	A207588	008	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.15MG	A207588	009	May 10, 2022	Feb CTEC
AB1, AB2,		0.175MG	A207588	010	May 10, 2022	Feb CTEC

TABLET; ORAL							
LEVOTHYROXINE SODIUM							
AB3, AB4							
AB1, AB2, AB3, AB4	0.2MG		A207588	011	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4	0.3MG		A207588	012	May 10, 2022	Feb	CTEC
<u>LIDOCAINE</u>							
OINTMENT; TOPICAL							
LIDOCAINE							
AT	AUROBINDO PHARMA LTD	5%	A217117	001	Jun 18, 2024	Jun	NEWA
	@ COSETTE	5%	A211019	001	Dec 12, 2018	Apr	DISC
	@ GENEYORK PHARMS	5%	A212486	001	Oct 17, 2019	Jul	CAHN
<u>LIDOCAINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
LIDOCAINE HYDROCHLORIDE							
AP	FRESENIUS KABI USA	1%	A088586	002		Apr	CMS1
AP		2%	A088586	003		Apr	CMS1
AP	+ INTL MEDICATION	1%	A083173	001		Aug	CRLD
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE							
AP	HIKMA	1%	A084625	001		Jun	CAHN
AP		2%	A084625	002		Jun	CAHN
SOLUTION; ORAL							
LIDOCAINE HYDROCHLORIDE VISCOUS							
AT	PAI HOLDINGS PHARM	2%	A218138	001	Feb 20, 2024	Feb	NEWA
SOLUTION; TOPICAL							
LIDOCAINE HYDROCHLORIDE							
AT	THE J MOLNER	4%	A218411	001	Apr 29, 2024	Apr	NEWA
<u>LIDOCAINE; PRILOCAINE</u>							
CREAM; TOPICAL							
LIDOCAINE AND PRILOCAINE							
	@ HIKMA	2.5%;2.5%	A076290	001	Sep 25, 2003	Mar	DISC
AB	PAI HOLDINGS PHARM	2.5%;2.5%	A205887	001	Jun 29, 2018	Jun	CMFD
	@ RHODES PHARMS	2.5%;2.5%	A213253	001	Sep 21, 2020	Sep	DISC
AB		2.5%;2.5%	A213253	001	Sep 21, 2020	Jun	CMFD
<u>LIDOCAINE; TETRACAINE</u>							
CREAM; TOPICAL							
PLIAGLIS							
	+ @ CRESCITA THERAP	7%;7%	N021717	001	Jun 29, 2006	Jul	CAHN
<u>LIFITEGRAST</u>							
SOLUTION/DROPS; OPHTHALMIC							
LIFITEGRAST							
	@ EUGIA PHARMA	5%	A215063	001	Nov 07, 2023	May	DISC
	@ MICRO LABS	5%	A215081	001	Aug 04, 2023	May	DISC
<u>LINAGLIPTIN</u>							
TABLET; ORAL							
LINAGLIPTIN							
AB	INVAGEN PHARMS	5MG	A208423	001	Sep 03, 2024	Aug	NEWA
<u>LINCOMYCIN HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
LINCOMYCIN HYDROCHLORIDE							
AP	ARTHUR GRP	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Jul	CAHN
AP	GENEYORK PHARMS	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	May	CMFD
	@ SLAYBACK	EQ 300MG BASE/ML	A063180	001	Apr 16, 1991	Sep	CAHN

LINEZOLID

TABLET;ORAL
LINEZOLID

>A> AB MACLEODS PHARMS LTD 600MG A210378 001 Oct 10, 2024 Oct NEWA

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION
TRIOSTAT

+ @ ENDO OPERATIONS EQ 0.01MG BASE/ML

N020105 001 Dec 31, 1991 May CAHN

TABLET;ORAL

LIOTHYRONINE SODIUM

AB	BIOCON PHARMA	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Mar	CAHN
AB		EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Feb	CAHN
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Mar	CAHN
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Feb	CAHN
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Mar	CAHN
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Feb	CAHN
AB	CARNEGIE	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Jan	NEWA
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Jan	NEWA
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Jan	NEWA
	@ NORVIUM BIOSCIENCE	EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Jul	CAHN
	@	EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Jul	CAHN
	@	EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Jul	CAHN
AB	ZYDUS LIFESCIENCES	EQ 0.005MG BASE	A214803	001	Jan 22, 2021	Aug	CAHN
AB		EQ 0.025MG BASE	A214803	002	Jan 22, 2021	Aug	CAHN
AB		EQ 0.05MG BASE	A214803	003	Jan 22, 2021	Aug	CAHN

LIRAGLUTIDE

SOLUTION;SUBCUTANEOUS
SAXENDA

+! NOVO 18MG/3ML (6MG/ML)

N206321 001 Dec 23, 2014 Mar CAIN

VICTOZA

+! NOVO NORDISK INC 18MG/3ML (6MG/ML)

N022341 001 Jan 25, 2010 Mar CAIN

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

>D>	@ ACTAVIS ELIZABETH	10MG	A202802	001	Aug 25, 2023	Oct	CMFD
>A>	AB	10MG	A202802	001	Aug 25, 2023	Oct	CMFD
	@	10MG	A202802	001	Aug 25, 2023	Feb	DISC
>D>	@	20MG	A202802	002	Aug 25, 2023	Oct	CMFD
>A>	AB	20MG	A202802	002	Aug 25, 2023	Oct	CMFD
	@	20MG	A202802	002	Aug 25, 2023	Feb	DISC
>D>	@	30MG	A202802	003	Aug 25, 2023	Oct	CMFD
>A>	AB	30MG	A202802	003	Aug 25, 2023	Oct	CMFD
	@	30MG	A202802	003	Aug 25, 2023	Feb	DISC
>D>	@	40MG	A202802	004	Aug 25, 2023	Oct	CMFD
>A>	AB	40MG	A202802	004	Aug 25, 2023	Oct	CMFD
	@	40MG	A202802	004	Aug 25, 2023	Feb	DISC
>D>	@	50MG	A202802	005	Aug 25, 2023	Oct	CMFD
>A>	AB	50MG	A202802	005	Aug 25, 2023	Oct	CMFD
	@	50MG	A202802	005	Aug 25, 2023	Feb	DISC
>D>	@	60MG	A202802	006	Aug 25, 2023	Oct	CMFD
>A>	AB	60MG	A202802	006	Aug 25, 2023	Oct	CMFD
	@	60MG	A202802	006	Aug 25, 2023	Feb	DISC
>D>	@	70MG	A202802	007	Aug 25, 2023	Oct	CMFD
>A>	AB	70MG	A202802	007	Aug 25, 2023	Oct	CMFD
	@	70MG	A202802	007	Aug 25, 2023	Feb	DISC
AB	HIKMA	10MG	A202827	007	Jan 17, 2024	Jan	NEWA
	@ SANDOZ	20MG	A202836	001	Jul 26, 2024	Aug	DISC
AB		20MG	A202836	001	Jul 26, 2024	Jul	NEWA
	@	30MG	A202836	002	Jul 26, 2024	Aug	DISC
AB		30MG	A202836	002	Jul 26, 2024	Jul	NEWA
	@	40MG	A202836	003	Jul 26, 2024	Aug	DISC
AB		40MG	A202836	003	Jul 26, 2024	Jul	NEWA
	@	50MG	A202836	004	Jul 26, 2024	Aug	DISC
AB		50MG	A202836	004	Jul 26, 2024	Jul	NEWA
	@	60MG	A202836	005	Jul 26, 2024	Aug	DISC
AB		60MG	A202836	005	Jul 26, 2024	Jul	NEWA
	@	70MG	A202836	006	Jul 26, 2024	Aug	DISC
AB		70MG	A202836	006	Jul 26, 2024	Jul	NEWA

TABLET, CHEWABLE;ORALLISDEXAMFETAMINE DIMESYLATE

AB	MSN	10MG	A218306	001	Feb 02, 2024	Jan	NEWA
AB		20MG	A218306	002	Feb 02, 2024	Jan	NEWA
AB		30MG	A218306	003	Feb 02, 2024	Jan	NEWA
AB		40MG	A218306	004	Feb 02, 2024	Jan	NEWA
AB		50MG	A218306	005	Feb 02, 2024	Jan	NEWA
AB		60MG	A218306	006	Feb 02, 2024	Jan	NEWA
AB	TEVA PHARMS	10MG	A215415	001	Aug 25, 2023	Aug	CMFD
	@	10MG	A215415	001	Aug 25, 2023	Feb	DISC
AB		20MG	A215415	002	Aug 25, 2023	Aug	CMFD
	@	20MG	A215415	002	Aug 25, 2023	Feb	DISC
AB		30MG	A215415	003	Aug 25, 2023	Aug	CMFD
	@	30MG	A215415	003	Aug 25, 2023	Feb	DISC
AB		40MG	A215415	004	Aug 25, 2023	Aug	CMFD
	@	40MG	A215415	004	Aug 25, 2023	Feb	DISC
AB		50MG	A215415	005	Aug 25, 2023	Aug	CMFD
	@	50MG	A215415	005	Aug 25, 2023	Feb	DISC
AB		60MG	A215415	006	Aug 25, 2023	Aug	CMFD
	@	60MG	A215415	006	Aug 25, 2023	Feb	DISC

LISINAPRIL

TABLET;ORAL

LISINAPRIL

	@	ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013	May	DISC
	@		5MG	A202554	002	Jul 30, 2013	May	DISC
	@		10MG	A202554	003	Jul 30, 2013	May	DISC
	@		20MG	A202554	004	Jul 30, 2013	May	DISC
	@		30MG	A202554	005	Jul 30, 2013	May	DISC
	@		40MG	A202554	006	Jul 30, 2013	May	DISC

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

	@	PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Feb	DISC
AA	!	RUBICON	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	NEWA
	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	CTEC
AA	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Feb	CHRS

LOFEXIDINE HYDROCHLORIDE

TABLET;ORAL

LOFEXIDINE HYDROCHLORIDE

AB		INDOCO	EQ 0.18MG BASE	A218613	001	Aug 20, 2024	Aug	NFTG
		LUCEMYRA						
AB	+	USWM	EQ 0.18MG BASE	N209229	001	May 16, 2018	Aug	CFTG

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

+		CHIESI	EQ 5MG BASE	N203858	001	Dec 21, 2012	Jan	CAHN
+			EQ 10MG BASE	N203858	002	Dec 21, 2012	Jan	CAHN
+			EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan	CAHN
+			EQ 30MG BASE	N203858	004	Apr 23, 2015	Jan	CAHN
+	@		EQ 40MG BASE	N203858	005	Apr 23, 2015	Jan	CAHN
+	@		EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan	CAHN

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

+	@	LATINA PHARMA	5MG	N017588	004	Dec 19, 2014	Feb	CAHN
+			10MG	N017588	001		Feb	CAHN
+	!		40MG	N017588	002		May	CHRS
+			40MG	N017588	002		Feb	CAHN
+			100MG	N017588	003		May	CHRS
+	!		100MG	N017588	003		Feb	CAHN

LONAFARNIB

CAPSULE;ORAL

ZOKINVY

+		SENTYNL THERAPS INC	50MG	N213969	001	Nov 20, 2020	May	CAHN
+	!		75MG	N213969	002	Nov 20, 2020	May	CAHN

LOPINAVIR; RITONAVIR

TABLET; ORAL

LOPINAVIR AND RITONAVIR

AB	MACLEODS PHARMS LTD	100MG;25MG	A204739	001	Jul 25, 2024	Jul	NEWA
AB		200MG;50MG	A204739	002	Jul 25, 2024	Jul	NEWA
AB	MYLAN LABS LTD	100MG;25MG	A079074	001	Feb 07, 2024	Jan	NEWA
AB		200MG;50MG	A079074	002	Feb 07, 2024	Jan	NEWA

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

@ HIKMA 2MG/ML

A200169 001 Jan 30, 2012 Mar DISC

INJECTABLE; INJECTION

LORAZEPAM

@ ENDO OPERATIONS 2MG/ML

A074793 001 Mar 16, 2000 Apr CAHN

@ 4MG/ML

A074793 002 Mar 16, 2000 Apr CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

@ AIPING PHARM INC 25MG

A090544 001 Oct 06, 2010 Feb CAHN

@ 50MG

A090544 002 Oct 06, 2010 Feb CAHN

@ 100MG

A090544 003 Oct 06, 2010 Feb CAHN

AB APOTEX 25MG

A218551 001 Jun 04, 2024 May NEWA

AB 50MG

A218551 002 Jun 04, 2024 May NEWA

AB 100MG

A218551 003 Jun 04, 2024 May NEWA

AB CHARTWELL RX 25MG

A077424 001 Oct 06, 2010 Jan CAHN

AB 50MG

A077424 002 Oct 06, 2010 Jan CAHN

AB 100MG

A077424 003 Oct 06, 2010 Jan CAHN

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEPREDNOL ETABONATE

>D> AB HIKMA 0.5%

A213956 001 Nov 29, 2023 Oct DISC

>A> @ 0.5%

A213956 001 Nov 29, 2023 Oct DISC

AB 0.5%

A213956 001 Nov 29, 2023 Apr CAHN

SUSPENSION/DROPS; OPHTHALMIC

LOTEPREDNOL ETABONATE

AB LUPIN LTD 0.5%

A215719 001 Apr 24, 2024 Apr NEWA

AB PADAGIS US 0.2%

A215203 001 Jul 10, 2024 Jun NEWA

LUBIPROSTONE

CAPSULE; ORAL

LUBIPROSTONE

@ ENDO OPERATIONS 8MCG

A201442 001 Jun 27, 2022 Apr CAHN

@ 24MCG

A201442 002 Jun 27, 2022 Apr CAHN

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

AB ANNORA PHARMA 20MG

A218174 001 Aug 21, 2024 Aug NEWA

AB 40MG

A218174 002 Aug 21, 2024 Aug NEWA

AB 60MG

A218174 003 Aug 21, 2024 Aug NEWA

AB 80MG

A218174 004 Aug 21, 2024 Aug NEWA

AB 120MG

A218174 005 Aug 21, 2024 Aug NEWA

>D> AB AVET LIFESCIENCES 20MG

A208058 001 Sep 04, 2019 Oct CAHN

>D> AB 40MG

A208058 002 Sep 04, 2019 Oct CAHN

>D> AB 60MG

A208058 003 Sep 04, 2019 Oct CAHN

>D> AB 80MG

A208058 004 Sep 04, 2019 Oct CAHN

>D> AB 120MG

A208058 005 Feb 28, 2023 Oct CAHN

>A> AB HERITAGE PHARMA AVET 20MG

A208058 001 Sep 04, 2019 Oct CAHN

>A> AB 40MG

A208058 002 Sep 04, 2019 Oct CAHN

>A> AB 60MG

A208058 003 Sep 04, 2019 Oct CAHN

>A> AB 80MG

A208058 004 Sep 04, 2019 Oct CAHN

>A> AB 120MG

A208058 005 Feb 28, 2023 Oct CAHN

AB SLATE RUN PHARMA 20MG

A212091 001 Dec 28, 2020 Feb CAHN

AB 40MG

A212091 002 Dec 28, 2020 Feb CAHN

AB 60MG

A212091 003 Dec 28, 2020 Feb CAHN

AB 80MG

A212091 004 Dec 28, 2020 Feb CAHN

AB 120MG

A212091 005 Dec 28, 2020 Feb CAHN

MACITENTAN

TABLET;ORAL		MACITENTAN					
	@ APOTEX	10MG	A211195	001	Jan 09, 2024	Apr	DISC
	@ TORRENT	10MG	A211107	001	Aug 05, 2024	Aug	DISC
AB		10MG	A211107	001	Aug 05, 2024	Jul	NFTG
	@ ZYDUS LIFESCIENCES	10MG	A211224	001	Apr 06, 2021	May	CAHN
OPSUMIT							
	+! ACTELION	10MG	N204410	001	Oct 18, 2013	Aug	CTEC
AB	+!	10MG	N204410	001	Oct 18, 2013	Jul	CFTG
	+!	10MG	N204410	001	Oct 18, 2013	Apr	CTEC

MACITENTAN; TADALAFIL

TABLET;ORAL		OPSYNVI					
	+ ACTELION	10MG;20MG	N218490	001	Mar 22, 2024	Mar	NEWA
	+!	10MG;40MG	N218490	002	Mar 22, 2024	Mar	NEWA

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL		MAFENIDE ACETATE					
	@ ENDO OPERATIONS	5%	A201511	001	Feb 12, 2013	May	CAHN

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS		MAGNESIUM SULFATE					
	@ EXELA PHARMA	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Aug	DISC

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL		MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE					
AA	TARO	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A206431	001	Mar 19, 2024	Mar	NEWA
	SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE						
>A> AA	ANNORA PHARMA	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A212903	001	Oct 18, 2024	Oct	NEWA
AA	BIONPHARMA	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A204135	001	Jun 24, 2024	Jun	NEWA
AA	LANNETT CO INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A209941	001	Jul 15, 2024	Jul	NEWA
AA	PAI HOLDINGS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A209941	001	Jul 15, 2024	Sep	CAHN
AA	TARO	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A206431	001	Mar 19, 2024	Jun	CMS1

MANNITOL

INJECTABLE;INJECTION		OSMITROL 20% IN WATER IN PLASTIC CONTAINER					
AP	+! BAXTER HLTHCARE	20GM/100ML	N013684	007		Jul	CHRS
AP	+	20GM/100ML	N013684	007		Jul	CRLD
POWDER;INHALATION		ARIDOL KIT					
	+! PHARMAXIS EUROPE	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010	May	CAHN
BRONCHITOL							
	+! PHARMAXIS EUROPE	40MG	N202049	001	Oct 30, 2020	Aug	CAHN

MARALIXIBAT CHLORIDE

SOLUTION;ORAL		LIVMARLI					
	+! MIRUM	EQ 19MG BASE/ML	N214662	002	Jul 24, 2024	Jul	NEWA

MARAVIROC

TABLET;ORAL		SELZENTRY					
	+ @ VIIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016	Jan	DISC
	+ @	75MG	N022128	004	Nov 04, 2016	Jan	DISC

MAVORIXAFOR

CAPSULE;ORAL		XOLREMDI					
	+! X4 PHARMS	100MG	N218709	001	Apr 26, 2024	Apr	NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA		AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011	Mar	CHRS
AA	!		50MG	A201451	003	Feb 23, 2011	Feb	CMFD
	@	CHARTWELL RX	12.5MG	A205136	001	Feb 22, 2019	Sep	CAHN
	@		25MG	A205136	002	Feb 22, 2019	Sep	CAHN
	@		50MG	A205136	003	Feb 22, 2019	Sep	CAHN
	@	INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Mar	DISC
	@		25MG	A200432	002	Feb 17, 2022	Mar	DISC
	@		50MG	A200432	003	Feb 17, 2022	Mar	DISC
	@	WILSHIRE PHARMS INC	12.5MG	A205136	001	Feb 22, 2019	Jul	DISC
	@		25MG	A205136	002	Feb 22, 2019	Jul	DISC
	@		50MG	A205136	003	Feb 22, 2019	Jul	DISC

TABLET, CHEWABLE;ORAL

MECLIZINE HYDROCHLORIDE

	@	INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Mar	DISC
--	---	----------------	------	---------	-----	--------------	-----	------

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

AB		HONG KONG	150MG/ML	A076553	001	Jul 28, 2004	Jan	CAHN
----	--	-----------	----------	---------	-----	--------------	-----	------

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE ES

AB	+!	ENDO OPERATIONS	125MG/ML	N021778	001	Jul 05, 2005	May	CAHN
	@	CHARTWELL	125MG/ML	A204688	001	Dec 01, 2017	Mar	CAHN
	@	HIKMA	40MG/ML	A203960	001	Jun 09, 2017	Mar	DISC
AB		NOVITIUM PHARMA	40MG/ML	A077404	001	Feb 16, 2006	May	CMFD

MELOXICAM

TABLET;ORAL

MELOXICAM

AB		AIPING PHARM INC	7.5MG	A077920	001	Jul 19, 2006	Jun	CAHN
AB			15MG	A077920	002	Jul 19, 2006	Jun	CAHN
AB		SCIEGEN PHARMS INC	7.5MG	A077920	001	Jul 19, 2006	Apr	CMFD
AB			15MG	A077920	002	Jul 19, 2006	Apr	CMFD
AB	!	ZYDUS PHARMS USA	15MG	A077921	002	Jul 19, 2006	Jan	CTEC
		MOBIC						
	+ @	BOEHRINGER INGELHEIM	7.5MG	N020938	001	Apr 13, 2000	Jan	DISC
	+ @		15MG	N020938	002	Aug 23, 2000	Jan	DISC

MELPHALAN

TABLET;ORAL

MELPHALAN

	@	ALVOGEN	2MG	A207809	001	Mar 22, 2017	May	DISC
--	---	---------	-----	---------	-----	--------------	-----	------

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

>A>	AP	AVET LIFESCIENCES	EQ 50MG BASE/VIAL	A206523	001	Oct 29, 2024	Oct	NEWA
	@	ENDO OPERATIONS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016	May	CAHN
AP		HETERO LABS	EQ 50MG BASE/VIAL	A215024	001	May 23, 2024	May	NEWA
		SOLUTION;INTRAVENOUS						
		IVRA						
	+!	APOTEX	EQ 90MG BASE/ML (EQ 90MG BASE/ML)	N217110	001	Aug 18, 2023	Jul	CTNA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

	@	ENDO OPERATIONS	7MG	A205784	001	Jun 09, 2017	Apr	CAHN
	@		14MG	A205784	002	Jun 09, 2017	Apr	CAHN
	@		21MG	A205784	003	Jun 09, 2017	Apr	CAHN
	@		28MG	A205784	004	Jun 09, 2017	Apr	CAHN
AB		XIAMEN LP PHARM CO	21MG	A213985	004	Feb 06, 2024	Jan	NEWA
AB	!	ZYDUS PHARMS	28MG	A203293	004	Aug 03, 2017	Jul	CHRS
		NAMENDA XR						
	+ @	ABBVIE	14MG	N022525	002	Jun 21, 2010	Jul	DISC
	+ @		21MG	N022525	003	Jun 21, 2010	Jul	DISC

	CAPSULE, EXTENDED RELEASE;ORAL							
	NAMENDA XR							
	+ @	28MG		N022525	004	Jun 21, 2010	Jul	DISC
	SOLUTION;ORAL							
	MEMANTINE HYDROCHLORIDE							
	@	2MG/ML	SCIEGEN PHARMS INC	A205446	001	Dec 07, 2015	Sep	CAHN
	TABLET;ORAL							
	MEMANTINE HYDROCHLORIDE							
AB	ACME LABS	5MG		A209527	001	May 07, 2018	Aug	CAHN
AB		10MG		A209527	002	May 07, 2018	Aug	CAHN
AB	RENATA	5MG		A209527	001	May 07, 2018	Jan	CAHN
AB		10MG		A209527	002	May 07, 2018	Jan	CAHN
	<u>MEPERIDINE HYDROCHLORIDE</u>							
	INJECTABLE; INJECTION							
	DEMEROL							
	@	25MG/ML	QUAGEN	N005010	007		Sep	CAHN
	@	50MG/ML		N005010	002		Sep	CAHN
	@	75MG/ML		N005010	009		Sep	CAHN
	@	100MG/ML		N005010	003		Sep	CAHN
	SYRUP;ORAL							
	DEMEROL							
	@	50MG/5ML	QUAGEN	N005010	005		Sep	CAHN
	TABLET;ORAL							
	DEMEROL							
	+ @	50MG	QUAGEN	N005010	001		Sep	CAHN
	+ @	100MG		N005010	004		Sep	CAHN
	MEPERIDINE HYDROCHLORIDE							
AA	!	50MG	EPIC PHARMA LLC	A040331	001	May 28, 1999	Feb	CTEC
	!	50MG		A040331	001	May 28, 1999	Feb	CHRS
AA		50MG	GENUS	A040893	001	Jun 24, 2009	Feb	CMFD
	@	50MG		A040893	001	Jun 24, 2009	Jan	CAHN
	@	75MG		A040893	002	Jun 24, 2009	Jan	CAHN
	@	100MG		A040893	003	Jun 24, 2009	Jan	CAHN
	@	150MG		A040893	004	Jun 24, 2009	Jan	CAHN
	<u>MEROPENEM</u>							
	INJECTABLE; INJECTION							
	MEROPENEM							
AP		500MG/VIAL	QILU	A216424	001	Jul 22, 2024	Jul	NEWA
AP		1GM/VIAL		A216424	002	Jul 22, 2024	Jul	NEWA
	<u>MESALAMINE</u>							
	CAPSULE, EXTENDED RELEASE;ORAL							
	MESALAMINE							
AB		375MG	NOVAST LABS	A218410	001	Aug 22, 2024	Aug	NEWA
	SUPPOSITORY;RECTAL							
	MESALAMINE							
AB		1GM	RISING	A207448	001	Apr 19, 2019	Sep	CAHN
	TABLET, DELAYED RELEASE;ORAL							
	MESALAMINE							
AB		1.2GM	ANNORA PHARMA	A216334	001	Feb 05, 2024	Jan	NEWA
AB		800MG	TEVA PHARMS INC	A213191	001	Aug 22, 2024	Aug	NEWA
AB	!	800MG	ZYDUS PHARMS	A203286	001	Jul 21, 2017	Aug	CTEC
	<u>MESNA</u>							
	INJECTABLE; INTRAVENOUS							
	MESNA							
	@	100MG/ML	RISING	A203364	001	Jul 18, 2014	Feb	CAHN
	<u>METAPROTERENOL SULFATE</u>							
	SYRUP;ORAL							
	METAPROTERENOL SULFATE							
	!	10MG/5ML	CHARTWELL	A073632	001	Jul 22, 1992	Sep	CAHN
	!	10MG/5ML	GENUS	A073632	001	Jul 22, 1992	Jan	CAHN

METARAMINOL BITARTRATE

INJECTABLE; INJECTION
 METARAMINOL BITARTRATE
 AZURITY

EQ 10MG BASE/ML

A211304 001 Aug 24, 2021 Jul CAHN

METAXALONE

TABLET; ORAL
 METAXALONE

BX RISING 800MG

A208774 001 Sep 24, 2018 Sep CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL
 METFORMIN HYDROCHLORIDE
 @ AMNEAL PHARMS NY 500MG
 @ 850MG
 @ 1GM

A077880 001 Jun 05, 2006 Jul DISC
 A077880 002 Jun 05, 2006 Jul DISC
 A077880 003 Jun 05, 2006 Jul DISC

TABLET, EXTENDED RELEASE; ORAL
 METFORMIN HYDROCHLORIDE

>A> AB2 AUROBINDO PHARMA 500MG
 >A> AB2 1GM
 AB1 HARMAN FINOCHEM 500MG
 AB 750MG
 AB3 MACLEODS PHARMS LTD 1GM
 @ UTOPIC PHARMS 500MG
 @ 1GM

A209694 001 Oct 18, 2024 Oct NEWA
 A209694 002 Oct 18, 2024 Oct NEWA
 A218673 001 Jul 05, 2024 Jun NEWA
 A218673 002 Jul 05, 2024 Jun NEWA
 A211163 001 Mar 13, 2024 Mar NEWA
 A213394 001 Aug 03, 2021 Sep CAHN
 A213394 002 Aug 03, 2021 Sep CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE
 @ CHARTWELL RX 500MG; EQ 15MG BASE
 @ 850MG; EQ 15MG BASE

A091273 001 Apr 16, 2013 Jan CAHN
 A091273 002 Apr 16, 2013 Jan CAHN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN

TABLET, EXTENDED RELEASE; ORAL
 ZITUVIMET XR
 + ZYDUS 500MG; 50MG
 + 1GM; 50MG
 +! 1GM; 100MG
 + ZYDUS LIFESCIENCES 500MG; 50MG
 + 1GM; 50MG
 +! 1GM; 100MG

N216778 001 Jul 18, 2024 Jul NEWA
 N216778 002 Jul 18, 2024 Jul NEWA
 N216778 003 Jul 18, 2024 Jul NEWA
 N216778 001 Jul 18, 2024 Aug CAHN
 N216778 002 Jul 18, 2024 Aug CAHN
 N216778 003 Jul 18, 2024 Aug CAHN

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL
 METHADONE HYDROCHLORIDE
 VISTAPHARM LLC 10MG/ML

AA

A040088 001 Nov 30, 1994 Apr CAHN

SOLUTION; ORAL
 METHADONE HYDROCHLORIDE
 @ VISTAPHARM LLC 5MG/5ML
 @ 10MG/5ML
 @ 10MG/5ML

AA
 AA

A090707 001 Jun 30, 2010 Jun DISC
 A090707 001 Jun 30, 2010 Apr CAHN
 A090707 002 Jun 30, 2010 Jun DISC
 A090707 002 Jun 30, 2010 Apr CAHN

TABLET; ORAL
 METHADONE HYDROCHLORIDE

AA ELITE LABS INC 5MG
 @ 5MG
 AA 10MG
 @ 10MG
 @ VISTAPHARM LLC 5MG
 AA 10MG
 AA 10MG

A210484 001 Aug 02, 2018 Aug CMFD
 A210484 001 Aug 02, 2018 Jun CAHN
 A210484 002 Aug 02, 2018 Aug CMFD
 A210484 002 Aug 02, 2018 Jun CAHN
 A040241 001 May 29, 1998 Apr CAHN
 A040241 002 May 29, 1998 Apr CAHN
 A204166 001 Mar 16, 2020 Apr CAHN

METHENAMINE HIPPURATE

TABLET; ORAL
 HIPREX

>A> AB + ESJAY PHARMA 1GM
 >D> AB + SS PHARMA 1GM
 AB JUBILANT CADISTA 1GM

N017681 001 Oct CAHN
 N017681 001 Oct CAHN
 A217675 001 Dec 01, 2023 Apr CAHN

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

>D>	AP	NAVINTA LLC	1GM/10ML (100MG/ML)	A206071	001	Nov 24, 2017	Oct	DISC
>A>		@	1GM/10ML (100MG/ML)	A206071	001	Nov 24, 2017	Oct	DISC
		@ NORVIUM BIOSCIENCE	1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Jul	CAHN

TABLET;ORAL

METHOCARBAMOL

AA		ALLIED	500MG	A212623	001	Apr 30, 2021	Aug	CAHN
AA			750MG	A212623	002	Apr 30, 2021	Aug	CAHN
AA		DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb	CAHN
AA			750MG	A203550	002	Feb 08, 2017	Feb	CAHN
AA		HANGZHOU BINJIANG	500MG	A200958	001	Oct 21, 2011	Mar	CAHN
AA			750MG	A200958	002	Oct 21, 2011	Mar	CAHN
AB	!		1GM	A200958	003	Dec 06, 2021	Mar	CAHN
AA		HLTHCARE	500MG	A203550	001	Feb 08, 2017	Sep	CAHN
AA			750MG	A203550	002	Feb 08, 2017	Sep	CAHN
		ROBAXIN						
	+	@ ENDO OPERATIONS	500MG	N011011	004		May	CAHN
		ROBAXIN-750						
	+	@ ENDO OPERATIONS	750MG	N011011	006		May	CAHN

METHOHEXITAL SODIUM

INJECTABLE;INJECTION

BREVITAL SODIUM

AP	+	!	ENDO OPERATIONS	500MG/VIAL	N011559	001		Sep	CFTG
			METHOHEXITAL SODIUM						
>D>	AP		STERISCIENCE	500MG/VIAL	A215488	001	Oct 03, 2024	Oct	CAHN
	AP			500MG/VIAL	A215488	001	Oct 03, 2024	Sep	NFTG
>A>	AP		STERISCIENCE SPECLTS	500MG/VIAL	A215488	001	Oct 03, 2024	Oct	CAHN

METHOTREXATE SODIUM

TABLET;ORAL

METHOTREXATE SODIUM

AB		ALEMBIC	EQ 2.5MG BASE	A217552	001	Jun 03, 2024	May	NEWA
		@ AMNEAL PHARMS	EQ 2.5MG BASE	A210040	001	Dec 22, 2017	Sep	DISC
AB		ELITE LABS INC	EQ 2.5MG BASE	A216453	001	May 16, 2024	May	NEWA
		@ LOTUS PHARM CO LTD	EQ 2.5MG BASE	A209787	001	Apr 23, 2021	Apr	DISC

METHSCOPOLAMINE BROMIDE

TABLET;ORAL

METHSCOPOLAMINE BROMIDE

AA		AACE PHARMS	2.5MG	A216786	001	Feb 01, 2024	Jan	NEWA
AA			5MG	A216786	002	Feb 01, 2024	Jan	NEWA
AA		NE RX PHARMA	2.5MG	A216786	001	Feb 01, 2024	May	CAHN
AA			5MG	A216786	002	Feb 01, 2024	May	CAHN

METHYLDOPA

TABLET;ORAL

METHYLDOPA

		@ CHARTWELL RX	250MG	N018934	001	Jun 29, 1984	Feb	DISC
			250MG	N018934	001	Jun 29, 1984	Jan	CMFD
		@	500MG	N018934	002	Jun 29, 1984	Feb	DISC
		!	500MG	N018934	002	Jun 29, 1984	Jan	CMFD

METHYLENE BLUE

SOLUTION;INTRAVENOUS

METHYLENE BLUE

AP		ZYDUS LIFESCIENCES	10MG/2ML (5MG/ML)	A215636	001	Dec 05, 2023	Apr	CAHN
AP			50MG/10ML (5MG/ML)	A215636	002	Dec 05, 2023	Apr	CAHN

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB		TRUPHARMA	0.2MG	A212233	001	May 01, 2020	Sep	CAHN
----	--	-----------	-------	---------	-----	--------------	-----	------

METHYLNALTREXONE BROMIDE

SOLUTION;SUBCUTANEOUS

METHYLNALTREXONE BROMIDE

AP	ACTAVIS LLC	8MG/0.4ML (8MG/0.4ML)	A208112	001	Aug 26, 2024	Aug	NFTG
AP		12MG/0.6ML (12MG/0.6ML)	A208112	002	Aug 26, 2024	Aug	NFTG
	RELISTOR						
AP	+! SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Aug	CFTG
AP	+!	12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Aug	CFTG

METHYLPHENIDATETABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
COTEMPLA XR-ODT

	+ @ NEOS THERAPS INC	34.6MG	N205489	004	Aug 19, 2024	Sep	DISC
	+	34.6MG	N205489	004	Aug 19, 2024	Aug	NEWA

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
JORNAY PM

>D>	+ IRONSHORE PHARMS	20MG	N209311	001	Aug 08, 2018	Oct	CAHN
>A>	+	20MG	N209311	001	Aug 08, 2018	Oct	CAHN
>D>	+	40MG	N209311	002	Aug 08, 2018	Oct	CAHN
>A>	+	40MG	N209311	002	Aug 08, 2018	Oct	CAHN
>D>	+	60MG	N209311	003	Aug 08, 2018	Oct	CAHN
>A>	+	60MG	N209311	003	Aug 08, 2018	Oct	CAHN
>D>	+	80MG	N209311	004	Aug 08, 2018	Oct	CAHN
>A>	+	80MG	N209311	004	Aug 08, 2018	Oct	CAHN
>D>	+!	100MG	N209311	005	Aug 08, 2018	Oct	CAHN
>A>	+!	100MG	N209311	005	Aug 08, 2018	Oct	CAHN

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	ANDA REPOSITORY	5MG/5ML	A210764	001	Apr 10, 2020	Sep	CAHN
AA		10MG/5ML	A210764	002	Apr 10, 2020	Sep	CAHN
	@ BRECKENRIDGE	5MG/5ML	A201466	001	Nov 12, 2013	Mar	DISC
	@	10MG/5ML	A201466	002	Nov 12, 2013	Mar	DISC

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	CEDIPROF INC	5MG	A208737	001	Feb 01, 2019	Mar	CMFD
AB		10MG	A208737	002	Feb 01, 2019	Mar	CMFD
AB		20MG	A208737	003	Feb 01, 2019	Mar	CMFD

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

AB	ENDO OPERATIONS	4MG	A040183	001	Dec 22, 1998	Apr	CAHN
	@ PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb	DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB	ENDO OPERATIONS	40MG/ML	A214297	001	Jan 21, 2022	Apr	CAHN
AB		80MG/ML	A214297	002	Jan 21, 2022	Apr	CAHN
AB	HONG KONG	40MG/ML	A040557	001	Feb 23, 2005	Jan	CAHN
AB		80MG/ML	A040557	002	Feb 23, 2005	Jan	CAHN
	@ TEVA PHARMS USA	40MG/ML	A040620	001	Oct 27, 2006	Jan	DISC
	@	80MG/ML	A040620	002	Oct 27, 2006	Jan	DISC
AB	WILSHIRE PHARMS INC	40MG/ML	A214870	002	May 10, 2023	Jul	CAHN
AB		80MG/ML	A214870	001	Jan 03, 2023	Jul	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	! GENUS	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	Apr	CAHN
----	---------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>A>	AB AIPING PHARM INC	EQ 5MG BASE	A072215	002	Nov 05, 2024	Oct	NEWA
>D>	@	EQ 10MG BASE	A072215	001	Jan 30, 1990	Oct	CMFD
>A>	AB	EQ 10MG BASE	A072215	001	Jan 30, 1990	Oct	CMFD

METOLAZONE

TABLET; ORAL

METOLAZONE

AB	CHEMISTRY HLTH	2.5MG	A218606	001	Apr 17, 2024	Sep	CAHN
AB		5MG	A218606	002	Apr 17, 2024	Sep	CAHN
AB		10MG	A218606	003	Apr 17, 2024	Sep	CAHN
AB	LEADING	2.5MG	A218606	001	Apr 17, 2024	Apr	NEWA
AB		5MG	A218606	002	Apr 17, 2024	Apr	NEWA
AB		10MG	A218606	003	Apr 17, 2024	Apr	NEWA
>A>	MICRO LABS	2.5MG	A217563	001	Nov 06, 2024	Oct	NEWA
>A>		5MG	A217563	002	Nov 06, 2024	Oct	NEWA
>A>		10MG	A217563	003	Nov 06, 2024	Oct	NEWA

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

	@ GRANULES	EQ 25MG TARTRATE	A216509	001	Aug 07, 2023	Mar	DISC
	@	EQ 50MG TARTRATE	A216509	002	Aug 07, 2023	Mar	DISC
	@	EQ 100MG TARTRATE	A216509	003	Aug 07, 2023	Mar	DISC
	@	EQ 200MG TARTRATE	A216509	004	Aug 07, 2023	Mar	DISC
AB	SUNSHINE	EQ 25MG TARTRATE	A214004	004	May 23, 2024	May	NEWA
AB	ZHEJIANG JUTAI PHARM	EQ 50MG TARTRATE	A214110	001	Jul 26, 2024	Jul	NEWA
AB		EQ 100MG TARTRATE	A214110	002	Jul 26, 2024	Jul	NEWA
AB		EQ 200MG TARTRATE	A214110	003	Jul 26, 2024	Jul	NEWA

METRONIDAZOLE

GEL; TOPICAL

METROGEL

	+ @ GALDERMA LABS LP	0.75%	N019737	001	Nov 22, 1988	May	DISC
>A>	AUROBINDO PHARMA LTD	1%	A218941	001	Oct 15, 2024	Oct	NEWA
AB	! COSETTE	0.75%	A078178	001	Jan 19, 2011	May	CHRS

GEL; VAGINAL

METRONIDAZOLE

AB	ENCUBE	1.3%	A216795	001	Mar 18, 2024	Mar	NFTG	
AB	+! CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	Mar	CFTG	
>A>	AB	APPCO	250MG	A205245	001	Sep 23, 2015	Oct	CAHN
>A>	AB		500MG	A205245	002	Sep 23, 2015	Oct	CAHN
	@ FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	Mar	DISC	
	@	500MG	A207309	002	May 16, 2016	Mar	DISC	
>D>	AB	HERITAGE PHARMS INC	250MG	A205245	001	Sep 23, 2015	Oct	CAHN
>D>	AB		500MG	A205245	002	Sep 23, 2015	Oct	CAHN
>A>		INNOGENIX	125MG	A070772	003	Oct 29, 2024	Oct	NEWA

METYROSINE

CAPSULE; ORAL

METYROSINE

AB	LEADING	250MG	A215541	001	Sep 17, 2024	Sep	NEWA
----	---------	-------	---------	-----	--------------	-----	------

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB	LEADING	150MG	A215876	001	Feb 27, 2023	Aug	CAHN	
AB		200MG	A215876	002	Feb 27, 2023	Aug	CAHN	
AB		250MG	A215876	003	Feb 27, 2023	Aug	CAHN	
>A>	AB	RISING	150MG	A215315	001	Aug 26, 2022	Oct	CAHN
>A>	AB		200MG	A215315	002	Aug 26, 2022	Oct	CAHN
>A>	AB		250MG	A215315	003	Aug 26, 2022	Oct	CAHN
>D>	AB	ZENARA	150MG	A215315	001	Aug 26, 2022	Oct	CAHN
AB		150MG	A215315	001	Aug 26, 2022	Apr	CAHN	
>D>	AB		200MG	A215315	002	Aug 26, 2022	Oct	CAHN
AB		200MG	A215315	002	Aug 26, 2022	Apr	CAHN	
>D>	AB		250MG	A215315	003	Aug 26, 2022	Oct	CAHN
AB		250MG	A215315	003	Aug 26, 2022	Apr	CAHN	

MICAFUNGIN SODIUM

	INJECTABLE; INTRAVENOUS						
	MICAFUNGIN SODIUM						
	@ APOTEX	EQ 50MG BASE/VIAL	A208366	001	Nov 05, 2020	Jul	DISC
	@	EQ 100MG BASE/VIAL	A208366	002	Nov 05, 2020	Jul	DISC
AP	BIOCON PHARMA	EQ 50MG BASE/VIAL	A216438	001	May 29, 2024	May	NEWA
AP		EQ 100MG BASE/VIAL	A216438	002	May 29, 2024	May	NEWA

MIDAZOLAM

	SOLUTION; INTRAVENOUS						
	MIDAZOLAM IN 0.8% SODIUM CHLORIDE						
	+ @ EXELA PHARMA	50MG/50ML (1MG/ML)	N215868	001	Jul 20, 2022	May	DISC
	MIDAZOLAM IN 0.9% SODIUM CHLORIDE						
AP	GLAND PHARMA LTD	50MG/50ML (1MG/ML)	A218993	001	Aug 12, 2024	Aug	NEWA
AP		100MG/100ML (1MG/ML)	A218993	002	Aug 12, 2024	Aug	NEWA

MIDAZOLAM HYDROCHLORIDE

	INJECTABLE; INJECTION						
	MIDAZOLAM HYDROCHLORIDE						
	@ ENDO OPERATIONS	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Sep	CAHN
	@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Sep	CAHN
	@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Sep	CAHN
	@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Sep	CAHN
	@ FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Jan	DISC
	MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE						
AP	STERISCIENCE SPECLTS	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Aug	CAHN
AP		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Aug	CAHN
	MIDAZOLAM HYDROCHLORIDE						
AP	STERISCIENCE SPECLTS	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Aug	CAHN
AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Aug	CAHN
	SYRUP; ORAL						
	MIDAZOLAM HYDROCHLORIDE						
	@ PAI HOLDINGS	EQ 2MG BASE/ML	A075958	001	Sep 04, 2003	Jul	CAHN

MIDODRINE HYDROCHLORIDE

	TABLET; ORAL						
	MIDODRINE HYDROCHLORIDE						
AB	ENDO OPERATIONS	2.5MG	A207169	001	Oct 29, 2018	Apr	CAHN
AB		5MG	A207169	002	Oct 29, 2018	Apr	CAHN
AB		10MG	A207169	003	Oct 29, 2018	Apr	CAHN

MIDOSTAURIN

	CAPSULE; ORAL						
	MIDOSTAURIN						
AB	DR REDDYS	25MG	A215921	001	Jun 28, 2024	Jun	NEWA
AB	LUPIN	25MG	A216015	001	May 10, 2024	May	NEWA
>D>	AB	TEVA PHARMS	A216076	001	Apr 29, 2024	Oct	DISC
>A>	@	25MG	A216076	001	Apr 29, 2024	Oct	DISC
AB		25MG	A216076	001	Apr 29, 2024	Apr	NFTG
	RYDAPT						
AB	+! NOVARTIS	25MG	N207997	001	Apr 28, 2017	Apr	CFTG

MIGLUSTAT

	CAPSULE; ORAL						
	MIGLUSTAT						
>D>	AB	BRECKENRIDGE	A209325	001	Feb 03, 2022	Oct	DISC
>A>	@	100MG	A209325	001	Feb 03, 2022	Oct	DISC

MILNACIPRAN HYDROCHLORIDE

	TABLET; ORAL						
	MILNACIPRAN HYDROCHLORIDE						
AB	HETERO LABS LTD V	12.5MG	A205147	001	Oct 03, 2024	Sep	NFTG
AB		25MG	A205147	002	Oct 03, 2024	Sep	NFTG
AB		50MG	A205147	003	Oct 03, 2024	Sep	NFTG
AB		100MG	A205147	004	Oct 03, 2024	Sep	NFTG
	@ ORYZA	12.5MG	A205071	001	Jan 27, 2016	Sep	CAHN
	@	25MG	A205071	002	Jan 27, 2016	Sep	CAHN
	@	50MG	A205071	003	Jan 27, 2016	Sep	CAHN
	@	100MG	A205071	004	Jan 27, 2016	Sep	CAHN
	SAVELLA						
AB	+ ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Sep	CFTG

TABLET; ORAL
SAVELLA

AB	+		25MG	N022256	002	Jan 14, 2009	Sep	CFTG
AB	+	!	50MG	N022256	003	Jan 14, 2009	Sep	CFTG
AB	+		100MG	N022256	004	Jan 14, 2009	Sep	CFTG

MINOCYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
MINOCIN

>D>	+	!	REMPLEX	EQ	100MG	BASE/VIAL	N050444	001		Oct	CFTG
>A>	AP	+	!	EQ	100MG	BASE/VIAL	N050444	001		Oct	CFTG

MINOCYCLINE HYDROCHLORIDE

>D>	AP		NEXUS PHARMS	EQ	100MG	BASE/VIAL	A214934	001	Jul 22, 2022	Oct	NFTG
>A>	AP			EQ	100MG	BASE/VIAL	A214934	001	Oct 24, 2024	Oct	NFTG

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

@	SUN PHARM INDUSTRIES	EQ	50MG	BASE	A090217	001	Jan 29, 2016	Jul	DISC
@		EQ	75MG	BASE	A090217	002	Jan 29, 2016	Jul	DISC
@		EQ	100MG	BASE	A090217	003	Jan 29, 2016	Jul	DISC

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	!	!	ALKEM LABS LTD	EQ	115MG	BASE	A204453	007	Mar 16, 2018	Jul	CHRS
AB	!			EQ	135MG	BASE	A204453	005	Sep 28, 2016	Jul	CHRS
AB			SANDOZ	EQ	135MG	BASE	A090422	003	Aug 13, 2009	Jul	CHRS
AB			SUN PHARM	EQ	45MG	BASE	A204394	001	Dec 30, 2015	Aug	CAHN
AB				EQ	55MG	BASE	A204394	002	Oct 07, 2022	Aug	CAHN
AB				EQ	65MG	BASE	A204394	003	Oct 07, 2022	Aug	CAHN
AB				EQ	80MG	BASE	A204394	004	Dec 30, 2015	Aug	CAHN
AB				EQ	105MG	BASE	A204394	005	Dec 30, 2015	Aug	CAHN
AB				EQ	115MG	BASE	A204394	006	Oct 07, 2022	Aug	CAHN
AB				EQ	135MG	BASE	A204394	007	Dec 30, 2015	Aug	CAHN
	@		SUN PHARM INDS LTD	EQ	45MG	BASE	A091118	001	Sep 25, 2014	Jan	DISC
	@			EQ	65MG	BASE	A091118	003	Dec 03, 2019	Jan	DISC
	@			EQ	80MG	BASE	A091118	004	Sep 25, 2014	Jan	DISC
	@			EQ	90MG	BASE	A091118	005	Sep 25, 2014	Jan	DISC
	@			EQ	105MG	BASE	A091118	006	Sep 25, 2014	Jan	DISC
	@			EQ	115MG	BASE	A091118	007	Dec 03, 2019	Jan	DISC
	@			EQ	135MG	BASE	A091118	008	Sep 25, 2014	Jan	DISC
	@		ZYDUS PHARMS	EQ	45MG	BASE	A203553	001	Nov 16, 2017	Jan	DISC
	@			EQ	55MG	BASE	A203553	002	Jun 16, 2023	Jan	DISC
	@			EQ	65MG	BASE	A203553	003	Jun 16, 2023	Jan	DISC
	@			EQ	80MG	BASE	A203553	004	Nov 16, 2017	Jan	DISC
	@			EQ	90MG	BASE	A203553	005	Nov 16, 2017	Jan	DISC
	@			EQ	105MG	BASE	A203553	006	Nov 16, 2017	Jan	DISC
	@			EQ	115MG	BASE	A203553	007	Jun 16, 2023	Jan	DISC
	@			EQ	135MG	BASE	A203553	008	Nov 16, 2017	Jan	DISC

MINOLIRA

@	EPI HLTH	EQ	105MG	BASE	N209269	001	May 08, 2017	Jul	DISC
@		EQ	135MG	BASE	N209269	002	May 08, 2017	Jul	DISC

SOLODYN

+	@	BAUSCH	EQ	55MG	BASE	N050808	008	Aug 27, 2010	Jun	DISC
+	@		EQ	65MG	BASE	N050808	004	Jul 23, 2009	Jun	DISC
+	@		EQ	80MG	BASE	N050808	007	Aug 27, 2010	Jun	DISC
+	@		EQ	105MG	BASE	N050808	006	Aug 27, 2010	Jun	DISC
+	@		EQ	115MG	BASE	N050808	005	Jul 23, 2009	Jun	DISC

MINOXIDIL

TABLET; ORAL
MINOXIDIL

AB			ENDO OPERATIONS		2.5MG		A071826	001	Nov 14, 1988	Apr	CAHN
AB					10MG		A071839	001	Nov 14, 1988	Apr	CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL
MIRABEGRON

AB			ALKEM LABS LTD		25MG		A215948	001	Feb 12, 2024	Feb	NEWA
AB					50MG		A215948	002	Feb 12, 2024	Feb	NEWA
AB			ZYDUS PHARMS		25MG		A209488	001	Sep 29, 2022	Mar	CMFD
AB					50MG		A209488	002	Sep 29, 2022	Mar	CMFD

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

AB	AIPING PHARM INC	15MG	A076219	001	Jun 19, 2003	Feb	CAHN
AB		30MG	A076219	002	Jun 19, 2003	Feb	CAHN
AB		45MG	A076219	003	Jun 19, 2003	Feb	CAHN
AB	CHARTWELL RX	15MG	A076219	001	Jun 19, 2003	Jun	CAHN
AB		30MG	A076219	002	Jun 19, 2003	Jun	CAHN
AB		45MG	A076219	003	Jun 19, 2003	Jun	CAHN

MISOPROSTOL

TABLET; ORAL

MISOPROSTOL

>D>	@ ACQ PHARMA	0.1MG	A210201	001	Jul 02, 2019	Oct	CMFD
>A> AB		0.1MG	A210201	001	Jul 02, 2019	Oct	CMFD
>D>	@	0.2MG	A210201	002	Jul 02, 2019	Oct	CMFD
>A> AB		0.2MG	A210201	002	Jul 02, 2019	Oct	CMFD

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

AP	FRESENIUS KABI USA	5MG/VIAL	A211269	001	Apr 05, 2024	Mar	NEWA
AP		20MG/VIAL	A211269	002	Apr 05, 2024	Mar	NEWA
AP		40MG/VIAL	A211269	003	Apr 05, 2024	Mar	NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

@ RISING	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Mar	CAHN
----------	------------------------------------	---------	-----	--------------	-----	------

MOMETASONE FUROATE

LOTION; TOPICAL

MOMETASONE FUROATE

@ COSETTE	0.1%	A077678	001	Nov 21, 2007	Apr	DISC
-----------	------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

MOMETASONE FUROATE

AB	AUROBINDO PHARMA	0.05MG/SPRAY	A215878	001	Mar 18, 2024	Mar	NEWA
----	------------------	--------------	---------	-----	--------------	-----	------

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

@ TEVA PHARMS	EQ 4MG BASE/PACKET	A090955	001	Aug 03, 2012	Jan	DISC
---------------	--------------------	---------	-----	--------------	-----	------

TABLET; ORAL

MONTELUKAST SODIUM

AB	RISING	EQ 10MG BASE	A209012	001	Apr 24, 2017	Aug	CAHN
	@ SANDOZ INC	EQ 10MG BASE	A200889	001	Aug 03, 2012	Jul	DISC

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

@ SANDOZ INC	EQ 4MG BASE	A091414	001	Aug 03, 2012	Sep	DISC
@	EQ 5MG BASE	A091414	002	Aug 03, 2012	Sep	DISC

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

UPSHER SMITH LABS	10MG	A202104	001	Jun 03, 2013	Sep	CHRS
-------------------	------	---------	-----	--------------	-----	------

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MORPHINE SULFATE

+ @ FRESENIUS KABI USA	5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013	Sep	DISC
+ @	8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013	Sep	DISC

SOLUTION; ORAL

MORPHINE SULFATE

@ HIKMA	100MG/5ML	A208809	001	Jul 06, 2017	Mar	DISC	
@ PHARM ASSOC	10MG/5ML	A206573	002	Sep 12, 2023	Aug	DISC	
@	100MG/5ML	A206573	001	Nov 14, 2016	Aug	DISC	
AA	WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Jan	CMFD
AA		20MG/5ML	A211454	002	Feb 12, 2021	Jan	CMFD
AA		100MG/5ML	A211454	003	Feb 12, 2021	Jan	CMFD

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

AT1	ADAPTIS	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Aug CAHN
	VIGAMOX					
AT1	+! HARROW EYE	EQ 0.5% BASE	N021598	001	Apr 15, 2003	Jan CAHN
	TABLET;ORAL					
	MOXIFLOXACIN HYDROCHLORIDE					
	@ NATCO	EQ 400MG BASE	A204635	001	Aug 31, 2015	Jun CAHN

MYCOPHENOLATE MOFETILCAPSULE;ORAL
MYCOPHENOLATE MOFETIL

>A>	AB	HETERO LABS LTD V	250MG	A207022	001	Oct 22, 2024	Oct NEWA
		FOR SUSPENSION;ORAL					
		MYCOPHENOLATE MOFETIL					
	AB	AUROBINDO PHARMA LTD	200MG/ML	A218227	001	Sep 26, 2024	Sep NEWA
		SUSPENSION;ORAL					
		MYHIBBIN					
	+!	AZURITY	200MG/ML	N216482	001	May 01, 2024	May NEWA
		TABLET;ORAL					
		MYCOPHENOLATE MOFETIL					
	@	AMNEAL	500MG	A090606	001	Jul 16, 2010	Feb DISC
	AB	AUROBINDO PHARMA	500MG	A217937	001	Feb 20, 2024	Feb NEWA
>A>	AB	HETERO LABS LTD V	500MG	A208119	001	Oct 22, 2024	Oct NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDEINJECTABLE;INJECTION
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP	ENDO OPERATIONS	500MG/VIAL	A203575	001	Oct 28, 2016	Apr CAHN
AP	STERISCIENCE SPECLTS	500MG/VIAL	A216390	001	Dec 23, 2022	Aug CAHN

MYCOPHENOLIC SODIUMTABLET, DELAYED RELEASE;ORAL
MYCOPHENOLIC SODIUM

AB	AUROBINDO PHARMA LTD	EQ 180MG BASE	A218603	001	Feb 27, 2024	Feb NEWA
AB		EQ 360MG BASE	A218603	002	Feb 27, 2024	Feb NEWA
AB	BIOCON PHARMA	EQ 180MG BASE	A217031	001	Nov 29, 2023	Jun CAHN
AB		EQ 360MG BASE	A217031	002	Nov 29, 2023	Jun CAHN
AB	NOVUGEN	EQ 180MG BASE	A216637	001	May 29, 2024	May NEWA
AB		EQ 360MG BASE	A216637	002	May 29, 2024	May NEWA
AB	SKG PHARMA	EQ 180MG BASE	A217031	001	Nov 29, 2023	Apr CAHN
AB		EQ 360MG BASE	A217031	002	Nov 29, 2023	Apr CAHN
AB	WANBANG BIOPHARMS	EQ 180MG BASE	A216637	001	May 29, 2024	Jun CAHN
AB		EQ 360MG BASE	A216637	002	May 29, 2024	Jun CAHN

NABILONECAPSULE;ORAL
CESAMET

+ @	BAUSCH	1MG	N018677	001	Dec 26, 1985	Aug DISC
-----	--------	-----	---------	-----	--------------	----------

NADOLOLTABLET;ORAL
CORCARD

+ @	USWM	20MG	N018063	005	Oct 28, 1986	Aug DISC
+ @		40MG	N018063	001		Aug DISC
+ @		80MG	N018063	002		Aug DISC
	NADOLOL					
AB	! INVAGEN PHARMS	80MG	A203455	003	Dec 18, 2015	Aug CHRS

NALBUPHINE HYDROCHLORIDEINJECTABLE;INJECTION
NALBUPHINE HYDROCHLORIDE

AP	SOMERSET THERAPS LLC	10MG/ML	A216049	001	Sep 19, 2024	Sep NEWA
AP		10MG/ML	A216050	001	Sep 19, 2024	Sep NEWA
AP		20MG/ML	A216049	002	Sep 19, 2024	Sep NEWA
AP		20MG/ML	A216050	002	Sep 19, 2024	Sep NEWA
	NUBAIN					
+ @	ENDO OPERATIONS	10MG/ML	N018024	001		May CAHN
+ @		20MG/ML	N018024	002	May 27, 1982	May CAHN

NALMEFENE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS		NALMEFENE HYDROCHLORIDE							
	!	CHENGDU SHUODE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	Jun	CMFD	
	@		EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	May	DISC	
AP	@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	Jun	CMFD	
	@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	May	DISC	
AP	!	PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	Jun	CTEC	
	!		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	May	CTEC	
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS		ZURNAI (AUTOINJECTOR)							
	+	PURDUE PHARMA LP	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Aug	NEWA	

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION		NALOXONE HYDROCHLORIDE							
	@	EUGIA PHARMA	0.4MG/ML	A212455	001	Oct 15, 2019	Jun	DISC	
AP		FRESENIUS KABI USA	0.4MG/ML	A213573	001	Apr 02, 2024	Mar	NEWA	
AP			1MG/ML	A213573	002	Apr 02, 2024	Mar	NEWA	
AP		HIKMA	0.4MG/ML	A212300	002	Mar 07, 2024	Mar	NEWA	
AP		MANKIND PHARMA	0.4MG/ML	A218404	001	Feb 29, 2024	Feb	NEWA	
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS		ZIMHI							
	+	ZMI PHARMA	5MG/0.5ML (5MG/0.5ML)	N212854	001	Oct 15, 2021	May	CAHN	
SPRAY;NASAL		REZENOPY							
	+	SUMMIT BIOSCI	10MG/SPRAY	N215487	001	Apr 19, 2024	Apr	NEWA	
SPRAY, METERED;NASAL		REXTOVY							
	+	AMPHASTAR PHARMS INC	4MG/SPRAY	N208969	001	Mar 07, 2023	Apr	CMFD	

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR		NALTREXONE							
	@	TEVA PHARMS USA INC	380MG/VIAL	A213195	001	Jul 06, 2023	Jan	DISC	
	+	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006	Jan	CTEC	

NAPROXEN

TABLET;ORAL		NAPROXEN							
AB		ADAPTIS	250MG	A091416	001	Feb 14, 2011	Sep	CAHN	
AB			375MG	A091416	002	Feb 14, 2011	Sep	CAHN	
AB			500MG	A091416	003	Feb 14, 2011	Sep	CAHN	
	@	INVAGEN PHARMS	250MG	A091305	001	Aug 24, 2011	Mar	DISC	
	@		375MG	A091305	002	Aug 24, 2011	Mar	DISC	
	@		500MG	A091305	003	Aug 24, 2011	Mar	DISC	
TABLET, DELAYED RELEASE;ORAL		NAPROXEN							
AB		NOVITIUM PHARMA	375MG	A218497	001	Jun 12, 2024	May	NEWA	
AB			500MG	A218497	002	Jun 12, 2024	May	NEWA	
AB		TRUPHARMA	375MG	A216908	001	May 31, 2023	Sep	CAHN	
AB			500MG	A216908	002	May 31, 2023	Sep	CAHN	

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL		NARATRIPTAN							
	@	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	May	DISC	

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL		NEBIVOLOL HYDROCHLORIDE							
	@	APOTEX	EQ 10MG BASE	A209741	001	Feb 27, 2024	May	DISC	
AB			EQ 10MG BASE	A209741	001	Feb 27, 2024	Feb	NEWA	
	@		EQ 20MG BASE	A209741	002	Feb 27, 2024	May	DISC	
AB			EQ 20MG BASE	A209741	002	Feb 27, 2024	Feb	NEWA	
AB		GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017	Jun	CMFD	
AB			EQ 5MG BASE	A203821	002	May 25, 2017	Jun	CMFD	

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

AB		EQ 10MG BASE	A203821	003	May 25, 2017	Jun	CMFD
AB		EQ 20MG BASE	A203821	004	May 25, 2017	Jun	CMFD
AB	MSN	EQ 2.5MG BASE	A217397	001	Oct 01, 2024	Sep	NEWA
AB		EQ 5MG BASE	A217397	002	Oct 01, 2024	Sep	NEWA
AB		EQ 10MG BASE	A217397	003	Oct 01, 2024	Sep	NEWA
AB		EQ 20MG BASE	A217397	004	Oct 01, 2024	Sep	NEWA
AB	UNICHEM	EQ 2.5MG BASE	A213830	001	Mar 15, 2022	Aug	CMFD
AB		EQ 5MG BASE	A213830	002	Mar 15, 2022	Aug	CMFD
AB		EQ 10MG BASE	A213830	003	Mar 15, 2022	Aug	CMFD
AB		EQ 20MG BASE	A213830	004	Mar 15, 2022	Aug	CMFD

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

@ CHARTWELL RX

@

@

@

@

@

		50MG	A076302	001	Sep 16, 2003	Jun	CAHN
		100MG	A076302	002	Sep 16, 2003	Jun	CAHN
		150MG	A076302	003	Sep 16, 2003	Jun	CAHN
		200MG	A076302	004	Sep 16, 2003	Jun	CAHN
		250MG	A076302	005	Sep 16, 2003	Jun	CAHN

NELARABINE

INJECTABLE; INTRAVENOUS

NELARABINE

AP	ALEMBIC	250MG/50ML (5MG/ML)	A218554	001	Aug 01, 2024	Jul	NEWA
AP	MEITHEAL	250MG/50ML (5MG/ML)	A216038	001	Jan 10, 2023	Jun	CAHN
AP	MSN	250MG/50ML (5MG/ML)	A216948	001	Sep 13, 2024	Sep	NEWA
AP	XGEN PHARMS	250MG/50ML (5MG/ML)	A216510	001	Sep 05, 2024	Aug	NEWA

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

AA	ADRASTEIA PHARMA	500MG	A065220	001	Jul 28, 2006	Sep	CAHN
----	------------------	-------	---------	-----	--------------	-----	------

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

+ @ EXELA PHARMA

NEOSTIGMINE METHYLSULFATE

		5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023	May	DISC
AP	ADAPTIS	5MG/10ML (0.5MG/ML)	A210652	001	Oct 01, 2021	Aug	CAHN
AP		10MG/10ML (1MG/ML)	A210652	002	Oct 01, 2021	Aug	CAHN
AP	ENDO OPERATIONS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017	Apr	CAHN
AP		10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017	Apr	CAHN
	@ EUGIA PHARMA	5MG/10ML (0.5MG/ML)	A213244	001	Nov 02, 2023	May	DISC
	@	10MG/10ML (1MG/ML)	A213244	002	Nov 02, 2023	May	DISC
AP	NIVAGEN PHARMS INC	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Jan	CAHN
AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Jan	CAHN
AP	UMEDICA	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Aug	CAHN
AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Aug	CAHN

NESIRITIDE

FOR SOLUTION; INTRAVENOUS

NATRECOR

+ @ SCIOS LLC

		1.5MG/VIAL	N020920	001	Aug 10, 2001	Mar	CAIN
--	--	------------	---------	-----	--------------	-----	------

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

AA	! AUROBINDO	50MG/5ML	A077702	001	May 22, 2012	Jun	CHRS
	VIRAMUNE						
	+ @ BOEHRINGER INGELHEIM	50MG/5ML	N020933	001	Sep 11, 1998	Jun	DISC

TABLET; ORAL

NEVIRAPINE

@ NORVIUM BIOSCIENCE

		200MG	A078864	001	May 22, 2012	Jul	CAHN
--	--	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

AB	! MACLEODS PHARMS LTD	400MG	A206879	001	Oct 06, 2017	Jun	CHRS
	VIRAMUNE XR						
	+ @ BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012	Jun	DISC
	+ @	400MG	N201152	001	Mar 25, 2011	Jun	DISC

NIACIN

TABLET, EXTENDED RELEASE;ORAL
 NIACIN

AB	HIBROW HLTHCARE	500MG	A213090	001	Aug 25, 2023	Jul	CAHN
AB		750MG	A213090	002	Aug 25, 2023	Jul	CAHN
AB		1GM	A213090	003	Aug 25, 2023	Jul	CAHN

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL
 NICARDIPINE HYDROCHLORIDE

AB	SKG PHARMA	20MG	A218202	001	Apr 10, 2024	Mar	NEWA
AB		30MG	A218202	002	Apr 10, 2024	Mar	NEWA

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

>A>	AP	AMNEAL	25MG/10ML (2.5MG/ML)	A215406	001	Oct 31, 2024	Oct	NEWA
	AP	CHENGDU SHUODE	25MG/10ML (2.5MG/ML)	A217548	001	Sep 06, 2024	Aug	NEWA
	AP	RK PHARMA	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Feb	CMFD
	AP	WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009	Aug	CMFD

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

AP	+	CHIESI	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr	CFTG
			CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER					
AP	+	CHIESI	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr	CFTG
			NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE					
AP		INFORLIFE	40MG/200ML (0.2MG/ML)	A203978	002	Apr 17, 2024	Apr	NFTG
			NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE					
AP		INFORLIFE	20MG/200ML (0.1MG/ML)	A203978	001	Apr 17, 2024	Apr	NFTG
			NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE					
AP		CIPLA	20MG/200ML (0.1MG/ML)	A215592	001	Sep 24, 2024	Sep	NFTG
AP			40MG/200ML (0.2MG/ML)	A215592	002	Sep 24, 2024	Sep	NFTG
AP	+	HIKMA INTL PHARMS	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Sep	CFTG
AP	+		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Sep	CFTG

NICOTINE

INHALANT;ORAL

NICOTROL

+	@	PFIZER	4MG/CARTRIDGE	N020714	001	May 02, 1997	Sep	DISC
---	---	--------	---------------	---------	-----	--------------	-----	------

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

	@	ACTAVIS ELIZABETH	20MG	A072556	001	Sep 20, 1990	Aug	DISC
AB		VELZEN PHARMA PVT	10MG	A073250	001	Oct 08, 1991	Aug	CAHN
AB			20MG	A074045	001	Apr 30, 1992	Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

@ ENDO OPERATIONS

30MG

A077899	001	Dec 13, 2006	May	CAHN
---------	-----	--------------	-----	------

@

60MG

A077899	002	Dec 13, 2006	May	CAHN
---------	-----	--------------	-----	------

@

90MG

A077899	003	May 25, 2012	May	CAHN
---------	-----	--------------	-----	------

@ SWISS PHARM

30MG

A216019	001	Nov 18, 2022	Jul	CAHN
---------	-----	--------------	-----	------

@

60MG

A216019	002	Nov 18, 2022	Jul	CAHN
---------	-----	--------------	-----	------

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

NILOTINIB HYDROCHLORIDE

@ APOTEX EQ 50MG BASE

A203640	001	Jan 05, 2024	Apr	DISC
---------	-----	--------------	-----	------

@ EQ 150MG BASE

A203640	002	Jan 05, 2024	Apr	DISC
---------	-----	--------------	-----	------

@ EQ 200MG BASE

A203640	003	Jan 05, 2024	Apr	DISC
---------	-----	--------------	-----	------

TASIGNA

+	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr	CTEC
---	----------	--------------	---------	-----	--------------	-----	------

+		EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr	CTEC
---	--	---------------	---------	-----	--------------	-----	------

+		EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr	CTEC
---	--	---------------	---------	-----	--------------	-----	------

NIMODIPINE

SOLUTION;ORAL

NIMODIPINE

ANNORA PHARMA 3MG/ML

A216937	001	Jul 09, 2024	Jun	NFTG
---------	-----	--------------	-----	------

NIRAPARIB TOSYLATE

CAPSULE;ORAL
ZEJULA

+ @ GLAXOSMITHKLINE EQ 100MG BASE N208447 001 Mar 27, 2017 Feb DISC

NIRMATRELVIR; RITONAVIR

TABLET;ORAL
PAXLOVID (COPACKAGED)

+! PFIZER 150MG;100MG N217188 001 May 25, 2023 Jul CHRS

NIROGACESTAT HYDROBROMIDE

TABLET;ORAL
OGSIVEO

+ SPRINGWORKS EQ 50MG BASE N217677 001 Nov 27, 2023 Apr CHRS

+ EQ 100MG BASE N217677 002 Apr 04, 2024 Apr NEWA

+! EQ 150MG BASE N217677 003 Apr 04, 2024 Apr NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL
NISOLDIPINE

@ AMTA 8.5MG A216606 001 Apr 10, 2023 Sep DISC

AB 8.5MG A216606 001 Apr 10, 2023 Jun CMFD

NITAZOXANIDE

FOR SUSPENSION;ORAL
ALINIA

+ @ ROMARK 100MG/5ML N021498 001 Nov 22, 2002 Sep DISC

TABLET;ORAL
ALINIA

+ @ ROMARK 500MG N021497 001 Jul 21, 2004 Sep DISC

NITAZOXANIDE

! RISING 500MG A213820 001 Nov 27, 2020 Sep CTEC

AB ! 500MG A213820 001 Nov 27, 2020 Sep CHRS

NITRIC OXIDE

GAS;INHALATION
INOMAX

+! MALLINCKRODT HOSP 4880PPM N020845 004 Jan 17, 2023 May NEWA

NOXIVENT

! LINDE GAS EQUIP 100PPM A207141 001 Oct 02, 2018 May CHRS

NITROFURANTOIN

SUSPENSION;ORAL
NITROFURANTOIN

>A> AB CARNEGIE 25MG/5ML A218346 001 Oct 28, 2024 Oct NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN

@ ACTAVIS LABS FL INC 25MG A091095 001 Jun 18, 2015 Feb DISC

@ 50MG A091095 002 Jun 18, 2015 Feb DISC

@ 100MG A091095 003 Jun 18, 2015 Feb DISC

AB AUROBINDO PHARMA USA 25MG A077025 002 Oct 02, 2024 Sep NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB MICRO LABS 75MG;25MG A217073 001 Nov 03, 2023 Sep CAHN

NITROGLYCERIN

OINTMENT;INTRA-ANAL
NITROGLYCERIN

AB COSETTE 0.4% A216103 001 Feb 16, 2024 Feb NFTG

RECTIV

AB +! ABBVIE 0.4% N021359 001 Jun 21, 2011 Feb CFTG

TABLET;SUBLINGUAL
NITROGLYCERIN

>A> AB VIWIT PHARM 0.3MG A218583 001 Oct 15, 2024 Oct NEWA

>A> AB 0.4MG A218583 002 Oct 15, 2024 Oct NEWA

>A> AB 0.6MG A218583 003 Oct 15, 2024 Oct NEWA

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

@	NORVIUM BIOSCIENCE	150MG	A075806	001	Jul 05, 2002	Aug	CAHN
@		300MG	A075806	002	Jul 05, 2002	Aug	CAHN

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP	DDREG PHARMA	EQ 1MG BASE/ML	A218758	001	May 13, 2024	May	NEWA
AP	RISING	EQ 1MG BASE/ML	A218758	001	May 13, 2024	May	CAHN
>D>	AP	SUN PHARM	A211980	001	Jan 29, 2021	Oct	DISC
>A>	@	EQ 1MG BASE/ML	A211980	001	Jan 29, 2021	Oct	DISC

SOLUTION; INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+!	LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Jan	CMFD
+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Jan	CMFD
+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Jan	CMFD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

@	RISING	EQ 10MG BASE	A074234	001	Jul 26, 1993	Feb	CAHN
@		EQ 25MG BASE	A074234	002	Jul 26, 1993	Feb	CAHN
@		EQ 50MG BASE	A074234	003	Jul 26, 1993	Feb	CAHN
@		EQ 75MG BASE	A074234	004	Jul 26, 1993	Feb	CAHN

NYSTATIN

POWDER; TOPICAL

NYSTATIN

AT	ADRASTEIA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Mar	CAHN
----	------------------	------------------	---------	-----	--------------	-----	------

SUSPENSION; ORAL

NYSTATIN

@	MLV	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Sep	DISC
@	PAI HOLDINGS	100,000 UNITS/ML	A064042	001	Feb 28, 1994	Jul	CAHN
AA	WOCKHARDT BIO AG	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jul	CHRS

TABLET; ORAL

NYSTATIN

@	SUN PHARM INDUSTRIES	500,000 UNITS	A062838	001	Dec 22, 1988	Aug	DISC
---	----------------------	---------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

@	COSETTE	100,000 UNITS/GM; 0.1%	A062367	001	May 28, 1985	Apr	DISC
---	---------	------------------------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

MYKACET

@	COSETTE	100,000 UNITS/GM; 0.1%	A062733	001	Mar 06, 1987	Apr	DISC
---	---------	------------------------	---------	-----	--------------	-----	------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

>D>	AP	SHUANGCHENG	EQ 0.1MG BASE/ML	A217860	001	May 02, 2024	Oct	DISC
>A>	@		EQ 0.1MG BASE/ML	A217860	001	May 02, 2024	Oct	DISC
AP			EQ 0.1MG BASE/ML	A217860	001	May 02, 2024	Apr	NEWA
AB	TEVA PHARMS USA INC	EQ 10MG BASE/VIAL	A210317	001	Dec 05, 2023	Jan	CTEC	
AB		EQ 20MG BASE/VIAL	A210317	002	Dec 05, 2023	Jan	CTEC	
AB		EQ 30MG BASE/VIAL	A210317	003	Dec 05, 2023	Jan	CTEC	
		SANDOSTATIN LAR						
AB	+	NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998	Jan	CTEC
AB	+		EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998	Jan	CTEC
AB	+		EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998	Jan	CTEC

ODEVIXIBAT

CAPSULE; ORAL

BYLVAY

+	IPSEN	0.4MG	N215498	002	Jul 20, 2021	Jan	CAHN
+		1.2MG	N215498	004	Jul 20, 2021	Jan	CAHN

CAPSULE, PELLETS;ORAL
BYLVAY

	+	IPSEN	0.2MG	N215498	001	Jul 20, 2021	Jan CAHN
	+	!	0.6MG	N215498	003	Jul 20, 2021	Jan CAHN

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT		AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb NEWA
AT		CAPLIN	0.3%	A217904	001	Apr 12, 2024	Apr NEWA
AT		SOMERSET	0.3%	A213597	001	Aug 01, 2024	Jul NEWA

SOLUTION/DROPS;OTIC

OFLOXACIN

	&	HIKMA	0.3%	A076616	001	Mar 17, 2008	Mar DISC
>A>	AT	SOMERSET THERAPS LLC	0.3%	A216328	001	Oct 15, 2024	Oct NEWA

TABLET;ORAL

OFLOXACIN

	&	CHARTWELL RX	200MG	A076093	001	Sep 02, 2003	Sep CAHN
	&		300MG	A076093	002	Sep 02, 2003	Sep CAHN
AB			400MG	A076093	003	Sep 02, 2003	Sep CAHN

OLANZAPINE

TABLET;ORAL

OLANZAPINE

	&	NATCO PHARMA	2.5MG	A076866	001	Apr 23, 2012	Aug CAHN
	&		5MG	A076866	002	Apr 23, 2012	Aug CAHN
	&		7.5MG	A076866	003	Apr 23, 2012	Aug CAHN
	&		10MG	A076866	004	Apr 23, 2012	Aug CAHN
	&		15MG	A076866	005	Apr 23, 2012	Aug CAHN
	&		20MG	A076866	006	Apr 23, 2012	Aug CAHN
	&	SUN PHARM INDS	2.5MG	A091038	001	Apr 23, 2012	May DISC
	&		5MG	A091038	002	Apr 23, 2012	May DISC
	&		7.5MG	A091038	003	Apr 23, 2012	May DISC
	&		10MG	A091038	004	Apr 23, 2012	May DISC
	&		15MG	A091038	005	Apr 23, 2012	May DISC
	&		20MG	A091038	006	Apr 23, 2012	May DISC

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

	&	SUN PHARM INDS	5MG	A090881	001	Feb 28, 2012	May DISC
	&		10MG	A090881	002	Feb 28, 2012	May DISC
	&		15MG	A090881	003	Feb 28, 2012	May DISC
	&		20MG	A090881	004	Feb 28, 2012	May DISC

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB		BRECKENRIDGE	5MG	A206227	001	Jan 25, 2024	Jan NEWA
AB			20MG	A206227	002	Jan 25, 2024	Jan NEWA
AB			40MG	A206227	003	Jan 25, 2024	Jan NEWA
AB		CHARTWELL RX	5MG	A206227	001	Jan 25, 2024	Mar CAHN
AB			20MG	A206227	002	Jan 25, 2024	Mar CAHN
AB			40MG	A206227	003	Jan 25, 2024	Mar CAHN
>A>	AB	HETERO LABS LTD V	5MG	A205499	001	Oct 31, 2024	Oct NEWA
>A>	AB		20MG	A205499	002	Oct 31, 2024	Oct NEWA
>A>	AB		40MG	A205499	003	Oct 31, 2024	Oct NEWA
AB		INVENTIA	5MG	A208659	001	May 18, 2020	May CMFD
AB			20MG	A208659	002	May 18, 2020	May CMFD
AB			40MG	A208659	003	May 18, 2020	May CMFD

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

	&	HIKMA	0.665MG/SPRAY	A213757	001	Aug 19, 2020	Mar DISC
--	---	-------	---------------	---------	-----	--------------	----------

OMACETAXINE MEPESUCCINATE

POWDER;SUBCUTANEOUS

SYNRIBO

	+	&	TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Jun DISC
--	---	---	------------------	------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	CHARTWELL	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Mar	CAHN
AB	WILSHIRE PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211345	001	Dec 07, 2023	Jul	CAHN

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	! AJANTA PHARMA LTD	40MG;1.1GM ZEGERID	A204228	002	Jul 15, 2016	Mar	CHRS
	+ @ SALIX	20MG;1.1GM	N021849	001	Feb 27, 2006	Mar	DISC
	+ @	40MG;1.1GM	N021849	002	Feb 27, 2006	Mar	DISC
FOR SUSPENSION;ORAL							
OMEPRAZOLE AND SODIUM BICARBONATE							
AB	! AJANTA PHARMA LTD	40MG/PACKET;1.68GM/PACKET ZEGERID	A205545	002	Jul 27, 2016	Mar	CHRS
	+ @ SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Mar	DISC
	+ @	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Mar	DISC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

	@ MYLAN	4MG	A078139	001	Jun 25, 2007	Jun	DISC
	@	8MG	A078139	002	Jun 25, 2007	Jun	DISC
	@ SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Jan	DISC
	@	8MG	A078602	002	Feb 24, 2011	Jan	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

	@ ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	May	DISC
--	-------------------	----------------	---------	-----	--------------	-----	------

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

	@ PHARM ASSOC	EQ 4MG BASE/5ML	A078127	001	Jun 25, 2007	Feb	DISC
	@ TARO	EQ 4MG BASE/5ML	A077009	001	Nov 30, 2007	May	DISC

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

	@ CHARTWELL RX	EQ 4MG BASE	A077517	001	Jun 25, 2007	Jun	CAHN
	@	EQ 8MG BASE	A077517	002	Jun 25, 2007	Jun	CAHN
	@	EQ 24MG BASE	A077517	003	Jun 25, 2007	Jun	CAHN

OPICAPONE

CAPSULE;ORAL

ONGENTYS

	+ AMNEAL	25MG	N212489	001	Apr 24, 2020	Apr	CAHN
	+!	50MG	N212489	002	Apr 24, 2020	Apr	CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL

ORPHENADRINE CITRATE

	@ STEVENS J	100MG	A040368	001	Jun 23, 2000	Jun	CAHN
--	-------------	-------	---------	-----	--------------	-----	------

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	LURUS	EQ 30MG BASE	A218565	001	May 01, 2024	Apr	NEWA	
AB		EQ 45MG BASE	A218565	002	May 01, 2024	Apr	NEWA	
AB		EQ 75MG BASE	A218565	003	May 01, 2024	Apr	NEWA	
>A>	AB	NANJING DAOQUN	EQ 30MG BASE	A217133	001	Oct 30, 2024	Oct	NEWA
>A>	AB		EQ 75MG BASE	A217133	002	Oct 30, 2024	Oct	NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	AUROBINDO PHARMA LTD	EQ 6MG BASE/ML	A218131	001	May 10, 2024	May	NEWA
AB	INVAGEN PHARMS	EQ 6MG BASE/ML	A212858	001	Aug 30, 2021	Sep	CAHN
	@ LEADING	EQ 6MG BASE/ML	A214949	001	Feb 28, 2022	Aug	CAHN
AB	ORYZA	EQ 6MG BASE/ML	A217303	001	Jul 02, 2024	Jun	NEWA

OSPEMIFENETABLET; ORAL
OSPEMIFENE

AB		HETERO LABS LTD V	60MG	A215574	001	Feb 13, 2024	Feb NFTG
AB	+	OSPHERA					
AB	+	! DUCHESNAY	60MG	N203505	001	Feb 26, 2013	Feb CFTG

OXACILLIN SODIUMINJECTABLE; INJECTION
OXACILLIN SODIUM

>D>	AP		FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A206198	001	Jul 20, 2020	Oct CHRS
>A>	AP	!		EQ 1GM BASE/VIAL	A206198	001	Jul 20, 2020	Oct CHRS
>D>	AP			EQ 2GM BASE/VIAL	A206198	002	Jul 20, 2020	Oct CHRS
>A>	AP	!		EQ 2GM BASE/VIAL	A206198	002	Jul 20, 2020	Oct CHRS
>D>	AP	!	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246	001	Mar 30, 2012	Oct DISC
>A>		@		EQ 1GM BASE/VIAL	A091246	001	Mar 30, 2012	Oct DISC
>D>	AP	!		EQ 2GM BASE/VIAL	A091246	002	Mar 30, 2012	Oct DISC
>A>		@		EQ 2GM BASE/VIAL	A091246	002	Mar 30, 2012	Oct DISC
		@	STERISCIENCE SPECLTS	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014	Aug CAHN
AP				EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014	Aug CAHN

OXALIPLATININJECTABLE; INTRAVENOUS
ELOXATIN

		+	@ SANOFI AVENTIS US	50MG/10ML (5MG/ML)	N021759	001	Jan 31, 2005	Jun DISC
		+	@	100MG/20ML (5MG/ML)	N021759	002	Jan 31, 2005	Jun DISC
			@ ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Sep DISC
			@	100MG/VIAL	A078803	002	Aug 08, 2012	Sep DISC
AP	!		GLAND	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jun CHRS
AP	!			100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jun CHRS
AP			KINDOS	50MG/10ML (5MG/ML)	A217348	001	Jan 11, 2024	Jan NEWA
AP				100MG/20ML (5MG/ML)	A217348	002	Jan 11, 2024	Jan NEWA
AP			MEITHEAL	50MG/10ML (5MG/ML)	A217348	001	Jan 11, 2024	Jun CAHN
AP				100MG/20ML (5MG/ML)	A217348	002	Jan 11, 2024	Jun CAHN
		@	NORVIUM BIOSCIENCE	50MG/VIAL	A200979	001	Aug 08, 2012	Jul CAHN
		@		100MG/VIAL	A200979	002	Aug 08, 2012	Jul CAHN

OXAPROZINTABLET; ORAL
OXAPROZIN

AB			ABRAXEOLUS	600MG	A075845	001	Jan 31, 2001	Sep CAHN
AB			PANGEA	600MG	A075845	001	Jan 31, 2001	Jun CAHN
		@	TEVA	600MG	A075849	001	Jul 03, 2002	Jan DISC

OXAZEPAMCAPSULE; ORAL
OXAZEPAM

AB			TRUPHARMA	10MG	A071026	002	Aug 10, 1987	Sep CAHN
AB				15MG	A071026	003	Aug 10, 1987	Sep CAHN
AB				30MG	A071026	001	Aug 10, 1987	Sep CAHN

OXCARBAZEPINESUSPENSION; ORAL
OXCARBAZEPINE

AB			ALKEM LABS LTD	300MG/5ML	A213183	001	Mar 18, 2023	Mar NEWA
AB			BIOCON PHARMA	300MG/5ML	A218278	001	Mar 01, 2024	Apr CAHN
AB			CARNEGIE	300MG/5ML	A218278	001	Mar 01, 2024	Feb NEWA
AB			KANCHAN HLTHCARE	300MG/5ML	A217782	001	Feb 14, 2024	Sep CAHN
AB			MEDLEY PHARMS	300MG/5ML	A217782	001	Feb 14, 2024	Feb NEWA
AB			RISING	300MG/5ML	A218278	001	Mar 01, 2024	Mar CAHN

TABLET; ORAL
OXCARBAZEPINE

AB			ANI PHARMS	150MG	A078005	001	Dec 11, 2007	Jul CMFD
AB				300MG	A078005	002	Dec 11, 2007	Jul CMFD
AB				600MG	A078005	003	Dec 11, 2007	Jul CMFD
AB			RUBICON	150MG	A207717	001	Mar 05, 2024	Feb NEWA
AB				300MG	A207717	002	Mar 05, 2024	Feb NEWA
AB				600MG	A207717	003	Mar 05, 2024	Feb NEWA
		@	ZYDUS	150MG	A211747	001	Jul 03, 2023	Jan DISC
		@		300MG	A211747	002	Jul 03, 2023	Jan DISC

<u>TABLET;ORAL</u>									
OXCARBAZEPINE									
	@	600MG		A211747	003	Jul 03, 2023	Jan	DISC	
<u>TABLET, EXTENDED RELEASE;ORAL</u>									
OXCARBAZEPINE									
	@	AJANTA PHARMA LTD	150MG	A217659	001	Feb 22, 2024	Aug	DISC	
AB			150MG	A217659	001	Feb 22, 2024	Feb	NEWA	
	@		300MG	A217659	002	Feb 22, 2024	Aug	DISC	
AB			300MG	A217659	002	Feb 22, 2024	Feb	NEWA	
	@		600MG	A217659	003	Feb 22, 2024	Aug	DISC	
AB			600MG	A217659	003	Feb 22, 2024	Feb	NEWA	
AB		APOTEX	150MG	A213369	001	Jul 13, 2023	Aug	CMFD	
AB			300MG	A213369	002	Jul 13, 2023	Aug	CMFD	
AB			600MG	A213369	003	Jul 13, 2023	Aug	CMFD	
<u>OXTELLAR XR</u>									
AB	+	SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012	Feb	CTEC	
AB	+		300MG	N202810	002	Oct 19, 2012	Feb	CTEC	
AB	+		600MG	N202810	003	Oct 19, 2012	Feb	CTEC	
<u>OXYBUTYNIN CHLORIDE</u>									
<u>SYRUP;ORAL</u>									
OXYBUTYNIN CHLORIDE									
	@	PHARM ASSOC	5MG/5ML	A075137	001	Dec 18, 1998	Feb	DISC	
<u>TABLET;ORAL</u>									
OXYBUTYNIN CHLORIDE									
	@	EYWA	5MG	A211062	001	Feb 06, 2019	Mar	DISC	
	@	HIBROW HLTHCARE	5MG	A211062	001	Feb 06, 2019	Jul	CAHN	
AB		TRUPHARMA	5MG	A210125	001	Sep 06, 2018	Sep	CAHN	
<u>OXYCODONE HYDROCHLORIDE</u>									
<u>SOLUTION;ORAL</u>									
OXYCODONE HYDROCHLORIDE									
	@	HIKMA	5MG/5ML	A208817	001	Aug 10, 2017	Mar	DISC	
	@		100MG/5ML	A208795	001	Aug 07, 2017	Mar	DISC	
	+	@ VISTAPHARM LLC	5MG/5ML	N201194	001	Jan 12, 2012	Apr	CAHN	
	@	XTTRIUM LABS INC	5MG/5ML	A206456	001	Jun 16, 2015	Mar	CAHN	
<u>TABLET;ORAL</u>									
OXYCODONE HYDROCHLORIDE									
AB		STRIDES PHARMA	5MG	A077712	003	Mar 02, 2009	Aug	CMFD	
AB			10MG	A077712	004	Apr 13, 2015	Aug	CMFD	
AB			15MG	A077712	001	Jan 31, 2007	Aug	CMFD	
AB			20MG	A077712	005	Apr 13, 2015	Aug	CMFD	
AB			30MG	A077712	002	Jan 31, 2007	Aug	CMFD	
	@	SUN PHARM INDS INC	5MG	A090659	001	Apr 10, 2009	Jun	DISC	
	@		10MG	A090659	005	Nov 06, 2012	Jun	DISC	
	@		15MG	A090659	002	Apr 10, 2009	Jun	DISC	
	@		20MG	A090659	004	Nov 06, 2012	Jun	DISC	
	@		30MG	A090659	003	Apr 10, 2009	Jun	DISC	
<u>ROXYBOND</u>									
		PROTEGA PHARMS	10MG	N209777	004	Sep 05, 2024	Sep	NEWA	
<u>OXYMETHOLONE</u>									
<u>TABLET;ORAL</u>									
ANADROL-50									
	+	@ NORVIUM BIOSCIENCE	50MG	N016848	001		Jun	CAHN	
<u>OXYMORPHONE HYDROCHLORIDE</u>									
<u>TABLET, EXTENDED RELEASE;ORAL</u>									
OPANA ER									
	+	@ ENDO OPERATIONS	5MG	N021610	001	Jun 22, 2006	May	CAHN	
	+	@	7.5MG	N021610	005	Feb 29, 2008	May	CAHN	
	+	@	10MG	N021610	002	Jun 22, 2006	May	CAHN	
	+	@	15MG	N021610	006	Feb 29, 2008	May	CAHN	
	+	@	20MG	N021610	003	Jun 22, 2006	May	CAHN	
	+	@	30MG	N021610	007	Feb 29, 2008	May	CAHN	
	+	@	40MG	N021610	004	Jun 22, 2006	May	CAHN	

OZANIMOD HYDROCHLORIDE

CAPSULE; ORAL
ZEPOSIA

+	BRISTOL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	Jan CAHN
+		EQ 0.46MG BASE	N209899	002	Mar 25, 2020	Jan CAHN
+	!	EQ 0.92MG BASE	N209899	003	Mar 25, 2020	Jan CAHN

>D> OZENOXACIN

>D> CREAM; TOPICAL
>D> XEPTI

>D>	+	!	FERRER INTERNACIONAL	1%	N208945	001	Dec 11, 2017	Oct DISC
>A>	+	@		1%	N208945	001	Dec 11, 2017	Oct DISC

PACLITAXEL

POWDER; INTRAVENOUS
ABRAXANE

AB	+	!	BRISTOL-MYERS	100MG/VIAL	N021660	001	Jan 07, 2005	Jan CTEC
			PACLITAXEL					
AB	+	!	AM REGENT	100MG/VIAL	N211875	001	Jul 27, 2022	Apr CTEC
AB			HENGRUI PHARMA	100MG/VIAL	A212700	001	Oct 08, 2024	Sep NEWA
AB	+	!	TEVA PHARMS INC	100MG/VIAL	N216338	001	May 11, 2023	Jan CMFD

PALBOCICLIB

TABLET; ORAL
IBRANCE

AB	+		PFIZER	75MG	N212436	001	Nov 01, 2019	May CFTG
				75MG	N212436	001	Nov 01, 2019	Jan CTEC
AB	+			100MG	N212436	002	Nov 01, 2019	May CFTG
				100MG	N212436	002	Nov 01, 2019	Jan CTEC
AB	+	!		125MG	N212436	003	Nov 01, 2019	May CFTG
				125MG	N212436	003	Nov 01, 2019	Jan CTEC
			PALBOCICLIB					
AB			SYNTHON PHARMS INC	75MG	A215570	001	Jun 05, 2024	May NFTG
AB				100MG	A215570	002	Jun 05, 2024	May NFTG
AB				125MG	A215570	003	Jun 05, 2024	May NFTG

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL
PALIPERIDONE

	@		ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015	Jul DISC
	@			3MG	A202645	002	Aug 03, 2015	Jul DISC
	@			6MG	A202645	003	Aug 03, 2015	Jul DISC
	@			9MG	A202645	004	Aug 03, 2015	Jul DISC
AB			AJANTA PHARMA LTD	1.5MG	A218514	001	Jun 26, 2024	Jun NEWA
AB				3MG	A218514	002	Jun 26, 2024	Jun NEWA
AB				6MG	A218514	003	Jun 26, 2024	Jun NEWA
AB				9MG	A218514	004	Jun 26, 2024	Jun NEWA
AB			ALEMBIC	1.5MG	A218330	001	Sep 26, 2024	Sep NEWA
AB				3MG	A218330	002	Sep 26, 2024	Sep NEWA
AB				6MG	A218330	003	Sep 26, 2024	Sep NEWA
AB				9MG	A218330	004	Sep 26, 2024	Sep NEWA
BX			LUPIN LTD	1.5MG	A208643	001	Jun 29, 2022	Jun CTEC
BX				3MG	A208643	002	Jun 29, 2022	Jun CTEC
BX				6MG	A208643	003	Jun 29, 2022	Jun CTEC
BX				9MG	A208643	004	Jun 29, 2022	Jun CTEC
AB			ZYDUS PHARMS	1.5MG	A217445	001	Oct 08, 2024	Sep NEWA
AB				3MG	A217445	002	Oct 08, 2024	Sep NEWA
AB				6MG	A217445	003	Oct 08, 2024	Sep NEWA
AB				9MG	A217445	004	Oct 08, 2024	Sep NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
ERZOFRI

+	!		LUYE INNOMIND PHARMA	39MG/0.25ML (39MG/0.25ML)	N216352	001	Jul 26, 2024	Aug CHRS
+				39MG/0.25ML (39MG/0.25ML)	N216352	001	Jul 26, 2024	Jul NEWA
+	!			78MG/0.5ML (78MG/0.5ML)	N216352	002	Jul 26, 2024	Aug CHRS
+				78MG/0.5ML (78MG/0.5ML)	N216352	002	Jul 26, 2024	Jul NEWA
+	!			117MG/0.75ML (117MG/0.75ML)	N216352	003	Jul 26, 2024	Aug CHRS
+				117MG/0.75ML (117MG/0.75ML)	N216352	003	Jul 26, 2024	Jul NEWA
+	!			156MG/ML (156MG/ML)	N216352	004	Jul 26, 2024	Aug CHRS
+				156MG/ML (156MG/ML)	N216352	004	Jul 26, 2024	Jul NEWA
+	!			234MG/1.5ML (156MG/ML)	N216352	005	Jul 26, 2024	Aug CHRS

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR							
ERZOFRI							
	+	234MG/1.5ML (156MG/ML)	N216352	005	Jul 26, 2024	Jul	NEWA
	+	351MG/2.25ML (156MG/ML)	N216352	006	Jul 26, 2024	Jul	NEWA
INVEGA SUSTENNA							
AB	+	JANSSEN PHARMS 39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	May	CTEC
AB	+	78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	May	CTEC
AB	+	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	May	CTEC
AB	+	156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	May	CTEC
AB	+	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	May	CTEC
INVEGA TRINZA							
	+	JANSSEN PHARMS 273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	Aug	CHRS
	+	410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	Aug	CHRS
	+	546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	Aug	CHRS
PALIPERIDONE PALMITATE							
AB		TEVA PHARMS USA 39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	May	CMFD
AB		78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	May	CMFD
AB		117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	May	CMFD
AB		156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	May	CMFD
AB		234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	May	CMFD
<u>PALONOSETRON HYDROCHLORIDE</u>							
INJECTABLE; INTRAVENOUS							
PALONOSETRON HYDROCHLORIDE							
AP		MEITHEAL EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A215861	001	Aug 14, 2023	Jun	CAHN
SOLUTION; INTRAVENOUS							
POSFREA							
	+	@ AVYXA HOLDINGS EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Aug	CTNA
	+	@ EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Aug	CRLD
	@	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Apr	CAHN
	+	! EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Aug	CTNA
	+	! EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Aug	CMFD
	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Apr	CAHN
<u>PALOPEGTERIPARATIDE</u>							
SOLUTION; SUBCUTANEOUS							
YORVIPATH							
	+	! ASCENDIS PHARMA BONE EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	N216490	001	Aug 09, 2024	Aug	NEWA
	+	EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	N216490	002	Aug 09, 2024	Aug	NEWA
	+	EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	N216490	003	Aug 09, 2024	Aug	NEWA
<u>PANCURONIUM BROMIDE</u>							
INJECTABLE; INJECTION							
PANCURONIUM BROMIDE							
	!	DR REDDYS 1MG/ML	A072759	001	Jul 31, 1990	May	CTEC
	@	HOSPIRA 1MG/ML	A072320	001	Jan 19, 1989	May	DISC
<u>PANTOPRAZOLE SODIUM</u>							
INJECTABLE; INTRAVENOUS							
PANTOPRAZOLE SODIUM							
AP		HANGZHOU ZHONGMEI EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Mar	CAHN
	@	SUN PHARM EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Feb	DISC
POWDER; INTRAVENOUS							
PANTOPRAZOLE SODIUM							
AP		FRESENIUS KABI USA EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	Jul	NEWA
AP	+	! HIKMA EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Jul	CFTG
SOLUTION; INTRAVENOUS							
PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE							
	+	! BAXTER HLTHCARE CORP EQ 40MG BASE/100ML (EQ 0.4MG BASE/ML)	N217512	001	Feb 14, 2024	Feb	NEWA
	+	! EQ 40MG BASE/50ML (EQ 0.8MG BASE/ML)	N217512	002	Feb 14, 2024	Feb	NEWA
	+	! EQ 80MG BASE/100ML (EQ 0.8MG BASE/ML)	N217512	003	Feb 14, 2024	Feb	NEWA

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

>D>	AB	MANKIND PHARMA	EQ 20MG BASE	A215880	002	Apr 25, 2024	Oct	DISC
>A>		@	EQ 20MG BASE	A215880	002	Apr 25, 2024	Oct	DISC
	AB		EQ 20MG BASE	A215880	002	Apr 25, 2024	Apr	NEWA

PARICALCITOL

SOLUTION;INTRAVENOUS

PARICALCITOL

		@ HOSPIRA	0.002MG/ML (0.002MG/ML)	N201657	001	Oct 21, 2014	May	DISC
		@	0.005MG/ML (0.005MG/ML)	N201657	002	Oct 21, 2014	May	DISC
		@	0.01MG/2ML (0.005MG/ML)	N201657	003	Oct 21, 2014	May	DISC

PATIROMER SORBITE X CALCIUM

POWDER;ORAL

VELTASSA

	+	VIFOR PHARMA	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Aug	CMFD
	+	@	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Feb	DISC
	+	!	EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Jul	CHRS
	+	@	EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Jul	DISC

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

PAZOPANIB HYDROCHLORIDE

AB		NOVUGEN	EQ 200MG BASE	A218231	001	Apr 23, 2024	Apr	NEWA
----	--	---------	---------------	---------	-----	--------------	-----	------

PEGULICIANINE ACETATE

POWDER;INTRAVENOUS

LUMISIGHT

	+	!	LUMICELL	EQ 40MG BASE/VIAL	N214511	001	Apr 17, 2024	Apr	NEWA
--	---	---	----------	-------------------	---------	-----	--------------	-----	------

PEMETREXED DIPOTASSIUM

POWDER;INTRAVENOUS

PEMETREXED

	+	!	AVYXA HOLDINGS	EQ 100MG BASE/VIAL	N210661	001	Jun 28, 2024	Jun	NEWA
	+	!		EQ 500MG BASE/VIAL	N210661	002	Jun 28, 2024	Jun	NEWA

PEMETREXED DISODIUM

POWDER;INTRAVENOUS

PEMETREXED DISODIUM

AP		HETERO LABS LTD VI	EQ 100MG BASE/VIAL	A215460	001	Jun 14, 2024	Jun	NEWA
AP			EQ 500MG BASE/VIAL	A215460	002	Jun 14, 2024	Jun	NEWA
AP		RELIANCE LIFE	EQ 100MG BASE/VIAL	A211899	001	May 25, 2022	Jun	CAHN
AP			EQ 500MG BASE/VIAL	A211899	002	May 25, 2022	Jun	CAHN

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

	+	@	ENDO OPERATIONS	10MG	N018976	001	Dec 30, 1987	May	CAHN
	+	@		20MG	N018976	004	Jan 05, 1989	May	CAHN

PENCICLOVIR

CREAM;TOPICAL

PENCICLOVIR

AB		PADAGIS ISRAEL	1%	A212368	001	Sep 27, 2024	Sep	NEWA
----	--	----------------	----	---------	-----	--------------	-----	------

PENICILLAMINE

CAPSULE;ORAL

LUXZYLA

	@	ANI PHARMS	250MG	A209921	001	May 07, 2019	Aug	CTNA
AB			250MG	A209921	001	May 07, 2019	Aug	CTNA

PENICILLAMINE

AB		ENDO OPERATIONS	250MG	A211231	001	Dec 23, 2019	Apr	CAHN
----	--	-----------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

PENICILLAMINE

AB		ENDO OPERATIONS	250MG	A211196	001	Dec 23, 2019	Apr	CAHN
----	--	-----------------	-------	---------	-----	--------------	-----	------

PENICILLIN V POTASSIUM

TABLET;ORAL

PENICILLIN V POTASSIUM

AB	!	AUROBINDO PHARMA	EQ 500MG BASE	A 065435	002	Apr 29, 2008	Jan	CHRS
		@ SANDOZ	EQ 250MG BASE	A 064071	001	Nov 30, 1995	Jan	DISC
		@	EQ 500MG BASE	A 064071	002	Nov 30, 1995	Jan	DISC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

AB		ANI PHARMS	400MG	A 074878	001	Jul 09, 1997	Jan	CMFD
AB		RISING	400MG	A 074425	001	Jul 08, 1997	Jun	CMFD

PERMETHRIN

CREAM;TOPICAL

PERMETHRIN

		@ DR REDDYS LABS EU	5%	A 209732	001	Aug 01, 2023	Jan	DISC
--	--	---------------------	----	----------	-----	--------------	-----	------

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB		ENDO OPERATIONS	2MG	A 040226	001	Dec 31, 1998	Apr	CAHN
AB			4MG	A 040226	002	Dec 31, 1998	Apr	CAHN
AB			8MG	A 040226	003	Dec 31, 1998	Apr	CAHN
AB			16MG	A 040226	004	Dec 31, 1998	Apr	CAHN
AB		MACLEODS PHARMS LTD	2MG	A 212545	001	May 06, 2024	Apr	NEWA
AB			4MG	A 212545	002	May 06, 2024	Apr	NEWA
AB			8MG	A 212545	003	May 06, 2024	Apr	NEWA
AB			16MG	A 212545	004	May 06, 2024	Apr	NEWA

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

AB	!	ENDO OPERATIONS	10MG	A 204522	001	Jan 24, 2017	May	CAHN
----	---	-----------------	------	----------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

ADIPEX-P

	+	@ TEVA	37.5MG	A 088023	001	Aug 02, 1983	Feb	DISC
--	---	--------	--------	----------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

		@ INVAGEN PHARMS	15MG	A 202858	001	Feb 14, 2014	Mar	DISC
--	--	------------------	------	----------	-----	--------------	-----	------

		@	30MG	A 202858	002	Feb 14, 2014	Mar	DISC
--	--	---	------	----------	-----	--------------	-----	------

		@	30MG	A 204414	001	May 05, 2014	Mar	DISC
--	--	---	------	----------	-----	--------------	-----	------

		@	37.5MG	A 202846	001	Feb 05, 2014	Mar	DISC
--	--	---	--------	----------	-----	--------------	-----	------

AA	!	NUVO PHARM	37.5MG	A 205017	001	Sep 25, 2014	Feb	CHRS
----	---	------------	--------	----------	-----	--------------	-----	------

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

AA		AUROBINDO PHARMA LTD	37.5MG	A 203068	001	Aug 06, 2014	Sep	CAHN
----	--	----------------------	--------	----------	-----	--------------	-----	------

		@ INVAGEN PHARMS	37.5MG	A 202942	001	Feb 05, 2014	Mar	DISC
--	--	------------------	--------	----------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE

AB		ACTAVIS LABS FL INC	EQ 3.75MG BASE;23MG	A 204982	001	Jun 25, 2024	Jun	NFTG
AB			EQ 7.5MG BASE;46MG	A 204982	002	Jun 25, 2024	Jun	NFTG
AB			EQ 11.25MG BASE;69MG	A 204982	003	Jun 25, 2024	Jun	NFTG
AB			EQ 15MG BASE;92MG	A 204982	004	Jun 25, 2024	Jun	NFTG

QSYMIA

AB	+	VIVUS LLC	EQ 3.75MG BASE;23MG	N 022580	001	Jul 17, 2012	Jun	CFTG
----	---	-----------	---------------------	----------	-----	--------------	-----	------

	+		EQ 3.75MG BASE;23MG	N 022580	001	Jul 17, 2012	May	CAHN
--	---	--	---------------------	----------	-----	--------------	-----	------

AB	+		EQ 7.5MG BASE;46MG	N 022580	002	Jul 17, 2012	Jun	CFTG
----	---	--	--------------------	----------	-----	--------------	-----	------

	+		EQ 7.5MG BASE;46MG	N 022580	002	Jul 17, 2012	May	CAHN
--	---	--	--------------------	----------	-----	--------------	-----	------

AB	+		EQ 11.25MG BASE;69MG	N 022580	003	Jul 17, 2012	Jun	CFTG
----	---	--	----------------------	----------	-----	--------------	-----	------

	+		EQ 11.25MG BASE;69MG	N 022580	003	Jul 17, 2012	May	CAHN
--	---	--	----------------------	----------	-----	--------------	-----	------

AB	+	!	EQ 15MG BASE;92MG	N 022580	004	Jul 17, 2012	Jun	CFTG
----	---	---	-------------------	----------	-----	--------------	-----	------

	+	!	EQ 15MG BASE;92MG	N 022580	004	Jul 17, 2012	May	CAHN
--	---	---	-------------------	----------	-----	--------------	-----	------

PHENTOLAMINE MESYLATESOLUTION;OPHTHALMIC
RYZUMVI

+! FAMYGEN LIFE SCI EQ 0.75% BASE N217064 001 Sep 25, 2023 Jan CAHN

PHENYLBUZAZONECAPSULE;ORAL
PHENYLBUZAZONE

@ CHARTWELL RX 100MG A087774 001 Jun 16, 1982 Aug CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

	@ ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	May	DISC
	@	50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	May	DISC
	@	100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	May	DISC
AP1	ASPIRO	10MG/ML (10MG/ML)	A218110	001	May 10, 2024	May	NEWA
AP1		50MG/5ML (10MG/ML)	A218110	002	May 10, 2024	May	NEWA
AP1		100MG/10ML (10MG/ML)	A218110	003	May 10, 2024	May	NEWA
	@ ENDO OPERATIONS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Apr	CAHN
AP1		50MG/5ML (10MG/ML)	A210025	002	Dec 21, 2018	Apr	CAHN
AP1		100MG/10ML (10MG/ML)	A210025	003	Dec 21, 2018	Apr	CAHN
	@ HAINAN POLY	10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Sep	DISC
AP1		10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Mar	NEWA
	@	50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Sep	DISC
AP1		50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Mar	NEWA
	@	100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Sep	DISC
AP1		100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Mar	NEWA

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	CAPLIN	2.5%	A215183	001	May 23, 2024	May	NEWA
AT		10%	A215183	002	May 23, 2024	May	NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	! GENUS	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Apr	CAHN
	@ HIKMA	5MG/5ML;6.25MG/5ML	A040675	001	Dec 23, 2014	Mar	DISC

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

	@ PAI HOLDINGS PHARM	125MG/5ML	A040420	001	Apr 19, 2002	Feb	DISC
	@ VISTAPHARM	125MG/5ML	A040342	001	Jan 31, 2001	Apr	DISC
	@	125MG/5ML	A040342	002	Aug 18, 2005	Apr	DISC

TABLET, CHEWABLE;ORAL

PHENYTOIN

AB	TARO	50MG	A200565	001	Apr 17, 2014	Apr	CAHN
----	------	------	---------	-----	--------------	-----	------

PHENYTOIN SODIUM

INJECTABLE;INJECTION

PHENYTOIN SODIUM

AP	+! HIKMA	50MG/ML	A084307	001		Jun	CAHN
----	----------	---------	---------	-----	--	-----	------

PHYTONADIONE

TABLET;ORAL

PHYTONADIONE

AB	! ZYDUS LIFESCIENCES	5MG	A210189	001	Feb 20, 2019	Jul	CAHN
----	----------------------	-----	---------	-----	--------------	-----	------

PIMAVANSERIN TARTRATE

CAPSULE;ORAL

NUPLAZID

AB	+! ACADIA PHARMS INC	EQ 34MG BASE	N210793	001	Jun 28, 2018	Jul	CTEC
	+!	EQ 34MG BASE	N210793	001	Jun 28, 2018	Jan	CFTG

PIMAVANSERIN

	@ MSN	EQ 34MG BASE	A214925	001	Jan 16, 2024	Feb	DISC
AB		EQ 34MG BASE	A214925	001	Jan 16, 2024	Jan	NEWA
	@ ZYDUS	EQ 34MG BASE	A214493	001	Jan 16, 2024	Jul	DISC
AB		EQ 34MG BASE	A214493	001	Jan 16, 2024	Jan	CAHN
AB	ZYDUS PHARMS	EQ 34MG BASE	A214493	001	Jan 16, 2024	Jan	NEWA

TABLET;ORAL							
NUPLAZID							
	+!	ACADIA PHARMS INC	EQ 10MG BASE	N207318	002	Jun 28, 2018	Jul CTEC
AB	+!		EQ 10MG BASE	N207318	002	Jun 28, 2018	Jan CFGT
PIMAVANSERIN							
	@	ZYDUS	EQ 10MG BASE	A214502	001	Jan 16, 2024	Jul DISC
AB			EQ 10MG BASE	A214502	001	Jan 16, 2024	Jan CAHN
AB		ZYDUS PHARMS	EQ 10MG BASE	A214502	001	Jan 16, 2024	Jan NEWA
<u>PIMOZIDE</u>							
TABLET;ORAL							
PIMOZIDE							
		ENDO OPERATIONS	1MG	A204521	001	Sep 28, 2015	Apr CAHN
	!		2MG	A204521	002	Sep 28, 2015	Apr CAHN
<u>PIOGLITAZONE HYDROCHLORIDE</u>							
TABLET;ORAL							
PIOGLITAZONE HYDROCHLORIDE							
AB		COREPHARMA	EQ 15MG BASE	A210165	001	Jan 22, 2021	Jul CAHN
AB			EQ 30MG BASE	A210165	002	Jan 22, 2021	Jul CAHN
AB			EQ 45MG BASE	A210165	003	Jan 22, 2021	Jul CAHN
	@	NORVIUM BIOSCIENCE	EQ 15MG BASE	A076801	001	Aug 17, 2012	Sep CAHN
	@		EQ 30MG BASE	A076801	002	Aug 17, 2012	Sep CAHN
	@		EQ 45MG BASE	A076801	003	Aug 17, 2012	Sep CAHN
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM</u>							
INJECTABLE;INJECTION							
PIPERACILLIN AND TAZOBACTAM							
	@	EUGIA PHARMA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A217409	002	Oct 12, 2023	Apr DISC
	@		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A217409	001	Oct 12, 2023	Apr DISC
AP		STERISCIENCE SPECLTS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Aug CAHN
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Aug CAHN
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Aug CAHN
<u>PIROXICAM</u>							
CAPSULE;ORAL							
PIROXICAM							
	@	FLAMINGO PHARMS	10MG	A207938	001	Sep 09, 2016	Mar DISC
	@		20MG	A207938	002	Sep 09, 2016	Mar DISC
<u>PITAVASTATIN CALCIUM</u>							
TABLET;ORAL							
PITAVASTATIN CALCIUM							
AB		AMNEAL PHARMS NY	EQ 1MG BASE	A205961	001	Aug 20, 2024	Aug NEWA
AB			EQ 2MG BASE	A205961	002	Aug 20, 2024	Aug NEWA
AB			EQ 4MG BASE	A205961	003	Aug 20, 2024	Aug NEWA
AB		HETERO LABS LTD V	EQ 1MG BASE	A205977	001	Apr 30, 2024	Apr NEWA
AB			EQ 2MG BASE	A205977	002	Apr 30, 2024	Apr NEWA
AB			EQ 4MG BASE	A205977	003	Apr 30, 2024	Apr NEWA
<u>PIVMECILLINAM HYDROCHLORIDE</u>							
TABLET;ORAL							
PIVYA							
	+ @	UTILITY THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Aug DISC
	+!		EQ 185MG BASE	N216483	001	Apr 24, 2024	Apr NEWA
<u>PLERIXAFOR</u>							
SOLUTION;SUBCUTANEOUS							
PLERIXAFOR							
AP		GLAND PHARMA LTD	24MG/1.2ML (20MG/ML)	A206644	001	May 03, 2024	Apr NEWA
AP		MEITHEAL	24MG/1.2ML (20MG/ML)	A215698	001	Jul 24, 2023	Jun CAHN
	@	ZYDUS PHARMS	24MG/1.2ML (20MG/ML)	A208980	001	Jul 26, 2023	May DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL						
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE						
AA	NOVEL LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090019	001	May 27, 2009	Jun CMFD

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL						
COLYTE						
	@ NORVIUM BIOSCIENCE	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Jul CAHN
	@	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Jul CAHN
	@	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jul CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jul CAHN
	@	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Jul CAHN
COLYTE WITH FLAVOR PACKS						
	@ MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr DISC
	@ NORVIUM BIOSCIENCE	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jul CAHN
COLYTE-FLAVORED						
	@ NORVIUM BIOSCIENCE	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jul CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jul CAHN
PEG 3350 AND ELECTROLYTES						
	NOVEL LABS INC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009	Apr CTEC

POLYMYXIN B SULFATE

INJECTABLE; INJECTION						
POLYMYXIN B SULFATE						
AP	ADRASTEIA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb CAHN

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC						
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE						
AT	SOMERSET THERAPS LLC	10,000 UNITS/ML;EQ 1MG BASE/ML	A211572	001	Aug 05, 2024	Jul NEWA

POMALIDOMIDE

CAPSULE;ORAL						
POMALIDOMIDE						
AB	APOTEX	1MG	A210164	001	Jun 11, 2024	May NEWA
AB		2MG	A210164	002	Jun 11, 2024	May NEWA
AB		3MG	A210164	003	Jun 11, 2024	May NEWA
AB		4MG	A210164	004	Jun 11, 2024	May NEWA
AB	HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Sep NEWA
AB		2MG	A210236	002	Sep 26, 2024	Sep NEWA
AB		3MG	A210236	003	Sep 26, 2024	Sep NEWA
AB		4MG	A210236	004	Sep 26, 2024	Sep NEWA
POMALYST						
AB	+ BRISTOL	1MG	N204026	001	Feb 08, 2013	May CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	May CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	May CTEC
AB	+	4MG	N204026	004	Feb 08, 2013	May CTEC

PONESIMOD

TABLET;ORAL						
PONVORY						
+	VANDA PHARMS INC	2MG	N213498	001	Mar 18, 2021	May CAHN
+		3MG	N213498	002	Mar 18, 2021	May CAHN
+		4MG	N213498	003	Mar 18, 2021	May CAHN
+		5MG	N213498	004	Mar 18, 2021	May CAHN
+		6MG	N213498	005	Mar 18, 2021	May CAHN
+		7MG	N213498	006	Mar 18, 2021	May CAHN
+		8MG	N213498	007	Mar 18, 2021	May CAHN

TABLET;ORAL
PONVORY

	+		9MG	N213498	008	Mar 18, 2021	May	CAHN
	+		10MG	N213498	009	Mar 18, 2021	May	CAHN
	+		20MG	N213498	010	Mar 18, 2021	May	CAHN

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL
POSACONAZOLE

AB	!	AET PHARMA	100MG	A213454	001	Feb 01, 2021	Aug	CHRS
AB		AUROBINDO PHARMA	100MG	A217119	001	Jul 18, 2024	Jul	NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

	@	ANCHEN PHARMS	8MEQ	A202886	001	Dec 26, 2013	Feb	DISC
	@		10MEQ	A202886	002	Dec 26, 2013	Feb	DISC
	@	ENDO OPERATIONS	8MEQ	A202886	001	Dec 26, 2013	May	CAHN
	@		10MEQ	A202886	002	Dec 26, 2013	May	CAHN
	@	GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016	Sep	DISC

FOR SOLUTION;ORAL

POKONZA

	+	GENUS	10MEQ	N208019	002	Aug 25, 2023	Jun	CAHN
AA	+	GENUS	20MEQ	N208019	001	Aug 19, 2015	Jun	CAHN
	+	!	40MEQ	N208019	003	Aug 25, 2023	Jun	CAHN

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA		STRIDES PHARMA	20MEQ/15ML	A211665	002	Jan 16, 2024	Jan	NEWA
----	--	----------------	------------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

	@	CHARTWELL RX	10MEQ	A206630	001	Mar 29, 2019	May	CAHN
	@		15MEQ	A206630	002	Mar 29, 2019	May	CAHN
	@		20MEQ	A206630	003	Mar 29, 2019	May	CAHN
AB2		MACLEODS PHARMS LTD	8MEQ	A212987	001	Sep 06, 2024	Aug	NEWA
AB2			10MEQ	A212987	002	Sep 06, 2024	Aug	NEWA
AB1			10MEQ	A216269	001	May 09, 2024	May	NEWA
AB1			15MEQ	A216269	002	May 09, 2024	May	NEWA
AB1			20MEQ	A216269	003	May 09, 2024	May	NEWA
	!	RUBICON	15MEQ	A215725	003	Aug 22, 2024	Aug	NEWA
>A>	AB2	TWI PHARMS	8MEQ	A218979	001	Oct 28, 2024	Oct	NEWA
>A>	AB2		10MEQ	A218979	002	Oct 28, 2024	Oct	NEWA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB		HIBROW HLTHCARE	5MEQ	A214426	001	Feb 19, 2021	Jul	CAHN
AB			10MEQ	A214426	002	Feb 19, 2021	Jul	CAHN
AB			15MEQ	A214426	003	Feb 19, 2021	Jul	CAHN
	@	TORRENT	5MEQ	A213986	001	Feb 06, 2024	Feb	DISC
AB			5MEQ	A213986	001	Feb 06, 2024	Jan	NEWA
	@		10MEQ	A213986	002	Feb 06, 2024	Feb	DISC
AB			10MEQ	A213986	002	Feb 06, 2024	Jan	NEWA
	@		15MEQ	A213986	003	Feb 06, 2024	Feb	DISC
AB			15MEQ	A213986	003	Feb 06, 2024	Jan	NEWA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS

POTASSIUM PHOSPHATES

>D>	+	!	CMP DEV LLC	4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)	N212121	001	Sep 19, 2019	Oct	DISC
>A>	+	@		4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)	N212121	001	Sep 19, 2019	Oct	DISC
AP			SOMERSET THERAPS LLC	1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)	A217726	001	Jul 11, 2024	Jun	NEWA
AP				3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)	A217726	002	Jul 11, 2024	Jun	NEWA
	+	!	AMNEAL	POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE 1.18GM/250ML (4.72MG/ML);1.12GM/250ML	N218343	001	Jul 26, 2024	Jul	NEWA

PRALSETINIB

CAPSULE;ORAL

GAVRETO

+!	BLUEPRINT MEDICINES	100MG	N213721	001	Sep 04, 2020	Feb	CAHN
+!	RIGEL PHARMS	100MG	N213721	001	Sep 04, 2020	Jun	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		GLENMARK PHARMS LTD	0.125MG	A090781	001	Oct 08, 2010	Mar	CAHN
AB	!		0.25MG	A090781	002	Oct 08, 2010	Mar	CAHN
AB			0.5MG	A090781	003	Oct 08, 2010	Mar	CAHN
AB			0.75MG	A090781	006	Sep 11, 2015	Mar	CAHN
AB			1MG	A090781	004	Oct 08, 2010	Mar	CAHN
AB			1.5MG	A090781	005	Oct 08, 2010	Mar	CAHN
	@	NATCO	0.125MG	A077854	001	Oct 08, 2010	Aug	CAHN
	@		0.25MG	A077854	002	Oct 08, 2010	Aug	CAHN
	@		0.5MG	A077854	003	Oct 08, 2010	Aug	CAHN
	@		1MG	A077854	004	Oct 08, 2010	Aug	CAHN
	@		1.5MG	A077854	005	Oct 08, 2010	Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER

+	@	BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010	Aug	DISC
+	@		0.75MG	N022421	002	Feb 19, 2010	Aug	DISC
+	@		1.5MG	N022421	003	Feb 19, 2010	Aug	DISC
+	@		2.25MG	N022421	006	Jun 17, 2011	Aug	DISC
+	@		3MG	N022421	004	Feb 19, 2010	Aug	DISC
+	@		3.75MG	N022421	007	Jun 17, 2011	Aug	DISC
+	@		4.5MG	N022421	005	Feb 19, 2010	Aug	DISC

PRAMIPEXOLE DIHYDROCHLORIDE

AB	!	DR REDDYS	0.375MG	A203354	001	Aug 07, 2015	Aug	CHRS
	@	ENDO OPERATIONS	0.375MG	A202206	001	Feb 06, 2014	May	CAHN
	@		0.75MG	A202206	002	Feb 06, 2014	May	CAHN
	@		1.5MG	A202206	003	Feb 06, 2014	May	CAHN
	@		2.25MG	A202206	004	Feb 06, 2014	May	CAHN
	@		3MG	A202206	005	Feb 06, 2014	May	CAHN
	@		3.75MG	A202206	006	Feb 06, 2014	May	CAHN
	@		4.5MG	A202206	007	Feb 06, 2014	May	CAHN

PRAZIQUANTEL

TABLET;ORAL

BILTRICIDE

AB	+	@	BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982	Sep	DISC
	+			600MG	N018714	001	Dec 29, 1982	Jun	CHRS

PRAZIQUANTEL

AB	!	ENDO OPERATIONS	600MG	A208820	001	Nov 27, 2017	Sep	CTEC
AB	!		600MG	A208820	001	Nov 27, 2017	Jun	CHRS
AB			600MG	A208820	001	Nov 27, 2017	Apr	CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

	@	LANNETT CO INC	EQ 1MG BASE	A214083	001	Jan 03, 2024	Jul	DISC
	@		EQ 2MG BASE	A214083	002	Jan 03, 2024	Jul	DISC
	@		EQ 5MG BASE	A214083	003	Jan 03, 2024	Jul	DISC
AB		MSN	EQ 1MG BASE	A216727	001	Sep 17, 2024	Sep	NEWA
AB			EQ 2MG BASE	A216727	002	Sep 17, 2024	Sep	NEWA
AB			EQ 5MG BASE	A216727	003	Sep 17, 2024	Sep	NEWA

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

@	HIKMA	15MG/5ML	A040401	001	Feb 27, 2003	Mar	DISC
@	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	Feb	DISC

TABLET;ORAL

PREDNISOLONE

>D>	@	HEATHER	5MG	A080326	001		Oct	CRLD
>A>	+	@	5MG	A080326	001		Oct	CRLD
AB		ZHEJIANG XIANJU	5MG	A218083	001	May 02, 2024	Apr	NEWA

PREDNISOLONE ACETATE

SUSPENSION;ORAL						
FLO-PRED						
	@ TARO	EQ 5MG BASE/5ML	N022067	001	Jan 17, 2008	Aug CAHN
	@	EQ 15MG BASE/5ML	N022067	002	Jan 17, 2008	Aug CAHN
SUSPENSION/DROPS;OPHTHALMIC						
PREDNISOLONE ACETATE						
AB	LUPIN LTD	1%	A216935	001	Aug 02, 2024	Jul NFTG

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL						
PREDNISOLONE SODIUM PHOSPHATE						
	@ ENDO OPERATIONS	EQ 15MG BASE/5ML	A079010	001	May 26, 2009	May CAHN
	@ HIKMA	EQ 5MG BASE/5ML	A075183	001	Mar 26, 2003	Mar DISC
	@ PHARM ASSOC	EQ 30MG BASE/5ML	A204962	001	Mar 11, 2020	Mar DISC
	@ PHARMOBEDIENT	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Sep CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC						
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE						
	@ GENUS	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	Aug CAHN

PREDNISON

SOLUTION;ORAL							
PREDNISON INTENSOL							
	+! HIKMA	5MG/ML	A088810	001	Feb 20, 1985	Jan CRLD	
TABLET;ORAL							
PREDNISON							
	@ ALLIED	5MG	A212629	001	Dec 05, 2023	Aug CAHN	
	@	10MG	A212629	002	Dec 05, 2023	Aug CAHN	
	@	20MG	A212629	003	Dec 05, 2023	Aug CAHN	
BX	CHARTWELL MOLECULAR	20MG	A084275	001		Jul CMFD	
AB	ENDO OPERATIONS	1MG	A040584	001	Dec 21, 2004	Apr CAHN	
AB		2.5MG	A040581	001	Dec 21, 2004	Apr CAHN	
AB		5MG	A040256	001	Jul 12, 2002	Apr CAHN	
AB		10MG	A040256	002	Jul 12, 2002	Apr CAHN	
AB		20MG	A040392	001	Feb 12, 2003	Apr CAHN	
	@ GENEYORK PHARMS	1MG	A211496	001	Dec 28, 2018	Feb DISC	
	@	2.5MG	A210525	004	Dec 07, 2018	Feb DISC	
	@	5MG	A210525	005	Dec 07, 2018	Feb DISC	
	@	10MG	A210525	001	Dec 04, 2018	Feb DISC	
	@	20MG	A210525	002	Dec 04, 2018	Feb DISC	
	@	50MG	A210525	003	Dec 04, 2018	Feb DISC	
	@ GRANULATION TECH	5MG	A212629	001	Dec 05, 2023	Jul DISC	
	@	10MG	A212629	002	Dec 05, 2023	Jul DISC	
	@	20MG	A212629	003	Dec 05, 2023	Jul DISC	
AB	STRIDES PHARMA	2.5MG	A208412	004	Nov 20, 2020	Jun CMS1	
AB		5MG	A208412	005	Nov 20, 2020	Jun CMS1	
TABLET, DELAYED RELEASE;ORAL							
PREDNISON							
>D>	AB	ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Oct CTEC
>A>		@	1MG	A204867	001	Apr 25, 2017	Oct DISC
>A>			1MG	A204867	001	Apr 25, 2017	Oct CTEC
>D>	AB		2MG	A204867	002	Apr 25, 2017	Oct CTEC
>A>		@	2MG	A204867	002	Apr 25, 2017	Oct DISC
>A>			2MG	A204867	002	Apr 25, 2017	Oct CTEC
>D>	AB		5MG	A204867	003	Apr 25, 2017	Oct CHRS
>A>		@	5MG	A204867	003	Apr 25, 2017	Oct DISC
>A>		!	5MG	A204867	003	Apr 25, 2017	Oct CHRS
>D>		RAYOS					
>D>	AB	+ HORIZON	1MG	N202020	001	Jul 26, 2012	Oct DISC
>A>		+ @	1MG	N202020	001	Jul 26, 2012	Oct DISC
>D>	AB	+	2MG	N202020	002	Jul 26, 2012	Oct DISC
>A>		+ @	2MG	N202020	002	Jul 26, 2012	Oct DISC
>D>	AB	+!	5MG	N202020	003	Jul 26, 2012	Oct DISC
>A>		+ @	5MG	N202020	003	Jul 26, 2012	Oct DISC

PREGABALIN

CAPSULE; ORAL

PREGABALIN

AB	ACME LABS	50MG	A210585	001	Dec 26, 2019	Aug	CAHN	
AB		75MG	A210585	002	Dec 26, 2019	Aug	CAHN	
AB		100MG	A210585	003	Dec 26, 2019	Aug	CAHN	
AB		150MG	A210585	004	Dec 26, 2019	Aug	CAHN	
AB		200MG	A210585	005	Dec 26, 2019	Aug	CAHN	
AB		300MG	A210585	006	Dec 26, 2019	Aug	CAHN	
AB	ADAPTIS	25MG	A208113	001	May 17, 2024	Aug	CAHN	
AB		50MG	A208113	002	May 17, 2024	Aug	CAHN	
AB		75MG	A208113	004	May 17, 2024	Aug	CAHN	
AB		100MG	A208113	005	May 17, 2024	Aug	CAHN	
AB		150MG	A208113	003	May 17, 2024	Aug	CAHN	
AB		200MG	A208113	006	May 17, 2024	Aug	CAHN	
AB		225MG	A208113	007	May 17, 2024	Aug	CAHN	
AB		300MG	A208113	008	May 17, 2024	Aug	CAHN	
	@ CADILA PHARMS LTD	25MG	A206452	001	Jul 12, 2023	Jan	DISC	
	@	50MG	A206452	002	Jul 12, 2023	Jan	DISC	
	@	75MG	A206452	003	Jul 12, 2023	Jan	DISC	
	@	100MG	A206452	004	Jul 12, 2023	Jan	DISC	
	@	150MG	A206452	005	Jul 12, 2023	Jan	DISC	
	@	200MG	A206452	006	Jul 12, 2023	Jan	DISC	
	@	225MG	A206452	007	Jul 12, 2023	Jan	DISC	
	@	300MG	A206452	008	Jul 12, 2023	Jan	DISC	
AB	CHANGZHOU PHARM	25MG	A214322	008	Sep 26, 2024	Sep	NEWA	
	@ CIPLA	25MG	A212280	001	Jan 10, 2020	May	DISC	
	@	50MG	A212280	002	Jan 10, 2020	May	DISC	
	@	75MG	A212280	003	Jan 10, 2020	May	DISC	
	@	100MG	A212280	004	Jan 10, 2020	May	DISC	
	@	150MG	A212280	005	Jan 10, 2020	May	DISC	
	@	200MG	A212280	006	Jan 10, 2020	May	DISC	
	@	225MG	A212280	007	Jan 10, 2020	May	DISC	
	@	300MG	A212280	008	Jan 10, 2020	May	DISC	
>A>	AB	ESKAYEF	25MG	A212988	001	Mar 08, 2022	Oct	CAHN
>A>	AB		50MG	A212988	002	Mar 08, 2022	Oct	CAHN
>A>	AB		75MG	A212988	003	Mar 08, 2022	Oct	CAHN
>A>	AB		100MG	A212988	004	Mar 08, 2022	Oct	CAHN
>A>	AB		150MG	A212988	005	Mar 08, 2022	Oct	CAHN
>A>	AB		200MG	A212988	006	Mar 08, 2022	Oct	CAHN
>A>	AB		225MG	A212988	007	Mar 08, 2022	Oct	CAHN
>A>	AB		300MG	A212988	008	Mar 08, 2022	Oct	CAHN
	AB	INDOCO	25MG	A208113	001	May 17, 2024	May	NEWA
	AB		50MG	A208113	002	May 17, 2024	May	NEWA
	AB		75MG	A208113	004	May 17, 2024	May	NEWA
	AB		100MG	A208113	005	May 17, 2024	May	NEWA
	AB		150MG	A208113	003	May 17, 2024	May	NEWA
	AB		200MG	A208113	006	May 17, 2024	May	NEWA
	AB		225MG	A208113	007	May 17, 2024	May	NEWA
	AB		300MG	A208113	008	May 17, 2024	May	NEWA
>D>	AB	RK PHARMA	25MG	A212988	001	Mar 08, 2022	Oct	CAHN
	AB		25MG	A212988	001	Mar 08, 2022	Aug	CAHN
>D>	AB		50MG	A212988	002	Mar 08, 2022	Oct	CAHN
	AB		50MG	A212988	002	Mar 08, 2022	Aug	CAHN
>D>	AB		75MG	A212988	003	Mar 08, 2022	Oct	CAHN
	AB		75MG	A212988	003	Mar 08, 2022	Aug	CAHN
>D>	AB		100MG	A212988	004	Mar 08, 2022	Oct	CAHN
	AB		100MG	A212988	004	Mar 08, 2022	Aug	CAHN
>D>	AB		150MG	A212988	005	Mar 08, 2022	Oct	CAHN
	AB		150MG	A212988	005	Mar 08, 2022	Aug	CAHN
>D>	AB		200MG	A212988	006	Mar 08, 2022	Oct	CAHN
	AB		200MG	A212988	006	Mar 08, 2022	Aug	CAHN
>D>	AB		225MG	A212988	007	Mar 08, 2022	Oct	CAHN
	AB		225MG	A212988	007	Mar 08, 2022	Aug	CAHN
>D>	AB		300MG	A212988	008	Mar 08, 2022	Oct	CAHN
	AB		300MG	A212988	008	Mar 08, 2022	Aug	CAHN
	@ STRIDES PHARMA	25MG	A209883	001	Jan 24, 2024	Jul	DISC	
	AB		25MG	A209883	001	Jan 24, 2024	Jan	NEWA
	@	50MG	A209883	002	Jan 24, 2024	Jul	DISC	
	AB		50MG	A209883	002	Jan 24, 2024	Jan	NEWA
	@	75MG	A209883	003	Jan 24, 2024	Jul	DISC	
	AB		75MG	A209883	003	Jan 24, 2024	Jan	NEWA
	@	100MG	A209883	004	Jan 24, 2024	Jul	DISC	

CAPSULE;ORAL								
PREGABALIN								
AB		100MG	A209883	004	Jan 24, 2024	Jan	NEWA	
	@	150MG	A209883	005	Jan 24, 2024	Jul	DISC	
AB		150MG	A209883	005	Jan 24, 2024	Jan	NEWA	
	@	200MG	A209883	006	Jan 24, 2024	Jul	DISC	
AB		200MG	A209883	006	Jan 24, 2024	Jan	NEWA	
	@	225MG	A209883	007	Jan 24, 2024	Jul	DISC	
AB		225MG	A209883	007	Jan 24, 2024	Jan	NEWA	
	@	300MG	A209883	008	Jan 24, 2024	Jul	DISC	
AB		300MG	A209883	008	Jan 24, 2024	Jan	NEWA	
	@ SUN PHARM	25MG	A091157	001	Nov 29, 2019	Jan	DISC	
	@	50MG	A091157	002	Nov 29, 2019	Jan	DISC	
	@	75MG	A091157	003	Nov 29, 2019	Jan	DISC	
	@	100MG	A091157	004	Nov 29, 2019	Jan	DISC	
	@	150MG	A091157	005	Nov 29, 2019	Jan	DISC	
	@	200MG	A091157	006	Nov 29, 2019	Jan	DISC	
	@	225MG	A091157	007	Nov 29, 2019	Jan	DISC	
	@	300MG	A091157	008	Nov 29, 2019	Jan	DISC	
	@ TEVA PHARMS	25MG	A091219	001	Jul 19, 2019	Aug	DISC	
	@	50MG	A091219	002	Jul 19, 2019	Aug	DISC	
	@	75MG	A091224	001	Jul 19, 2019	Aug	DISC	
	@	100MG	A091224	002	Jul 19, 2019	Aug	DISC	
	@	150MG	A091224	003	Jul 19, 2019	Aug	DISC	
	@	200MG	A091224	004	Jul 19, 2019	Aug	DISC	
	@	225MG	A091224	005	Jul 19, 2019	Aug	DISC	
	@	300MG	A091224	006	Jul 19, 2019	Aug	DISC	
SOLUTION;ORAL								
PREGABALIN								
AA	ANDA REPOSITORY	20MG/ML	A212604	001	Feb 18, 2022	Sep	CAHN	
TABLET, EXTENDED RELEASE;ORAL								
PREGABALIN								
	@ NORVIUM BIOSCIENCE	330MG	A211431	001	Jul 02, 2021	Jun	CAHN	
<u>PRIMIDONE</u>								
SUSPENSION;ORAL								
MYSOLINE								
	+ @ FHTA	250MG/5ML	N010401	001		Jan	CAHN	
TABLET;ORAL								
PRIMIDONE								
AB	CARNEGIE	50MG	A218366	001	Jan 23, 2024	Jan	NEWA	
AB		250MG	A218366	002	Jan 23, 2024	Jan	NEWA	
>A>	<u>PROBENECID; SULOPENEM ETZADROXIL</u>							
>A>	TABLET;ORAL							
>A>	ORLYNVAH							
>A>	+!	ITERUM THERAP	500MG;500MG	N213972	001	Oct 25, 2024	Oct	NEWA
<u>PROCAINAMIDE HYDROCHLORIDE</u>								
INJECTABLE;INJECTION								
PROCAINAMIDE HYDROCHLORIDE								
AP	GLAND PHARMA LTD	100MG/ML	A218135	001	Jul 22, 2024	Jul	NEWA	
AP		500MG/ML	A218135	002	Jul 22, 2024	Jul	NEWA	
	@ HIKMA	100MG/ML	A089029	001	Apr 17, 1986	Jun	CAHN	
<u>PROCHLORPERAZINE EDISYLATE</u>								
INJECTABLE;INJECTION								
PROCHLORPERAZINE EDISYLATE								
	@ HIKMA	EQ 5MG BASE/ML	A213630	001	Nov 22, 2022	Jul	DISC	
AP	SOMERSET THERAPS LLC	EQ 5MG BASE/ML	A212257	001	Sep 13, 2024	Sep	NEWA	
<u>PROCHLORPERAZINE MALEATE</u>								
TABLET;ORAL								
PROCHLORPERAZINE MALEATE								
AB	AJANTA PHARMA LTD	EQ 5MG BASE	A218515	001	May 09, 2024	Apr	NEWA	
AB		EQ 10MG BASE	A218515	002	May 09, 2024	Apr	NEWA	
AB	LEADING	EQ 5MG BASE	A218912	001	Sep 30, 2024	Sep	NEWA	
AB		EQ 10MG BASE	A218912	002	Sep 30, 2024	Sep	NEWA	

PROGESTERONE

INJECTABLE; INJECTION

PROGESTERONE

@ ACCORD HLTHCARE 50MG/ML A217707 001 Nov 21, 2023 Jul DISC

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

AP +! HIKMA 25MG/ML A083312 001 Jun CAHN
 AP +! 50MG/ML A083312 002 Jun CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

AB SINOTHERAPEUTICS INC 225MG A210339 001 Jan 04, 2019 May CTEC
 AB 325MG A210339 002 Jan 04, 2019 May CTEC
 AB 425MG A210339 003 Jan 04, 2019 May CTEC
 @ TWI PHARMS 225MG A212928 001 Jun 18, 2020 Aug DISC
 AB 225MG A212928 001 Jun 18, 2020 Mar CAHN
 @ 325MG A212928 002 Jun 18, 2020 Aug DISC
 AB 325MG A212928 002 Jun 18, 2020 Mar CAHN
 @ 425MG A212928 003 Jun 18, 2020 Aug DISC
 AB 425MG A212928 003 Jun 18, 2020 Mar CAHN

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

@ SUN PHARM INDUSTRIES 150MG A075998 001 Nov 29, 2001 Jul DISC
 @ 225MG A075998 002 Nov 29, 2001 Jul DISC
 @ 300MG A075998 003 Nov 29, 2001 Jul DISC

PROPACARCAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PROPACARCAINE HYDROCHLORIDE

AT SOMERSET THERAPS LLC 0.5% A215816 001 Aug 09, 2024 Aug NEWA

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

AB AMNEAL 10MG/ML A217525 001 Aug 15, 2024 Aug NEWA
 AB ASPIRO 10MG/ML A217013 001 Jun 20, 2024 Jun NEWA

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

@ LUPIN LTD 60MG A204349 001 Jan 12, 2024 Apr DISC
 AB 60MG A204349 001 Jan 12, 2024 Jan NEWA
 @ 80MG A204349 002 Jan 12, 2024 Apr DISC
 AB 80MG A204349 002 Jan 12, 2024 Jan NEWA
 @ 120MG A204349 003 Jan 12, 2024 Apr DISC
 AB 120MG A204349 003 Jan 12, 2024 Jan NEWA
 @ 160MG A204349 004 Jan 12, 2024 Apr DISC
 AB 160MG A204349 004 Jan 12, 2024 Jan NEWA

SOLUTION; ORAL

HEMANGEOL

+! PIERRE FABRE 4.28MG/ML N205410 001 Mar 14, 2014 May CAHN

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

@ AIPING PHARM INC 90MG A071288 001 Oct 22, 1986 Jul CAHN
 AB ENDO OPERATIONS 10MG A070221 002 Aug 01, 1986 Apr CAHN
 AB 20MG A070221 003 Aug 01, 1986 Apr CAHN
 AB 40MG A070221 004 Aug 01, 1986 Apr CAHN
 AB 60MG A070221 005 Sep 24, 1986 Apr CAHN
 AB 80MG A070221 001 Apr 14, 1986 Apr CAHN

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

AB +! ENDO OPERATIONS 50MG N006188 001 Apr CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET;ORAL

CORPHED

@ CHARTWELL RX	60MG;2.5MG	A088602	001	Apr 11, 1985	Aug CAHN
----------------	------------	---------	-----	--------------	----------

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

AB	ANI PHARMS	60MG	A040512	001	Oct 08, 2003	Jan CMFD
AB	MLV	30MG	A211181	002	May 14, 2019	Mar CAHN
AB		60MG	A211181	001	Jul 20, 2018	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

PYRIDOSTIGMINE BROMIDE

>A>	@ AMNEAL	105MG	N217604	001	Oct 04, 2024	Oct DISC
>A>		105MG	N217604	001	Oct 04, 2024	Oct NEWA

PYRIMETHAMINE

TABLET;ORAL

PYRIMETHAMINE

AB	SANALUZ	25MG	A207127	001	Feb 28, 2020	Sep CAHN
----	---------	------	---------	-----	--------------	----------

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB	IPCA LABS LTD	EQ 25MG BASE	A205983	001	May 20, 2024	May NEWA
AB		EQ 50MG BASE	A205983	002	May 20, 2024	May NEWA
AB		EQ 100MG BASE	A205983	003	May 20, 2024	May NEWA
AB		EQ 200MG BASE	A205983	004	May 20, 2024	May NEWA
AB		EQ 300MG BASE	A205983	005	May 20, 2024	May NEWA
AB		EQ 400MG BASE	A205983	006	May 20, 2024	May NEWA
AB	SCIEGEN PHARMS INC	EQ 25MG BASE	A090960	001	Mar 27, 2012	Sep CAHN
AB		EQ 50MG BASE	A090960	002	Mar 27, 2012	Sep CAHN
AB		EQ 100MG BASE	A090960	003	Mar 27, 2012	Sep CAHN
AB		EQ 200MG BASE	A090960	004	Mar 27, 2012	Sep CAHN
AB		EQ 300MG BASE	A090960	005	Mar 27, 2012	Sep CAHN
AB		EQ 400MG BASE	A090960	006	Mar 27, 2012	Sep CAHN

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

@ ENDO OPERATIONS	EQ 50MG BASE	A090482	001	May 09, 2017	May CAHN	
@	EQ 150MG BASE	A090482	002	May 09, 2017	May CAHN	
@	EQ 150MG BASE	A090757	001	Dec 01, 2017	May CAHN	
@	EQ 200MG BASE	A090482	003	May 09, 2017	May CAHN	
@	EQ 200MG BASE	A090757	002	Dec 01, 2017	May CAHN	
@	EQ 300MG BASE	A090482	004	May 09, 2017	May CAHN	
@	EQ 300MG BASE	A090757	003	Dec 01, 2017	May CAHN	
@	EQ 400MG BASE	A090482	005	May 09, 2017	May CAHN	
@	EQ 400MG BASE	A090757	004	Dec 01, 2017	May CAHN	
@ PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Feb DISC	
@	EQ 150MG BASE	A090482	002	May 09, 2017	Feb DISC	
@	EQ 200MG BASE	A090482	003	May 09, 2017	Feb DISC	
@	EQ 300MG BASE	A090482	004	May 09, 2017	Feb DISC	
@	EQ 400MG BASE	A090482	005	May 09, 2017	Feb DISC	
AB	PRINSTON INC	EQ 400MG BASE	A208781	005	Mar 11, 2024	Mar NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB	CHARTWELL RX	EQ 5MG BASE	A076803	001	Mar 02, 2005	Jul CMFD
AB		EQ 10MG BASE	A076803	002	Mar 02, 2005	Jul CMFD
AB		EQ 20MG BASE	A076803	003	Mar 02, 2005	Jul CMFD
AB		EQ 40MG BASE	A076803	004	Mar 02, 2005	Jul CMFD
@ INVAGEN PHARMS	EQ 5MG BASE	A078457	001	Aug 24, 2007	Mar DISC	
@	EQ 10MG BASE	A078457	002	Aug 24, 2007	Mar DISC	
@	EQ 20MG BASE	A078457	003	Aug 24, 2007	Mar DISC	
@	EQ 40MG BASE	A078457	004	Aug 24, 2007	Mar DISC	

<u>QUINIDINE GLUCONATE</u>							
TABLET, EXTENDED RELEASE;ORAL							
QUINIDINE GLUCONATE							
AB	HIBROW HLTHCARE	324MG	A212589	001	Sep 17, 2021	Sep	CAHN
<u>QUINIDINE SULFATE</u>							
TABLET;ORAL							
QUINIDINE SULFATE							
	@ CHARTWELL RX	300MG	A089839	001	Sep 29, 1988	Jul	CAHN
<u>QUININE SULFATE</u>							
CAPSULE;ORAL							
QUALAQUIN							
	+ @ SUN PHARM INDUSTRIES	324MG	N021799	001	Aug 12, 2005	Aug	DISC
QUININE SULFATE							
AB	! NOVAST LABS	324MG	A204372	001	Jul 22, 2015	Aug	CHRS
<u>RABEPRAZOLE SODIUM</u>							
TABLET, DELAYED RELEASE;ORAL							
ACIPHEX							
	+ @ WAYLIS THERAP	10MG	N020973	001	May 29, 2002	Apr	CAHN
AB	+!	20MG	N020973	002	Aug 19, 1999	Apr	CAHN
<u>RAMELTEON</u>							
TABLET;ORAL							
RAMELTEON							
AB	ANDAS 5 HOLDING	8MG	A215435	001	Aug 24, 2022	Aug	CAHN
<u>RAMIPRIL</u>							
CAPSULE;ORAL							
RAMIPRIL							
	@ ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	May	DISC
	@	2.5MG	A202392	002	Apr 15, 2014	May	DISC
	@	5MG	A202392	003	Apr 15, 2014	May	DISC
	@	10MG	A202392	004	Apr 15, 2014	May	DISC
<u>RANITIDINE HYDROCHLORIDE</u>							
SYRUP;ORAL							
RANITIDINE HYDROCHLORIDE							
	@ LANNETT CO INC	EQ 15MG BASE/ML	A091288	001	Dec 09, 2010	Mar	DISC
	@ PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	Mar	DISC
TABLET;ORAL							
RANITIDINE HYDROCHLORIDE							
	@ ENDO OPERATIONS	EQ 150MG BASE	A075180	001	Jan 28, 1999	May	CAHN
	@	EQ 300MG BASE	A075180	002	Jan 28, 1999	May	CAHN
	@ PAR PHARM	EQ 150MG BASE	A075180	001	Jan 28, 1999	Feb	DISC
	@	EQ 300MG BASE	A075180	002	Jan 28, 1999	Feb	DISC
<u>RANOLAZINE</u>							
GRANULES, EXTENDED RELEASE;ORAL							
ASPRUZYO SPRINKLE							
	+ @ SPIL	500MG	N216018	001	Feb 28, 2022	Aug	DISC
	+ @	1GM	N216018	002	Feb 28, 2022	Aug	DISC
TABLET, EXTENDED RELEASE;ORAL							
RANOLAZINE							
AB	ALLIED	500MG	A213517	001	Apr 27, 2022	Sep	CAHN
AB		1GM	A213517	002	Apr 27, 2022	Sep	CAHN
	@ PIRAMAL	500MG	A213085	001	Jul 25, 2023	Jan	DISC
	@	1GM	A213085	002	Jul 25, 2023	Jan	DISC
<u>RASAGILINE MESYLATE</u>							
TABLET;ORAL							
RASAGILINE MESYLATE							
AB	MACLEODS PHARMS LTD	EQ 0.5MG BASE	A208866	001	Jun 28, 2024	Jun	NEWA
AB		EQ 1MG BASE	A208866	002	Jun 28, 2024	Jun	NEWA
	@ RYAN LABS	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Sep	CAHN
	@	EQ 1MG BASE	A201942	002	Nov 18, 2021	Sep	CAHN
AB	SKG PHARMA	EQ 0.5MG BASE	A218163	001	Apr 09, 2024	Mar	NEWA
AB		EQ 1MG BASE	A218163	002	Apr 09, 2024	Mar	NEWA

REGADENOSON

SOLUTION; INTRAVENOUS
REGADENOSON

AP	GE HEALTHCARE	0.4MG/5ML (0.08MG/ML)	A215955	001	Aug 05, 2024	Jul	NEWA
AP	INDIES PHARMA	0.4MG/5ML (0.08MG/ML)	A218054	001	Aug 22, 2024	Aug	NEWA

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
REMIFENTANIL HYDROCHLORIDE

AP	NIVAGEN PHARMS INC	EQ 1MG BASE/VIAL	A215635	001	Jun 28, 2024	Jun	NEWA
AP		EQ 2MG BASE/VIAL	A215635	002	Jun 28, 2024	Jun	NEWA
AP		EQ 5MG BASE/VIAL	A215635	003	Jun 28, 2024	Jun	NEWA

REPOTRECTINIB

CAPSULE; ORAL
AUGTYRO

+	BRISTOL	160MG	N218213	002	Jun 11, 2024	Jul	NEWA
---	---------	-------	---------	-----	--------------	-----	------

RESMETIROM

TABLET; ORAL
REZDIFFRA

+	MADRIGAL	60MG	N217785	001	Mar 14, 2024	Mar	NEWA
+		80MG	N217785	002	Mar 14, 2024	Mar	NEWA
+	!	100MG	N217785	003	Mar 14, 2024	Mar	NEWA

RETAPAMULIN

OINTMENT; TOPICAL
ALTABAX

+	@ ALMIRALL	1%	N022055	001	Apr 12, 2007	May	DISC
---	------------	----	---------	-----	--------------	-----	------

REZAFUNGIN ACETATE

POWDER; INTRAVENOUS
REZZAYO

+	!	MUNDIPHARMA	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023	Jun	CAHN
---	---	-------------	--------------------	---------	-----	--------------	-----	------

RIFAMPIN

CAPSULE; ORAL
RIFAMPIN

@	HIKMA	150MG	A065028	001	Mar 14, 2001	Mar	DISC
@		300MG	A065028	002	Mar 14, 2001	Mar	DISC

>D> RIFAMYCIN SODIUM

>D> TABLET, DELAYED RELEASE; ORAL
>D> AEMCOLO

>D>	+	!	REDHILL	EQ 194MG BASE	N210910	001	Nov 16, 2018	Oct	DISC
>A>	+	@		EQ 194MG BASE	N210910	001	Nov 16, 2018	Oct	DISC

RILPIVIRINE HYDROCHLORIDE

TABLET, FOR SUSPENSION; ORAL
EDURANT PED

+	@	JANSSEN PRODS	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Aug	DISC
+	!		EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Mar	NEWA

RILUZOLE

FILM; ORAL
EXSERVAN

+	@	AQUESTIVE	50MG	N212640	001	Nov 22, 2019	Sep	DISC
---	---	-----------	------	---------	-----	--------------	-----	------

SUSPENSION; ORAL
RILUZOLE

AB	!	ALKEM LABS LTD	50MG/10ML	A216035	001	Aug 22, 2024	Aug	NFTG
----	---	----------------	-----------	---------	-----	--------------	-----	------

AB	+	!	ITALFARMACO SA	50MG/10ML	N209080	001	Sep 05, 2018	Aug	CFTG
----	---	---	----------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL
RILUTEK

+	@	COVIS	50MG	N020599	001	Dec 12, 1995	May	DISC
---	---	-------	------	---------	-----	--------------	-----	------

RILUZOLE

AB	!	ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	May	CHRS
>D> AB		SUN PHARM INDS LTD	50MG	A091417	001	Jun 18, 2013	Oct	DISC

>A>	@		50MG	A091417	001	Jun 18, 2013	Oct	DISC
-----	---	--	------	---------	-----	--------------	-----	------

RISEDRONATE SODIUM

TABLET;ORAL

RISEDRONATE SODIUM
 BX AUROBINDO PHARMA 150MG A206768 001 Oct 21, 2016 Jun CTEC

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

>D> RISVAN
 >D> + LABS FARMS ROVI SA 75MG N214835 001 Mar 29, 2024 Oct DISC
 >A> + @ 75MG N214835 001 Mar 29, 2024 Oct DISC
 + 75MG N214835 001 Mar 29, 2024 Mar NEWA
 >D> +! 100MG N214835 002 Mar 29, 2024 Oct DISC
 >A> + @ 100MG N214835 002 Mar 29, 2024 Oct DISC
 +! 100MG N214835 002 Mar 29, 2024 Mar NEWA

RYKINDO

+ SHANDONG LUYE 12.5MG N212849 001 Jan 13, 2023 Sep CHRS
 + 37.5MG N212849 003 Jan 13, 2023 Sep CHRS
 + 50MG N212849 004 Jan 13, 2023 Sep CHRS

INJECTABLE;INTRAMUSCULAR

RISPERDAL CONSTA

AB + JANSSEN PHARMS 12.5MG/VIAL N021346 004 Apr 12, 2007 Jan CMS1
 AB +! 25MG/VIAL N021346 001 Oct 29, 2003 Jan CMS1
 AB + 37.5MG/VIAL N021346 002 Oct 29, 2003 Jan CMS1
 AB + 50MG/VIAL N021346 003 Oct 29, 2003 Jan CMS1

RISPERIDONE

AB TEVA PHARMS USA INC 12.5MG/VIAL A214068 001 Dec 05, 2023 Jan CMS1
 AB 25MG/VIAL A214068 002 Dec 05, 2023 Jan CMS1
 AB 37.5MG/VIAL A214068 003 Dec 05, 2023 Jan CMS1
 AB 50MG/VIAL A214068 004 Dec 05, 2023 Jan CMS1

SOLUTION;ORAL

RISPERIDONE

@ HIKMA 1MG/ML A076904 001 Jul 29, 2009 Mar DISC
 @ PHARM ASSOC 1MG/ML A077719 001 Jul 29, 2009 Feb DISC
 @ SCIEGEN PHARMS INC 1MG/ML A078909 001 Jul 29, 2009 Sep CAHN

TABLET;ORAL

RISPERIDONE

AB ALLIED 0.25MG A078871 001 Oct 09, 2008 Jul CAHN
 AB 0.5MG A078871 002 Oct 09, 2008 Jul CAHN
 AB 1MG A078871 003 Oct 09, 2008 Jul CAHN
 AB 2MG A078871 004 Oct 09, 2008 Jul CAHN
 AB 3MG A078871 005 Oct 09, 2008 Jul CAHN
 AB 4MG A078871 006 Oct 09, 2008 Jul CAHN
 >A> AB ESJAY PHARMA 0.25MG A078871 001 Oct 09, 2008 Oct CAHN
 >A> AB 0.5MG A078871 002 Oct 09, 2008 Oct CAHN
 >A> AB 1MG A078871 003 Oct 09, 2008 Oct CAHN
 >A> AB 2MG A078871 004 Oct 09, 2008 Oct CAHN
 >A> AB 3MG A078871 005 Oct 09, 2008 Oct CAHN
 >A> AB 4MG A078871 006 Oct 09, 2008 Oct CAHN
 AB IPCA LABS LTD 0.25MG A205104 001 Jun 26, 2024 Jun NEWA
 AB 0.5MG A205104 002 Jun 26, 2024 Jun NEWA
 AB 1MG A205104 003 Jun 26, 2024 Jun NEWA
 AB 2MG A205104 004 Jun 26, 2024 Jun NEWA
 AB 3MG A205104 005 Jun 26, 2024 Jun NEWA
 AB 4MG A205104 006 Jun 26, 2024 Jun NEWA
 >D> AB NOVITIUM PHARMA 0.25MG A078871 001 Oct 09, 2008 Oct CAHN
 AB 0.25MG A078871 001 Oct 09, 2008 Aug CAHN
 >D> AB 0.5MG A078871 002 Oct 09, 2008 Oct CAHN
 AB 0.5MG A078871 002 Oct 09, 2008 Aug CAHN
 >D> AB 1MG A078871 003 Oct 09, 2008 Oct CAHN
 AB 1MG A078871 003 Oct 09, 2008 Aug CAHN
 >D> AB 2MG A078871 004 Oct 09, 2008 Oct CAHN
 AB 2MG A078871 004 Oct 09, 2008 Aug CAHN
 >D> AB 3MG A078871 005 Oct 09, 2008 Oct CAHN
 AB 3MG A078871 005 Oct 09, 2008 Aug CAHN
 >D> AB 4MG A078871 006 Oct 09, 2008 Oct CAHN
 AB 4MG A078871 006 Oct 09, 2008 Aug CAHN
 AB RENATA 0.25MG A078707 001 Dec 29, 2008 Feb CAHN
 AB 0.5MG A078707 002 Dec 29, 2008 Feb CAHN
 AB 1MG A078707 003 Dec 29, 2008 Feb CAHN
 AB 2MG A078707 004 Dec 29, 2008 Feb CAHN
 AB 3MG A078707 005 Dec 29, 2008 Feb CAHN
 AB 4MG A078707 006 Dec 29, 2008 Feb CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

	ENDO OPERATIONS	0.25MG	A077494	001	Apr 30, 2009	Apr	CAHN
AB		0.5MG	A077494	002	Apr 30, 2009	Apr	CAHN
AB		1MG	A077494	003	Oct 26, 2009	Apr	CAHN
AB		2MG	A077494	004	Apr 30, 2009	Apr	CAHN
AB		3MG	A077494	005	Apr 30, 2009	Apr	CAHN
AB		4MG	A077494	006	Apr 30, 2009	Apr	CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

>D>	AB	SUN PHARM	EQ 1.5MG BASE	A077131	001	Oct 22, 2007	Oct	DISC
>A>		@	EQ 1.5MG BASE	A077131	001	Oct 22, 2007	Oct	DISC
>D>	AB		EQ 3MG BASE	A077131	002	Oct 22, 2007	Oct	DISC
>A>		@	EQ 3MG BASE	A077131	002	Oct 22, 2007	Oct	DISC
>D>	AB		EQ 4.5MG BASE	A077131	003	Oct 22, 2007	Oct	DISC
>A>		@	EQ 4.5MG BASE	A077131	003	Oct 22, 2007	Oct	DISC
>D>	AB		EQ 6MG BASE	A077131	004	Oct 22, 2007	Oct	DISC
>A>		@	EQ 6MG BASE	A077131	004	Oct 22, 2007	Oct	DISC

SOLUTION;ORAL

EXELON

+	@	NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000	Apr	CRLD
---	---	----------	----------------	---------	-----	--------------	-----	------

RIZATRIPTAN BENZOATE

FILM;ORAL

RIZAFILM

+	@	GENSCO	EQ 10MG BASE	N205394	001	Apr 14, 2023	Jun	DISC
---	---	--------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL

RIZATRIPTAN BENZOATE

@	GLENMARK PHARMS LTD	EQ 5MG BASE	A201967	001	Dec 31, 2012	Aug	DISC
@		EQ 10MG BASE	A201967	002	Dec 31, 2012	Aug	DISC
@	INVAGEN PHARMS	EQ 5MG BASE	A204339	001	Jul 01, 2013	Apr	DISC
@		EQ 10MG BASE	A204339	002	Jul 01, 2013	Apr	DISC
@	NATCO PHARMA LTD	EQ 5MG BASE	A200482	001	Dec 31, 2012	Aug	DISC
@		EQ 10MG BASE	A200482	002	Dec 31, 2012	Aug	DISC

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

@	GLENMARK PHARMS LTD	EQ 5MG BASE	A201914	001	Jul 01, 2013	Aug	DISC
@		EQ 10MG BASE	A201914	002	Jul 01, 2013	Aug	DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

	@	HIKMA	50MG/5ML (10MG/ML)	A217034	001	May 24, 2023	Jul	DISC
AP		SHANDONG	50MG/5ML (10MG/ML)	A215684	001	Jul 12, 2024	Jul	NEWA
AP			100MG/10ML (10MG/ML)	A215684	002	Jul 12, 2024	Jul	NEWA
AP		STERISCIENCE	50MG/5ML (10MG/ML)	A217092	001	Jul 22, 2024	Jul	NEWA

ROFLUMILAST

CREAM;TOPICAL

ZORYVE

+	!	ARCUTIS	0.15%	N215985	002	Jul 09, 2024	Jul	NEWA
---	---	---------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

ROFLUMILAST

>A>	AB	BRECKENRIDGE	250MCG	A208236	002	Oct 19, 2023	Jul	DISC
		TORRENT	250MCG	A208272	002	Oct 18, 2024	Oct	NEWA

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP		CAPLIN	200MG/100ML (2MG/ML)	A212808	005	May 23, 2024	May	NEWA	
AP			400MG/200ML (2MG/ML)	A212808	006	May 23, 2024	May	NEWA	
AP		HIKMA	200MG/100ML (2MG/ML)	A211907	001	Aug 15, 2024	Aug	NEWA	
AP			400MG/200ML (2MG/ML)	A211907	002	Aug 15, 2024	Aug	NEWA	
AP			500MG/100ML (5MG/ML)	A211907	003	Aug 15, 2024	Aug	NEWA	
		@	HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	May	DISC
		@		40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	May	DISC
		@		100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	May	DISC
		@		150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	May	DISC
		@		150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	May	DISC
		@		200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	May	DISC

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	KINDOS	20MG/10ML (2MG/ML)	A218713	001	Jul 30, 2024	Jul	NEWA
AP		40MG/20ML (2MG/ML)	A218713	002	Jul 30, 2024	Jul	NEWA
AP		100MG/20ML (5MG/ML)	A218713	003	Jul 30, 2024	Jul	NEWA
AP		100MG/10ML (10MG/ML)	A218713	004	Jul 30, 2024	Jul	NEWA
AP		150MG/30ML (5MG/ML)	A218713	005	Jul 30, 2024	Jul	NEWA
AP		150MG/20ML (7.5MG/ML)	A218713	006	Jul 30, 2024	Jul	NEWA
AP		200MG/20ML (10MG/ML)	A218713	007	Jul 30, 2024	Jul	NEWA

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

>A>	AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A207296	001	Nov 06, 2024	Oct	NEWA
>A>	AB		EQ 10MG BASE	A207296	002	Nov 06, 2024	Oct	NEWA
>A>	AB		EQ 20MG BASE	A207296	003	Nov 06, 2024	Oct	NEWA
>A>	AB		EQ 40MG BASE	A207296	004	Nov 06, 2024	Oct	NEWA
		@ SANDOZ	EQ 5MG BASE	A079171	001	Jul 19, 2016	Jan	DISC
		@	EQ 10MG BASE	A079171	002	Jul 19, 2016	Jan	DISC
		@	EQ 20MG BASE	A079171	003	Jul 19, 2016	Jan	DISC
		@	EQ 40MG BASE	A079171	004	Jul 19, 2016	Jan	DISC
>D>	AB	SUN PHARM	EQ 5MG BASE	A079169	001	Jul 19, 2016	Oct	DISC
>A>		@	EQ 5MG BASE	A079169	001	Jul 19, 2016	Oct	DISC
>D>	AB		EQ 10MG BASE	A079169	002	Jul 19, 2016	Oct	DISC
>A>		@	EQ 10MG BASE	A079169	002	Jul 19, 2016	Oct	DISC
>D>	AB		EQ 20MG BASE	A079169	003	Jul 19, 2016	Oct	DISC
>A>		@	EQ 20MG BASE	A079169	003	Jul 19, 2016	Oct	DISC

RUCAPARIB CAMSYLATE

TABLET; ORAL

RUBRACA

+		PHARMAAND	EQ 200MG BASE	N209115	001	Dec 19, 2016	Jul	CAHN
+			EQ 250MG BASE	N209115	003	May 01, 2017	Jul	CAHN
+	!		EQ 300MG BASE	N209115	002	Dec 19, 2016	Jul	CAHN

SACUBITRIL; VALSARTAN

CAPSULE, PELLETS; ORAL

ENTRESTO SPRINKLE

+		NOVARTIS	6MG; 6MG	N218591	001	Apr 12, 2024	Apr	NEWA
+	!		15MG; 16MG	N218591	002	Apr 12, 2024	Apr	NEWA

TABLET; ORAL

ENTRESTO

AB	+	NOVARTIS PHARMS CORP	24MG; 26MG	N207620	001	Jul 07, 2015	May	CFTG
AB	+		49MG; 51MG	N207620	002	Jul 07, 2015	May	CFTG
AB	+	!	97MG; 103MG	N207620	003	Jul 07, 2015	May	CFTG

SACUBITRIL AND VALSARTAN

AB		ALEMBIC	24MG; 26MG	A213682	001	May 28, 2024	May	NFTG
AB			49MG; 51MG	A213682	002	May 28, 2024	May	NFTG
AB			97MG; 103MG	A213682	003	May 28, 2024	May	NFTG
AB		ALKEM LABS LTD	24MG; 26MG	A213764	001	Sep 16, 2024	Sep	NEWA
AB			49MG; 51MG	A213764	002	Sep 16, 2024	Sep	NEWA
AB			97MG; 103MG	A213764	003	Sep 16, 2024	Sep	NEWA
AB		BIOCON PHARMA	24MG; 26MG	A213680	001	Aug 30, 2024	Aug	NEWA
AB			49MG; 51MG	A213680	002	Aug 30, 2024	Aug	NEWA
AB			97MG; 103MG	A213680	003	Aug 30, 2024	Aug	NEWA
AB		CRYSTAL	24MG; 26MG	A213605	001	May 28, 2024	May	NFTG
AB			49MG; 51MG	A213605	002	May 28, 2024	May	NFTG
AB			97MG; 103MG	A213605	003	May 28, 2024	May	NFTG
AB		LAURUS	24MG; 26MG	A213676	001	May 28, 2024	May	NFTG
AB			49MG; 51MG	A213676	002	May 28, 2024	May	NFTG
AB			97MG; 103MG	A213676	003	May 28, 2024	May	NFTG
>A>	AB	MACLEODS PHARMS LTD	24MG; 26MG	A213728	001	Oct 16, 2024	Oct	NEWA
>A>	AB		49MG; 51MG	A213728	002	Oct 16, 2024	Oct	NEWA
>A>	AB		97MG; 103MG	A213728	003	Oct 16, 2024	Oct	NEWA
		MSN	24MG; 26MG	A213748	001	Jul 24, 2024	Jul	NEWA
			49MG; 51MG	A213748	002	Jul 24, 2024	Jul	NEWA
			97MG; 103MG	A213748	003	Jul 24, 2024	Jul	NEWA
>D>		@ TORRENT	24MG; 26MG	A213604	001	Aug 22, 2024	Oct	CMFD
>A>	AB		24MG; 26MG	A213604	001	Aug 22, 2024	Oct	CMFD
		@	24MG; 26MG	A213604	001	Aug 22, 2024	Sep	DISC
			24MG; 26MG	A213604	001	Aug 22, 2024	Aug	NEWA
>D>		@	49MG; 51MG	A213604	002	Aug 22, 2024	Oct	CMFD
>A>	AB		49MG; 51MG	A213604	002	Aug 22, 2024	Oct	CMFD

TABLET;ORAL

SACUBITRIL AND VALSARTAN

	@	49MG;51MG	A213604	002	Aug 22, 2024	Sep	DISC
AB		49MG;51MG	A213604	002	Aug 22, 2024	Aug	NEWA
>D>	@	97MG;103MG	A213604	003	Aug 22, 2024	Oct	CMFD
>A>	AB	97MG;103MG	A213604	003	Aug 22, 2024	Oct	CMFD
	@	97MG;103MG	A213604	003	Aug 22, 2024	Sep	DISC
AB		97MG;103MG	A213604	003	Aug 22, 2024	Aug	NEWA
AB	ZYDUS PHARMS	24MG;26MG	A213719	001	Jul 09, 2024	Jun	NEWA
AB		49MG;51MG	A213719	002	Jul 09, 2024	Jun	NEWA
AB		97MG;103MG	A213719	003	Jul 09, 2024	Jun	NEWA

SAFINAMIDE MESYLATE

TABLET;ORAL

SAFINAMIDE MESYLATE

AB	PRINSTON INC	EQ 50MG BASE	A215739	001	Apr 25, 2024	Apr	NEWA
AB		EQ 100MG BASE	A215739	002	Apr 25, 2024	Apr	NEWA
	XADAGO						
AB	+ MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Apr	CTEC
AB	+!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Apr	CTEC

SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

SAXAGLIPTIN

	@ AMNEAL	EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Feb	DISC
	@	EQ 5MG BASE	A205941	002	Jul 31, 2023	Feb	DISC

SCOPOLAMINE

SYSTEM;TRANSDERMAL

SCOPOLAMINE

AB	RHODES PHARMS	1MG/72HR	A215329	001	May 06, 2024	Apr	NEWA
AB	ZYDUS PHARMS	1MG/72HR	A217893	001	Aug 29, 2024	Aug	NEWA

SECNIDAZOLE

GRANULE;ORAL

SOLOSEC

+!	EVOFEM INC	2GM/PACKET	N209363	001	Sep 15, 2017	Sep	CAHN
----	------------	------------	---------	-----	--------------	-----	------

SELADELPAR LYSINE

CAPSULE;ORAL

LIVDELZI

+!	CYMABAY	EQ 10MG BASE	N217899	001	Aug 14, 2024	Aug	NEWA
+!	GILEAD SCIENCES INC	EQ 10MG BASE	N217899	001	Aug 14, 2024	Sep	CAHN

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

ELDEPRYL

+ @	NORVIUM BIOSCIENCE	5MG	N020647	001	May 15, 1996	Aug	CAHN
-----	--------------------	-----	---------	-----	--------------	-----	------

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

	@ KENTON	5MG	A074912	001	Apr 30, 1998	May	CAHN
AB	MLV	5MG	A074672	001	Apr 01, 1997	Sep	CAHN
	+ @ NORVIUM BIOSCIENCE	5MG	N019334	001	Jun 05, 1989	Aug	CAHN

SELEXIPAG

TABLET;ORAL

SELEXIPAG

	@ ZYDUS LIFESCIENCES	0.2MG	A214302	001	Dec 21, 2022	May	CAHN
	@	0.4MG	A214302	002	Dec 21, 2022	May	CAHN
	@	0.6MG	A214302	003	Dec 21, 2022	May	CAHN
	@	0.8MG	A214302	004	Dec 21, 2022	May	CAHN
	@	1MG	A214302	005	Dec 21, 2022	May	CAHN
	@	1.2MG	A214302	006	Dec 21, 2022	May	CAHN
	@	1.4MG	A214302	007	Dec 21, 2022	May	CAHN
	@	1.6MG	A214302	008	Dec 21, 2022	May	CAHN

SELPERCATINIB

TABLET;ORAL

RETEVMO

+	LOXO ONCOL ELI LILLY	40MG	N218160	001	Apr 10, 2024	Apr	NEWA
+		80MG	N218160	002	Apr 10, 2024	Apr	NEWA
+		120MG	N218160	003	Apr 10, 2024	Apr	NEWA

TABLET;ORAL
RETEVMO

+! 160MG N218160 004 Apr 10, 2024 Apr NEWA

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@ APPCO EQ 25MG BASE A077713 001 Feb 06, 2007 May CAHN
 @ EQ 50MG BASE A077713 002 Feb 06, 2007 May CAHN
 @ EQ 100MG BASE A077713 003 Feb 06, 2007 May CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

AB INVAGEN PHARMS 800MG/PACKET A206234 001 Jul 12, 2024 Jul NEWA
 AB 2.4GM/PACKET A206234 002 Jul 12, 2024 Jul NEWA
 AB MACLEODS PHARMS LTD 800MG/PACKET A207291 001 Apr 25, 2024 Apr NEWA
 AB 2.4GM/PACKET A207291 002 Apr 25, 2024 Apr NEWA

TABLET;ORAL

SEVELAMER CARBONATE

>A> AB @ ANXIN 800MG A212970 001 Apr 09, 2020 Apr DISC
 SHANDONG XINHUA 800MG A215998 001 Oct 24, 2024 Oct NEWA
 @ SINOTHERAPEUTICS INC 800MG A212970 001 Apr 09, 2020 Aug CAHN
 AB STRIDES PHARMA 800MG A211915 001 May 09, 2024 May NEWA

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

SILDENAFIL CITRATE

AB INVAGEN PHARMS EQ 10MG BASE/ML A213041 001 Aug 06, 2020 Sep CAHN
 AB SOMERSET THERAPS LLC EQ 10MG BASE/ML A213814 001 Apr 29, 2021 Sep CAHN

SUSPENSION;ORAL

LIQREV

+ @ CMP DEV LLC EQ 10MG BASE/ML N214952 001 Apr 28, 2023 Jul DISC

TABLET;ORAL

SILDENAFIL CITRATE

@ MYLAN PHARMS INC EQ 20MG BASE A201150 001 Nov 09, 2012 Apr DISC
 BX UMEDICA EQ 25MG BASE A209302 003 Jun 15, 2021 Jun CTEC
 BX EQ 50MG BASE A209302 001 Aug 25, 2020 Jun CTEC
 BX EQ 100MG BASE A209302 002 Aug 25, 2020 Jun CTEC

SILODOSIN

CAPSULE;ORAL

RAPAFLO

>A> AB +! ABBVIE 4MG N022206 001 Oct 08, 2008 Oct CAHN
 >A> AB + 8MG N022206 002 Oct 08, 2008 Oct CAHN
 >D> AB +! ALLERGAN 4MG N022206 001 Oct 08, 2008 Oct CAHN
 >D> AB + 8MG N022206 002 Oct 08, 2008 Oct CAHN

SILODOSIN

AB CHARTWELL RX 4MG A204726 001 Mar 31, 2017 Mar CAHN
 AB 8MG A204726 002 Mar 31, 2017 Mar CAHN

SILVER SULFADIAZINE

CREAM;TOPICAL

SSD

AB +! DR REDDYS LA 1% N018578 001 Feb 25, 1982 Jan CRLD
 AB ! 1% N018578 001 Feb 25, 1982 Jan CHRS

SIMVASTATIN

SUSPENSION;ORAL

FLOLIPID

+ SALERNO PHARMS 20MG/5ML N206679 001 Apr 21, 2016 Apr CAHN
 +! 40MG/5ML N206679 002 Apr 21, 2016 Apr CAHN

SINCALIDE

INJECTABLE; INJECTION

KINEVAC

AP +! BRACCO 0.005MG/VIAL N017697 001 May CTEC

POWDER; INTRAVENOUS

KINEVAC

AP +! BRACCO 0.005MG/VIAL N017697 001 May CDFR

	POWDER; INTRAVENOUS								
	SINCALIDE								
AP	+! MAIA PHARMS INC	0.005MG/VIAL		N210850	001	Nov 22, 2022	May	CTEC	
	<u>SIROLIMUS</u>								
	SOLUTION; ORAL								
	SIROLIMUS								
AA	HETERO LABS LTD V	1MG/ML		A215080	001	Sep 16, 2024	Sep	NEWA	
	<u>SODIUM ACETATE</u>								
	INJECTABLE; INJECTION								
	SODIUM ACETATE								
AP	FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)		A206687	001	Oct 30, 2017	Apr	CPOT	
AP	MILLA PHARMS	400MEQ/100ML (4MEQ/ML)		A214805	002	Aug 25, 2023	Apr	CPOT	
	SOLUTION; INTRAVENOUS								
	SODIUM ACETATE								
AP	! FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)		A206687	001	Oct 30, 2017	Apr	CDFR	
AP	HIKMA	40MEQ/20ML (2MEQ/ML)		A216920	001	Mar 15, 2024	Mar	NEWA	
AP		100MEQ/50ML (2MEQ/ML)		A216920	002	Mar 15, 2024	Mar	NEWA	
AP		200MEQ/100ML (2MEQ/ML)		A216920	003	Mar 15, 2024	Mar	NEWA	
AP	+! HOSPIRA	2MEQ/ML		N018893	001	May 04, 1983	Mar	CDFR	
AP	+!	40MEQ/20ML (2MEQ/ML)		N018893	001	May 04, 1983	Mar	CPOT	
AP	+!	100MEQ/50ML (2MEQ/ML)		N018893	002	Sep 02, 2014	Mar	CMS1	
AP	+!	200MEQ/100ML (2MEQ/ML)		N018893	003	Sep 02, 2014	Mar	CMS1	
AP	MILLA PHARMS	2MEQ/ML		A214805	001	May 04, 2021	Mar	CDFR	
AP		40MEQ/20ML (2MEQ/ML)		A214805	004	Jan 22, 2024	Mar	CMS1	
AP		100MEQ/50ML (2MEQ/ML)		A214805	001	May 04, 2021	Mar	CPOT	
AP		200MEQ/100ML (2MEQ/ML)		A214805	003	May 04, 2021	Mar	CMS1	
AP		400MEQ/100ML (4MEQ/ML)		A214805	002	Aug 25, 2023	Apr	CDFR	
	<u>SODIUM BENZOATE; SODIUM PHENYLACETATE</u>								
	SOLUTION; INTRAVENOUS								
	AMMONUL								
	+ @ BAUSCH	10%;10% (5GM/50ML;5GM/50ML)		N020645	001	Feb 17, 2005	Jul	DISC	
	SODIUM PHENYLACETATE AND SODIUM BENZOATE								
AP	! AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)		A207096	001	Feb 24, 2016	Jul	CHRS	
	<u>SODIUM BICARBONATE</u>								
	INJECTABLE; INJECTION								
	SODIUM BICARBONATE								
AP	LONG GROVE PHARMS	1MEQ/ML		A216042	001	Feb 27, 2024	Jun	CAHN	
AP	NIVAGEN PHARMS INC	1MEQ/ML		A216042	001	Feb 27, 2024	Feb	NEWA	
AP	STERISCIENCE	1MEQ/ML		A217594	001	Jun 28, 2023	Apr	CMFD	
	@	1MEQ/ML		A217594	001	Jun 28, 2023	Jan	DISC	
	<u>SODIUM CHLORIDE</u>								
	SOLUTION; INJECTION								
	SODIUM CHLORIDE 0.9%								
	@ HIKMA	90MG/10ML (9MG/ML)		A201850	001	Jan 20, 2012	Mar	DISC	
	SOLUTION; IRRIGATION								
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
AT	FRESENIUS KABI USA	900MG/100ML		A213688	001	Jun 24, 2024	Jun	NEWA	
	<u>SODIUM FLUORIDE F-18</u>								
	INJECTABLE; INTRAVENOUS								
	SODIUM FLUORIDE F-18								
AP	! PETNET	10-200mCi/ML		A203890	001	Sep 28, 2015	Jan	CHRS	
	<u>SODIUM NITROPRUSSIDE</u>								
	INJECTABLE; INJECTION								
	SODIUM NITROPRUSSIDE								
AP	SLATE RUN PHARMA	25MG/ML		A214199	001	Aug 25, 2020	Sep	CAHN	
	SOLUTION; INTRAVENOUS								
	SODIUM NITROPRUSSIDE								
	SLATE RUN PHARMA	10MG/50ML (0.2MG/ML)		A215846	001	Aug 26, 2022	Sep	CAHN	
AP		20MG/100ML (0.2MG/ML)		A215846	002	Aug 26, 2022	Sep	CAHN	
AP		50MG/100ML (0.5MG/ML)		A215846	003	Aug 26, 2022	Sep	CAHN	

SODIUM PHENYLBUTYRATE

POWDER;ORAL

SODIUM PHENYLBUTYRATE
 AB ENDO OPERATIONS 3GM/TEASPOONFUL A203918 001 Jun 15, 2016 Apr CAHN

TABLET;ORAL

SODIUM PHENYLBUTYRATE
 AB ENDO OPERATIONS 500MG A204395 001 Apr 15, 2016 Apr CAHN

>D> SODIUM PHENYLBUTYRATE; TAURURSODIOL

>D> FOR SUSPENSION;ORAL

>D> RELYVRIO

>D> +! AMYLYX 3GM/PACKET; 1GM/PACKET N216660 001 Sep 29, 2022 Oct DISC

>A> + @ 3GM/PACKET; 1GM/PACKET N216660 001 Sep 29, 2022 Oct DISC

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION

SODIUM PHOSPHATES

AP AM REGENT 142MG/ML;276MG/ML A218314 001 Jun 21, 2024 Jun NEWA

SOLUTION;INTRAVENOUS

SODIUM PHOSPHATES

AP AM REGENT 142MG/ML;276MG/ML A218314 001 Jun 21, 2024 Sep CDFR

AP 1.34GM/5ML;1.38GM/5ML A218314 001 Jun 21, 2024 Sep CPOT

(268MG/ML;276MG/ML)

AP ! FRESENIUS KABI USA 142MG/ML;276MG/ML A209997 001 Mar 30, 2022 Sep CDFR

AP ! 1.34GM/5ML;1.38GM/5ML A209997 001 Mar 30, 2022 Sep CPOT

(268MG/ML;276MG/ML)

SODIUM PHOSPHATES IN PLASTIC CONTAINER

AP +! HOSPIRA 142MG/ML;276MG/ML N018892 001 May 10, 1983 Sep CDFR

AP +! 4.02GM/15ML;4.14GM/15ML N018892 001 May 10, 1983 Sep CPOT

(268MG/ML;276MG/ML)

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

SOLUTION;INTRAVENOUS

SODIUM PHOSPHATES

AP AM REGENT 1.34GM/5ML;1.38GM/5ML A218314 001 Jun 21, 2024 Sep CAIN

(268MG/ML;276MG/ML)

AP 4.02GM/15ML;4.14GM/15ML A218314 002 Jun 21, 2024 Sep NEWA

(268MG/ML;276MG/ML)

AP 13.4GM/50ML;13.8GM/50ML A218314 003 Jun 21, 2024 Sep NEWA

(268MG/ML;276MG/ML)

AP ! FRESENIUS KABI USA 1.34GM/5ML;1.38GM/5ML A209997 001 Mar 30, 2022 Sep CAIN

(268MG/ML;276MG/ML)

AP 4.02GM/15ML;4.14GM/15ML A209997 002 Mar 30, 2022 Sep NEWA

(268MG/ML;276MG/ML)

AP ! 13.4GM/50ML;13.8GM/50ML A209997 003 Mar 30, 2022 Sep NEWA

(268MG/ML;276MG/ML)

SODIUM PHOSPHATES IN PLASTIC CONTAINER

AP +! HOSPIRA 4.02GM/15ML;4.14GM/15ML N018892 001 May 10, 1983 Sep CAIN

(268MG/ML;276MG/ML)

SOFPIRONIUM BROMIDE

GEL, METERED;TOPICAL

SOFDRA

+! BOTANIX SB EQ 12.45% BASE (EQ 72MG N217347 001 Jun 18, 2024 Jun NEWA

BASE/ACTUATION)

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB JUBILANT GENERICS 5MG A205484 001 Oct 02, 2024 Sep NEWA

AB 10MG A205484 002 Oct 02, 2024 Sep NEWA

AB MACLEODS PHARMS LTD 5MG A204374 001 Feb 20, 2024 Feb NEWA

AB 10MG A204374 002 Feb 20, 2024 Feb NEWA

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

@ RISING 80MG A075725 001 Dec 19, 2000 Feb CAHN

@ 120MG A075725 002 Dec 19, 2000 Feb CAHN

@ 160MG A075725 003 Dec 19, 2000 Feb CAHN

@ 240MG A075725 004 Dec 19, 2000 Feb CAHN

SOTORASIB

TABLET;ORAL
LUMAKRAS

+ AMGEN INC 240MG N214665 003 Jun 26, 2024 Jul NEWA

SOYBEAN OIL

INJECTABLE; INJECTION
NUTRILIPID 10%

+ @ B BRAUN 10% N019531 001 May 28, 1993 Jul DISC

SPINOSAD

SUSPENSION;TOPICAL
NATROBA

+! CIPHER 0.9% N022408 001 Jan 18, 2011 Aug CAHN

STERILE WATER FOR INJECTION

LIQUID;N/A
STERILE WATER FOR INJECTION

AP AM REGENT 100% (5ML) A217341 003 Feb 09, 2024 Feb NEWA

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION
STERILE WATER FOR IRRIGATION

AT FRESENIUS KABI USA 100% A216123 001 Aug 12, 2024 Aug NFTG

SUCCINYLMCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCCINYLMCHOLINE CHLORIDE

AP @ ACCORD HLTHCARE 20MG/ML A213705 001 May 20, 2020 May DISC

AP ADAPTIS 20MG/ML A214308 001 May 22, 2020 Aug CAHN

AP BAXTER HLTHCARE CORP 20MG/ML A218878 001 Sep 24, 2024 Sep NEWA

AP @ EUGIA PHARMA 20MG/ML A217808 001 Oct 16, 2023 Apr DISC

AP NIVAGEN PHARMS INC 20MG/ML A211625 001 May 19, 2020 Jan CAHN

AP UMEDICA 20MG/ML A211625 001 May 19, 2020 Aug CAHN

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
SUCCINYLMCHOLINE CHLORIDE

AP DR REDDYS 100MG/5ML (20MG/ML) A218467 001 Jan 17, 2024 Jan NEWA

AP +! HIKMA 100MG/5ML (20MG/ML) N215143 001 Aug 20, 2021 Jan CFTG

AP STERISCIENCE 100MG/5ML (20MG/ML) A217873 001 Jul 09, 2024 Jun NEWA

SUCRALFATE

SUSPENSION;ORAL
SUCRALFATE

AB ABON PHARMS LLC 1GM/10ML A216726 001 Mar 21, 2024 Mar NEWA

AB HIKMA 1GM/10ML A212769 001 Jul 23, 2024 Jul NEWA

AB PD PARTNERS 1GM/10ML A213549 001 Jan 17, 2024 Jan NEWA

AB STRIDES PHARMA 1GM/10ML A216474 001 May 21, 2024 May NEWA

AB VISTAPHARM LLC 1GM/10ML A211884 001 Mar 15, 2022 Apr CAHN

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS
SUGAMMADEX SODIUM

@ ZYDUS PHARMS EQ 200MG BASE/2ML (EQ 100MG BASE/ML) A214290 001 Oct 04, 2023 Mar DISC

@ EQ 500MG BASE/5ML (EQ 100MG BASE/ML) A214290 002 Oct 04, 2023 Mar DISC

SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC
SULFACETAMIDE SODIUM

>D> AT BAUSCH AND LOMB 10% A040066 001 Dec 28, 1994 Oct CHRS

>A> AT ! 10% A040066 001 Dec 28, 1994 Oct CHRS

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB ! AUROBINDO PHARMA 200MG/5ML;40MG/5ML A091348 001 Jun 08, 2010 Mar CHRS

@ HIKMA 200MG/5ML;40MG/5ML A074650 001 Dec 29, 1997 Mar DISC

SULFANILAMIDECREAM;VAGINAL
AVC

+ @ NORVIUM BIOSCIENCE 15% N006530 003 Jan 27, 1987 Jun CAHN

SUPPOSITORY;VAGINAL
AVC

@ NORVIUM BIOSCIENCE 1.05GM N006530 004 Jan 27, 1987 Jun CAHN

SUMATRIPTANSPRAY;NASAL
SUMATRIPTAN

AB ADAPTIS 20MG/SPRAY A208967 001 Feb 17, 2021 Sep CAHN

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATEAP CAPLIN EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) A213998 001 Jul 13, 2021 Jun CAHN@ ENDO OPERATIONS EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) A077332 001 Oct 09, 2009 May CAHN@ EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) A077871 001 Jul 09, 2009 May CAHNAP ! EUGIA PHARMA EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) A202758 001 Apr 23, 2013 Jan CHRS@ PAR PHARM EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) A077332 001 Oct 09, 2009 Feb DISC

SUMAVEL DOSEPRO

+ @ ENDO OPERATIONS EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) N022239 002 Nov 26, 2013 May CAHN

+ @ EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) N022239 001 Jul 15, 2009 May CAHNSUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB EUGIA PHARMA EQ 12.5MG BASE A218615 001 Mar 14, 2024 Mar NEWA

AB EQ 25MG BASE A218615 002 Mar 14, 2024 Mar NEWA

AB EQ 37.5MG BASE A218615 003 Mar 14, 2024 Mar NEWA

AB EQ 50MG BASE A218615 004 Mar 14, 2024 Mar NEWA

AB NOVUGEN EQ 12.5MG BASE A218012 001 Aug 21, 2023 May CMFD

@ EQ 12.5MG BASE A218012 001 Aug 21, 2023 Feb DISC

AB EQ 25MG BASE A218012 002 Aug 21, 2023 May CMFD

@ EQ 25MG BASE A218012 002 Aug 21, 2023 Feb DISC

AB EQ 37.5MG BASE A218012 003 Aug 21, 2023 May CMFD

@ EQ 37.5MG BASE A218012 003 Aug 21, 2023 Feb DISC

AB EQ 50MG BASE A218012 004 Aug 21, 2023 May CMFD

@ EQ 50MG BASE A218012 004 Aug 21, 2023 Feb DISC

AB WANBANG BIOPHARMS EQ 12.5MG BASE A218012 001 Aug 21, 2023 Aug CAHN

AB EQ 25MG BASE A218012 002 Aug 21, 2023 Aug CAHN

AB EQ 37.5MG BASE A218012 003 Aug 21, 2023 Aug CAHN

AB EQ 50MG BASE A218012 004 Aug 21, 2023 Aug CAHN

TACROLIMUS

CAPSULE, EXTENDED RELEASE;ORAL

ASTAGRAF XL

AB + ASTELLAS EQ 0.5MG BASE N204096 001 Jul 19, 2013 Jan CFTG

AB + EQ 1MG BASE N204096 002 Jul 19, 2013 Jan CFTG

AB +! EQ 5MG BASE N204096 003 Jul 19, 2013 Jan CFTG

TACROLIMUS

AB CHENGDU EQ 0.5MG BASE A215012 001 Jan 25, 2024 Jan NFTG

AB EQ 1MG BASE A215012 002 Jan 25, 2024 Jan NFTG

AB EQ 5MG BASE A215012 003 Jan 25, 2024 Jan NFTG

TADALAFIL

TABLET;ORAL

CIALIS

+ @ LILLY 2.5MG N021368 004 Jan 07, 2008 Sep DISC

TADALAFIL

AB1 FOURRTS LABS 2.5MG A217606 001 Aug 13, 2024 Aug NEWA

AB1 5MG A217606 002 Aug 13, 2024 Aug NEWA

AB1 10MG A217606 003 Aug 13, 2024 Aug NEWA

AB1 20MG A217606 004 Aug 13, 2024 Aug NEWA

AB1 HANGZHOU BINJIANG 2.5MG A208824 001 Oct 27, 2020 Mar CAHN

AB1 5MG A208824 002 Oct 27, 2020 Mar CAHN

TABLET;ORAL
TADALAFIL

AB1		10MG	A208824	003	Oct 27, 2020	Mar	CAHN
AB1		20MG	A208824	004	Oct 27, 2020	Mar	CAHN
AB1	HIBROW HLTHCARE	2.5MG	A217606	001	Aug 13, 2024	Sep	CAHN
AB1		5MG	A217606	002	Aug 13, 2024	Sep	CAHN
AB1		10MG	A217606	003	Aug 13, 2024	Sep	CAHN
AB1		20MG	A217606	004	Aug 13, 2024	Sep	CAHN
AB1	SHANDONG	20MG	A216279	001	Mar 04, 2024	Feb	NEWA
BX	UMEDICA	2.5MG	A211298	001	Oct 23, 2020	Jun	CTEC
BX		5MG	A211298	002	Oct 23, 2020	Jun	CTEC
BX		10MG	A211298	003	Oct 23, 2020	Jun	CTEC
BX		20MG	A211298	004	Oct 23, 2020	Jun	CTEC

TABLET, CHEWABLE;ORAL
CHEWTADZY

+ @ B BETTER	5MG	N218527	001	Jun 28, 2024	Aug	DISC
+	5MG	N218527	001	Jun 28, 2024	Jun	NEWA
+ @	10MG	N218527	002	Jun 28, 2024	Aug	DISC
+	10MG	N218527	002	Jun 28, 2024	Jun	NEWA
+ @	20MG	N218527	003	Jun 28, 2024	Aug	DISC
+!	20MG	N218527	003	Jun 28, 2024	Jun	NEWA

T AFLUPROST

SOLUTION/DROPS;OPHTHALMIC
T AFLUPROST

@ INGENUS PHARMS LLC	0.0015%	A218002	001	Apr 05, 2024	May	DISC
AT	0.0015%	A218002	001	Apr 05, 2024	Mar	NEWA

TALAZOPARIB TOSYLATE

CAPSULE;ORAL
TALZENNA

+ PFIZER	EQ 0.1MG BASE	N217439	001	Mar 07, 2024	Mar	NEWA
+	EQ 0.25MG BASE	N217439	002	Mar 07, 2024	Mar	NEWA
+	EQ 0.35MG BASE	N217439	003	Mar 07, 2024	Mar	NEWA
+	EQ 0.5MG BASE	N217439	004	Mar 07, 2024	Mar	NEWA
+	EQ 0.75MG BASE	N217439	005	Mar 07, 2024	Mar	NEWA
+!	EQ 1MG BASE	N217439	006	Mar 07, 2024	Mar	NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL
TAMSULOSIN HYDROCHLORIDE

@ ENDO OPERATIONS	0.4MG	A202010	001	Jan 04, 2013	May	CAHN
@ NORVIUM BIOSCIENCE	0.4MG	A090408	001	Apr 27, 2010	Jul	CAHN
>D> AB SUN PHARM INDS LTD	0.4MG	A090931	001	Jul 15, 2010	Oct	DISC
>A> @	0.4MG	A090931	001	Jul 15, 2010	Oct	DISC

TAVABOROLE

SOLUTION;TOPICAL
KERYDIN

+ @ ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014	Mar	DISC
AB ! ENCUBE	5%	A211297	001	Oct 13, 2020	Mar	CHRS

TAZAROTENE

CREAM;TOPICAL
TAZAROTENE

AB PADAGIS ISRAEL	0.05%	A217075	001	Jul 15, 2024	Jul	NFTG
AB +! ALLERGAN	0.05%	N021184	001	Sep 29, 2000	Jul	CFTG

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION
MYOVIEW

+! MEDI-PHYSICS	N/A	N020372	001	Feb 09, 1996	Jun	CAHN
+! MEDI-PHYSICS	N/A	N020372	002	Jul 07, 2005	Jun	CAHN

TEDUGLUTIDEPOWDER; SUBCUTANEOUS
GATTEX KIT

+! TAKEDA PHARMS USA 5MG/VIAL N203441 001 Dec 21, 2012 Mar CAIN

TELMISARTANTABLET; ORAL
TELMISARTAN

>A>	AB	MANKIND PHARMA	20MG	A218157	001	Oct 15, 2024	Oct	NEWA
>A>	AB		40MG	A218157	002	Oct 15, 2024	Oct	NEWA
>A>	AB		80MG	A218157	003	Oct 15, 2024	Oct	NEWA

TEMAZEPAMCAPSULE; ORAL
TEMAZEPAM

>D>	AB	AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	Oct	DISC
>A>		@	7.5MG	A203482	001	May 23, 2016	Oct	DISC
>D>	AB		15MG	A203482	002	May 23, 2016	Oct	DISC
>A>		@	15MG	A203482	002	May 23, 2016	Oct	DISC
>D>	AB		22.5MG	A203482	003	May 23, 2016	Oct	DISC
>A>		@	22.5MG	A203482	003	May 23, 2016	Oct	DISC
>D>	AB		30MG	A203482	004	May 23, 2016	Oct	DISC
>A>		@	30MG	A203482	004	May 23, 2016	Oct	DISC
	AB	CHARTWELL RX	15MG	A071427	001	Jan 12, 1988	Jan	CAHN
	AB		30MG	A071428	001	Jan 12, 1988	Jan	CAHN

TEMOZOLOMIDECAPSULE; ORAL
TEMOZOLOMIDE

AB		HETERO LABS LTD V	5MG	A210030	001	Aug 23, 2024	Aug	NEWA
AB			20MG	A210030	002	Aug 23, 2024	Aug	NEWA
AB			100MG	A210030	003	Aug 23, 2024	Aug	NEWA
AB			140MG	A210030	004	Aug 23, 2024	Aug	NEWA
AB			180MG	A210030	005	Aug 23, 2024	Aug	NEWA
AB			250MG	A210030	006	Aug 23, 2024	Aug	NEWA
		@ NIVAGEN PHARMS INC	5MG	A213328	001	Nov 23, 2021	Sep	DISC
		@	20MG	A213328	002	Nov 23, 2021	Sep	DISC
		@	100MG	A213328	003	Nov 23, 2021	Sep	DISC
		@	140MG	A213328	004	Nov 23, 2021	Sep	DISC
		@	180MG	A213328	005	Nov 23, 2021	Sep	DISC
		@	250MG	A213328	006	Nov 23, 2021	Sep	DISC

TENAPANOR HYDROCHLORIDETABLET; ORAL
XPHOZAH

+ @ ARDELYX INC EQ 10MG BASE N213931 001 Oct 17, 2023 Apr DISC

TENOFOVIR ALAFENAMIDE FUMARATETABLET; ORAL
TENOFOVIR ALAFENAMIDE FUMARATE

		@ APOTEX	EQ 25MG BASE	A213867	001	Mar 21, 2024	May	DISC
AB			EQ 25MG BASE	A213867	001	Mar 21, 2024	Mar	NEWA

TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
TENOFOVIR DISOPROXIL FUMARATE

AB		MYLAN LABS LTD	300MG	A079071	001	Feb 29, 2024	Feb	NEWA
AB		NORVIUM BIOSCIENCE	300MG	A079071	001	Feb 29, 2024	Sep	CAHN

TERAZOSIN HYDROCHLORIDECAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

AB		BIONPHARMA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Jan	CMFD
AB			EQ 2MG BASE	A075667	002	Jul 28, 2000	Jan	CMFD
AB			EQ 5MG BASE	A075667	003	Jul 28, 2000	Jan	CMFD
AB			EQ 10MG BASE	A075667	004	Jul 28, 2000	Jan	CMFD

SOLUTION; ORAL
TEZRULY

>D>		+ @ NOVITIUM PHARMA	EQ 1MG BASE/ML	N218139	001	Jul 29, 2024	Oct	CMFD
>A>		+!	EQ 1MG BASE/ML	N218139	001	Jul 29, 2024	Oct	CMFD
		+ @	EQ 1MG BASE/ML	N218139	001	Jul 29, 2024	Aug	DISC

	SOLUTION;ORAL								
	TEZRULY								
	+!	EQ 1MG BASE/ML		N218139	001	Jul 29, 2024		Jul	NEWA
	<u>TERBINAFINE</u>								
	GEL;TOPICAL								
	LAMISIL								
	@ KARO HLTHCARE	1%		N020846	001	Apr 29, 1998		Feb	CAHN
	<u>TERBINAFINE HYDROCHLORIDE</u>								
	SOLUTION;TOPICAL								
	LAMISIL								
	@ KARO HLTHCARE	1%		N020749	001	Oct 17, 1997		Feb	CAHN
	TABLET;ORAL								
	TERBINAFINE HYDROCHLORIDE								
	@ CIPLA	EQ 250MG BASE		A077137	001	Jul 02, 2007		Mar	DISC
	<u>TERBUTALINE SULFATE</u>								
	INJECTABLE;INJECTION								
	TERBUTALINE SULFATE								
AP	AREVA PHARMS	1MG/ML		A200122	001	Nov 08, 2013		Apr	CAHN
	<u>TERIFLUNOMIDE</u>								
	TABLET;ORAL								
	TERIFLUNOMIDE								
	@ AMNEAL PHARMS CO	7MG		A209613	001	Sep 28, 2018		May	DISC
	@	14MG		A209613	002	Sep 28, 2018		May	DISC
	@ MYLAN	7MG		A209702	001	Feb 28, 2020		Sep	CAHN
	@	7MG		A209702	001	Feb 28, 2020		Apr	DISC
	@	14MG		A209702	002	Feb 28, 2020		Sep	CAHN
	@	14MG		A209702	002	Feb 28, 2020		Apr	DISC
>D> AB	TORRENT	7MG		A209697	001	Apr 04, 2024		Oct	DISC
>A>	@	7MG		A209697	001	Apr 04, 2024		Oct	DISC
AB		7MG		A209697	001	Apr 04, 2024		Mar	NEWA
>D> AB		14MG		A209697	002	Apr 04, 2024		Oct	DISC
>A>	@	14MG		A209697	002	Apr 04, 2024		Oct	DISC
AB		14MG		A209697	002	Apr 04, 2024		Mar	NEWA
	<u>TERIPARATIDE</u>								
	SOLUTION;SUBCUTANEOUS								
	TERIPARATIDE								
	+! ALMAJECT	0.6MG/2.4ML (0.25MG/ML)		N218771	001	Jun 04, 2024		Jun	NEWA
	<u>TESTOSTERONE</u>								
	GEL;TRANSDERMAL								
	ANDROGEL								
>D>	+ @ BESINS HLTHCARE	1.62% (40.5MG/2.5GM PACKET)		N022309	003	Sep 07, 2012		Oct	CMFD
>A> AB2	+	1.62% (40.5MG/2.5GM PACKET)		N022309	003	Sep 07, 2012		Oct	CMFD
>D>	+ @	25MG/2.5GM PACKET		N021015	001	Feb 28, 2000		Oct	CMFD
>A> AB1	+	25MG/2.5GM PACKET		N021015	001	Feb 28, 2000		Oct	CMFD
>D>	+ @	50MG/5GM PACKET		N021015	002	Feb 28, 2000		Oct	CMFD
>A> AB1	+	50MG/5GM PACKET		N021015	002	Feb 28, 2000		Oct	CMFD
	TESTIM								
AB2	+! ENDO OPERATIONS	50MG/5GM PACKET		N021454	001	Oct 31, 2002		Apr	CAHN
	TESTOSTERONE								
>A> AB1	ENCUBE	25MG/2.5GM PACKET		A212984	003	Jul 11, 2024		Oct	NEWA
	<u>GEL, METERED;TRANSDERMAL</u>								
	ANDROGEL								
>D>	+ @ BESINS HLTHCARE	12.5MG/1.25GM ACTUATION		N021015	003	Sep 26, 2003		Oct	CMFD
>A> AB1	+	12.5MG/1.25GM ACTUATION		N021015	003	Sep 26, 2003		Oct	CMFD
	FORTESTA								
	+ @ ENDO OPERATIONS	10MG/0.5GM ACTUATION		N021463	001	Dec 29, 2010		Apr	CAHN
	+ @ ENDO PHARMS	10MG/0.5GM ACTUATION		N021463	001	Dec 29, 2010		Jan	DISC
	TESTOSTERONE								
AB	! ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION		A204571	001	Aug 05, 2015		Jan	CTEC
AB1	!	10MG/0.5GM ACTUATION		A204571	001	Aug 05, 2015		Jan	CHRS
AB1	!	12.5MG/1.25GM ACTUATION		A076737	003	Mar 09, 2015		Apr	CTEC
AB1	ENCUBE	12.5MG/1.25GM ACTUATION		A212984	002	Feb 09, 2024		Apr	NEWA
	<u>PELLET;IMPLANTATION</u>								
	TESTOPEL								
	! ENDO OPERATIONS	75MG		A080911	001			Apr	CAHN

SOLUTION, METERED;TRANSDERMAL
TESTOSTERONE

AT	ENCUBE	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Apr	CAHN
AT	FEMPHARM	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Mar	CAHN

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION
TESTOSTERONE CYPIONATE

>D>	AO	SUN PHARM INDS LTD	100MG/ML	A201720	001	Jun 03, 2013	Oct	DISC
>A>		@	100MG/ML	A201720	001	Jun 03, 2013	Oct	DISC
>D>	AO		200MG/ML	A201720	002	Jun 03, 2013	Oct	DISC
>A>		@	200MG/ML	A201720	002	Jun 03, 2013	Oct	DISC
		@ WATSON PHARMS INC	200MG/ML	A086030	001		Sep	DISC

SOLUTION;INTRAMUSCULAR

>A>		AZMIRO						
>A>	+!	AZURITY	200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Oct	CTNA
>D>		TESTOSTERONE CYPIONATE						
>D>	+!	AZURITY	200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Oct	CTNA
	+!		200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Sep	CMFD
	+ @		200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Jul	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION
TESTOSTERONE ENANTHATE

AO	EUGIA PHARMA	200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA
AO		200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA
AO	! HIKMA FARMACEUTICA	200MG/ML	A091120	001	Sep 18, 2012	Sep	CHRS
	@ WATSON PHARMS INC	200MG/ML	A085598	001		Sep	DISC

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL
TLANDO

+!	VERITY	112.5MG	N208088	001	Mar 28, 2022	Jan	CAHN
----	--------	---------	---------	-----	--------------	-----	------

INJECTABLE;INTRAMUSCULAR
AVEED

+!	ENDO OPERATIONS	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014	Apr	CAHN
----	-----------------	----------------------	---------	-----	--------------	-----	------

TETRABENAZINE

TABLET;ORAL
TETRABENAZINE

AB	SLATE RUN PHARMA	12.5MG	A213316	001	Jan 22, 2020	Feb	CAHN
AB		25MG	A213316	002	Jan 22, 2020	Feb	CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL
ACHROMYCIN V

>D>	+ @	AVET	250MG	N050278	003		Oct	CMFD
>A>	AB	+	250MG	N050278	003		Oct	CMFD
>D>	+ @		500MG	N050278	001		Oct	CMFD
>A>	AB	+	500MG	N050278	001		Oct	CMFD

SUSPENSION;ORAL
SUMYCIN

@	ENDO OPERATIONS	125MG/5ML	A060400	001		May	CAHN
---	-----------------	-----------	---------	-----	--	-----	------

TABLET;ORAL
SUMYCIN

	STRIDES PHARMA	250MG	A061147	001		Jan	CMFD
!		500MG	A061147	004		Jan	CMFD

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL
THEO-24

	ENDO OPERATIONS	100MG	A087943	002	Aug 22, 1983	Apr	CAHN
+		200MG	A087943	001	Aug 22, 1983	Apr	CAHN
		300MG	A087943	003	Aug 22, 1983	Apr	CAHN
!		400MG	A087943	004	Feb 28, 1992	Apr	CAHN

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

	@ RHODES PHARMS	600MG	A040086	001	Apr 15, 1996	Jul	DISC
AB	STRIDES PHARMA	300MG	A215312	001	Sep 05, 2024	Aug	NEWA
AB		450MG	A215312	002	Sep 05, 2024	Aug	NEWA
AB	VELZEN PHARMA PVT	300MG	A214950	001	Jan 30, 2023	Aug	CAHN
AB		450MG	A214950	002	Jan 30, 2023	Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

AB	ZYDUS LIFESCIENCES	300MG	A218063	001	May 21, 2024	May	CAHN
AB		450MG	A218063	002	May 21, 2024	May	CAHN
AB	ZYDUS PHARMS	300MG	A218063	001	May 21, 2024	May	NEWA
AB		450MG	A218063	002	May 21, 2024	May	NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

>A>	AP	ASPIRO	100MG/ML	A218471	001	Nov 06, 2024	Oct	NEWA
>A>	AP	STERISCIENCE	100MG/ML	A217181	001	Oct 29, 2024	Oct	NEWA

THIOTEPA

POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

THIOTEPA

AP	BELOTECA	15MG/VIAL	A217559	001	Aug 20, 2024	Aug	NEWA
AP	MEITHEAL	15MG/VIAL	A216037	001	Dec 26, 2023	Jun	CAHN
AP		100MG/VIAL	A216037	002	Dec 26, 2023	Jun	CAHN

SOLUTION; INTRAVENOUS

TEPYLUTE

+!	SHORLA	15MG/1.5ML (10MG/ML)	N216984	001	Jun 25, 2024	Jun	NEWA
----	--------	----------------------	---------	-----	--------------	-----	------

TICAGRELOR

TABLET; ORAL

TICAGRELOR

>A>	AB	DR REDDYS	90MG	A208541	001	Oct 29, 2024	Oct	NEWA
	AB	PRINSTON INC	90MG	A208599	001	Aug 16, 2024	Aug	NEWA

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE

@	ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	May	DISC
---	---------------------	-----------	---------	-----	--------------	-----	------

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

>D>	+!	THEA PHARMA	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Oct	CPOT
>A>	+!		0.25%	N020439	001	Mar 31, 1995	Oct	CPOT
>D>	+!		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Oct	CTEC
>A>	AT	+!	0.5%	N020439	002	Mar 31, 1995	Oct	CPOT
>A>	AT	+!	EQ 0.5% BASE	N020439	002	Mar 31, 1995	Oct	CTEC

TIMOLOL

>D>	@	EPIC PHARMA LLC	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Oct	CPOT
>A>	@		0.25%	A205309	001	Sep 30, 2016	Oct	CPOT
>D>	@		EQ 0.5% BASE	A205309	002	Sep 30, 2016	Oct	CPOT
>A>	@		0.5%	A205309	002	Sep 30, 2016	Oct	CPOT
>A>	AT	SOMERSET	0.5%	A216654	001	Oct 10, 2024	Oct	NEWA

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

	@	AMNEAL	EQ 0.25% BASE	A216343	001	May 23, 2024	Jun	DISC
AB			EQ 0.25% BASE	A216343	001	May 23, 2024	May	NEWA
	@		EQ 0.5% BASE	A216343	002	May 23, 2024	Jun	DISC
AB			EQ 0.5% BASE	A216343	002	May 23, 2024	May	NEWA
AB		SOMERSET THERAPS LLC	EQ 0.25% BASE	A210640	001	Sep 16, 2024	Sep	NEWA
AB			EQ 0.5% BASE	A210640	002	Sep 16, 2024	Sep	NEWA

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

>D>	AT1	BAUSCH AND LOMB	EQ 0.25% BASE	A074778	001	Mar 25, 1997	Oct	DISC
>A>	@		EQ 0.25% BASE	A074778	001	Mar 25, 1997	Oct	DISC
>D>	AT1		EQ 0.5% BASE	A074776	001	Mar 25, 1997	Oct	DISC
>A>	@		EQ 0.5% BASE	A074776	001	Mar 25, 1997	Oct	DISC
	AT1	CAPLIN	EQ 0.5% BASE	A218460	001	Aug 07, 2024	Jul	NEWA
	AT1	SOMERSET	EQ 0.25% BASE	A217764	002	Jul 03, 2024	Jun	NEWA
	AT1		EQ 0.5% BASE	A217764	001	Jul 03, 2024	Jun	NEWA
	AT2	SOMERSET THERAPS LLC	EQ 0.5% BASE	A216653	001	Jul 03, 2024	Jun	NEWA

TIOPRONIN

TABLET, DELAYED RELEASE;ORAL

THIOLA EC

AB	+	MISSION PHARMACAL	100MG	N211843	001	Jun 28, 2019	Jan CFTG
		TIOPRONIN					
AB		ENDO OPERATIONS	100MG	A217219	001	Feb 24, 2023	Jun CMFD
AB			300MG	A217219	002	Feb 24, 2023	Jun CMFD
AB		TEVA PHARMS INC	100MG	A216456	001	Jul 22, 2024	Jul NEWA
AB			300MG	A216456	002	Jul 22, 2024	Jul NEWA
AB		TORRENT	100MG	A216990	001	Jan 30, 2024	Jan NFTG
AB			300MG	A216990	002	Jan 30, 2024	Jan NEWA

TIRZEPATIDE

SOLUTION;SUBCUTANEOUS

MOUNJARO

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	007	Jul 28, 2023	Jan NEWA
+	!		5MG/0.5ML (5MG/0.5ML)	N215866	008	Jul 28, 2023	Jan NEWA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	009	Jul 28, 2023	Jan NEWA
+	!		10MG/0.5ML (10MG/0.5ML)	N215866	010	Jul 28, 2023	Jan NEWA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	011	Jul 28, 2023	Jan NEWA
+	!		15MG/0.5ML (15MG/0.5ML)	N215866	012	Jul 28, 2023	Jan NEWA
		MOUNJARO (AUTOINJECTOR)					
+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	001	May 13, 2022	Jan CTNA
+	!		5MG/0.5ML (5MG/0.5ML)	N215866	002	May 13, 2022	Jan CTNA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	003	May 13, 2022	Jan CTNA
+	!		10MG/0.5ML (10MG/0.5ML)	N215866	004	May 13, 2022	Jan CTNA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	005	May 13, 2022	Jan CTNA
+	!		15MG/0.5ML (15MG/0.5ML)	N215866	006	May 13, 2022	Jan CTNA

ZEPBOUND

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	007	Mar 28, 2024	Mar NEWA
+	!		5MG/0.5ML (5MG/0.5ML)	N217806	008	Mar 28, 2024	Mar NEWA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	009	Mar 28, 2024	Mar NEWA
+	!		10MG/0.5ML (10MG/0.5ML)	N217806	010	Mar 28, 2024	Mar NEWA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	011	Mar 28, 2024	Mar NEWA
+	!		15MG/0.5ML (15MG/0.5ML)	N217806	012	Mar 28, 2024	Mar NEWA

ZEPBOUND (AUTOINJECTOR)

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	001	Nov 08, 2023	Mar CTNA
+	!		5MG/0.5ML (5MG/0.5ML)	N217806	002	Nov 08, 2023	Mar CTNA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	003	Nov 08, 2023	Mar CTNA
+	!		10MG/0.5ML (10MG/0.5ML)	N217806	004	Nov 08, 2023	Mar CTNA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	005	Nov 08, 2023	Mar CTNA
+	!		15MG/0.5ML (15MG/0.5ML)	N217806	006	Nov 08, 2023	Mar CTNA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB		APPCO	EQ 4MG BASE	A213365	001	May 13, 2024	May NEWA
AB			EQ 6MG BASE	A213365	002	May 13, 2024	May NEWA
		@ ENDO OPERATIONS	EQ 2MG BASE	A207199	001	Mar 14, 2017	May CAHN
		@	EQ 4MG BASE	A207199	002	Mar 14, 2017	May CAHN
		@	EQ 6MG BASE	A207199	003	Mar 14, 2017	May CAHN
AB		SOMERSET THERAPS LLC	EQ 4MG BASE	A213365	001	May 13, 2024	Sep CAHN
AB			EQ 6MG BASE	A213365	002	May 13, 2024	Sep CAHN

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

		@ ENDO OPERATIONS	EQ 2MG BASE	A207170	001	Jan 26, 2017	May CAHN
		@	EQ 4MG BASE	A207170	002	Jan 26, 2017	May CAHN
AB		GRAVITI PHARMS	EQ 4MG BASE	A218920	002	Aug 07, 2024	Jul NEWA
AB			EQ 2MG BASE	A218920	001	Aug 07, 2024	Jul NEWA

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

>D>		@ MYLAN	300MG/5ML	A209554	001	Oct 13, 2017	Oct CAHN
>A>		@ NORVIUM BIOSCIENCE	300MG/5ML	A209554	001	Oct 13, 2017	Oct CAHN

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT	!	SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Apr CHRS
		TOBEX					
	+	@ NOVARTIS	0.3%	N050541	001		Apr DISC

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
 TOBRAMYCIN SULFATE
 AP SLATE RUN PHARMA EQ 1.2GM BASE/VIAL A217029 001 Feb 01, 2023 Sep CAHN

TOFACITINIB CITRATE

SOLUTION; ORAL
 TOFACITINIB CITRATE
 >D> AA HIKMA EQ 1MG BASE/ML A216878 001 Sep 25, 2023 Oct DISC
 >A> @ EQ 1MG BASE/ML A216878 001 Sep 25, 2023 Oct DISC
 AA EQ 1MG BASE/ML A216878 001 Sep 25, 2023 Apr CAHN
 XELJANZ
 >D> AA +! PFIZER EQ 1MG BASE/ML N213082 001 Sep 25, 2020 Oct CTEC
 >A> +! EQ 1MG BASE/ML N213082 001 Sep 25, 2020 Oct CTEC
 TABLET, EXTENDED RELEASE; ORAL
 TOFACITINIB
 @ AUROBINDO PHARMA LTD EQ 11MG BASE A218462 001 Jun 03, 2024 Jun DISC
 AB EQ 11MG BASE A218462 001 Jun 03, 2024 May NEWA
 XELJANZ XR
 + PFIZER EQ 11MG BASE N208246 001 Feb 23, 2016 Jun CTEC
 AB + EQ 11MG BASE N208246 001 Feb 23, 2016 May CTEC

TOLAZAMIDE

TABLET; ORAL
 TOLAZAMIDE
 @ NATCO 250MG A070259 001 Jan 02, 1986 Aug CAHN
 @ 500MG A070259 003 Mar 17, 1986 Aug CAHN

TOLCAPONE

TABLET; ORAL
 TOLCAPONE
 @ ENDO OPERATIONS 100MG A204584 001 Mar 26, 2015 May CAHN
 @ PAR PHARM INC 100MG A204584 001 Mar 26, 2015 Mar DISC

TOLMETIN SODIUM

CAPSULE; ORAL
 TOLMETIN SODIUM
 @ CHARTWELL RX EQ 400MG BASE A073462 001 Apr 30, 1992 Aug CAHN
 >D> RISING EQ 400MG BASE A073393 001 May 27, 1993 Oct CHRS
 >A> ! EQ 400MG BASE A073393 001 May 27, 1993 Oct CHRS
 TABLET; ORAL
 TOLMETIN SODIUM
 @ CHARTWELL RX EQ 200MG BASE A073588 001 Jul 31, 1992 Aug CAHN
 @ EQ 600MG BASE A074002 001 Sep 27, 1993 Aug CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
 TOLTERODINE TARTRATE
 AB UNICHEM 2MG A216917 001 Aug 27, 2024 Aug NEWA
 AB 4MG A216917 002 Aug 27, 2024 Aug NEWA
 AB UTOPIC PHARMS 2MG A213858 001 Feb 02, 2021 Sep CAHN
 AB 4MG A213858 002 Feb 02, 2021 Sep CAHN

TOPIRAMATE

CAPSULE; ORAL
 TOPIRAMATE
 AB ALKEM LABS LTD 15MG A218482 001 Jun 13, 2024 Jun NEWA
 AB 25MG A218482 002 Jun 13, 2024 Jun NEWA
 @ CHARTWELL RX 15MG A079206 001 Oct 14, 2009 Aug CAHN
 @ 25MG A079206 002 Oct 14, 2009 Aug CAHN
 AB GLENMARK PHARMS LTD 15MG A217869 001 Jul 16, 2024 Jul NEWA
 AB 25MG A217869 002 Jul 16, 2024 Jul NEWA
 >A> AB SENORES PHARMS 15MG A218642 001 Oct 10, 2024 Oct NEWA
 >A> AB 25MG A218642 002 Oct 10, 2024 Oct NEWA
 AB STRIDES PHARMA 15MG A078418 001 Oct 14, 2009 Apr CMFD
 AB 25MG A078418 002 Oct 14, 2009 Apr CMFD
 >A> ZYDUS PHARMS USA INC 50MG A078877 003 Oct 23, 2024 Oct NFTG
 CAPSULE, EXTENDED RELEASE; ORAL
 TOPIRAMATE
 @ AJANTA PHARMA LTD 25MG A215663 001 Aug 15, 2023 Feb DISC
 @ 50MG A215663 002 Aug 15, 2023 Feb DISC

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE

	@	100MG	A215663	003	Aug 15, 2023	Feb	DISC
	@	200MG	A215663	004	Aug 15, 2023	Feb	DISC
AB1	LUPIN LTD	25MG	A215561	001	Jul 11, 2024	Jul	NEWA
AB1		50MG	A215561	002	Jul 11, 2024	Jul	NEWA
AB1		100MG	A215561	003	Jul 11, 2024	Jul	NEWA
AB1		200MG	A215561	004	Jul 11, 2024	Jul	NEWA
>A>	AB2	XIAMEN LP PHARM CO	A215638	001	Nov 05, 2024	Oct	NEWA
>A>	AB2		A215638	002	Nov 05, 2024	Oct	NEWA
>A>	AB2		A215638	003	Nov 05, 2024	Oct	NEWA
>A>	AB2		A215638	004	Nov 05, 2024	Oct	NEWA
>A>	AB2		A215638	005	Nov 05, 2024	Oct	NEWA

SOLUTION;ORAL

EPRONTIA

>D>	+	!	AZURITY	25MG/ML	N214679	001	Nov 05, 2021	Oct	CFTG
>A>	AB	+		25MG/ML	N214679	001	Nov 05, 2021	Oct	CFTG
>A>			TOPIRAMATE						
>A>	AB		ALKEM LABS LTD	25MG/ML	A217795	001	Oct 31, 2024	Oct	NFTG

TABLET;ORAL

TOPIRAMATE

@ AIPING PHARM INC
 @
 @
 @
 @ SUN PHARM INDS LTD
 @
 @

25MG	A078499	001	Jan 07, 2010	Feb	CAHN
50MG	A078499	002	Jan 07, 2010	Feb	CAHN
100MG	A078499	003	Jan 07, 2010	Feb	CAHN
200MG	A078499	004	Jan 07, 2010	Feb	CAHN
25MG	A076327	001	Mar 27, 2009	Jan	DISC
100MG	A076327	002	Mar 27, 2009	Jan	DISC
200MG	A076327	003	Mar 27, 2009	Jan	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

@ RISING EQ 4MG BASE/VIAL A091542 001 Aug 28, 2012 Mar CAHN

SOLUTION;INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

@ MEITHEAL EQ 4MG BASE/4ML (EQ 1MG BASE/ML) N022453 001 Dec 20, 2012 Sep DISC

TOREMIFENE CITRATE

TABLET;ORAL

FARESTON

+	@	KYOWA KIRIN	EQ 60MG BASE	N020497	001	May 29, 1997	Aug	DISC
AB	!	RISING	EQ 60MG BASE	A208813	001	Dec 04, 2018	Aug	CHRS

TORSEMIDE

SOLUTION;INTRAVENOUS

DEMADEX

+	@	ROCHE	50MG/5ML (10MG/ML)	N020137	002	Aug 23, 1993	Mar	CDFR
+	@		20MG/2ML (10MG/ML)	N020137	001	Aug 23, 1993	Mar	CDFR

TORSEMIDE

@	AM REGENT	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Mar	CDFR
@		50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Mar	CDFR
@	WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Mar	CDFR
@		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Mar	CDFR

TABLET;ORAL

DEMADEX

+	@	NORVIUM BIOSCIENCE	5MG	N020136	001	Aug 23, 1993	Jul	CAHN
+	@		10MG	N020136	002	Aug 23, 1993	Jul	CAHN
+	@		20MG	N020136	003	Aug 23, 1993	Jul	CAHN
+	@		100MG	N020136	004	Aug 23, 1993	Jul	CAHN

TORSEMIDE

AB	HERITAGE	5MG	A076894	001	May 31, 2005	Sep	CAHN
AB		10MG	A076894	002	May 31, 2005	Sep	CAHN
AB		20MG	A076894	003	May 31, 2005	Sep	CAHN
AB		100MG	A076894	004	May 31, 2005	Sep	CAHN

TOVORAFENIB

FOR SUSPENSION;ORAL

OJEMDA

+	!	DAY ONE BIOPHARMS	25MG/ML	N218033	001	Apr 23, 2024	Apr	NEWA
---	---	-------------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

OJEMDA

+! DAY ONE BIOPHARMS 100MG N217700 001 Apr 23, 2024 Apr NEWA

TRAMADOL HYDROCHLORIDE

SOLUTION;ORAL

>D> QDOLO

>D> +! ATHENA 5MG/ML N214044 001 Sep 01, 2020 Oct DISC

>A> + @ 5MG/ML N214044 001 Sep 01, 2020 Oct DISC

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB GRAVITI PHARMS 100MG A075968 002 Aug 02, 2024 Jul NEWA

RUBICON 75MG A208708 004 Apr 04, 2024 Mar NFTG

AB 100MG A208708 002 Jun 28, 2019 Jul CTEC

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

@ ENDO OPERATIONS 100MG A200491 001 Jun 27, 2012 Apr CAHN

@ 200MG A200491 002 Jun 27, 2012 Apr CAHN

@ 300MG A200491 003 Jun 27, 2012 Apr CAHN

@ SUN PHARM 100MG A091607 001 Dec 30, 2011 May DISC

@ 300MG A091607 003 Dec 30, 2011 May DISC

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

AB + NOVARTIS EQ 0.5MG N204114 001 May 29, 2013 Aug CTEC

+ EQ 0.5MG N204114 001 May 29, 2013 Jul CFTG

AB +! EQ 2MG N204114 003 May 29, 2013 Aug CTEC

+! EQ 2MG N204114 003 May 29, 2013 Jul CFTG

TRAMETINIB DIMETHYL SULFOXIDE

AB @ NOVUGEN EQ 0.5MG A219002 001 Aug 06, 2024 Aug DISC

EQ 0.5MG A219002 001 Aug 06, 2024 Jul NFTG

AB @ EQ 2MG A219002 002 Aug 06, 2024 Aug DISC

EQ 2MG A219002 002 Aug 06, 2024 Jul NFTG

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP HERITAGE 100MG/ML A202436 001 Feb 11, 2014 Sep CAHN

SOLUTION;INTRAVENOUS

TRANEXAMIC ACID

AP FRESENIUS KABI USA 1GM/100ML (10MG/ML) A218242 001 Aug 15, 2024 Aug NEWA

AP GLAND PHARMA LTD 1GM/100ML (10MG/ML) A218599 001 Apr 16, 2024 Apr NEWA

AP NEXUS 1GM/100ML (10MG/ML) A216877 001 Apr 16, 2024 Apr NEWA

TABLET;ORAL

TRANEXAMIC ACID

AB RUBICON 650MG A218320 001 Jun 11, 2024 May NEWA

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVOPROST

>D> AT GLAND PHARMA LTD 0.004% A218159 001 Jul 12, 2024 Jul NEWA

AT LUPIN LTD 0.004% A207040 001 May 03, 2024 Oct DISC

>A> @ 0.004% A207040 001 May 03, 2024 Oct DISC

AT 0.004% A207040 001 May 03, 2024 Apr NEWA

AT SOMERSET THERAPS LLC 0.004% A217228 001 Sep 23, 2024 Sep NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB @ AIPING PHARM INC 100MG A072483 001 Apr 30, 1990 Sep CAHN

AB CROSSMEDIKA SA 50MG A211116 001 May 20, 2024 May NEWA

AB 100MG A211116 002 May 20, 2024 May NEWA

AB 150MG A211116 003 May 20, 2024 May NEWA

AB 300MG A211116 004 May 20, 2024 May NEWA

AB GRANULES 50MG A218988 001 Aug 08, 2024 Aug NEWA

AB 100MG A218988 002 Aug 08, 2024 Aug NEWA

AB 150MG A218988 003 Aug 08, 2024 Aug NEWA

AB 300MG A218988 004 Aug 08, 2024 Aug NEWA

AB GRAVITI PHARMS 50MG A217740 001 Aug 27, 2024 Aug NEWA

AB 100MG A217740 002 Aug 27, 2024 Aug NEWA

AB 150MG A217740 003 Aug 27, 2024 Aug NEWA

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB		300MG		A217740	004	Aug 27, 2024	Aug	NEWA
----	--	-------	--	---------	-----	--------------	-----	------

TREPROSTINIL

>A> INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

>A> REMODULIN

>A>	+	UNITED THERAP	0.2MG/ML	N021272	007	Sep 28, 2023	Oct	CDFR
>A>	+		0.4MG/ML	N021272	008	Sep 28, 2023	Oct	CDFR
>A>	AP	+	1MG/ML	N021272	001	May 21, 2002	Oct	CDFR
>A>	AP	+	2.5MG/ML	N021272	002	May 21, 2002	Oct	CDFR
>A>	AP	+	5MG/ML	N021272	003	May 21, 2002	Oct	CDFR
>A>	AP	+	10MG/ML	N021272	004	May 21, 2002	Oct	CDFR

>A> TREPROSTINIL

>A>	AP	ALEMBIC GLOBAL	1MG/ML	A211574	001	Feb 11, 2021	Oct	CDFR
>A>	AP		2.5MG/ML	A211574	002	Feb 11, 2021	Oct	CDFR
>A>	AP		5MG/ML	A211574	003	Feb 11, 2021	Oct	CDFR
>A>	AP		10MG/ML	A211574	004	Feb 11, 2021	Oct	CDFR
>A>	AP	DR REDDYS	1MG/ML	A210214	001	May 22, 2020	Oct	CDFR
>A>	AP		2.5MG/ML	A210214	002	May 22, 2020	Oct	CDFR
>A>	AP		5MG/ML	A210214	003	May 22, 2020	Oct	CDFR
>A>	AP		10MG/ML	A210214	004	May 22, 2020	Oct	CDFR
>A>	AP	ENDO OPERATIONS	1MG/ML	A209382	001	Sep 24, 2019	Oct	CDFR
>A>	AP		2.5MG/ML	A209382	002	Sep 24, 2019	Oct	CDFR
>A>	AP		5MG/ML	A209382	003	Sep 24, 2019	Oct	CDFR
>A>	AP		10MG/ML	A209382	004	Sep 24, 2019	Oct	CDFR
>A>	AP	SANDOZ	1MG/ML	A203649	001	Nov 30, 2017	Oct	CDFR
>A>	AP		2.5MG/ML	A203649	002	Nov 30, 2017	Oct	CDFR
>A>	AP		5MG/ML	A203649	003	Nov 30, 2017	Oct	CDFR
>A>	AP		10MG/ML	A203649	004	Nov 30, 2017	Oct	CDFR
>A>	AP	TEVA PHARMS USA	1MG/ML	A206648	001	Sep 26, 2019	Oct	CDFR
>A>	AP		2.5MG/ML	A206648	002	Sep 26, 2019	Oct	CDFR
>A>	AP		5MG/ML	A206648	003	Sep 26, 2019	Oct	CDFR
>A>	AP		10MG/ML	A206648	004	Sep 26, 2019	Oct	CDFR

>D> INJECTABLE;IV (INFUSION), SUBCUTANEOUS

>D> REMODULIN

>D>	+	UNITED THERAP	0.1MG/ML	N021272	006	Sep 28, 2023	Oct	CDFR
>A>	+		0.1MG/ML	N021272	006	Sep 28, 2023	Oct	CDFR
>D>	+		0.2MG/ML	N021272	007	Sep 28, 2023	Oct	CDFR
>D>	+		0.4MG/ML	N021272	008	Sep 28, 2023	Oct	CDFR
>D>	AP	+	1MG/ML	N021272	001	May 21, 2002	Oct	CDFR
>D>	AP	+	2.5MG/ML	N021272	002	May 21, 2002	Oct	CDFR
>D>	AP	+	5MG/ML	N021272	003	May 21, 2002	Oct	CDFR
>D>	AP	+	10MG/ML	N021272	004	May 21, 2002	Oct	CDFR
>D>	+		20MG/ML	N021272	005	Jul 30, 2021	Oct	CDFR
>A>	+		20MG/ML	N021272	005	Jul 30, 2021	Oct	CDFR

>D> TREPROSTINIL

>D>	AP	ALEMBIC GLOBAL	1MG/ML	A211574	001	Feb 11, 2021	Oct	CDFR
>D>	AP		2.5MG/ML	A211574	002	Feb 11, 2021	Oct	CDFR
>D>	AP		5MG/ML	A211574	003	Feb 11, 2021	Oct	CDFR
>D>	AP		10MG/ML	A211574	004	Feb 11, 2021	Oct	CDFR
>D>	AP	DR REDDYS	1MG/ML	A210214	001	May 22, 2020	Oct	CDFR
>D>	AP		2.5MG/ML	A210214	002	May 22, 2020	Oct	CDFR
>D>	AP		5MG/ML	A210214	003	May 22, 2020	Oct	CDFR
>D>	AP		10MG/ML	A210214	004	May 22, 2020	Oct	CDFR
>D>	AP	ENDO OPERATIONS	1MG/ML	A209382	001	Sep 24, 2019	Oct	CDFR
>D>	AP		2.5MG/ML	A209382	002	Sep 24, 2019	Oct	CDFR
>D>	AP		5MG/ML	A209382	003	Sep 24, 2019	Oct	CDFR
>D>	AP		10MG/ML	A209382	004	Sep 24, 2019	Oct	CDFR
>D>	AP	SANDOZ	1MG/ML	A203649	001	Nov 30, 2017	Oct	CDFR
>D>	AP		2.5MG/ML	A203649	002	Nov 30, 2017	Oct	CDFR
>D>	AP		5MG/ML	A203649	003	Nov 30, 2017	Oct	CDFR
>D>	AP		10MG/ML	A203649	004	Nov 30, 2017	Oct	CDFR
>D>	AP	TEVA PHARMS USA	1MG/ML	A206648	001	Sep 26, 2019	Oct	CDFR
>D>	AP		2.5MG/ML	A206648	002	Sep 26, 2019	Oct	CDFR
>D>	AP		5MG/ML	A206648	003	Sep 26, 2019	Oct	CDFR
>D>	AP		10MG/ML	A206648	004	Sep 26, 2019	Oct	CDFR

POWDER;INHALATION

TYVASO DPI

>A>	+	UNITED THERAP	0.08MG/INH	N214324	005	Oct 24, 2024	Oct	NEWA
-----	---	---------------	------------	---------	-----	--------------	-----	------

TRETINOIN

	CAPSULE; ORAL						
	TRETINOIN						
AB	ENDO OPERATIONS	10MG	A201687	001	Oct 24, 2012	Apr	CAHN
	CREAM; TOPICAL						
	TRETINOIN						
AB	ALEMBIC	0.1%	A217804	001	Apr 29, 2024	Apr	NEWA
AB	ZYDUS LIFESCIENCES	0.1%	A218561	001	Apr 25, 2024	Apr	NEWA
	GEL; TOPICAL						
	TRETINOIN						
	@ NORVIUM BIOSCIENCE	0.1%	A202026	001	Jul 17, 2013	Aug	CAHN

TRIAMCINOLONE ACETONIDE

	OINTMENT; TOPICAL						
	TRIAMCINOLONE ACETONIDE						
	@ AUROBINDO PHARMA LTD	0.1%	A211315	001	Mar 18, 2020	Jan	CAHN
	@	0.5%	A211315	002	Mar 18, 2020	Jan	CAHN
	@ COSETTE	0.5%	A208925	001	Oct 06, 2017	Apr	DISC
	PASTE; DENTAL						
	TRIAMCINOLONE ACETONIDE						
AT	RISING	0.1%	A040771	001	Jul 01, 2010	Sep	CAHN

TRIAMCINOLONE HEXACETONIDE

	INJECTABLE; INJECTION						
	ARISTOSPAN						
>A>	+ @ ANIKA THERAPS INC	5MG/ML	N016466	001		Oct	CAHN
>A>	+ @	20MG/ML	N016466	002		Oct	CAHN
>D>	+ @ SANDOZ	5MG/ML	N016466	001		Oct	CAHN
>D>	+ @	20MG/ML	N016466	002		Oct	CAHN

TRIAMTERENE

	CAPSULE; ORAL						
	TRIAMTERENE						
>A>	@ BIOCON GENERICS	50MG	A214768	001	Jul 06, 2022	Oct	CAHN
>A>	@	100MG	A214768	002	Jul 06, 2022	Oct	CAHN
>D>	@ HIBROW HLTHCARE	50MG	A214768	001	Jul 06, 2022	Oct	CAHN
	@	50MG	A214768	001	Jul 06, 2022	Sep	CAHN
>D>	@	100MG	A214768	002	Jul 06, 2022	Oct	CAHN
	@	100MG	A214768	002	Jul 06, 2022	Sep	CAHN

TRIAZOLAM

	TABLET; ORAL						
	TRIAZOLAM						
	@ HIKMA	0.125MG	A074224	001	Jun 01, 1994	Feb	DISC
	@	0.25MG	A074224	002	Jun 01, 1994	Feb	DISC

TRIENTINE HYDROCHLORIDE

	CAPSULE; ORAL						
	TRIENTINE HYDROCHLORIDE						
AB	ENDO OPERATIONS	250MG	A210096	001	Sep 25, 2019	Apr	CAHN

TRIFLUOPERAZINE HYDROCHLORIDE

	CONCENTRATE; ORAL						
	TRIFLUOPERAZINE HYDROCHLORIDE						
	@ CHARTWELL RX	EQ 10MG BASE/ML	A085787	001	Apr 15, 1982	Aug	CAHN

TRILACICLIB DIHYDROCHLORIDE

	POWDER; INTRAVENOUS						
	COSELA						
	+! PHARMACOSMOS	EQ 300MG BASE/VIAL	N214200	001	Feb 12, 2021	Sep	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

	CAPSULE; ORAL							
	TRIMETHOBENZAMIDE HYDROCHLORIDE							
>D>	AB	! AVET LIFESCIENCES	300MG	A205950	001	Nov 21, 2023	Oct	CAHN
	AB	! AVET LIFESCIENCES	300MG	A205950	001	Nov 21, 2023	Aug	CHRS
>A>	AB	! HERITAGE PHARMA AVET	300MG	A205950	001	Nov 21, 2023	Oct	CAHN
		@ SUN PHARM INDUSTRIES	300MG	A076570	001	Aug 28, 2003	Aug	DISC

INJECTABLE; INJECTION
TIGAN

+!	ENDO OPERATIONS	100MG/ML	N017530	001			Apr	CAHN
----	-----------------	----------	---------	-----	--	--	-----	------

TRIMETHOPRIM HYDROCHLORIDESOLUTION; ORAL
PRIMSOL

>D>	@ ALLEGIS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Oct	CAHN
>D>	+ @	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Oct	CAHN
>A>	@ PANGEA	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Oct	CAHN
>A>	+ @	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Oct	CAHN

TRIMIPRAMINE MALEATECAPSULE; ORAL
TRIMIPRAMINE MALEATE

AB	BRECKENRIDGE	EQ 25MG BASE	A208127	001	Apr 15, 2016	Mar	CAHN
AB	!	EQ 50MG BASE	A208127	002	Apr 15, 2016	Mar	CAHN
AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Mar	CAHN

TROSPIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL
TROSPIUM CHLORIDE

AB	UTOPIC PHARMS	60MG	A214760	001	Apr 30, 2021	Sep	CAHN
----	---------------	------	---------	-----	--------------	-----	------

TABLET; ORAL
TROSPIUM CHLORIDE

AB	CHARTWELL RX	20MG	A215781	001	Feb 16, 2022	Sep	CAHN
AB	MACLEODS PHARMS LTD	20MG	A206472	001	Jun 18, 2024	Jun	NEWA
AB	ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Feb	CAHN

TROSPIUM CHLORIDE; XANOMELINE TARTRATECAPSULE; ORAL
COBENFY

+	BRISTOL-MYERS	20MG;EQ 50MG BASE	N216158	001	Sep 26, 2024	Sep	NEWA
+		20MG;EQ 100MG BASE	N216158	002	Sep 26, 2024	Sep	NEWA
+!		30MG;EQ 125MG BASE	N216158	003	Sep 26, 2024	Sep	NEWA

UMECLIDINIUM BROMIDEPOWDER; INHALATION
INCRUSE ELLIPTA

+!	GLAXO GRP ENGLAND	EQ 0.0625MG BASE/INH	N205382	001	Apr 30, 2014	Jan	CPOT
----	-------------------	----------------------	---------	-----	--------------	-----	------

UPADACITINIBSOLUTION; ORAL
RINVOQ LQ

+!	ABBVIE	1MG/ML	N218347	001	Apr 26, 2024	Apr	NEWA
----	--------	--------	---------	-----	--------------	-----	------

UREA, C-14CAPSULE; ORAL
PYTEST

+	@ AVENT	1uCi	N020617	001	May 09, 1997	Sep	DISC
---	---------	------	---------	-----	--------------	-----	------

URSODIOLCAPSULE; ORAL
URSODIOL

AB	HIBROW HLTHCARE	300MG	A212452	001	Oct 30, 2019	Jul	CAHN
	! LGM PHARMA	200MG	A205789	001	May 08, 2020	Aug	CHRS

TABLET; ORAL
URSODIOL

AB	ENDO OPERATIONS	250MG	A202540	001	Feb 14, 2013	Apr	CAHN
AB		500MG	A202540	002	Feb 14, 2013	Apr	CAHN
AB	EPIC PHARMA LLC	250MG	A214717	001	Aug 14, 2024	Aug	NEWA
AB		500MG	A214717	002	Aug 14, 2024	Aug	NEWA

VADADUSTATTABLET; ORAL
VAFSEO

+	AKEBIA	150MG	N215192	001	Mar 27, 2024	Mar	NEWA
+		300MG	N215192	002	Mar 27, 2024	Mar	NEWA
+!		450MG	N215192	003	Mar 27, 2024	Mar	NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

	@ CIPLA	EQ 500MG BASE	A 077135	001	May 24, 2010	Apr	DISC
	@	EQ 1GM BASE	A 077135	002	May 24, 2010	Apr	DISC
AB	GRAVITI PHARMS	EQ 500MG BASE	A 079012	001	May 24, 2010	Jun	CAHN
AB		EQ 1GM BASE	A 079012	002	May 24, 2010	Jun	CAHN
	@ SANDOZ	EQ 500MG BASE	A 077478	001	May 24, 2010	Sep	DISC
	@	EQ 1GM BASE	A 077478	002	May 24, 2010	Sep	DISC

VALBENAZINE TOSYLATE

CAPSULE;ORAL

INGREZZA

AB	+ NEUROCRINE	EQ 40MG BASE	N 209241	001	Apr 11, 2017	Mar	CFTG
AB	+	EQ 60MG BASE	N 209241	003	Apr 23, 2021	Jul	CFTG
AB	+!	EQ 80MG BASE	N 209241	002	Oct 04, 2017	Mar	CFTG

INGREZZA SPRINKLE

	+ NEUROCRINE	EQ 40MG BASE	N 218390	001	Apr 30, 2024	Apr	NEWA
	+	EQ 60MG BASE	N 218390	002	Apr 30, 2024	Apr	NEWA
	+!	EQ 80MG BASE	N 218390	003	Apr 30, 2024	Apr	NEWA

VALBENAZINE TOSYLATE

AB	LUPIN LTD	EQ 40MG BASE	A 216064	001	Apr 05, 2024	Mar	NFTG
AB		EQ 80MG BASE	A 216064	002	Apr 05, 2024	Mar	NFTG
AB	ZYDUS	EQ 40MG BASE	A 216137	001	Aug 07, 2024	Jul	NEWA
AB		EQ 60MG BASE	A 216137	002	Aug 07, 2024	Jul	NFTG
AB		EQ 80MG BASE	A 216137	003	Aug 07, 2024	Jul	NEWA

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB	GPP	EQ 450MG BASE	A 212876	001	Jun 11, 2024	May	NEWA
AB	SOMERSET THERAPS LLC	EQ 450MG BASE	A 212876	001	Jun 11, 2024	Sep	CAHN

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

	@ EYWA	250MG	A 207611	001	Aug 05, 2019	Mar	DISC
	@ HIBROW HLTHCARE	250MG	A 207611	001	Aug 05, 2019	Jul	CAHN
	@ SUN PHARM INDS LTD	250MG	A 091037	001	Feb 22, 2013	May	DISC

SYRUP;ORAL

VALPROIC ACID

	@ HIKMA	250MG/5ML	A 074060	001	Jan 13, 1995	Mar	DISC
AA	QUAGEN	250MG/5ML	A 090517	001	May 28, 2010	Jan	CAHN

VALRUBICIN

SOLUTION;INTRAVESICAL

VALSTAR PRESERVATIVE FREE

AO	+! ENDO OPERATIONS	40MG/ML	N 020892	001	Sep 25, 1998	Apr	CAHN
----	--------------------	---------	----------	-----	--------------	-----	------

VALSARTAN

TABLET;ORAL

VALSARTAN

>A>	AB	RYAN LABS	40MG	A 218169	001	Aug 05, 2024	Oct	CAHN
>A>	AB		80MG	A 218169	002	Aug 05, 2024	Oct	CAHN
>A>	AB		160MG	A 218169	003	Aug 05, 2024	Oct	CAHN
>A>	AB		320MG	A 218169	004	Aug 05, 2024	Oct	CAHN
>D>	AB	ZENARA	40MG	A 218169	001	Aug 05, 2024	Oct	CAHN
	AB		40MG	A 218169	001	Aug 05, 2024	Jul	NEWA
>D>	AB		80MG	A 218169	002	Aug 05, 2024	Oct	CAHN
	AB		80MG	A 218169	002	Aug 05, 2024	Jul	NEWA
>D>	AB		160MG	A 218169	003	Aug 05, 2024	Oct	CAHN
	AB		160MG	A 218169	003	Aug 05, 2024	Jul	NEWA
>D>	AB		320MG	A 218169	004	Aug 05, 2024	Oct	CAHN
	AB		320MG	A 218169	004	Aug 05, 2024	Jul	NEWA
	AB	ZYDUS LIFESCIENCES	40MG	A 218991	001	Jul 22, 2024	Jul	NEWA
	AB		80MG	A 218991	002	Jul 22, 2024	Jul	NEWA
	AB		160MG	A 218991	003	Jul 22, 2024	Jul	NEWA
	AB		320MG	A 218991	004	Jul 22, 2024	Jul	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

@ PAI HOLDINGS PHARM	EQ 125MG BASE	A065478	001	Apr 09, 2012	Feb	DISC
@	EQ 250MG BASE	A065478	002	Apr 09, 2012	Feb	DISC

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	HIKMA	EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015	Sep	CAHN
AP		EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015	Sep	CAHN
	@ MEDIMETRIKS PHARMS	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Aug	CAHN
	@	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Aug	CAHN
	@ PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb	DISC
	@	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb	DISC
	@ SANDOZ INC	EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Apr	DISC
	@	EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Apr	DISC
AP	SLATE RUN PHARMA	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	Sep	CAHN
AP		EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	Sep	CAHN
AP		EQ 5GM BASE/VIAL	A215821	001	Nov 18, 2021	Sep	CAHN
AP		EQ 10GM BASE/VIAL	A215821	002	Nov 18, 2021	Sep	CAHN

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb	CTNA
+	!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb	CTNA
+	!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb	CTNA

POWDER; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+	!	MYLAN LABS LTD	EQ 1.75GM BASE/VIAL	N209481	005	Jun 26, 2024	Jul	NEWA
+	!		EQ 2GM BASE/VIAL	N209481	006	Jun 26, 2024	Jul	NEWA

SOLUTION; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N050671	001	Apr 29, 1993	Feb	CPOT
+	!		EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb	CDFR
+	!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N050671	002	Dec 20, 2010	Feb	CPOT
+	!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb	CDFR
+	!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N050671	003	Mar 01, 1999	Feb	CPOT
+	!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb	CDFR
+	!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N050671	004	Jan 25, 2024	Feb	NEWA
+	!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N050671	005	Jan 25, 2024	Feb	NEWA

VARENICLINE TARTRATE

TABLET; ORAL

VARENICLINE TARTRATE

AB	AJANTA PHARMA LTD	EQ 0.5MG BASE	A213019	001	Mar 19, 2024	Mar	NEWA	
AB		EQ 1MG BASE	A213019	002	Mar 19, 2024	Mar	NEWA	
>D>	AB	AVALANCHE PHARM	EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Oct	CAHN
AB		EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Feb	NEWA	
>D>	AB		EQ 1MG BASE	A217283	002	Mar 06, 2024	Oct	CAHN
AB		EQ 1MG BASE	A217283	002	Mar 06, 2024	Feb	NEWA	
>A>	AB	BIONPHARMA	EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Oct	CAHN
>A>	AB		EQ 1MG BASE	A217283	002	Mar 06, 2024	Oct	CAHN
AB	DR REDDYS	EQ 0.5MG BASE	A215931	001	Oct 01, 2024	Sep	NEWA	
AB		EQ 1MG BASE	A215931	002	Oct 01, 2024	Sep	NEWA	
>A>	AB	INDOCO	EQ 0.5MG BASE	A219106	001	Oct 29, 2024	Oct	NEWA
>A>	AB		EQ 1MG BASE	A219106	002	Oct 29, 2024	Oct	NEWA
AB	MYLAN	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Feb	NEWA	
AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	Feb	NEWA	
AB	PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Sep	CAHN	
AB		EQ 1MG BASE	A217115	002	Jul 23, 2024	Sep	CAHN	
AB	SLATE RUN PHARMA	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Jul	NEWA	
AB		EQ 1MG BASE	A217115	002	Jul 23, 2024	Jul	NEWA	

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN

AP	DR REDDYS	20UNITS/ML (20UNITS/ML)	A213988	001	May 08, 2024	Apr	NEWA	
AP	GLAND PHARMA LTD	20UNITS/ML (20UNITS/ML)	A216963	001	Feb 09, 2024	Feb	NEWA	
		VASOPRESSIN IN SODIUM CHLORIDE 0.9%						
+	!	LONG GROVE PHARMS	20UNITS/100ML (0.2UNITS/ML)	N217766	001	Jul 11, 2024	Jul	NEWA
+	!		40UNITS/100ML (0.4UNITS/ML)	N217766	002	Jul 11, 2024	Jul	NEWA

SOLUTION;INTRAVENOUS

VASOPRESSIN IN SODIUM CHLORIDE 0.9%

+	!		50UNITS/50ML (1UNIT/ML)	N217766	003	Jul 11, 2024	Jul	NEWA
---	---	--	-------------------------	---------	-----	--------------	-----	------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		ALEMBIC	EQ 37.5MG BASE	A217767	001	Jun 06, 2024	May	NEWA
AB			EQ 75MG BASE	A217767	002	Jun 06, 2024	May	NEWA
AB			EQ 150MG BASE	A217767	003	Jun 06, 2024	May	NEWA
	@	ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012	May	CAHN
	@		EQ 75MG BASE	A078087	002	Mar 16, 2012	May	CAHN
	@		EQ 150MG BASE	A078087	003	Mar 16, 2012	May	CAHN
	@	NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	May	DISC
	@		EQ 75MG BASE	A200430	002	Apr 04, 2023	May	DISC
	@		EQ 150MG BASE	A200430	003	Apr 04, 2023	May	DISC
>D>	AB	VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Oct	DISC
>A>		@	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Oct	DISC
>D>	AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Oct	DISC
>A>		@	EQ 75MG BASE	A090071	002	Apr 15, 2011	Oct	DISC
>D>	AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Oct	DISC
>A>		@	EQ 150MG BASE	A090071	003	Apr 15, 2011	Oct	DISC

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

	@	AMNEAL PHARMS	EQ 25MG BASE	A079098	001	May 11, 2010	Jun	DISC
	@		EQ 37.5MG BASE	A079098	002	May 11, 2010	Jun	DISC
	@		EQ 50MG BASE	A079098	003	May 11, 2010	Jun	DISC
	@		EQ 75MG BASE	A079098	004	May 11, 2010	Jun	DISC
	@		EQ 100MG BASE	A079098	005	May 11, 2010	Jun	DISC
	@	NORVIUM BIOSCIENCE	EQ 25MG BASE	A077166	001	Jun 13, 2008	Sep	CAHN
	@		EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Sep	CAHN
	@		EQ 50MG BASE	A077166	003	Jun 13, 2008	Sep	CAHN
	@		EQ 75MG BASE	A077166	004	Jun 13, 2008	Sep	CAHN
	@		EQ 100MG BASE	A077166	005	Jun 13, 2008	Sep	CAHN

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

	@	SWISS PHARM	EQ 75MG BASE	A214423	001	Jan 04, 2022	Aug	CAHN
	@		EQ 150MG BASE	A214423	002	Jan 04, 2022	Aug	CAHN

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB	+	AZURITY	120MG	N019614	001	May 29, 1990	Aug	CAHN
AB	+		180MG	N019614	003	Jan 09, 1992	Aug	CAHN
AB	+		240MG	N019614	002	May 29, 1990	Aug	CAHN
	+	!	360MG	N019614	004	May 10, 1996	Aug	CAHN
		VERELAN PM						
	+	AZURITY	100MG	N020943	001	Nov 25, 1998	Aug	CAHN
	+		200MG	N020943	002	Nov 25, 1998	Aug	CAHN
	+	!	300MG	N020943	003	Nov 25, 1998	Aug	CAHN

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

AP		HERITAGE	2.5MG/ML	A215829	001	Mar 17, 2022	Sep	CAHN
----	--	----------	----------	---------	-----	--------------	-----	------

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP		NEPHRON	5MG/2ML (2.5MG/ML)	A213352	002	Sep 16, 2020	Apr	CAHN
AP			10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020	Apr	CAHN

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

+	!	BAUSCH LOMB IRELAND	15MG/VIAL	N021119	001	Apr 12, 2000	Jul	CAHN
---	---	---------------------	-----------	---------	-----	--------------	-----	------

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

>D>	AA	PROPEL PHARMA	500MG/PACKET	A213390	001	Jul 29, 2021	Oct	DISC
>A>		@	500MG/PACKET	A213390	001	Jul 29, 2021	Oct	DISC

SOLUTION;ORAL

VIGAFYDE

+	!	PYROS PHARMS	100MG/ML	N217684	001	Jun 17, 2024	Jun	NEWA
---	---	--------------	----------	---------	-----	--------------	-----	------

	TABLET;ORAL							
	VIGABATRIN							
AB	RYAN LABS	500MG	A215519	001	Apr 28, 2023	Sep	CAHN	
	<u>VINORELBINE TARTRATE</u>							
	INJECTABLE;INJECTION							
	VINORELBINE TARTRATE							
	@ RISING	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Mar	CAHN	
	<u>VORAPAXAR SULFATE</u>							
	TABLET;ORAL							
	ZONTIVITY							
	+ @ KEY THERAP	EQ 2.08MG BASE	N204886	001	May 08, 2014	May	DISC	
	+!	EQ 2.08MG BASE	N204886	001	May 08, 2014	Apr	CAHN	
	<u>VORASIDENIB</u>							
	TABLET;ORAL							
	VORANIGO							
	+ SERVIER	10MG	N218784	001	Aug 06, 2024	Aug	NEWA	
	+!	40MG	N218784	002	Aug 06, 2024	Aug	NEWA	
	<u>VORICONAZOLE</u>							
	INJECTABLE;INTRAVENOUS							
	VORICONAZOLE							
AP	ASPIRO	200MG/VIAL	A218533	001	Apr 03, 2024	Mar	NEWA	
AP	CHARTWELL RX	200MG/VIAL	N208562	001	Mar 09, 2017	Sep	CAHN	
	@ NORVIUM BIOSCIENCE	200MG/VIAL	A210849	001	Oct 11, 2022	Jul	CAHN	
>D>	<u>VOXELOTOR</u>							
>D>	TABLET;ORAL							
>D>	OXBRYTA							
>D>	+ GLOBAL BLOOD THERAPS	300MG	N213137	002	Oct 14, 2022	Oct	DISC	
>A>	+ @	300MG	N213137	002	Oct 14, 2022	Oct	DISC	
>D>	+!	500MG	N213137	001	Nov 25, 2019	Oct	DISC	
>A>	+ @	500MG	N213137	001	Nov 25, 2019	Oct	DISC	
>D>	TABLET, FOR SUSPENSION;ORAL							
>D>	OXBRYTA							
>D>	+! GLOBAL BLOOD THERAPS	300MG	N216157	001	Dec 17, 2021	Oct	DISC	
>A>	+ @	300MG	N216157	001	Dec 17, 2021	Oct	DISC	
	<u>WARFARIN SODIUM</u>							
	TABLET;ORAL							
	WARFARIN SODIUM							
	@ BARR	1MG	A040145	001	Mar 26, 1997	Jun	DISC	
	@	2MG	A040145	002	Mar 26, 1997	Jun	DISC	
	@	2.5MG	A040145	003	Mar 26, 1997	Jun	DISC	
	@	3MG	A040145	008	Nov 05, 1998	Jun	DISC	
	@	4MG	A040145	004	Mar 26, 1997	Jun	DISC	
	@	5MG	A040145	005	Mar 26, 1997	Jun	DISC	
	@	6MG	A040145	009	Nov 05, 1998	Jun	DISC	
	@	7.5MG	A040145	006	Mar 26, 1997	Jun	DISC	
	@	10MG	A040145	007	Mar 26, 1997	Jun	DISC	
	<u>ZINC CHLORIDE</u>							
	INJECTABLE;INJECTION							
	ZINC CHLORIDE							
>A>	AP SOMERSET	EQ 1MG ZINC/ML	A216152	001	Oct 16, 2024	Oct	NEWA	
	<u>ZINC SULFATE</u>							
	SOLUTION;INTRAVENOUS							
	ZINC SULFATE							
>A>	AP APOTEX	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A218059	002	Oct 28, 2024	Oct	NEWA	
AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A218059	001	Jun 10, 2024	May	NEWA	
AP	NIVAGEN PHARMS INC	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A214597	001	Jul 05, 2024	Jun	NEWA	
AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A214597	002	Jul 05, 2024	Jun	NEWA	
AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A214597	003	Jul 05, 2024	Jun	NEWA	
AP	SOMERSET THERAPS LLC	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216135	001	Jul 17, 2024	Jul	NEWA	
AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216135	002	Jul 17, 2024	Jul	NEWA	

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

ZOLEDRONIC ACID

@ HOSPIRA	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	May DISC
-----------	-----------------	---------	-----	--------------	----------

ZOLMITRIPTAN

SPRAY; NASAL

ZOLMITRIPTAN

AB	! PADAGIS ISRAEL	5MG/SPRAY	A212469	002	Sep 30, 2021	Feb CHRS
----	------------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

ZOLMITRIPTAN

	@ INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar DISC
--	------------------	-------	---------	-----	--------------	----------

	@	5MG	A204284	002	Apr 09, 2014	Mar DISC
--	---	-----	---------	-----	--------------	----------

AB	SOMERSET THERAPS LLC	2.5MG	A206973	001	Jun 30, 2017	Sep CAHN
----	----------------------	-------	---------	-----	--------------	----------

AB		5MG	A206973	002	Jun 30, 2017	Sep CAHN
----	--	-----	---------	-----	--------------	----------

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

@ INVAGEN PHARMS	5MG	A078184	001	Sep 07, 2007	Mar DISC
------------------	-----	---------	-----	--------------	----------

@	10MG	A078184	002	Sep 07, 2007	Mar DISC
---	------	---------	-----	--------------	----------

TABLET; SUBLINGUAL

ZOLPIDEM TARTRATE

AB	ENDO OPERATIONS	1.75MG	A204229	001	Sep 11, 2017	Apr CAHN
----	-----------------	--------	---------	-----	--------------	----------

AB		3.5MG	A204229	002	Sep 11, 2017	Apr CAHN
----	--	-------	---------	-----	--------------	----------

AB		5MG	A201509	001	Aug 01, 2016	May CAHN
----	--	-----	---------	-----	--------------	----------

AB		10MG	A201509	002	Aug 01, 2016	May CAHN
----	--	------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

@ ENDO OPERATIONS	6.25MG	A078148	002	Apr 14, 2011	May CAHN
-------------------	--------	---------	-----	--------------	----------

@	12.5MG	A078148	001	Dec 03, 2010	May CAHN
---	--------	---------	-----	--------------	----------

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ COSETTE	120MG	N018060	001		Mar	DISC
@	325MG	A072344	001	Mar 27, 1992	Mar	DISC
@	650MG	A072237	001	Mar 27, 1992	Mar	DISC

ACETAMINOPHEN

>D>	+!	TARO	650MG	N018337	001	Oct	DISC
>A>	+	@	650MG	N018337	001	Oct	DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

@ AUROBINDO PHARMA LTD	250MG;125MG	A218359	001	Mar 26, 2024	Sep	DISC
	250MG;125MG	A218359	001	Mar 26, 2024	Apr	CTNA
	250MG;125MG	A218359	001	Mar 26, 2024	Mar	NEWA
DR REDDYS	250MG;125MG	A218247	001	Aug 23, 2024	Aug	NEWA
GLENMARK PHARMS LTD	250MG;125MG	A218311	001	Apr 26, 2024	Apr	NEWA

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

ALCAFTADINE

ALEMBIC	0.25%	A209290	001	Oct 02, 2024	Sep	NEWA
GLAND PHARMA LTD	0.25%	A209706	001	Mar 01, 2024	Feb	NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AMNEAL	0.2055MG/SPRAY	A216576	001	Jun 05, 2024	May	NEWA
@ PADAGIS ISRAEL	0.2055MG/SPRAY	A216801	001	May 08, 2024	May	DISC
	0.2055MG/SPRAY	A216801	001	May 08, 2024	Apr	NEWA

AZELASTINE HYDROCHLORIDE ALLERGY

APOTEX	0.2055MG/SPRAY	A216421	001	May 29, 2024	May	NEWA
AZELASTINE HYDROCHLORIDE CHILDREN'S ALLERGY						
APOTEX	0.2055MG/SPRAY	A216421	002	May 29, 2024	May	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

DR REDDYS LABS SA	0.025%	A216361	001	Feb 16, 2024	Feb	NFTG
LUMIFY PRESERVATIVE FREE						
+! BAUSCH AND LOMB INC	0.025%	N218424	001	Apr 19, 2024	Apr	NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009	Feb	CDFR
@ APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009	Feb	CDFR
AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010	Feb	CDFR
BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011	Feb	CDFR
CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011	Feb	CDFR
@ CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008	Feb	CDFR
@ CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Feb	CDFR
HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	CDFR
PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Feb	CDFR
	5MG/5ML	A090254	002	Apr 09, 2008	Feb	CDFR
@ PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008	Feb	CDFR
QUAGEN	5MG/5ML	A212266	001	May 16, 2019	Feb	CDFR
@ RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Feb	CDFR
TARO	5MG/5ML	A090182	002	Apr 22, 2008	Feb	CDFR
	5MG/5ML	A201546	001	May 20, 2011	Feb	CDFR
@ TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012	Feb	CDFR

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009	Feb	CDFR
@ APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009	Feb	CDFR
AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010	Feb	CDFR
BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011	Feb	CDFR
CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011	Feb	CDFR
@ CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008	Feb	CDFR
@ CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Feb	CDFR

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008	Feb CDFR
@ PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008	Feb CDFR
@ RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Feb CDFR
TARO	5MG/5ML	A090182	001	Apr 22, 2008	Feb CDFR
	5MG/5ML	A201546	002	May 20, 2011	Feb CDFR
@ TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012	Feb CDFR
CHILDREN'S ZYRTEC ALLERGY					
+! J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007	Feb CDFR
CHILDREN'S ZYRTEC HIVES RELIEF					
+! J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007	Feb CDFR

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE					
INDOCO	10MG	A218895	001	Oct 03, 2024	Sep NEWA
TABLET, CHEWABLE;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
@ SUN PHARM	5MG	A090142	001	Aug 30, 2011	Mar DISC
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
@ SUN PHARM	5MG	A090142	003	Aug 30, 2011	Mar DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
PPI-DAC	5MG;120MG	A210719	001	Nov 16, 2018	Jun CAHN
UNICHEM	5MG;120MG	A210507	001	Sep 10, 2024	Aug NEWA

CLOTRIMAZOLE

CREAM;VAGINAL					
TRIVAGIZOLE 3					
TARO	2%	N021143	001	Apr 12, 2000	Mar CAHN

DICLOFENAC SODIUM

GEL;TOPICAL					
DICLOFENAC SODIUM					
CIPLA	1%	A209903	001	Aug 03, 2018	Jul CMKT
@ HIKMA	1%	A209484	001	Nov 21, 2018	Mar DISC

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL					
IBUPROFEN AND DIPHENHYDRAMINE CITRATE					
PLD ACQUISITIONS LLC	38MG;200MG	A211404	001	Apr 11, 2024	Apr NEWA

DOCOSANOL

CREAM;TOPICAL					
DOCOSANOL					
AUROBINDO PHARMA LTD	10%	A217090	001	Mar 01, 2024	Feb NEWA
P AND L DEVELOPMENT	10%	A212385	001	Oct 07, 2022	Mar CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL					
ESOMEPRAZOLE MAGNESIUM					
ANDA REPOSITORY	EQ 20MG BASE	A216149	001	Mar 15, 2023	Sep CAHN
DR REDDYS	EQ 20MG BASE	A207198	001	Apr 30, 2024	Apr NEWA
GLENMARK SPECLT	EQ 20MG BASE	A218092	001	Jun 11, 2024	May NEWA
GUARDIAN DRUG	EQ 20MG BASE	A216149	001	Mar 15, 2023	Feb CAHN
TABLET, DELAYED RELEASE;ORAL					
ESOMEPRAZOLE MAGNESIUM					
AUROBINDO PHARMA LTD	EQ 20MG BASE	A214473	001	Jul 12, 2023	Apr CMFD
@	EQ 20MG BASE	A214473	001	Jul 12, 2023	Jan DISC

FAMOTIDINE

TABLET;ORAL					
FAMOTIDINE					
CONTRACT PHARMACAL	10MG	A218003	001	May 28, 2024	May NEWA
	20MG	A218003	002	May 28, 2024	May NEWA
GRAVITI PHARMS	10MG	A218461	001	Mar 14, 2024	Mar NEWA
	20MG	A218461	002	Mar 14, 2024	Mar NEWA
@ SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009	Apr DISC
@	20MG	A090283	002	Nov 17, 2009	Apr DISC

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

AUROBINDO PHARMA LTD	0.05MG/SPRAY	A217088	001	May 10, 2024	May NEWA
@ HIKMA	0.05MG/SPRAY	A208024	001	Apr 17, 2019	Mar DISC

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

@ AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A215777	001	Sep 14, 2023	Mar DISC
PATHEON SOFTGELS	EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Mar CAHN
	EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Feb NEWA

SUSPENSION;ORAL

IBUPROFEN

ANNORA PHARMA	100MG/5ML	A210602	001	Nov 23, 2018	Sep CAHN
---------------	-----------	---------	-----	--------------	----------

SUSPENSION/DROPS;ORAL

IBUPROFEN

>D>	AUROBINDO PHARMA LTD	40MG/ML	A213506	001	Apr 08, 2024	Oct DISC
>A>	@	40MG/ML	A213506	001	Apr 08, 2024	Oct DISC
		40MG/ML	A213506	001	Apr 08, 2024	Mar NEWA

TABLET;ORAL

IBUPROFEN

@ ADAPTIS	200MG	A071265	001	Oct 15, 1986	Sep CAHN
@	200MG	A071265	002	Sep 10, 1987	Sep CAHN
	200MG	A072299	001	Jul 01, 1988	Sep CAHN
ENDO OPERATIONS	200MG	A071229	001	Apr 01, 1987	May CAHN
@	200MG	A071639	001	Feb 02, 1988	May CAHN
@	200MG	A072249	001	Jan 10, 1989	May CAHN

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

NAARI PTE LTD	1.5MG	A207660	001	May 02, 2019	Apr CMFD
@ XIROMED	0.75MG	A202740	001	Sep 02, 2016	May CAHN
	1.5MG	A202739	001	Oct 31, 2014	May CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

@ SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006	May DISC
----------------------	-----------	---------	-----	--------------	----------

LORATADINE

SUSPENSION;ORAL

LORATADINE

+! TARO	1MG/ML	N021734	001	Oct 04, 2005	Aug CAHN
---------	--------	---------	-----	--------------	----------

TABLET;ORAL

LORATADINE

ANDA REPOSITORY	10MG	A207569	001	Mar 12, 2019	Sep CAHN
-----------------	------	---------	-----	--------------	----------

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

BIONPHARMA	10MG;240MG	A218017	001	May 14, 2024	May NEWA
------------	------------	---------	-----	--------------	----------

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

@ COSETTE	2%	A074366	001	Feb 22, 1996	Apr DISC
-----------	----	---------	-----	--------------	----------

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

COSETTE	2%,200MG	A074926	001	Apr 16, 1999	Jun CAHN
---------	----------	---------	-----	--------------	----------

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

COSETTE	100MG	A073507	001	Nov 19, 1993	Jun CAHN
@	100MG	A074414	001	Apr 30, 1997	Apr DISC

MINOXIDIL

AEROSOL, FOAM;TOPICAL						
MINOXIDIL (FOR MEN)						
	AUROBINDO PHARMA	5%	A218616	001	Apr 22, 2024	Apr NEWA
MINOXIDIL (FOR WOMEN)						
	AUROBINDO PHARMA	5%	A218616	002	Apr 22, 2024	Apr NEWA
SOLUTION;TOPICAL						
MINOXIDIL (FOR MEN)						
>D>	AUROBINDO PHARMA LTD	2%	A074767	001	Feb 28, 1997	Oct DISC
>A>	@	2%	A074767	001	Feb 28, 1997	Oct DISC

MOMETASONE FUROATE

SPRAY, METERED;NASAL						
MOMETASONE FUROATE						
	@ APOTEX	0.05MG/SPRAY	A217438	001	Apr 23, 2024	Sep DISC
		0.05MG/SPRAY	A217438	001	Apr 23, 2024	Apr NEWA

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL						
NALOXONE HYDROCHLORIDE						
	AMNEAL	4MG/SPRAY	A217992	001	Apr 23, 2024	Apr NEWA
	TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019	Jun CMKT

NAPROXEN SODIUM

TABLET;ORAL						
NAPROXEN SODIUM						
	@ SUN PHARM INDS LTD	220MG	A091183	001	May 20, 2011	Jan DISC

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL						
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE						
	AUROBINDO PHARMA	220MG;120MG	A211360	001	Jun 01, 2022	Jul CMFD

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL						
NICOTINE						
	DIFGEN PHARMS	7MG/24HR	A074612	002	Jul 28, 2003	Sep CAHN
		14MG/24HR	A074612	003	Oct 20, 1997	Sep CAHN
		21MG/24HR	A074612	001	Oct 20, 1997	Sep CAHN

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL						
NICORETTE						
+	HALEON US HOLDINGS	EQ 2MG BASE	N022360	001	May 18, 2009	Jan CAHN
+	!	EQ 4MG BASE	N022360	002	May 18, 2009	Jan CAHN
NICOTINE POLACRILEX						
	PPI-DAC	EQ 2MG BASE	A090711	001	Jul 10, 2009	Jun CAHN
		EQ 2MG BASE	A203690	001	Oct 09, 2012	Jun CAHN
		EQ 4MG BASE	A090711	002	Jul 10, 2009	Jun CAHN
		EQ 4MG BASE	A203690	002	Oct 09, 2012	Jun CAHN

NORGESTREL

TABLET;ORAL						
OPILL						
+	LABORATOIRE HRA	0.075MG	N017031	001		Feb CMFD

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC						
OLOPATADINE HYDROCHLORIDE						
	GLENMARK PHARMS INC	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Aug CMFD
	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Apr CMKT

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL						
OMEPRAZOLE AND SODIUM BICARBONATE						
	DR REDDYS	20MG/PACKET;1.68GM/PACKET	A217784	001	May 09, 2024	May NFTG

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

PPI-DAC

17GM/PACKET

A090685 001 Oct 06, 2009 Jun CAHN

17GM/SCOOPFUL

A090685 002 Oct 06, 2009 Jun CAHN

POVIDONE-IODINE

SPONGE;TOPICAL

E-Z SCRUB 201

+ @ BECTON DICKINSON 20%

N019240 001 Nov 29, 1985 Feb DISC

E-Z SCRUB 241

+ @ BECTON DICKINSON 10%

N019476 001 Jan 07, 1987 Feb DISC

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1%

N021958 001 Jul 24, 2006 Feb CAHN

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL

LAMISIL

+! KARO HLTHCARE 1%

N020980 001 Mar 09, 1999 Feb CAHN

SOLUTION;TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1%

N021124 001 Mar 17, 2000 Feb CAHN

SPRAY;TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1%

N021124 002 Mar 17, 2000 Feb CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2024

NO OCTOBER 2024 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2024 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11977067	Apr 30, 2038	DP			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Sep 28, 2031	DS DP U-1981			
	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11986468	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-2830			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11986468	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-2830			
<u>ACETAMINOPHEN; IBUPROFEN - ACETAMINOPHEN AND IBUPROFEN</u>						
A 218311 001					PC	Nov 03, 2024
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001	11918693	Jul 09, 2041	DP			
<u>ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV</u>						
N 215320 001	11896567	Oct 26, 2031	U-3744			
	11896567	Oct 26, 2031	U-3745			
	12083087	Jul 17, 2035	U-3744			
	12083087	Jul 17, 2035	U-3745			
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 001					NP	Feb 13, 2027
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 002					NP	Feb 13, 2027
<u>ACYCLOVIR - ACYCLOVIR</u>						
A 212361 001					CGT	Jun 12, 2024
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	10689377	May 17, 2037	DS DP U-3490			
	10689377	May 17, 2037	DS DP U-3953			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	10689377	May 17, 2037	DS DP U-3490			
	10689377	May 17, 2037	DS DP U-3953			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001					I-947 ODE-477	Apr 18, 2027 Apr 18, 2031
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - VIJOICE</u>						
N 218466 001	8227462	Apr 29, 2033	DS DP			
	8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11903908	Jun 17, 2034			U-3822	
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11903908	Jun 17, 2034			U-3822	
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	11890261	Feb 15, 2038			U-2497	
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	11890261	Feb 15, 2038			U-2497	
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	12016873	May 15, 2035			U-2414	
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	11918685	Oct 06, 2037			U-3447	
	11918685	Oct 06, 2037			U-3448	
	12053461	Oct 06, 2037	DP			
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	12005141	Feb 24, 2041	DP U-3309			
	12005141	Feb 24, 2041	DP U-3310			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	11878011	May 27, 2042			U-3816	
	11931463	Feb 12, 2034	DP U-3866			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	9839619	Jun 28, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	11896562	Mar 10, 2037	U-3299			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	11963952	Jan 30, 2040	U-3901			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	11963952	Jan 30, 2040	U-3901			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 002	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 003	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREPITANT - APONVIE</u>						
N 216457 001	11878074	Sep 18, 2035	U-3787			
<u>APROCITENTAN - TRYVIO</u>						
N 217686 001	10919881	Feb 26, 2038	DS DP		NCE	Mar 22, 2029
	11174247	Nov 06, 2037	U-3879			
	11680058	Jul 26, 2038	U-3878			
	11787782	Mar 02, 2038	U-3877			
	8324232	Sep 21, 2029	DS DP U-3878			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 001	>A> 11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	>A> 9289472	Aug 11, 2029	U-4021		>A> ODE-496	Sep 20, 2031
	>A> 9884058	Jun 26, 2029	U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 002	>A> 11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	>A> 9289472	Aug 11, 2029	U-4021		>A> ODE-496	Sep 20, 2031
	>A> 9884058	Jun 26, 2029	U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 003	>A> 11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	>A> 9289472	Aug 11, 2029	U-4021		>A> ODE-496	Sep 20, 2031
	>A> 9884058	Jun 26, 2029	U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 004	>A> 11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	>A> 9289472	Aug 11, 2029	U-4021		>A> ODE-496	Sep 20, 2031
	>A> 9884058	Jun 26, 2029	U-4021			
<u>ARIPIPRAZOLE - ABILIFY ASIMTUFI</u>						
N 217006 001	12016927	Apr 23, 2033	DP U-3245			
	12016927	Apr 23, 2033	DP U-543			
<u>ARIPIPRAZOLE - ABILIFY ASIMTUFI</u>						
N 217006 002	12016927	Apr 23, 2033	DP U-3245			
	12016927	Apr 23, 2033	DP U-543			
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036 001	>A> 12121506	Feb 16, 2044	DP			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	11407735	May 14, 2040	DS		NCE	Oct 29, 2026
	8829195	May 13, 2033	DS U-1374		ODE*	Oct 29, 2028
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENUVU</u>						
N 209381 001	12083179	Sep 10, 2033	DP U-2310			
<u>ATOGEPAANT - OULIPTA</u>						
N 215206 003	>A> 12090148	Jul 29, 2041	U-3534			
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	11925704	Jun 07, 2037	DP U-3853			
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 217791 001					CGT	Dec 04, 2024
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	12016875	Jul 11, 2034	U-3673			
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	11951214	Nov 27, 2039	DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
	12060354	Mar 08, 2042	U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
	12060354	Mar 08, 2042	U-2726			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040			U-3168	
	12060354	Mar 08, 2042			U-2726	
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	11964980	Apr 10, 2040	DS DP			
	12060354	Mar 08, 2042			U-2726	
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040			U-3168	
	11999744	Apr 10, 2040			U-3506	
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040			U-3168	
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	7638536	Jul 28, 2027	DS DP			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244		NPP	Jan 26, 2027
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
	7112592	Jan 07, 2026	DS DP U-3818			
<u>AXITINIB - INLYTA</u>						
N 202324 001	10570202	Feb 03, 2035			U-2844	
	10570202*PED	Aug 03, 2035				
	10869924	Jan 12, 2037			U-3044	
	10869924*PED	Jul 12, 2037				
	6534524	Apr 29, 2025	DS DP			
	6534524*PED	Oct 29, 2025				
	8791140	Dec 14, 2030	DS			
	8791140*PED	Jun 14, 2031				
<u>AXITINIB - INLYTA</u>						
N 202324 002	10570202	Feb 03, 2035			U-2844	
	10570202*PED	Aug 03, 2035				
	10869924	Jan 12, 2037			U-3044	
	10869924*PED	Jul 12, 2037				
	6534524	Apr 29, 2025	DS DP			
	6534524*PED	Oct 29, 2025				
	8791140	Dec 14, 2030	DS			
	8791140*PED	Jun 14, 2031				
<u>AZACITIDINE - ONUREG</u>						
N 214120 001	12053482	May 14, 2029			U-2950	
<u>AZACITIDINE - ONUREG</u>						
N 214120 002	12053482	May 14, 2029			U-2950	
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	12064438	Oct 09, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	12064438	Oct 09, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	12064438	Oct 09, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	11925648	Apr 21, 2041	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	8158616	May 31, 2032	DS DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001					M-306	Jun 21, 2027
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002					M-306	Jun 21, 2027
<u>BELUMOSUDIL MESYLATE - REZUROCK</u>						
N 214783 001 >A>	12097202	Jul 14, 2042	U-4014			
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	RE49948	Sep 05, 2034	DS DP U-3201		I-931	Dec 14, 2026
	RE49948	Sep 05, 2034	DS DP U-3780			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	11744816	Mar 14, 2036	U-3883		I-943	Mar 22, 2027
	11926584	Jun 19, 2040	U-3873		I-944	Mar 22, 2027
	7335799	Dec 03, 2030	DS			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10912751	Mar 14, 2036	U-3224		I-943	Mar 22, 2027
	10912751	Mar 14, 2036	U-3884		I-945	Mar 22, 2027
	11744816	Mar 14, 2036	U-3692			
	11744816	Mar 14, 2036	U-3883			
	11926584	Jun 19, 2040	U-3873			
	7335799	Dec 03, 2030	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11872214	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11872214	Jan 28, 2031	DP			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	11795176	Jan 13, 2042	DS	U-713		
	>A> 9763953	Dec 01, 2026		U-713		
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	11795176	Jan 13, 2042	DS	U-713		
	>A> 9763953	Dec 01, 2026		U-713		
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	11795176	Jan 13, 2042	DS	U-713		
	>A> 9763953	Dec 01, 2026		U-713		
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11865100	Feb 19, 2040		U-3357		
	11877997	Feb 19, 2040		U-3356		
	11986456	Feb 19, 2040		U-3947		
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902 001	12053546	Jun 29, 2032	DP			
	12070629	Dec 30, 2030	DP	U-3987		
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	10258564	Nov 22, 2034		U-3797	NCE	Jan 05, 2029
	10258564	Nov 22, 2034		U-3798		
	10258564	Nov 22, 2034		U-3799		
	10265334	Jul 03, 2032	DP			
	10322081	Jul 10, 2035		U-3793		
	10322081	Jul 10, 2035		U-3794		
	10322081	Jul 10, 2035		U-3795		
	10322081	Jul 10, 2035		U-3796		
	10376538	Aug 20, 2030	DP			
	10736839	Jul 10, 2035		U-3790		
	10736839	Jul 10, 2035		U-3791		
	10736839	Jul 10, 2035		U-3792		
	11040006	Jul 10, 2035	DP	U-3789		
	11285098	Feb 28, 2034	DP			
	11723858	Jul 10, 2035	DP	U-3788		
	8282967	May 30, 2026	DS			
	8956658	May 30, 2026	DS			
	9289442	Jul 03, 2032	DP	U-3803		
	9526738	Sep 03, 2031	DP			
	9737561	Aug 20, 2030		U-3802		
	9855211	Feb 27, 2034	DP	U-3800		
	9855211	Feb 27, 2034	DP	U-3801		
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001					I-942	Feb 23, 2027
					M-305	Apr 24, 2027
					ODE-468	Feb 23, 2031
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Apr 17, 2025	DS DP		I-942	Feb 23, 2027
	7390791*PED	Oct 17, 2025			ODE-468	Feb 23, 2031
	8754065	Aug 15, 2032	DS DP	U-257		
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP	U-257		
	9296769*PED	Feb 15, 2033				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2025	DS DP			
<u>BIRCH TRITERPENES - FILSUVEZ</u>						
N 215064 001	11083733	Jan 04, 2039	DP		NCE	Dec 18, 2028
	11266660	Jan 04, 2039	U-3811		ODE-460	Dec 18, 2030
	8828444	Jun 21, 2025	DP			
	9352041	Nov 24, 2030	U-3811			
	9827214	Nov 24, 2030	U-3811			
<u>BIVALIRUDIN - ANGIOMAX RTU</u>						
N 211215 001	11903993	May 20, 2039	U-3817			
	11918622	May 20, 2039	U-3817			
	11992514	May 20, 2039	DP			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 001	12005069	Sep 23, 2042	DP			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 002	12005069	Sep 23, 2042	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 003	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS	Y	I-913	May 10, 2026
	7888362*PED	Oct 12, 2026			M-14	May 08, 2027
	8349840	Apr 12, 2026	DP U-1529		PED	Nov 10, 2026
	8349840*PED	Oct 12, 2026			PED	Nov 08, 2027
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BRIMONIDINE TARTRATE - LUMIFY PRESERVATIVE FREE</u>						
N 218424 001	11596600	Jul 27, 2029	U-2222			
	8293742	Jul 14, 2030	U-2222			
	9259425	Jul 14, 2030	U-2222			
<u>BROMFENAC SODIUM - BROMFENAC SODIUM</u>						
A 206027 001					PC	Jul 06, 2024
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	>A> 11666567	Apr 30, 2032	U-4015			
	>A> 11666567	Apr 30, 2032	U-4016			
	>A> 11666567	Apr 30, 2032	U-4017			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	>A> 11666567	Apr 30, 2032	U-4018			
<u>BUDESONIDE - EOHILIA</u>						
N 213976 001	10293052	Nov 22, 2028	DP		NP	Feb 09, 2027
	11197822	Nov 09, 2026	DP		ODE-466	Feb 09, 2031
	11260064	Jan 10, 2039	DP			
	11357859	Nov 12, 2028	U-3820			
	11413296	Nov 09, 2026	DP			
	11564934	Jan 10, 2039	U-3820			
	8324192	Aug 03, 2029	U-3820			
	8497258	Nov 09, 2026	U-3820			
	8679545	Nov 09, 2026	DP			
	8975243	Nov 09, 2026	U-3820			
	9050368	Aug 01, 2029	DP			
	9119863	Nov 09, 2026	U-3820			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	11896719	Jan 23, 2043	U-3810		ODE-464	Dec 20, 2030
	8491932	May 07, 2029	DP U-3269			
	8491932	May 07, 2029	DP U-3781			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004					I-933	Jan 23, 2027
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11883373	Jan 23, 2043	U-3419			
	11896563	Dec 01, 2041	U-3419			
	11925636	Jan 20, 2043	U-3419			
	11969421	Nov 05, 2034	U-3419			
	11986444	Feb 15, 2043	U-3419			
	12036191	Feb 15, 2043	U-3419			
	12042473	Feb 23, 2043	U-3419			
	>A> 12109178	Nov 05, 2034	U-3419			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	11998542	Jul 02, 2034	U-1583			
	12048769	Nov 08, 2027	U-1585			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	11154509	Apr 25, 2028	U-3815			
	9498486	Apr 25, 2028	U-3814			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	11986446	Mar 15, 2033	U-3017		ODE-361	Jul 21, 2027
	11986446	Mar 15, 2033	U-3324		PED	Jan 21, 2028
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11865102	Apr 26, 2039	DS DP U-2781			
	11865102	Apr 26, 2039	DS DP U-3236			
	11865102	Apr 26, 2039	DS DP U-3277			
	11963937	Jun 17, 2035	U-2780			
	11963937	Jun 17, 2035	U-2781			
	12064399	Jun 17, 2035	U-3988			
	12064399	Jun 17, 2035	U-3989			
	>A> 12102619	Mar 01, 2041	U-3233			
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001					NCE	Jul 21, 2028
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	12084449	Nov 19, 2027	U-2813			
	7767675	Nov 19, 2032	DS DP			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	12084449	Nov 19, 2027	U-2813			
	7767675	Nov 19, 2032	DS DP			
<u>CARBDOPA; LEVODOPA - CREXONT</u>						
N 217186 001	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
	>A> 12109185	Dec 21, 2041	U-1649			
	>A> 12109185	Dec 21, 2041	U-219			
	>A> 12109185	Dec 21, 2041	U-4004			
	>A> 12109185	Dec 21, 2041	U-4005			
<u>CARBDOPA; LEVODOPA - CREXONT</u>						
N 217186 002	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
	>A> 12109185	Dec 21, 2041	U-1649			
	>A> 12109185	Dec 21, 2041	U-219			
	>A> 12109185	Dec 21, 2041	U-4004			
	>A> 12109185	Dec 21, 2041	U-4005			
<u>CARBDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	12064521	Oct 07, 2034	DP			
	>A> 12109185	Dec 21, 2041	U-1649			
	>A> 12109185	Dec 21, 2041	U-219			
	>A> 12109185	Dec 21, 2041	U-4004			
	>A> 12109185	Dec 21, 2041	U-4005			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
	>A> 12109185	Dec 21, 2041	U-1649			
	>A> 12109185	Dec 21, 2041	U-219			
	>A> 12109185	Dec 21, 2041	U-4004			
	>A> 12109185	Dec 21, 2041	U-4005			
<u>CEDAZURIDINE; DECITABINE - INQOVI</u>						
N 212576 001	11963971	Feb 24, 2041	DP			
<u>CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM - EXBLIFEP</u>						
N 216165 001	11124526	Nov 07, 2034	U-3852		NCE	Feb 22, 2029
	7687488	Dec 03, 2027	DS DP U-3851		GAIN	Feb 22, 2034
<u>CEFTOBIPROLE MEDOCARIL SODIUM - ZEVTERA</u>						
N 218275 001					NCE GAIN	Apr 03, 2029 Apr 03, 2034
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Mar 21, 2033	DS DP U-2586			
	8487093	Mar 21, 2033	DS DP U-2587			
	8487093	Mar 21, 2033	DS DP U-2840			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	11992472	Mar 15, 2033	U-1			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	11938141	Jul 24, 2028	DP			
	8865690	Jul 24, 2025	U-2942			
	9211295	May 31, 2025	DP			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
N 218158 001	10588913	May 09, 2036	DP		NP	Mar 04, 2027
	11376262	May 09, 2036	DP U-19			
<u>CLONIDINE HYDROCHLORIDE - ONYDA XR</u>						
N 217645 001	11918689	Jul 28, 2041	DP U-3944			
	8062667	Mar 29, 2029	DP			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	10130585	May 09, 2034	U-3642			
	10206891	Nov 01, 2033	U-3641			
	10265281	Nov 01, 2033	U-3639			
	10842762	Nov 01, 2033	U-3640			
	11026899	Nov 01, 2033	U-3639			
	11026900	Nov 01, 2033	U-3639			
	11026901	Nov 01, 2033	U-3638			
	11944594	Nov 01, 2033	U-3864			
	11944595	Nov 01, 2033	U-3867			
	11944595	Nov 01, 2033	U-3868			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COLCHICINE - LODOCO</u>						
N 215727 001	9744144	Nov 01, 2033	U-3643			
<u>COPPER - PARAGARD T 380A</u>						
N 018680 001					D-193	Jun 28, 2027
<u>COPPER CU-64 DOTATATE - DETECTNET</u>						
N 213227 001	>A> 12102696	Sep 03, 2041	DP			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 003	11752199	Feb 25, 2041	U-3686			
	11752199	Feb 25, 2041	U-3687			
	11752199	Feb 25, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 004	11752199	Feb 25, 2041	U-3686			
	11752199	Feb 25, 2041	U-3687			
	11752199	Feb 25, 2041	U-3688			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 001	12102662	Oct 27, 2043	U-3904			
	12102662	Oct 27, 2043	U-3905			
	12102662	Oct 27, 2043	U-3906			
	12102662	Oct 27, 2043	U-3907			
	12102662	Oct 27, 2043	U-3908			
	12102662	Oct 27, 2043	U-3909			
	12102662	Oct 27, 2043	U-3910			
	12102662	Oct 27, 2043	U-3911			
	12102662	Oct 27, 2043	U-3912			
	12102662	Oct 27, 2043	U-3913			
	12102662	Oct 27, 2043	U-3914			
	12102662	Oct 27, 2043	U-3915			
	12102662	Oct 27, 2043	U-3916			
	12102662	Oct 27, 2043	U-3917			
	12102662	Oct 27, 2043	U-3918			
	12102662	Oct 27, 2043	U-3919			
	12102662	Oct 27, 2043	U-3920			
	12102662	Oct 27, 2043	U-3921			
	12102662	Oct 27, 2043	U-3922			
	12102662	Oct 27, 2043	U-3923			
	12102662	Oct 27, 2043	U-3924			
	12102662	Oct 27, 2043	U-3925			
	12102662	Oct 27, 2043	U-3926			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	11975047	Oct 27, 2043	U-3904			
	11975047	Oct 27, 2043	U-3905			
	11975047	Oct 27, 2043	U-3906			
	11975047	Oct 27, 2043	U-3907			
	11975047	Oct 27, 2043	U-3908			
	11975047	Oct 27, 2043	U-3909			
	11975047	Oct 27, 2043	U-3910			
	11975047	Oct 27, 2043	U-3911			
	11975047	Oct 27, 2043	U-3912			
	11975047	Oct 27, 2043	U-3913			
	11975047	Oct 27, 2043	U-3914			
	11975047	Oct 27, 2043	U-3915			
	11975047	Oct 27, 2043	U-3916			
	11975047	Oct 27, 2043	U-3917			
	11975047	Oct 27, 2043	U-3918			
	11975047	Oct 27, 2043	U-3919			
	11975047	Oct 27, 2043	U-3920			
	11975047	Oct 27, 2043	U-3921			
	11975047	Oct 27, 2043	U-3922			
	11975047	Oct 27, 2043	U-3923			
	11975047	Oct 27, 2043	U-3924			
	11975047	Oct 27, 2043	U-3925			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	11975047	Oct 27, 2043	U-3926			
	12102662	Oct 27, 2043	U-3904			
	12102662	Oct 27, 2043	U-3905			
	12102662	Oct 27, 2043	U-3906			
	12102662	Oct 27, 2043	U-3907			
	12102662	Oct 27, 2043	U-3908			
	12102662	Oct 27, 2043	U-3909			
	12102662	Oct 27, 2043	U-3910			
	12102662	Oct 27, 2043	U-3911			
	12102662	Oct 27, 2043	U-3912			
	12102662	Oct 27, 2043	U-3913			
	12102662	Oct 27, 2043	U-3914			
	12102662	Oct 27, 2043	U-3915			
	12102662	Oct 27, 2043	U-3916			
	12102662	Oct 27, 2043	U-3917			
	12102662	Oct 27, 2043	U-3918			
	12102662	Oct 27, 2043	U-3919			
	12102662	Oct 27, 2043	U-3920			
	12102662	Oct 27, 2043	U-3921			
	12102662	Oct 27, 2043	U-3922			
	12102662	Oct 27, 2043	U-3923			
	12102662	Oct 27, 2043	U-3924			
	12102662	Oct 27, 2043	U-3925			
	12102662	Oct 27, 2043	U-3926			
<u>CUPRIC CHLORIDE - CUPRIC CHLORIDE</u>						
A 216113 001					CGT	Dec 21, 2024
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS</u>						
N 209376 003	11975022	Jul 01, 2041	U-3900			
	11998565	Jul 01, 2041	DP			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8629111	Aug 27, 2024	DP		Y	
	8633162	Aug 27, 2024	U-1479		Y	
	8642556	Aug 27, 2024	DP		Y	
	8648048	Aug 27, 2024	U-1483		Y	
	8685930	Aug 27, 2024	DP		Y	
	9248191	Aug 27, 2024	U-1479		Y	
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	11951153	Feb 28, 2037	U-1483			
<u>CYCLOSPORINE - VEVEE</u>						
N 217469 001	12059449	Apr 01, 2042	DP U-1483			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	11969439	Jan 15, 2039	U-2752			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
	11826383	Jan 15, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	001				I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	002				I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514	001	11504333	Jun 29, 2038	DP	NP	Mar 16, 2026
		11504333*PED	Dec 29, 2038		ODE-428	Mar 16, 2030
		7994185	Jan 20, 2030	DS DP	PED	Sep 16, 2026
		7994185*PED	Jul 20, 2030		PED	Sep 16, 2030
		8415345	Jan 20, 2030	DS DP		
		8415345*PED	Jul 20, 2030			
		8703781	Oct 15, 2030	DS DP U-3565		
		8703781*PED	Apr 15, 2031			
		8835443	Jun 10, 2025	U-3565		
		8835443*PED	Dec 10, 2025			
<u>DANICOPAN - VOYDEYA</u>						
N 218037	001	12076319	Aug 02, 2038	U-3933	NCE	Mar 29, 2029
		9796741	Feb 25, 2035	DS U-3933	ODE-476	Mar 29, 2031
<u>DANICOPAN - VOYDEYA</u>						
N 218037	002	12076319	Aug 02, 2038	U-3933	NCE	Mar 29, 2029
		9796741	Feb 25, 2035	DS U-3933	ODE-476	Mar 29, 2031
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	001	6515117	Oct 04, 2025	DS DP U-2139	M-298	May 08, 2026
		6515117	Oct 04, 2025	DS DP U-493	NPP	Jun 12, 2027
		6515117*PED	Apr 04, 2026		PED	Nov 08, 2026
		7456254	Jun 30, 2025	U-2139	PED	Dec 12, 2027
		7456254*PED	Dec 30, 2025			
		7851502	Aug 19, 2028	DP		
		7851502*PED	Feb 19, 2029			
		7919598	Dec 16, 2029	DS		
		7919598*PED	Jun 16, 2030			
		8221786	Mar 21, 2028	DP		
		8221786*PED	Sep 21, 2028			
		8329648	Aug 18, 2026	U-2139		
		8329648	Aug 18, 2026	U-2212		
		8329648	Aug 18, 2026	U-2213		
		8329648*PED	Feb 18, 2027			
		8361972	Mar 21, 2028	U-2139		
		8361972	Mar 21, 2028	U-493		
		8361972*PED	Sep 21, 2028			
		8431685	Apr 13, 2025	U-2139		
		8431685*PED	Oct 13, 2025			
		8461105	Apr 13, 2025	U-2139		
		8461105*PED	Oct 13, 2025			
		8501698	Jun 20, 2027	DP U-493		
		8501698*PED	Dec 20, 2027			
		8685934	May 26, 2030	U-1522		
		8685934*PED	Nov 26, 2030			
		8716251	Mar 21, 2028	DP		
		8716251*PED	Sep 21, 2028			
		8721615	Jan 18, 2030	DP	Y	
		8721615*PED	Jul 18, 2030			
		8906851	Aug 18, 2026	U-2139		
		8906851*PED	Feb 18, 2027			
		9238076	Apr 15, 2024	U-2139		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	10973836	Mar 09, 2040	U-3127		M-298	May 08, 2026
	10973836*PED	Sep 09, 2040			NPP	Jun 12, 2027
	11826376	Jul 18, 2039	U-3766		PED	Nov 08, 2026
	11826376*PED	Jan 18, 2040			PED	Dec 12, 2027
	11903955	Mar 09, 2040	U-3825			
	11903955*PED	Sep 09, 2040				
	6515117	Oct 04, 2025	DS DP U-2139			
	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7456254	Jun 30, 2025	U-2139			
	7456254*PED	Dec 30, 2025				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	U-2139			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	U-2139			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 001	12053502	Aug 28, 2038	U-3981			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 002	12053502	Aug 28, 2038	U-3981			
<u>DARIDOREXANT HYDROCHLORIDE - OUVIVIO</u>						
N 214985 001					>A> M-310	Sep 30, 2027
<u>DARIDOREXANT HYDROCHLORIDE - OUVIVIO</u>						
N 214985 002					>A> M-310	Sep 30, 2027
<u>DASATINIB - DASATINIB</u>						
A 202103 001					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 202103 002					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 202103 003					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 202103 004					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 203180 001					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 203180 002					PC	Mar 02, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - PHYRAGO</u>						
N 216099 001					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 002					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 003					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 004					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 005					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 006					M-307	Dec 05, 2026
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	12036219	Jun 02, 2034	U-3967			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	11963995	May 21, 2029	U-2327			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	11963995	May 21, 2029	U-2327			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	>A> 12090190	Jun 15, 2030	DP U-4003			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	>A> 12090190	Jun 15, 2030	DP U-4003			
<u>DEURUXOLITINIB PHOSPHATE - LEOSELVI</u>						
N 217900 001	10561659	May 04, 2037	U-3976		NCE	Jul 25, 2029
	11919907	May 21, 2041	DP U-3976			
	12076323	May 04, 2037	U-3976			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 004	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 005	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 006	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 006	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 007	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 008	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 008	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 218112 001					CGT	Mar 30, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 218112 002					CGT	Mar 30, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11890272	Jul 17, 2040	U-3756			
	11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
	12090140	Jan 12, 2043	U-3986			
>A>	12109196	Jul 17, 2040	U-3935			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11890272	Jul 17, 2040	U-3756			
	11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
	12090140	Jan 12, 2043	U-3986			
>A>	12109196	Jul 17, 2040	U-3935			
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 001	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 002	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 003	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 004	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 005	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001					NPP	Apr 05, 2027
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001	12011506	Sep 05, 2038	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8173708	Nov 22, 2025	U-1641	Y		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641	Y		
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP	Y		
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641	Y		
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP	Y		
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8168209	Nov 22, 2025	DP	Y		
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641	Y		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641	Y		
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP	Y		
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641	Y		
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP	Y		
	8598233*PED	May 22, 2026				
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001 >A>	12083090	May 18, 2027	U-620			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002 >A>	12083090	May 18, 2027	U-620			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	11951213	Jun 28, 2031	U-2553			
	12090231	Jun 28, 2031	U-2553			
<u>DROSPIRENONE - DROSPIRENONE</u>						
N 216285 001	11951213	Jun 28, 2031	U-2553			
	12090231	Jun 28, 2031	U-2553			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	11957694	Jun 17, 2036	DP			
	11964055	Jun 17, 2036	DP			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	11957660	Nov 01, 2039	DP		ODE-144	May 12, 2029
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-14	Oct 18, 2026
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11872218	Jan 03, 2028	U-1969			
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500 001					NP ODE-462	Dec 13, 2026 Dec 13, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 001	>A> 8399520	Dec 25, 2025	DS DP U-3523			
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 002	>A> 8399520	Dec 25, 2025	DS DP U-3523			
<u>ELAFIBRANOR - IQIRVO</u>						
N 218860 001	11185519	Mar 30, 2037	U-3955		NCE	Jun 10, 2029
	11331292	Mar 30, 2037	U-1854		ODE-486	Jun 10, 2031
	11850223	Mar 30, 2037	U-1854			
	11857523	Mar 30, 2037	U-3955			
	7632870	Sep 09, 2024	DP			
	7943661	Sep 09, 2024	DS DP			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	>A> 12102637	Aug 20, 2038	DP			
	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	>A> 12102637	Aug 20, 2038	DP			
	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	12083227	Aug 20, 2038	DP U-2842			
	7419983	Jul 06, 2029	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	>A> 10081621	Mar 25, 2031	DP U-3032			
	>A> 10081621	Mar 25, 2031	DP U-3157			
	>A> 10239867	Apr 09, 2027	DS DP U-3033			
	>A> 10239867	Apr 09, 2027	DS DP U-3158			
	>A> 10758534	Oct 06, 2035	DS DP U-3028			
	>A> 10758534	Oct 06, 2035	DS DP U-3144			
	>A> 10793547	Dec 08, 2037	DS DP U-3028			
	>A> 10793547	Dec 08, 2037	DS DP U-3144			
	>A> 8324242	Aug 05, 2027	U-3028			
	>A> 8324242	Aug 05, 2027	U-3144			
	>A> 8354427	Jul 06, 2026	U-3029			
	>A> 8354427	Jul 06, 2026	U-3145			
	>A> 8415387	Nov 12, 2027	U-3028			
	>A> 8415387	Nov 12, 2027	U-3144			
	>A> 8598181	May 01, 2027	U-3028			
	>A> 8598181	May 01, 2027	U-3144			
	>A> 8629162	Jun 24, 2025	U-3030			
	>A> 8629162	Jun 24, 2025	U-3146			
	>A> 9670163	Dec 28, 2026	DP U-3031			
	>A> 9670163	Dec 28, 2026	DP U-3155			
	>A> 9931334	Dec 28, 2026	DP U-3031			
	>A> 9931334	Dec 28, 2026	DP U-3155			
	>A> 9974781	Apr 09, 2027	DP U-3028			
	>A> 9974781	Apr 09, 2027	DP U-3144			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 001	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 002	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 003	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 003	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 004	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001 >A>	12097187	Mar 14, 2033		U-3475		
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002					ODE-457	Jan 07, 2029
<u>ENSIFENTRINE - OHTUVAYRE</u>						
N 217389 001	10945950	Sep 15, 2035		DP	NCE	Jun 26, 2029
	9062047	Aug 21, 2031	DS	U-3962		
	9956171	Sep 15, 2035		DP U-3962		
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
N 213994 002	12029710	Jan 22, 2040		U-3963		
<u>EPINEPHRINE - NEFFY</u>						
N 214697 001	10576156	Feb 06, 2038		DP		
	10682414	Feb 06, 2039		U-3979		
	11173209	Feb 06, 2038		U-3979		
	11191838	Feb 06, 2039		DP U-3979		
	11717571	Feb 06, 2039		U-3979		
	11744895	Feb 06, 2039		U-3979		
	11918655	Feb 06, 2039		DP U-3979		
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 001 >A>	12133837	Mar 21, 2039		DP		
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 002 >A>	12133837	Mar 21, 2039		DP		
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 003 >A>	12133837	Mar 21, 2039		DP		
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 004 >A>	12133837	Mar 21, 2039		DP		
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 005 >A>	12133837	Mar 21, 2039		DP		
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	10683499	Aug 25, 2034	DS DP U-2378		NCE	Dec 21, 2028
	8101743	Apr 01, 2025	DS DP		ODE-461	Dec 21, 2030
	9127276	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10478494	Aug 13, 2036		U-3902	I-930	Jan 19, 2027
	10898482	Feb 09, 2036		DP U-2518		
	10898482	Feb 09, 2036		DP U-3065		
	10898482	Feb 09, 2036		DP U-3066		
	10898482	Feb 09, 2036		DP U-3067		
	10898482	Feb 09, 2036		DP U-3805		
	10898482	Feb 09, 2036		DP U-3806		
	10898482	Feb 09, 2036		DP U-3807		
	11077106	Feb 02, 2038		U-3196		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			
<u>ERYTHROMYCIN - ERYTHROMYCIN</u>						
A 211975 003					>A> CGT	Apr 22, 2025
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
<u>ESTRADIOL - ESTRADIOL</u>						
A 216160 001					CGT	Oct 23, 2024
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	11957684	Sep 29, 2037	U-3129			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11865179	Nov 21, 2032	DS DP			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	11865179	Nov 21, 2032	DS DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	11959486	Jun 27, 2034	DP U-2014			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	11959486	Jun 27, 2034	DP U-2014			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMLYV</u>						
N 218718 001					NP	Jul 22, 2027
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	11850251	Jun 21, 2039	U-3785			
<u>ETRASIMOD ARGININE - VELSIPITY</u>						
N 216956 001	11884626	Jun 21, 2036	U-3731			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	>A> 12097206	May 03, 2033	U-4013			
	>A> 12097206*PED	Nov 03, 2033				
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2025	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 002	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 003	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001					NPP PED	Jul 01, 2027 Jan 01, 2028
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	8586551*PED	Jan 15, 2024				
<u>FINERENONE - KERENDIA</u>						
N 215341 001	RE49826	Jul 29, 2035	DS			
<u>FINERENONE - KERENDIA</u>						
N 215341 002	RE49826	Jul 29, 2035	DS			
<u>FLOTUFOLASTAT F-18 GALLIUM - POSLUMA</u>						
N 216023 001	12036290	Nov 27, 2041	DP U-3614			
	12036290	Nov 27, 2041	DP U-3615			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	11980674	Apr 23, 2042	U-2450			
<u>FLUOROMETHOLONE - FLUOROMETHOLONE</u>						
A 216348 001					CGT	Jul 07, 2024
<u>FLURPIRIDAZ F-18 - FLYRCADO</u>						
N 215168 001	>A> 7344702	May 26, 2026	DS		>A> NCE	Sep 27, 2029
	>A> 8226929	Jun 21, 2028		U-4011		
	>A> 8936777	Jun 30, 2031		U-4011		
	>A> 9161997	Feb 04, 2026	DS DP	U-4011		
	>A> 9603951	May 02, 2031		U-4011		
	>A> 9687571	Nov 01, 2032	DP	U-4011		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	12083270	Apr 04, 2031	U-2133		I-940	Mar 15, 2027
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FOSAPREPITANT DIMEGLUMINE - FOCINVEZ</u>						
N 216686 001	12042504	Jan 11, 2039	DP			
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950 001	8168615	Jul 13, 2029	DP			
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 001					NCE	Nov 08, 2028
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 002					NCE	Nov 08, 2028
<u>FUROSEMIDE - FUROSCIX</u>						
N 209988 001					NP	Oct 07, 2025
<u>GALLIUM GA-68 GOZETOTIDE - LOCAMETZ</u>						
N 215841 001	12109277	Mar 09, 2036	U-4002			
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001	11938130	Jul 01, 2036	DP			
	11938131	Jul 01, 2036	DP			
	11938132	Jul 01, 2036	DP			
	11938133	Jul 01, 2036	DP			
	11944620	Jul 01, 2036	DP			
	8969336	Nov 28, 2032	DS DP			
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	10688047	Oct 28, 2036	DP U-3885		NCE	Mar 21, 2029
	7329689	Jan 15, 2025	DS DP		ODE-473	Mar 21, 2031
	9421184	Feb 03, 2032	U-3885			
	9867799	Feb 03, 2032	U-3885			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	11891372	Apr 13, 2036	U-3254			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	11891372	Apr 13, 2036	U-3254			
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001	8404215	Mar 09, 2032	U-1383	Y		
	9254278	Sep 22, 2030	U-1816			
	9326966	Sep 22, 2030	U-1816			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	11938217	Oct 25, 2038	DP			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	RE47691	Jun 28, 2028	DP			
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
A 215266 001					PC	Jun 24, 2024
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	11957753	Nov 02, 2031	DP			
	11986527	Nov 02, 2031	U-2625			
	12076403	Nov 02, 2031	DP			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	11957753	Nov 02, 2031	DP			
	11986527	Nov 02, 2031	U-2625			
	12076403	Nov 02, 2031	DP			
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HYDROCORTISONE SODIUM SUCCINATE - HYDROCORTISONE SODIUM SUCCINATE</u>						
A 214050 001					CGT	Mar 25, 2025
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899 001					>A> PC	Apr 12, 2025
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899 002					PC	Nov 11, 2024
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899 003					PC	Dec 02, 2024
<u>HYDROXYUREA - XROMI</u>						
N 216593 001					NP ODE-470	Apr 04, 2027 Apr 04, 2031
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	>A> 8476284	Dec 28, 2026	U-1650		M-14	Aug 24, 2025
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-2241			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8497277	Dec 28, 2026	U-3422			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1491			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-2241			
	>A> 8952015	Dec 28, 2026	U-2242			
	>A> 8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	>A> 8476284	Dec 28, 2026	U-1650		M-14	Aug 24, 2025
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-2241			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8497277	Dec 28, 2026	U-3422			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-2241			
	>A> 8952015	Dec 28, 2026	U-2242			
	>A> 8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	>A> 8476284	Dec 28, 2026	U-1650		M-14	Aug 24, 2025
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-2241			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8497277	Dec 28, 2026	U-3422			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-2241			
	>A> 8952015	Dec 28, 2026	U-2242			
	>A> 8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004					M-14	Aug 24, 2025
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10004746	Jun 03, 2031	U-3846			
	10004746	Jun 03, 2031	U-3847			
	10004746	Jun 03, 2031	U-3848			
	10004746	Jun 03, 2031	U-3849			
	10016435	Jun 03, 2031	U-3845			
	10463668	Oct 24, 2034	U-2970			
	10478439	Jun 03, 2031	U-2666			
	10478439	Jun 03, 2031	U-2970			
	10478439	Jun 03, 2031	U-3422			
	10478439	Jun 03, 2031	U-3842			
	10478439	Jun 03, 2031	U-3843			
	10478439	Jun 03, 2031	U-3844			
	10478439	Jun 03, 2031	U-3845			
	10478439*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2970			
	10751342	Jun 03, 2031	U-2666			
	10751342	Jun 03, 2031	U-3842			
	10751342	Jun 03, 2031	U-3843			
	10751342	Jun 03, 2031	U-3844			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	11672803	Jun 03, 2031	U-2666			
	11672803	Jun 03, 2031	U-3842			
	11672803	Jun 03, 2031	U-3843			
	11672803	Jun 03, 2031	U-3844			
	8476284	Dec 28, 2026	U-3843			
	8476284	Dec 28, 2026	U-3844			
	8476284	Dec 28, 2026	U-3845			
	8497277	Dec 28, 2026	U-2666			
	8497277	Dec 28, 2026	U-2970			
	8497277	Dec 28, 2026	U-3422			
	8497277	Dec 28, 2026	U-3842			
	8497277	Dec 28, 2026	U-3843			
	8497277	Dec 28, 2026	U-3844			
	8497277	Dec 28, 2026	U-3845			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-2666			
	8563563	Apr 26, 2027	U-3842			
	8563563	Apr 26, 2027	U-3843			
	8563563	Apr 26, 2027	U-3844			
	8563563	Apr 26, 2027	U-3845			
	8703780	Dec 28, 2026	U-2666			
	8703780	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-2666			
	8952015	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-3843			
	8952015	Dec 28, 2026	U-3844			
	8952015	Dec 28, 2026	U-3845			
	8999999	Jun 03, 2031	U-2666			
	8999999	Jun 03, 2031	U-3842			
	8999999	Jun 03, 2031	U-3843			
	8999999	Jun 03, 2031	U-3844			
	9125889	Jun 03, 2031	U-3845			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-3846			
	9801881	Jun 03, 2031	U-3847			
	9801883	Jun 03, 2031	U-2666			
	9801883	Jun 03, 2031	U-3842			
	9801883	Jun 03, 2031	U-3843			
	9801883	Jun 03, 2031	U-3844			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003					NPP	May 11, 2026
<u>LLOPERIDONE - FANAPT</u>						
N 022192 001					I-939	Apr 02, 2027
<u>LLOPERIDONE - FANAPT</u>						
N 022192 002					I-939	Apr 02, 2027
<u>LLOPERIDONE - FANAPT</u>						
N 022192 003					I-939	Apr 02, 2027
<u>LLOPERIDONE - FANAPT</u>						
N 022192 004					I-939	Apr 02, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192	005				I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192	006				I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192	007				I-939	Apr 02, 2027
<u>ILOPROST - AURLUMYN</u>						
N 217933	001				NP ODE-465	Feb 13, 2027 Feb 13, 2031
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779	001	7494982	Dec 27, 2025	DS DP	ODE-482	Jun 06, 2031
		9375485	Mar 15, 2033	U-3956		
		9388415	Sep 09, 2024	U-3956		
		9388416	Sep 09, 2024	U-3956		
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779	002	7494982	Dec 27, 2025	DS DP	ODE-482	Jun 06, 2031
		9375485	Mar 15, 2033	U-3956		
		9388415	Sep 09, 2024	U-3956		
		9388416	Sep 09, 2024	U-3956		
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483	001	11850245	Apr 30, 2030	U-1455		
		11850245	Apr 30, 2030	U-172		
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 217883	001				CGT	Jul 10, 2024
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276	001	10093663	Jul 14, 2034	U-3980	I-949	Aug 07, 2027
		11723901	Aug 30, 2038	U-3980	NCE	Dec 05, 2028
		11951101	Jul 15, 2041	U-3895	ODE-456	Dec 05, 2030
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793	001	11344552	Aug 19, 2036	U-3824	I-932	Feb 13, 2027
		12059497	Oct 15, 2036	DP	ODE-463	Feb 13, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500	001				NPP ODE-454 ODE-458 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500	002				NPP ODE-454 ODE-458 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501	001				NPP ODE-453 ODE-459 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501	001				NPP	Dec 08, 2026
					ODE-453	Dec 08, 2030
					ODE-459	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051	001				PC	Jan 11, 2025
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051	002				PC	Jan 11, 2025
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491	001	>A> 10058546	Jul 15, 2033	U-3022		
		>A> 10058546	Jul 15, 2033	U-3023		
		>A> 10081621	Mar 25, 2031	DP U-3024		
		>A> 10081621	Mar 25, 2031	DP U-3025		
		>A> 10206877	Apr 14, 2035	DP U-3026		
		>A> 10206877	Apr 14, 2035	DP U-3027		
		11951212	Apr 14, 2035	DP U-3894		
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491	002	>A> 10058546	Jul 15, 2033	U-3022		
		>A> 10058546	Jul 15, 2033	U-3023		
		>A> 10081621	Mar 25, 2031	DP U-3024		
		>A> 10081621	Mar 25, 2031	DP U-3025		
		>A> 10206877	Apr 14, 2035	DP U-3026		
		>A> 10206877	Apr 14, 2035	DP U-3027		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	001	12065432	Dec 04, 2028	U-3984		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	002	12065432	Dec 04, 2028	U-3984		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358	001	12065432	Dec 04, 2028	U-3983		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358	002	12065432	Dec 04, 2028	U-3983		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358	003	12065432	Dec 04, 2028	U-3983		
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185	001	11337943	Jun 05, 2040	DP U-3660		
		11337943	Jun 05, 2040	DP U-3954		
		11883374	Jun 05, 2040	DP U-3660		
		11883374	Jun 05, 2040	DP U-3954		
		12042474	Jun 05, 2040	DP U-3660		
		12042474	Jun 05, 2040	DP U-3954		
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185	002	11337943	Jun 05, 2040	DP U-3660		
		11337943	Jun 05, 2040	DP U-3954		
		11883374	Jun 05, 2040	DP U-3660		
		11883374	Jun 05, 2040	DP U-3954		
		12042474	Jun 05, 2040	DP U-3660		
		12042474	Jun 05, 2040	DP U-3954		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 003	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	11883374	Jun 05, 2040	DP U-3660			
	11883374	Jun 05, 2040	DP U-3954			
	12042474	Jun 05, 2040	DP U-3660			
	12042474	Jun 05, 2040	DP U-3954			
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025 001	11986554	Apr 21, 2036	DP			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	12071423	Jul 06, 2040	DP			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	12071423	Jul 06, 2040	DP			
<u>LATANOPROST - IYUZEH</u>						
N 216472 001	8637054	Jul 08, 2031	DP U-446			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	11020385	Mar 14, 2034	U-1524			
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795 001	8058467	Feb 21, 2029	DS U-2144			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 001	11453656	Apr 18, 2038	DS DP		NCE	Aug 19, 2029
	11850248	Aug 01, 2041	U-3985			
	11879013	May 21, 2040	U-3985			
	11981659	Apr 18, 2038	U-3985			
	9593098	Oct 13, 2035	DS DP U-3985			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 002	11453656	Apr 18, 2038	DS DP		NCE	Aug 19, 2029
	11850248	Aug 01, 2041	U-3985			
	11879013	May 21, 2040	U-3985			
	11981659	Apr 18, 2038	U-3985			
	9593098	Oct 13, 2035	DS DP U-3985			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001	11944611	Jun 04, 2041	U-3507			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974 001	11944611	Jun 04, 2041	DS DP U-3507			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-14	Apr 03, 2027
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	10407393*PED	Feb 26, 2036			M-272	Dec 19, 2024
	11090386	Feb 23, 2036	U-3519		ODE-196	Aug 15, 2025
	11090386*PED	Aug 23, 2036			PED	Feb 15, 2026
	11186547	Aug 26, 2035	DS		PED	Oct 03, 2027
	11186547*PED	Feb 26, 2036				
	12083112	Mar 03, 2036	U-3996			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	12083112	Mar 03, 2036	U-3997			
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027	U-1695			
	9006256*PED	Jan 27, 2028				
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-14	Apr 03, 2027
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	10407393*PED	Feb 26, 2036			M-272	Dec 19, 2024
	11090386	Feb 23, 2036	U-3519		ODE-196	Aug 15, 2025
	11090386*PED	Aug 23, 2036			PED	Feb 15, 2026
	11186547	Aug 26, 2035	DS		PED	Oct 03, 2027
	11186547*PED	Feb 26, 2036				
	12083112	Mar 03, 2036	U-3996			
	12083112	Mar 03, 2036	U-3997			
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027	U-1695			
	9006256*PED	Jan 27, 2028				
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	RE46791	Jan 18, 2029	DS DP		NPP	Aug 30, 2027
					>A> ODE-495	Aug 30, 2031
					>A> ODE-497	Aug 30, 2031
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	RE46791	Jan 18, 2029	DS DP		NPP	Aug 30, 2027
					>A> ODE-495	Aug 30, 2031
					>A> ODE-497	Aug 30, 2031
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	RE46791	Jan 18, 2029	DS DP		NPP	Aug 30, 2027
					>A> ODE-495	Aug 30, 2031
					>A> ODE-497	Aug 30, 2031
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	RE46791	Jan 18, 2029	DS DP		NPP	Aug 30, 2027
					>A> ODE-495	Aug 30, 2031
					>A> ODE-497	Aug 30, 2031
<u>LETERMOVIR - PREVYMIS</u>						
N 219104 001	RE46791	Jan 18, 2029	DS DP		NP	Aug 30, 2027
					ODE*	Nov 08, 2024
					ODE*	Jun 05, 2030
					>A> ODE-495	Aug 30, 2031
					>A> ODE-497	Aug 30, 2031
<u>LETERMOVIR - PREVYMIS</u>						
N 219104 002	RE46791	Jan 18, 2029	DS DP		NP	Aug 30, 2027
					ODE*	Nov 08, 2024
					ODE*	Jun 05, 2030
					>A> ODE-495	Aug 30, 2031
					>A> ODE-497	Aug 30, 2031
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	12064434	Apr 14, 2036	DP		I-951	Sep 17, 2027
	8962630	Dec 09, 2029	U-2505			
	8962630	Dec 09, 2029	U-3264			
	8962630	Dec 09, 2029	U-3998			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	9416136	Aug 20, 2029	U-2505			
	9416136	Aug 20, 2029	U-3264			
	9416136	Aug 20, 2029	U-3998			
	9868739	Nov 09, 2031	U-2505			
	9868739	Nov 09, 2031	U-3264			
	9868739	Nov 09, 2031	U-3998			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	9617303	Mar 22, 2028	U-4001			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021343 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	11931559	Dec 22, 2041	DS			
<u>LEVACETYLLUCINE - AONEURSA</u>						
N 219132 001					NCE >A> ODE-498	Sep 24, 2029 Sep 24, 2031
<u>LEVOKETONAZOLE - RECORLEV</u>						
N 214133 001	11903940	Mar 02, 2040	U-3821			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004					M-304	Mar 24, 2026
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	12004992	Oct 06, 2033	DS			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	11850182	Sep 14, 2029	DP U-3819			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	11911388	Apr 10, 2030	U-3854			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	11911388	Apr 10, 2030	U-3854			
<u>LOFEXIDINE HYDROCHLORIDE - LOFEXIDINE HYDROCHLORIDE</u>						
A 218613 001					CGT	Feb 24, 2025
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2025	U-3070			
	8828356	Oct 17, 2025	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2025	U-3070			
	8828356	Oct 17, 2025	U-3070			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11872318	May 03, 2033	DP			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11872318	May 03, 2033	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	11980617	Oct 27, 2039	U-3940			
	12070459	Aug 30, 2039	DP U-3362			
	12070459	Aug 30, 2039	DP U-3363			
	12090155	Jul 07, 2040	DP U-4000			
	>A> 12122792	Dec 10, 2040	DP U-4019			
	>A> 12122792	Dec 10, 2040	DP U-4020			
	>A> 12128043	Aug 30, 2039	DP U-3362			
	>A> 12128043	Aug 30, 2039	DP U-3363			
	8598119	Dec 28, 2029	U-543	Y		
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	11980617	Oct 27, 2039	U-3940			
	>A> 12122792	Dec 10, 2040	DP U-4019			
	>A> 12122792	Dec 10, 2040	DP U-4020			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	11980617	Oct 27, 2039	U-3940			
	>A> 12122792	Dec 10, 2040	DP U-4019			
	>A> 12122792	Dec 10, 2040	DP U-4020			
<u>LUTETIUM LU 177 DOTATATE - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP		NPP	Apr 23, 2027
	10596276*PED	Jan 25, 2039			ODE-166	Jan 26, 2025
	10596278	Jul 25, 2038	DP		ODE-479	Apr 23, 2031
	10596278*PED	Jan 25, 2039			PED	Jul 26, 2025
	11904027	Jul 25, 2038	DP		PED	Oct 23, 2027
	11904027*PED	Jan 25, 2039			PED	Oct 23, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAJETAN - PLUVICTO</u>						
N 215833 001	11951190	Nov 12, 2035	U-3345			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 001	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 002	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	10512657	Oct 26, 2032	U-3850		I-938	Mar 13, 2027
	11229647	Feb 12, 2040	U-3290		ODE-471	Mar 13, 2031
	11229647	Feb 12, 2040	U-3974			
	11229661	Oct 26, 2032	U-3850			
	11260053	May 26, 2031	U-3290			
	11260053	May 26, 2031	U-3974			
	11376251	Oct 26, 2032	U-3290			
	11376251	Oct 26, 2032	U-3974			
	11497745	Feb 12, 2040	U-3290			
	11497745	Feb 12, 2040	U-3974			
	11918578	Feb 12, 2040	U-3290			
	11918578	Feb 12, 2040	U-3974			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 002	10512657	Oct 26, 2032	U-3973		NCE	Sep 29, 2026
	11229661	Oct 26, 2032	U-3973		ODE*	Sep 29, 2028
					ODE*	Mar 13, 2030
					ODE*	Mar 13, 2031
					ODE-490	Jul 24, 2031
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001	RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002	RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003	RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004	RE50050	Jun 19, 2034	DS DP			
<u>MAVORIXAFOR - XOLREMDI</u>						
N 218709 001	10548889	Dec 11, 2038	DP		NCE	Apr 26, 2029
	10610527	Dec 22, 2036	U-3932		ODE-480	Apr 26, 2031
	10953003	Dec 14, 2036	DP			
	11045461	Dec 11, 2038	DP			
	11219621	Dec 22, 2036	U-3932			
	>A> 12115156	Dec 11, 2038	DP			
<u>METAXALONE - METAXALONE</u>						
N 022503 001	11918559	Jul 29, 2039	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	11969503	Jan 02, 2033	DP			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					M-303	Jan 08, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					M-303	Jan 08, 2027
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11911518	Mar 23, 2032	U-2357			
<u>MIFEPRISTONE - MIFEPRISTONE</u>						
A 211436 001					PC	Jul 17, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	11969435	Jun 19, 2037	U-1643			
	12097210	Jun 19, 2037	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11903938	Aug 17, 2038	DS U-2371			
	12042488	May 30, 2038	DS			
	12042489	May 30, 2038	DS U-2371			
	12042490	May 30, 2038	U-2371			
>A>	12109205	May 30, 2038	DS U-2371			
	RE48608	Oct 20, 2031	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	11944634	Oct 16, 2032	DP			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	12059409	Sep 28, 2029	DP			
	12097189	Sep 28, 2029	U-2996			
	12097189	Sep 28, 2029	U-3670			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	12059409	Sep 28, 2029	DP			
	12097189	Sep 28, 2029	U-2996			
	12097189	Sep 28, 2029	U-3670			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	11878049	Jul 31, 2041	U-3782			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 001	11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 002	11963962	Dec 02, 2040	U-3928			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 003	11963962	Dec 02, 2040	U-3928			
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	12064442	Sep 04, 2034	U-3297			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	11903918	Feb 27, 2035	U-1384			
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	11931455	Aug 16, 2039	DP U-1752			
	12097284	Aug 16, 2039	DP			
	12097285	Aug 16, 2039	DP U-1752			
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216049 001					CGT	Mar 30, 2025
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216049 002					CGT	Mar 30, 2025
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216050 001					CGT	Mar 24, 2025
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216050 002					CGT	Mar 24, 2025
<u>NALMEFENE HYDROCHLORIDE - ZURNAL (AUTOINJECTOR)</u>						
N 218590 001	10279131	Jul 31, 2031	DP		NP	Aug 07, 2027
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	11185642	Aug 28, 2031	DP			
	11191908	Oct 18, 2035	DP			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	11813435	Feb 25, 2035	DP			
	11857547	Nov 05, 2039	DP			
	11865112	Nov 05, 2039	DP U-3630			
	8021335	Oct 04, 2026	DP			
	8496619	Aug 21, 2031	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9364610	Aug 21, 2031	DP			
	9364611	Aug 21, 2031	DP			
	9446195	Aug 21, 2031	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001					NP	Apr 29, 2024
<u>NALOXONE HYDROCHLORIDE - REZENOPY</u>						
N 215487 001					NP	Apr 19, 2027
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	11806428	May 11, 2032	DP			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	11020385	Mar 14, 2034	U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	12042494	Nov 18, 2030	DP U-3522			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	11872211	May 19, 2043	U-3754		NCE	Nov 27, 2028
	11884634	Aug 09, 2039	DP		ODE-452	Nov 27, 2030
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
	12036207	May 19, 2043	U-3754			
>A>	12110277	Jul 08, 2042	DP			
>A>	12116347	Aug 09, 2039	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS	U-3754	ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS	U-3754		
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP	U-3754		
	11807611	Sep 08, 2042	DP	U-3754		
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP	U-3754		
	11845732	Aug 09, 2039	DS	U-3754		
	11872211	May 19, 2043	U-3754			
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
	12036207	May 19, 2043	U-3754			
>A>	12110277	Jul 08, 2042	DP			
>A>	12116347	Aug 09, 2039	DP			
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS	U-3754	ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS	U-3754		
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP	U-3754		
	11807611	Sep 08, 2042	DP	U-3754		
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP	U-3754		
	11845732	Aug 09, 2039	DS	U-3754		
	11872211	May 19, 2043	U-3754			
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
	12036207	May 19, 2043	U-3754			
>A>	12110277	Jul 08, 2042	DP			
>A>	12116347	Aug 09, 2039	DP			
	7342118	Aug 18, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	11931377	Jun 03, 2029	DS DP U-3903			
	11931377*PED	Dec 03, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 004	11931377	Jun 03, 2029	DS DP U-3903			
<u>NITROGLYCERIN - NITROGLYCERIN</u>						
A 216103 001					CGT	Aug 21, 2024
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 001	12097170	Mar 08, 2041	DP U-3995			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 002	12097170	Mar 08, 2041	DP U-3995			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 003	12097170	Mar 08, 2041	DP U-3995			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	12013403	Mar 04, 2036	U-1941			
	12013403	Mar 04, 2036	U-1942			
	12013403	Mar 04, 2036	U-1943			
	12013403	Mar 04, 2036	U-1944			
	12013403	Mar 04, 2036	U-2093			
	12013403	Mar 04, 2036	U-2094			
	8361977	Dec 23, 2030	DS DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11857595	Feb 03, 2036	U-3784		ODE-474	Jun 26, 2027
	11890316	Dec 28, 2040	U-3232			
	11969471	Sep 17, 2029	DP			
	11986529	Sep 17, 2029	U-2857			
<u>OCTREOTIDE ACETATE - BYNFEZIA PEN</u>						
N 213224 001	>A> 10342850	May 15, 2038	DP			
	>A> 11052196	Nov 03, 2040	U-4007			
	>A> 11052196	Nov 03, 2040	U-4008			
	>A> 11052196	Nov 03, 2040	U-4009			
	>A> 11246991	Nov 03, 2040	U-4007			
	>A> 11246991	Nov 03, 2040	U-4008			
	>A> 11246991	Nov 03, 2040	U-4009			
	>A> 11534553	Nov 03, 2040	U-4007			
	>A> 11534553	Nov 03, 2040	U-4008			
	>A> 11534553	Nov 03, 2040	U-4009			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	>A> 12091394	Jun 20, 2039	DS			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	>A> 12091394	Jun 20, 2039	DS			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	>A> 12091394	Jun 20, 2039	DS			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	>A> 12091394	Jun 20, 2039	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
	12048695	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
	12048695	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001	11931350	Mar 23, 2032	DS U-2986			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002	11931350	Mar 23, 2032	DS U-2986			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003	11931350	Mar 23, 2032	DS U-2986			
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001					NPP	Apr 24, 2027
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	12053463	May 16, 2039	DS DP			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7553828	Jun 02, 2025	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7553828	Jun 02, 2025	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11919838	Apr 20, 2029	U-3862			
	11919838	Apr 20, 2029	U-3863			
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	11911473	Jul 16, 2039	U-623			
	11911473	Jul 16, 2039	U-624			
	12042539	Jul 16, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10583130	Mar 31, 2030	U-3869			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10583130	Mar 31, 2030	U-3869			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	>A> 10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	>A> 10183020	Jan 02, 2035	DP U-2289			
	>A> 10183020	Jan 02, 2035	DP U-3016			
	>A> 10183020	Jan 02, 2035	DP U-3823			
	>A> 10183020	Jan 02, 2035	DP U-4010			
	>A> 8946235	Aug 08, 2032	DS DP U-1777			
	>A> 8946235	Aug 08, 2032	DS DP U-2289			
	>A> 8946235	Aug 08, 2032	DS DP U-3016			
	>A> 8946235	Aug 08, 2032	DS DP U-3823			
	>A> 8946235	Aug 08, 2032	DS DP U-4010			
	>A> 9732058	Jul 25, 2032	DS DP U-1777			
	>A> 9732058	Jul 25, 2032	DS DP U-2289			
	>A> 9732058	Jul 25, 2032	DS DP U-3016			
	>A> 9732058	Jul 25, 2032	DS DP U-3823			
	>A> 9732058	Jul 25, 2032	DS DP U-4010			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	>A> 10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	>A> 10183020	Jan 02, 2035	DP U-2289			
	>A> 10183020	Jan 02, 2035	DP U-3016			
	>A> 10183020	Jan 02, 2035	DP U-3823			
	>A> 10183020	Jan 02, 2035	DP U-4010			
	>A> 8946235	Aug 08, 2032	DS DP U-1777			
	>A> 8946235	Aug 08, 2032	DS DP U-2289			
	>A> 8946235	Aug 08, 2032	DS DP U-3016			
	>A> 8946235	Aug 08, 2032	DS DP U-3823			
	>A> 8946235	Aug 08, 2032	DS DP U-4010			
	>A> 9732058	Jul 25, 2032	DS DP U-1777			
	>A> 9732058	Jul 25, 2032	DS DP U-2289			
	>A> 9732058	Jul 25, 2032	DS DP U-3016			
	>A> 9732058	Jul 25, 2032	DS DP U-3823			
	>A> 9732058	Jul 25, 2032	DS DP U-4010			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	11896599	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200534 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 002					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 201194 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 004	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	10239846	Nov 15, 2030	U-3740		>A> M-309	Aug 30, 2027
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	10239846	Nov 15, 2030	U-3740		>A> M-309	Aug 30, 2027
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	10239846	Nov 15, 2030	U-3740		>A> M-309	Aug 30, 2027
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 001	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	>A> 12128049	Oct 26, 2038	U-3968			
	>A> 12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 002	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	>A> 12128049	Oct 26, 2038	U-3968			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 002	>A> 12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 003	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	>A> 12128049	Oct 26, 2038	U-3968			
	>A> 12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 004	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	>A> 12128049	Oct 26, 2038	U-3968			
	>A> 12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 005	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	>A> 12128049	Oct 26, 2038	U-3968			
	>A> 12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 006	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	>A> 12128049	Oct 26, 2038	U-3968			
	>A> 12128049	Oct 26, 2038	U-3969			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 001	11590207	Sep 28, 2037	U-3982		NP	Aug 09, 2027
	11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	11857603	Sep 28, 2037	U-3982			
	11890326	Sep 28, 2037	DS DP			
	11918628	Sep 28, 2037	DS DP			
	8906847	Apr 30, 2031	DS DP U-3982			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 002	11590207	Sep 28, 2037	U-3982		NP	Aug 09, 2027
	11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	11857603	Sep 28, 2037	U-3982			
	11890326	Sep 28, 2037	DS DP			
	11918628	Sep 28, 2037	DS DP			
	8906847	Apr 30, 2031	DS DP U-3982			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 003	11590207	Sep 28, 2037	U-3982		NP	Aug 09, 2027
	11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	11857603	Sep 28, 2037	U-3982			
	11890326	Sep 28, 2037	DS DP			
	11918628	Sep 28, 2037	DS DP			
	8906847	Apr 30, 2031	DS DP U-3982			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	12023312	Aug 31, 2031	U-3966			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	12023312	Aug 31, 2031	U-3966			
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988 001					NPP	Aug 12, 2027
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922 001					M-270	Jan 13, 2026
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11844841	Dec 09, 2038	DP U-3172			
	11844841	Dec 09, 2038	DP U-3173			
	11844841	Dec 09, 2038	DP U-3174			
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	11903994	Feb 22, 2037	U-3826			
	11903994	Feb 22, 2037	U-3827			
	11903994	Feb 22, 2037	U-3828			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	10285759	Dec 08, 2031	U-3890		NCE	Apr 17, 2029
	9032965	Dec 08, 2031	U-3890			
	9155471	Oct 12, 2031	U-3890			
	9532835	Dec 08, 2031	U-3890			
	9763577	Sep 14, 2034	DS DP U-3890			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11857646	Mar 16, 2037		U-665		
	11925695	Mar 16, 2037		U-665		
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11857646	Mar 16, 2037		U-665		
	11925695	Mar 16, 2037		U-665		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 001					>A> M-308	Sep 13, 2027
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 002					>A> M-308	Sep 13, 2027
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 003					>A> M-308	Sep 13, 2027
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 004					>A> M-308	Sep 13, 2027
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	10278918	Jan 31, 2034	DP			
	10772829	Jan 31, 2034	DP			
	11090261	Jan 31, 2034	DP			
	11400077	Oct 25, 2039		U-3804		
	11844858	Jan 31, 2034	DP			
	9795560	Jan 31, 2034	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001	11839487	Jul 15, 2031		U-3685		
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	11851407	Jun 09, 2037	DS DP U-3130			
<u>PILOCARPINE HYDROCHLORIDE - QLOSI</u>						
N 217836 001	11974986	Aug 18, 2037		U-3741		
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	>A> 12109193	Sep 14, 2041	DP		ODE-451	Dec 01, 2030
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	>A> 12109193	Sep 14, 2041	DP		ODE-451	Dec 01, 2030
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001					NPP ODE-489	Jun 21, 2027 Jun 21, 2031
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002					NPP ODE-489	Jun 21, 2027 Jun 21, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONESIMOD - PONVORY</u>						
N 213498 001	11951097	Oct 10, 2042		U-3891		
	>A> RE43728	Nov 16, 2025	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	11951097	Oct 10, 2042		U-3891		
	>A> RE43728	Nov 16, 2025	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	11951097	Oct 10, 2042		U-3891		
	>A> RE43728	Nov 16, 2025	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	11951097	Oct 10, 2042		U-3891		
	>A> RE43728	Nov 16, 2025	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	11951097	Oct 10, 2042		U-3891		
	>A> RE43728	Nov 16, 2025	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	11951097	Oct 10, 2042		U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498 007	11951097	Oct 10, 2042		U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498 008	11951097	Oct 10, 2042		U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498 009	11951097	Oct 10, 2042		U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498 010	11951097	Oct 10, 2042		U-3891		
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	11872192	Apr 03, 2039		U-2952		
	11963958	Apr 03, 2039		U-2828		
<u>PREDNISOLONE ACETATE - PREDNISOLONE ACETATE</u>						
A 216935 001					>A> CGT	Apr 09, 2025
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
N 217604 001	>A> 10881617	Jun 18, 2038		DP		
	>A> 10925833	Jun 18, 2038		DP		
	>A> 10987311	Jun 18, 2038		DP		
	>A> 11229606	Jun 18, 2038		DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
N 217604 001	>A> 11478425	Jun 18, 2038	DP U-4012			
	>A> 11666536	Jun 18, 2038	DP			
	>A> 11911515	Jun 18, 2038	DP			
	>A> 12042559	Jun 18, 2038	DP			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	12097198	Sep 29, 2037	U-3020			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10675296	Jul 10, 2038	DP		NCE	Oct 22, 2025
	10675296*PED	Jan 10, 2039			NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3831		PED	Jul 21, 2025
	10695361	Sep 16, 2036	U-3832		PED	Oct 25, 2025
	10695361*PED	Mar 16, 2037			PED	Apr 22, 2026
	11007208	Sep 16, 2036	U-3831		PED	Jan 13, 2027
	11007208	Sep 16, 2036	U-3832			
	11007208*PED	Mar 16, 2037				
	11266681	Jul 10, 2038	U-3831			
	11266681	Jul 10, 2038	U-3832			
	11266681*PED	Jan 10, 2039				
	11382926	Sep 16, 2036	U-3831			
	11382926	Sep 16, 2036	U-3832			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3835			
	11491169	May 28, 2041	U-3836			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3835			
	11903953	May 28, 2041	U-3836			
	11903953*PED	Nov 28, 2041				
	11975012	May 28, 2041	U-3835			
	11975012	May 28, 2041	U-3836			
	11975012*PED	Nov 28, 2041				
	11975017	Jul 10, 2038	DP			
	11975017*PED	Jan 10, 2039				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10695361	Sep 16, 2036	U-3829		NCE	Oct 22, 2025
	10695361	Sep 16, 2036	U-3830		NPP	Apr 25, 2025
	10695361*PED	Mar 16, 2037			PED	Jul 21, 2025
	11007208	Sep 16, 2036	U-3829		PED	Oct 25, 2025
	11007208	Sep 16, 2036	U-3830		PED	Apr 22, 2026
	11007208*PED	Mar 16, 2037			PED	Jan 13, 2027
	11382926	Sep 16, 2036	U-3829			
	11382926	Sep 16, 2036	U-3830			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3833			
	11491169	May 28, 2041	U-3834			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3833			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	11903953	May 28, 2041	U-3834			
	11903953*PED	Nov 28, 2041				
	11975012	May 28, 2041	U-3833			
	11975012	May 28, 2041	U-3834			
	11975012*PED	Nov 28, 2041				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001	9827251	Jan 13, 2034	U-2968			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	11452725	Jul 24, 2036	U-3755		NCE	Nov 15, 2028
	11452725	Jul 24, 2036	U-3961		ODE-455	Nov 15, 2030
					ODE-483	Jun 13, 2031
					ODE-488	Jun 13, 2031
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 002	10294242	Jul 05, 2036	DS		NCE	Nov 15, 2028
	11452725	Jul 24, 2036	U-3755		ODE*	Nov 15, 2030
	11452725	Jul 24, 2036	U-3961		ODE-488	Jun 13, 2031
	9714258	Jan 23, 2035	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 001	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 002	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 003	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	12048692	Aug 29, 2039	U-2440			
	7288657	Oct 31, 2028	DS			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	12064434	Apr 14, 2036	DP		I-950	Sep 17, 2027
	8962630	Dec 09, 2029	U-1981			
	8962630	Dec 09, 2029	U-2355			
	8962630	Dec 09, 2029	U-2356			
	8962630	Dec 09, 2029	U-3265			
	8962630	Dec 09, 2029	U-3266			
	8962630	Dec 09, 2029	U-3975			
	8962630	Dec 09, 2029	U-3999			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	9416136	Aug 20, 2029	U-1981			
	9416136	Aug 20, 2029	U-2355			
	9416136	Aug 20, 2029	U-2356			
	9416136	Aug 20, 2029	U-3265			
	9416136	Aug 20, 2029	U-3266			
	9416136	Aug 20, 2029	U-3975			
	9416136	Aug 20, 2029	U-3999			
	9868739	Nov 09, 2031	U-1981			
	9868739	Nov 09, 2031	U-2355			
	9868739	Nov 09, 2031	U-2356			
	9868739	Nov 09, 2031	U-3265			
	9868739	Nov 09, 2031	U-3266			
	9868739	Nov 09, 2031	U-3975			
	9868739	Nov 09, 2031	U-3999			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
	7125879	Apr 21, 2025	DS DP U-3874			
	7125879*PED	Oct 21, 2025				
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT PED</u>						
N 219016 001	11065198	Oct 23, 2037	DP			
	7125879	Apr 21, 2025	DS DP U-3874			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11896585	Dec 30, 2040	DP			
	11903933	Dec 30, 2040	DP			
	11911370	Dec 30, 2040	DP			
	11918564	Dec 30, 2040	DP			
	11969414	Feb 08, 2041	U-3897			
	11969415	Dec 30, 2040	U-3219			
	12023325	Aug 12, 2040	U-3960			
	12023326	Aug 12, 2040	U-3959			
	12023327	Aug 12, 2040	U-3958			
	12023328	Dec 30, 2040	U-3957			
	12059410	Aug 12, 2040	U-3153			
	12059411	Aug 12, 2040	U-3971			
	12064422	Dec 30, 2040	U-3219			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	11938136	Nov 08, 2036	DP			
<u>RISPERIDONE - RISVAN</u>						
N 214835 001	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031	U-3942			
	11173110	May 31, 2031	U-3941			
	11241377	May 31, 2031	U-3939			
	11752092	May 31, 2031	U-3941			
	11752093	May 31, 2031	DP			
	11752094	May 31, 2031	U-3942			
	11759416	May 31, 2031	U-3939			
<u>RISPERIDONE - RISVAN</u>						
N 214835 002	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISVAN</u>						
N 214835 002	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031		U-3942		
	11173110	May 31, 2031		U-3941		
	11241377	May 31, 2031		U-3939		
	11752092	May 31, 2031		U-3941		
	11752093	May 31, 2031	DP			
	11752094	May 31, 2031		U-3942		
	11759416	May 31, 2031		U-3939		
<u>RITLECITINIB TOSYLATE - LITFULO</u>						
N 215830 001	12077533	Dec 03, 2034		U-3994		
	>A> 12116368	Oct 17, 2041	DS			
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP			
	7157456*PED	Feb 28, 2025				
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	11992480	Jun 07, 2037		U-3748		
	12005051	Jun 07, 2037		U-3748		
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 002	10940142	Jun 07, 2037	DP		NS	Jul 09, 2027
	11129818	Aug 25, 2037		U-3970		
	11793796	Jun 07, 2037	DP			
	11819496	Jun 07, 2037		U-3970		
	11992480	Jun 07, 2037		U-3970		
	12005051	Jun 07, 2037		U-3970		
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037		U-3970		
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001	11992480	Jun 07, 2037		U-3773	NP	Dec 15, 2026
	12005051	Jun 07, 2037		U-3773		
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 001	10722471	Feb 02, 2037	DP	U-3896		
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026		U-1723		
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 002	10722471	Feb 02, 2037	DP	U-3896		
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026		U-1723		
<u>SELADELPAR LYSINE - LIVDELZI</u>						
N 217899 001	10272058	Mar 19, 2035		U-1854	NCE	Aug 14, 2029
	11406611	Mar 19, 2035		U-1854	ODE-486	Aug 14, 2031
	11596614	Mar 19, 2035		U-1854		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELADELPAR LYSINE - LIVDELZI</u>						
N 217899 001	7301050	Aug 02, 2025	DS DP			
	7709682	Sep 13, 2026	DS			
	9486428	Mar 19, 2035			U-1854	
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 001	11998565	Jul 01, 2041	DP			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 002	11998565	Jul 01, 2041	DP			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 003	11998565	Jul 01, 2041	DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	>A> 10137124	Oct 10, 2037			NPP	May 29, 2027
	>A> 10137124	Oct 10, 2037		U-3450	ODE-484	May 29, 2031
	>A> 10137124	Oct 10, 2037		U-3949	ODE-485	May 29, 2031
	>A> 10137124	Oct 10, 2037		U-3950	ODE-487	May 29, 2031
	>A> 10172851	Oct 10, 2037		U-3951		
	>A> 10172851	Oct 10, 2037		U-3450		
	>A> 10172851	Oct 10, 2037		U-3949		
	>A> 10172851	Oct 10, 2037		U-3950		
	>A> 10172851	Oct 10, 2037		U-3951		
	>A> 10584124	Oct 10, 2038	DS	U-3450		
	>A> 10584124	Oct 10, 2038	DS	U-3949		
	>A> 10584124	Oct 10, 2038	DS	U-3950		
	>A> 10584124	Oct 10, 2038	DS	U-3951		
	>A> 10786489	Oct 10, 2038	DP	U-3450		
	>A> 10786489	Oct 10, 2038	DP	U-3949		
	>A> 10786489	Oct 10, 2038	DP	U-3950		
	>A> 10786489	Oct 10, 2038	DP	U-3951		
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002	>A> 10137124	Oct 10, 2037			NPP	May 29, 2027
	>A> 10137124	Oct 10, 2037		U-3450	ODE-484	May 29, 2031
	>A> 10137124	Oct 10, 2037		U-3949	ODE-485	May 29, 2031
	>A> 10137124	Oct 10, 2037		U-3950	ODE-487	May 29, 2031
	>A> 10137124	Oct 10, 2037		U-3951		
	>A> 10172851	Oct 10, 2037		U-3450		
	>A> 10172851	Oct 10, 2037		U-3949		
	>A> 10172851	Oct 10, 2037		U-3950		
	>A> 10172851	Oct 10, 2037		U-3951		
	>A> 10584124	Oct 10, 2038	DS	U-3450		
	>A> 10584124	Oct 10, 2038	DS	U-3949		
	>A> 10584124	Oct 10, 2038	DS	U-3950		
	>A> 10584124	Oct 10, 2038	DS	U-3951		
	>A> 10786489	Oct 10, 2038	DP	U-3450		
	>A> 10786489	Oct 10, 2038	DP	U-3949		
	>A> 10786489	Oct 10, 2038	DP	U-3950		
	>A> 10786489	Oct 10, 2038	DP	U-3951		
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 001	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037		U-3450		
	10137124	Oct 10, 2037		U-3949		
	10137124	Oct 10, 2037		U-3950		
	10137124	Oct 10, 2037		U-3951		
	10172851	Oct 10, 2037		U-3450		
	10172851	Oct 10, 2037		U-3949		
	10172851	Oct 10, 2037		U-3950		
	10172851	Oct 10, 2037		U-3951		
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 002	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037		U-3450		
	10137124	Oct 10, 2037		U-3949		
	10137124	Oct 10, 2037		U-3950		
	10137124	Oct 10, 2037		U-3951		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 002	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 003	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 004	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12029779	Oct 10, 2038	U-3162		I-935	Mar 08, 2027
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					ODE-469	Jan 31, 2030
<u>SILDENAFIL CITRATE - LIQREV</u>						
N 214952 001	12005062	Dec 24, 2038	DP U-3582			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	11944602	Jul 24, 2036	U-3889			
	12071402	Jan 05, 2032	DP			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Jul 24, 2036	U-3889			
	12071402	Jan 05, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Jul 24, 2036	U-3889			
	12071402	Jan 05, 2032	DP			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	11944602	Jul 24, 2036	U-3889			
	12071402	Jan 05, 2032	DP			
<u>SIROLIMUS - FYARRO</u>						
N 213312 001	12061183	Mar 05, 2036	DP			
<u>SODIUM ACETATE - SODIUM ACETATE</u>						
A 216920 001					CGT	Nov 16, 2024
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	11986446	Mar 15, 2033	U-3324			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	11896572	Jul 21, 2037	DP		>A> ODE-494	Oct 16, 2031
	11986451	Jul 21, 2037	U-3934			
	>A> 12097175	Jul 21, 2037	DP			
	>A> 12097176	Jul 21, 2037	U-4006			
	>A> 12109186	Jul 21, 2037	DP			
	>A> 12115142	Jul 21, 2037	DP			
	>A> 12115143	Jul 21, 2037	DP			
	>A> 12115144	Jul 21, 2037	DP			
	>A> 12115145	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	11896572	Jul 21, 2037	DP		>A> ODE-494	Oct 16, 2031
	11986451	Jul 21, 2037	U-3934			
	>A> 12097175	Jul 21, 2037	DP			
	>A> 12097176	Jul 21, 2037	U-4006			
	>A> 12109186	Jul 21, 2037	DP			
	>A> 12115142	Jul 21, 2037	DP			
	>A> 12115143	Jul 21, 2037	DP			
	>A> 12115144	Jul 21, 2037	DP			
	>A> 12115145	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	11896572	Jul 21, 2037	DP		>A> ODE-494	Oct 16, 2031
	11986451	Jul 21, 2037	U-3934			
	>A> 12097175	Jul 21, 2037	DP			
	>A> 12097176	Jul 21, 2037	U-4006			
	>A> 12109186	Jul 21, 2037	DP			
	>A> 12115142	Jul 21, 2037	DP			
	>A> 12115143	Jul 21, 2037	DP			
	>A> 12115144	Jul 21, 2037	DP			
	>A> 12115145	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	11896572	Jul 21, 2037	DP		>A> ODE-494	Oct 16, 2031
	11986451	Jul 21, 2037	U-3934			
	>A> 12097175	Jul 21, 2037	DP			
	>A> 12097176	Jul 21, 2037	U-4006			
	>A> 12109186	Jul 21, 2037	DP			
	>A> 12115142	Jul 21, 2037	DP			
	>A> 12115143	Jul 21, 2037	DP			
	>A> 12115144	Jul 21, 2037	DP			
	>A> 12115145	Jul 21, 2037	DP			
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	11964018	Jul 01, 2039	U-3898			
	11992530	Jul 01, 2039	U-3948			
	11998604	Jul 01, 2039	U-3952			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOPFIRONIUM BROMIDE - SOFDRA</u>						
N 217347 001	>A> 10383846	Mar 14, 2034	U-2398		NCE	Jun 20, 2029
	>A> 10947192	May 22, 2034	U-2398			
	>A> 10952990	May 22, 2034	U-2398			
	>A> 10959983	May 22, 2034	U-2398			
	>A> 10961191	May 22, 2034	U-2398			
	>A> 11026919	May 22, 2034	DP U-2398			
	>A> 11034652	May 22, 2034	DP U-2398			
	>A> 11052067	May 22, 2034	DP U-2398			
	>A> 11084788	May 22, 2034	DP U-2398			
	>A> 11123325	Jul 20, 2037	DP U-2398			
	11566000	May 22, 2040	DS DP			
	11584715	May 22, 2040	DS DP			
	8147809	Mar 26, 2027	DS DP			
	>A> 8628759	Nov 13, 2026	U-2398			
	>A> 9220707	Mar 14, 2034	U-2398			
	>A> 9492429	Mar 14, 2034	DP U-2398			
	>A> 9895350	Mar 14, 2034	U-2398			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
	12036194	Dec 30, 2042	U-3693			
	12064411	Dec 30, 2042	U-3693			
	12090126	Dec 30, 2042	U-3693			
	>A> 12102609	Dec 30, 2042	U-3693			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
	12036194	Dec 30, 2042	U-3693			
	12064411	Dec 30, 2042	U-3693			
	12090126	Dec 30, 2042	U-3693			
	>A> 12102609	Dec 30, 2042	U-3693			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 003	10519146	May 21, 2038	DS DP		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP U-3306		ODE*	May 28, 2028
	11426404	Sep 15, 2040	U-3306			
	11827635	May 20, 2040	DS DP U-3306			
<u>SPARSENTAN - FILSPARI</u>						
N 216403 001	9993461	Mar 29, 2030	U-3269		ODE-493	Sep 05, 2031
	9993461	Mar 29, 2030	U-3993			
<u>SPARSENTAN - FILSPARI</u>						
N 216403 002	9993461	Mar 29, 2030	U-3269		ODE-493	Sep 05, 2031
	9993461	Mar 29, 2030	U-3993			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	12033733	Mar 16, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001 >A>	12090139	Jun 16, 2030	DP			
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223 001 >A>	12097183	Jan 29, 2036	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004	11980623	May 29, 2033	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	12083103	May 30, 2028	U-2678			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	12083103	May 30, 2028	U-2678			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	12083103	May 30, 2028	U-2678			
<u>TADALAFIL - TADLIQ</u>						
N 214522 001	11975006	Dec 24, 2038	DP U-3397			
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	7214695	Dec 19, 2025	DS DP			
	7214696	Dec 19, 2025	U-2524			
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Dec 19, 2025	DS DP			
	7214696	Dec 19, 2025	U-2524			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 001	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 002	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 003	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 004	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 005	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 006	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 001					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 002					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 003					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	11344512	Apr 21, 2028		U-3391		
	11344512	Apr 21, 2028		U-3392		
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028		U-1276		
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	11344512	Apr 21, 2028		U-3391		
	11344512	Apr 21, 2028		U-3392		
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028		U-1276		
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	11344512	Apr 21, 2028		U-3391		
	11344512	Apr 21, 2028		U-3392		
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028		U-1276		
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	11344512	Apr 21, 2028		U-3391		
	11344512	Apr 21, 2028		U-3392		
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028		U-1276		
	8536130*PED	Mar 22, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 203794 001					NPP	Jul 03, 2026
					PED	Jan 03, 2027
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11826339	Jan 25, 2033	U-3342			
	11826339	Jan 25, 2033	U-3343			
	11918556	Apr 07, 2033	U-3342			
	11918556	Apr 07, 2033	U-3343			
	11918557	Jan 25, 2033	U-3003			
	11918557	Jan 25, 2033	U-3865			
	12049457	Feb 12, 2035	DS DP			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001	11826339	Jan 25, 2033	U-3342			
	11918556	Apr 07, 2033	U-3342			
	11918557	Jan 25, 2033	U-3003			
	12049457	Feb 12, 2035	DS DP			
<u>TAZAROTENE - TAZAROTENE</u>						
A 217075 001					CGT	Mar 08, 2025
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2852			
	10420775	Sep 12, 2031	U-2853			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-2852			
	11052093	Apr 13, 2032	DS DP U-2853			
	11491163	Apr 11, 2033	U-2736			
	11491163	Apr 11, 2033	U-2852			
	11491163	Apr 11, 2033	U-2853			
	8765732	Sep 12, 2031	U-2852			
	8765732	Sep 12, 2031	U-2853			
	9090562	Sep 12, 2031	DS DP			
	9549931	Sep 12, 2031	U-2736			
	9549931	Sep 12, 2031	U-2852			
	9549931	Sep 12, 2031	U-2853			
	9855275	Sep 12, 2031	U-2736			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	11890270	Aug 08, 2032	U-2346			
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 001	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 002	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 003	12016856	Dec 30, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	8754065	Aug 15, 2032	DS DP U-1275			
	8754065	Aug 15, 2032	DS DP U-3880			
	8754065	Aug 15, 2032	DS DP U-999			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1275			
	9296769	Aug 15, 2032	DS DP U-3880			
	9296769	Aug 15, 2032	DS DP U-999			
	9296769*PED	Feb 15, 2033				
<u>TERAZOSIN HYDROCHLORIDE - TEZRULY</u>						
N 218139 001	11224572	Jan 18, 2042	DP U-3990			
	11224572	Jan 18, 2042	DP U-3991			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	11844804	Jun 04, 2033		U-2418		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	11844804	Jun 04, 2033		U-2418		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	11844804	Jun 04, 2033		U-2418		
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	12011503	Oct 16, 2040	DP U-3964			
	12011503	Oct 16, 2040	DP U-3965			
<u>THEOPHYLLINE - THEOPHYLLINE</u>						
A 215312 001					CGT	Mar 26, 2025
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 001	11975013	Aug 16, 2041	DP			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001					D-192	Jun 07, 2027
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	11918623	Jun 14, 2039	U-3855		>A> M-82	Oct 18, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	11918623	Jun 14, 2039	U-3855		>A> M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	11918623	Jun 14, 2039	U-3855		>A> M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	11918623	Jun 14, 2039	U-3855		>A> M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	11918623	Jun 14, 2039	U-3855		>A> M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	11918623	Jun 14, 2039	U-3855		>A> M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	11357820	Jun 14, 2039	DP		>A> M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	11357820	Jun 14, 2039	DP		>A> M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	11357820	Jun 14, 2039	DP		>A> M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	11357820	Jun 14, 2039	DP		>A> M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	11357820	Jun 14, 2039	DP		>A> M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	11357820	Jun 14, 2039	DP		>A> M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11911362	Aug 21, 2040	DP U-3413			
	11911362	Aug 21, 2040	DP U-3414			
	11911362	Aug 21, 2040	DP U-3415			
<u>TOVORAFENIB - OJEMDA</u>						
N 217700 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOVORAFENIB - OJEMDA</u>						
N 218033 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 217513 001	7378423	May 29, 2027	DS DP		NP	Mar 16, 2026
	7378423*PED	Nov 29, 2027			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-3564		PED	Sep 16, 2026
	8703781*PED	Apr 15, 2031			PED	Sep 16, 2030
	8835443	Jun 10, 2025	U-3564			
	8835443*PED	Dec 10, 2025				
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001					NP	Dec 13, 2026
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	11826327	Feb 03, 2042	U-3749		NP	May 23, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	11826327	Feb 03, 2042	U-3749		NP	May 23, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	11826327	Feb 03, 2042	U-3749		NP	May 23, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	11826327	Feb 03, 2042	U-3749		NP	May 23, 2025
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	>A> 9604901	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	>A> 9604901	Dec 15, 2028	DS		Y	
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	11040042	Oct 25, 2031	DP			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	11827600	Jul 12, 2042	DS DP U-3556			
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 001	>A> 10238643	Jul 21, 2030	DP		>A> NCE	Sep 26, 2029
	>A> 10265311	Jul 21, 2030	U-3513			
	>A> 10369143	Jul 21, 2030	U-3513			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 001	>A> 10369144	Jul 21, 2030	DP U-3513			
	>A> 10695339	Jul 21, 2030	U-3513			
	>A> 10925832	Sep 27, 2039	DP			
	>A> 10933020	Sep 27, 2039	DP U-3513			
	>A> 11452692	Sep 27, 2039	U-3513			
	>A> 11471413	Sep 27, 2039	U-3513			
	>A> 11890378	Sep 27, 2039	DP U-3513			
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 002	>A> 10238643	Jul 21, 2030	DP		>A> NCE	Sep 26, 2029
	>A> 10265311	Jul 21, 2030	U-3513			
	>A> 10369143	Jul 21, 2030	U-3513			
	>A> 10369144	Jul 21, 2030	DP U-3513			
	>A> 10695339	Jul 21, 2030	U-3513			
	>A> 10925832	Sep 27, 2039	DP			
	>A> 10933020	Sep 27, 2039	DP U-3513			
	>A> 11452692	Sep 27, 2039	U-3513			
	>A> 11471413	Sep 27, 2039	U-3513			
	>A> 11890378	Sep 27, 2039	DP U-3513			
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 003	>A> 10238643	Jul 21, 2030	DP		>A> NCE	Sep 26, 2029
	>A> 10265311	Jul 21, 2030	U-3513			
	>A> 10369143	Jul 21, 2030	U-3513			
	>A> 10369144	Jul 21, 2030	DP U-3513			
	>A> 10695339	Jul 21, 2030	U-3513			
	>A> 10925832	Sep 27, 2039	DP			
	>A> 10933020	Sep 27, 2039	DP U-3513			
	>A> 11452692	Sep 27, 2039	U-3513			
	>A> 11471413	Sep 27, 2039	U-3513			
	>A> 11890378	Sep 27, 2039	DP U-3513			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
	12048698	Apr 27, 2038	U-3783			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
	12048698	Apr 27, 2038	U-3783			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	11857542	Dec 22, 2041	U-3786			
	11925709	Jan 30, 2035	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	11925709	Jan 30, 2035	DP			
	12070450	Dec 22, 2041	U-3992			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11365198	Oct 17, 2036	U-3275		I-946	Apr 26, 2027
	11365198	Oct 17, 2036	U-3946		NPP	Apr 26, 2027
	11512092	Oct 17, 2036	U-3275		ODE-481	Apr 26, 2031
	11512092	Oct 17, 2036	U-3371			
	11512092	Oct 17, 2036	U-3487			
	11512092	Oct 17, 2036	U-3946			
	11773106	Oct 17, 2036	U-3275			
	11773106	Oct 17, 2036	U-3371			
	11773106	Oct 17, 2036	U-3487			
	11773106	Oct 17, 2036	U-3946			
	11976077	Oct 17, 2036	U-3298			
	11993605	Oct 17, 2036	U-3275			
	11993605	Oct 17, 2036	U-3946			
	11993606	Oct 17, 2036	U-3487			
	12077545	Oct 17, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO</u>						
N 211675 001 >A>	12103933	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3255			
	8962629	Jan 15, 2031	DS U-3275			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
	8962629	Jan 15, 2031	DS U-3624			
	8962629	Jan 15, 2031	DS U-3945			
	8962629	Jan 15, 2031	DS U-3946			
	RE47221	Aug 16, 2033	DS			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	12077545	Oct 17, 2036	DP		I-946	Apr 26, 2027
>A>	12091415	Oct 17, 2036	DP		NPP	Apr 26, 2027
	RE47221	Aug 16, 2033	DS		ODE-481	Apr 26, 2031
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	12077545	Oct 17, 2036	DP		I-946	Apr 26, 2027
	RE47221	Aug 16, 2033	DS		NPP	Apr 26, 2027
					ODE-481	Apr 26, 2031
<u>UPADACITINIB - RINVOO LO</u>						
N 218347 001	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS		NP	Apr 26, 2027
	11661425	Oct 17, 2036	DS		ODE-481	Apr 26, 2031
	11680069	Oct 17, 2036	DS			
	11718627	Oct 17, 2036	DS			
	11773105	Oct 17, 2036	DS			
>A>	12110298	Oct 17, 2036	DS			
	8962629	Jan 15, 2031	DS U-3945			
	8962629	Jan 15, 2031	DS U-3946			
	9951080	Oct 17, 2036	DS			
	RE47221	Aug 16, 2033	DS			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP U-3876			
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036	U-3876			
	11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027	U-3876			
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034	U-3876			
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP U-3876			
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036	U-3876			
	11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027	U-3876			
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034	U-3876			
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP U-3876			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036	U-3876			
	11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027	U-3876			
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034	U-3876			
	RE47437	Jun 26, 2027	DS DP			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 001	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 002	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 002	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 003	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	11690853	Mar 07, 2033	U-3747			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11903941	Oct 19, 2035	U-1900			
	11903942	Oct 19, 2035	DP			
	11903943	Oct 19, 2035	U-1900			
	11911380	Oct 19, 2035	U-1900			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	12102638	Mar 22, 2040	U-3045			
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001	12016857	Aug 16, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	7332472	Oct 17, 2025	DS DP U-3056			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001					I-948	Jul 17, 2027
<u>VORASIDENIB - VORANIGO</u>						
N 218784 001	10172864	Jul 11, 2034	DS DP		NCE	Aug 06, 2029
	11345677	Jan 16, 2039	DS DP U-3978		ODE-491	Aug 06, 2031
	11844758	Dec 04, 2035	U-3977			
	9579324	Jul 11, 2034	DS			
<u>VORASIDENIB - VORANIGO</u>						
N 218784 002	10172864	Jul 11, 2034	DS DP		NCE	Aug 06, 2029
	11345677	Jan 16, 2039	DS DP U-3978		ODE-491	Aug 06, 2031
	11844758	Dec 04, 2035	U-3977			
	9579324	Jul 11, 2034	DS			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002	11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	11944612	Dec 02, 2036	U-3893			
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001	12049628	Jul 28, 2036	DS DP U-3396			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2145		ODE-467	Mar 07, 2031
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	10570139	Apr 22, 2034	U-3860			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	11142528	Apr 22, 2034	DP U-3860			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 001	11965040	Jun 12, 2035	DP			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 002	11965040	Jun 12, 2035	DP			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 003	11965040	Jun 12, 2035	DP			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Dec 24, 2037	U-2552			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 44TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm